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SUMMARY
Inflammatory bowel disease (IBD), Crohn's disease (CD)
and ulcerative colitis (UC) , are disorders of the
gastro-intestinal system whose aetiology and pathogenesis
remain unknown. It has long been known that changes in
the diet can be beneficial and elemental diets (ED),
devoid of polypeptide antigens, have been successfully
used in some of these conditions. Thus, the aim
of this thesis was to study the role of food antigens and
the effect of their withdrawal on IBD immune activity
by the use of ED.
Humoral immunity was studied by measuring total
immunoglobulins and antibodies to: ovalbumin,
6-lactoglobulin and gliadin in serum, whole gut lavage
fluid (WGLF) and parotid saliva. T cell activity was
studied by measuring soluble interleukin-2 receptor in
WGLF (LIL2R) and in serum (SIL2R). Macrophage activity
was studied by measuring tumour necrosis factor (TNF) in
WGLF and a-1 acid glycoprotein (a-lAP) in serum and WGLF.
Comparisons were made between levels of these parameters
in active and inactive IBD and controls. Disease activity
was guantified by measuring the total concentration of
immunoglobulin (Ig)G in WGLF. Patients with active IBD
were prescribed ED for at least 7 days. During the
course of the ED, WGLF and serum were collected prior to
and after the 7th day and assayed for the above
mentioned factors.
There was no difference in serum immunoglobulins and
antibodies between IBD patients and controls. Total IgM
and IgG in WGLF were higher in active IBD than in
controls. Food antibodies were also higher in CD, but not
in UC patients compared with controls. However, there was
no change in the level of immunoglobulins and food
antibodies in serum, WGLF or parotid saliva in patients
treated with ED, regardless of the clinical outcome.
LIL2R and SIL2R were higher in active IBD compared to
controls. Patients with high initial LIL2R responded to
ED and showed reduction of LIL2R with improvement of
disease. a-lAP was raised in all IBD (active and
inactive) patients in both serum and WGLF compared to
controls. a-lAP changes in IBD patients on ED were
unrelated to disease response. TNF levels were higher in
active IBD patients than in controls. Patients with high
levels did worse on ED.
These results indicate that LIL2R levels identify those
patients with predominant intestinal immune upregulation
which would be amenable to antigen withdrawal.
Additionally or alternatively ED may act by
downregulating interleukin-2 receptors in analogue with
cyclosporin treatment of IBD. We, therefore, suggest that
high TNF indicates prolonged continuous upregulation of
the immune activity. In this, macrophages become the
prominent cells involved and are less responsive to
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antigen withdrawal compared with T cells. Therefore,
LIL2R and TNF can be used as markers to identify a cohort
of IBD patients amenable to ED treatment. This in turn
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FOREWORD
The aetiology and pathogenesis of the Crohn's disease and
ulcerative colitis remain largely unknown. Therapy is
largely empirical and based mainly on the use of
anti-inflammatory drugs, but there is also some evidence
that chemically defined, elemental diets (ED) are
effective as primary therapy. The mechanism by which such
diets act is not known.
My hypothesis was that immune responses to foods are
involved in some way in the pathogenesis of IBD, and that
ED act by virtue of their being devoid of dietary
antigens so that deleterious immune responses to these
antigens are down regulated during treatment.
Our research team has developed whole gut lavage fluid
(WGLF) as source of material for non-invasive research in
intestinal immunity in man, and its use as a simpler yet
accurate way or indice of defining disease activity
in both Crohn's disease and ulcerative colitis. I
participated in the early appraisal and applications of
this approach.
In my first series of studies related to my main
questions I used ELISA to measure antibody to three
common food antigens, gliadin, 6-lactoglobulin and
ovalbumin, in serum and secretions (parotid saliva and
WGLF) , and enzyme-linked immunospot (ELISPOT) assay to
-xxxiv-
monitor changes in numbers of circulating antibody
secreting B cells produced by withdrawal of dietary
antigen.
I used these techniques to answer the following
questions.
1. Do inflammatory bowel disease patients have higher
food antibodies levels in serum and WGLF than controls?
2. What changes, if any, occur in food antibody levels in
serum and mucosal secretions (saliva and WGLF) when pa¬
tients are on ED, prescribed for purely clinical reasons?
3. Are there any differences between responders and
non-responders to ED therapy?
4. Does ED lead to a fall in the numbers of antibody
producing cells in peripheral circulation? L'_caX
}'
For the next phase I developed a new method for study of
the cellular arm of the immune response in the gut, using
WGLF, and applied this in an attempt to define the likely
mechanism of immune tissue injury that is affected by ED.
The markers chosen for this were IL-2 receptor to monitor
T cell activity and TNF and a-1 acid glycoprotein (a-lAP)
for macrophage activity.
Having established that these factors (sIL-2R, TNF and
a-lAP) could be measured in WGLF as well I addressed the
following questions;
1. What was the pattern of these factors in blood and
whole gut lavage fluid of inflammatory bowel disease and
-xxxv-
normal controls?
2. Within inflammatory bowel disease patients was there
any difference in these factors which might explain the
differences in response to elemental diet?
3. What was the pattern of these markers in responders
and non-responders and what was the effect of elemental
diet on the levels?
The results of this research are presented and discussed
in the following chapters.
This I hope would go some way in answering a few
questions about elemental diets and the immune response







HISTORICAL AND CLINICO-PATHOLOGICAL PERSPECTIVES
INFLAMMATORY BOWEL DISEASE
DEFINITION
Inflammatory bowel disease (IBD) is a general term for a
group of chronic inflammatory disorders of unknown
aetiology involving the gastrointestinal tract. In a
strict sense the diagnosis remains by exclusion as there
are no pathognomonic features or specific diagnostic
tests. There are two main varieties of IBD; non-specific
ulcerative colitis and Crohn's disease. The diagnosis is
based on the presence of typical clinical, radiographic,
and pathological features.
The original description of Crohn's disease, attributed
to Crohn, Ginzberg and Oppenheimer (1932), referred to
disease localised to the ileum. They reported a series of
patients with non-tuberculous ileal disease which they
termed 'regional enteritis*. It later became evident
that Crohn's disease can affect any part of the
gastrointestinal tract.
The distinction between ulcerative colitis and infective
colitis was first made by Samuel Wilks in 1859 though it
took another half a century for ulcerative colitis to be
accepted as a clinical entity in itself (Allchin, 1909).
Ulcerative colitis affects mainly the large bowel.
This chapter covers briefly the general aspects, clinical
and pathological aspects of IBD followed by a discussion
1
of the possible aetiological factors and postulated
mechanisms of tissue injury in IBD.
PATHOLOGICAL AND CLINICAL FEATURES OF IBP
There are some broad similarities and distinguishing
features between the two diseases (see TABLES 1:1 and
1:2). As there are no clearly defined pathognomonic
features or specific diagnostic tests for either
ulcerative colitis or Crohn's disease sometimes the
features are insufficient to permit distinction,
especially between ulcerative colitis and Crohn's
colitis. This situation arises in 10-20% of such cases.




Transmural Involvement -/+ ++
Granulomas - +/++(50%)
Fibrosis + ++
Fissuring, Fistula - ++
Mesenteric fat,
lymph node involvement - ++
+ = 30% ++ = 60% - = < 5%
2




Rectal bleeding ++ +
Abdominal pain + ++
Palpable mass - ++
Fistula - ++
Strictures - ++
Small bowel involvement -/+ ++
(backwash ileitis)
Rectal involvement ++ +/++
Perianal disease -/+ +
Extraintestinal disease + +/++
Toxic megacolon + +/-
Recurrence after colectomy - +
Malignancy (with long¬
standing disease) + +/-
+ = 30% ++ = 60% - = < 5%
Crohn's disease affects any part of the gastro-intestinal
system, and therefore the symptoms will depend on the
part affected. As Crohn's disease affects all layers of
the bowel, fistula formation, strictures and palpable
3
masses are more common. Ulcerative
affects the mucosa of the colon.




The aetiology of inflammatory bowel disease is unknown.
The factors listed below may contribute to the




3. Mucosal functional and ultrastructural abnormalities
a. Permeability
b. Na+/K+ ATPase activity
4. Psychological and environmental factors.
5. Intestinal Flora a. Mycobacterium
b. Other bacteria
c. Bacterial Constituents
6. Altered immunity to luminal antigens.
7. Inappropriate regulation of immune mediators.
Aspects of altered immune response to luminal antigens
are covered in this chapter (Bacterial antigens) and also
in chapter 2 as food antigens.
Inappropriate regulation of the immune mediators refers
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mainly to cytokine activity and this is discussed in
chapter 4.
GENETIC FACTORS
The familial incidence of IBD is 10-35% (Kirsner and
Spencer, 1963). This is many times higher than the
predicted rate by the prevalence of IBD in the general
population. There is some evidence that the risk of IBD
for females is slightly higher. The observations that IBD
is more common among people of the Jewish faith (Monk et
a 1 . . 1969 ) ,as well as family members and twins of
affected individuals have been confirmed recently (Tysk
et al., 1988) . However within Israel itself the incidence
of Crohn's disease (among Jews) is less than that found
in the white populations of USA and Northern Europe.
Ashkenazi Jews in Israel born in Europe or America are
particularly prone to Crohn's disease whilst Israel born
or non-Ashkenazi Jews are less susceptible (Rozen et al.,
1979). These reports would suggest that though genetic
factors may be important environment also plays a role.
Several rare genetic syndromes such as Turner's syndrome
and subjects with Hermansky-Pudlak syndrome show an
increased incidence of IBD (Shanahan et al., 1988).
There has been no clear association of IBD with HLA-A, B, C
and DR antigens (Smolen et al. . 1982). Extensive analysis
and summation of different studies showed an increased
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association in Caucasians of Crohn's disease with
HLA-DR2 and ulcerative colitis with HLA B27 and HLA Cw35.
In the Japanese UC was increasingly associated with HLA
B5 (Biemond et al. . 1986). An association between
Crohn's disease and HLA-DR4 has also been reported among
the Japanese (Fujita et al.. 1984).
The lack of a clear pattern of association could be
explained on polygenic influence, incomplete or variable
penetrance or difficulty with diagnosis in the less clear
cut varieties. Linkage testing, sibpair analysis suggests
that Crohn's disease and ulcerative colitis are not
single diseases, and that there are subsets of patients
who can be defined by a combination of serological
markers and molecular methods showing HLA linkage, and
that other subsets exist where this does not apply. This
would be in keeping with the findings of Lewkonia and
McConnell (1976) who concluded, in family studies, that
UC and CD have a polygenic basis and that CD would
develop in individuals with many of the relevant genes
while UC would occur in people with few of these genes.
AUTOIMMUNITY
Broberger and Perlmann (1962) described anticolon
antibodies directed against gastrointestinal epithelial
cells which also cross-reacted with Escherichia coli fE.
coli) 0:14. These antibodies were present in the sera
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from 56% of patients with UC and 67% of patients with CD.
Further work, however, proved conclusively that this was
not specific to IBD patients (Carlsson et al.. 1977).
Antilymphocytic antibodies occurred in approximately 40%
of IBD patients, 40% of household contacts, 50% of
spouses and 34% of relatives of patients with IBD
(Korsmeyer et al., 1975). As these antibodies reacted
against combinations of DRW types (reviewed in MacDermott
and Stenson, 1988) it is possible that sensitization to
DR antigens may have been involved in their development.
The high prevalence of these antibodies in unaffected
spouses makes the role of these antibodies less clear in
IBD.
More recently antibodies specific for a colonic
epithelial Mr 40,000 protein have been described in sera
of patients with ulcerative colitis but not in the sera
of patients with Crohn's disease (Takahashi and Das,
1985). This protein is located exclusively in the colonic
epithelial cells mainly along the baso-lateral domains of
the plasma membrane. It is present in normal and diseased
colon but its antibodies are found only in ulcerative
colitis. Mr 40,000 is also present in RPMI 4788 colon
cancer cells. The antibody dependent cell-mediated
cytolysis by UC sera against RPMI 4788 cells was
inhibited by anti-Mr 40,000 polyclonal antibody. This
suggested that Mr 4 0,000 protein and its antibody may be
involved in an autoimmune reaction that is important in
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the pathogenesis of ulcerative colitis.
MUCOSAL FUNCTIONAL AND ULTRA-STRUCTURAL ABNORMALITIES
PERMEABILITY
Crohn's disease patients with small bowel disease but not
those with colitis have increased absorption of orally
administered 51Cr-EDTA (Katz et al. , 1989) compared with
healthy relatives and healthy controls. However when
administered by enema 51Cr-EDTA is absorbed in higher
amounts from patients with proctitis or distal colitis
(O'Morain et al.. 1986). It is equally probable that this
may be a secondary phenomenon caused by mucosal
inflammation leading to a breakdown in the mucosal
barrier.
ENZYME ACTIVITY
Rectal mucosal sodium and potassium ATPase activity in
severe ulcerative proctitis is less than in controls. In
ulcerative colitis patients with or without rectal
inflammation and in Crohn's colitis this enzyme activity
is not significantly different from that found
in controls. The reduced ATPase activity in severe
ulcerative proctitis is probably secondary to the severe
inflammation (Edjerham et al.. 1989).
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PSYCHOLOGICAL AND ENVIRONMENTAL FACTORS
Inflammatory bowel disease patients, both those
previously diagnosed and those at diagnosis were found to
have a higher prevalence of neuroticism and introversion
than controls (Robertson et al.. 1989).
Non-smokers have been shown to have an increased risk of
developing UC than smokers (Lorusso et al., 1989); whereas
Crohn's disease patients are more likely to be smokers
(Silverstein et al.. 1989).
Environment may also play a part as shown by the reported
higher incidence of IBD in Afro-Caribbean and Indian
children living in the UK as compared to their immigrant
parents (Walker-Smith et al., 1986). A change in life
style such as diet might play an important role in this
increased incidence in these children though no definite
factors have been established yet. However the fact that
it is the offspring of the immigrants other than the
immigrants themselves who show a higher incidence
suggests that early and prolonged exposure to the
factor(s) may be important.
INTESTINAL FLORA
Some species of the intestinal microflora (Ruseler-van et
al♦, 1989) or their products (Juhlin, Krause and Shelley,
1980) may induce and maintain IBD by causing an
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unrestrained normal or abnormal immunological reaction to
themselves or unknown antigen(s). These antigens may be
persistent or ubiquitous (or both).
INTRODUCTION
In 1913, Dalziel described cases of what was then termed
chronic interstitial enteritis. He had the impression
that the enteritis was tuberculous , "even though", he
commented, "the uniform character of the affliction made
it evidently not so". Repeated microscopy and histology
was negative for mycobacteria. Comparatively the
histology closely resembled Johne's disease, a chronic
bacterial enteritis of cattle which was called
pseudo-tuberculous.
It was the absence of detectable mycobacteria that led
Crohn, Ginzberg and Oppenheimer (1932) to distinguish and
describe CD as different from tuberculosis. Grossly
and histologically Crohn's disease is very similar to
mycobacterial, Yersinia or chlamydial infections.
Ulcerative colitis is also very similar to Campylobacter
jejuni. Shigella and Cytomegalovirus colitis.
MYCOBACTERIA AND IBP
A number of workers have looked for many strains of
mycobacteria and mycobacterial antigens in Crohn's
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disease with varying degrees of success. Burnman and
Lennard-Jones (1978) reported the isolation of
Mvcobacterium kansasii from mesenteric lymph nodes of
Crohn's disease patients. Das and colleagues (1988)
detected Mycobacterium avium antigens in fresh frozen
sections of gut wall from patients with Crohn's disease.
Several recent reports suggest a role for Mycobacterium
pseudoparatuberculosis (Mptbc) (Chiodin et al.. 1984;
1989; Coloe et al..1986; Haagsma et al.. 1989; Gitnick et
al.. 1989).
There have also been a number of negative reports
regarding the involvement of Mptbc in CD (Stanford et
al. . 1988 ; Graham et al. . 1987 ;) Negative reports are
also important as the tendency among most workers is not
to report negative results. What is more striking about
Mptbc is that it has only been isolated in patients with
Crohn's disease and not those with ulcerative colitis.
Antimycobacterial therapeutic trials in Crohn's disease
Therapeutic trials as used in confirming diagnosis
of difficult cases of mycobacterium tuberculosis
have yielded conflicting results. Thayer et al. (1988)
reported promising results in an open trial when they
treated Crohn's disease patients with a combination of
streptomycin and rifabutin for 4 to 6 months. There have
also been reports of successful treatment of Crohn's
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uveitis with the addition of rifampicin to steroid
therapy and the withdrawal of rifampicin led to a
recrudescence of uveitis (Wirostko, Johnson and Wirostko,
1987). Other workers (Shaffer et al. , 1984; Rutgeerts et
al. . 1988) have not had any success with therapeutic
trials. These poor therapeutic responses must not be
overinterpreted, as even bacteriologically proven
Mycobacterium tuberculosis infections of the
intestines respond poorly to medical therapy.
Explanations for the negative results include the fact
that gut inflammation could be associated with infection
by cell wall deficient forms of Mycobacteria
('spheroplasts1) or Mycobacteria in very small fragments
such as 1 Much's granules' in small areas and in small
numbers (Stanford et al.. 1988) or indeed just persistent
mycobacterial antigens.
The response to appropriate antibiotics, as stated
above, has been at best inconclusive if not overtly
disappointing. In addition, the improvement in disease
activity with immunosuppressive drugs (steroids,
6-Mercaptopurine, Azathioprine) does not support the
idea of infection; neither does the dramatic improvement
reported in a Crohn's disease patient who developed
acquired immune deficiency syndrome (AIDS) (James, 1988).
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OTHER BACTERIA
Burke and Axon (1988) in Leeds have shown that ulcerative
colitis patients are more likely to harbour E.coli
expressing adhesins than controls. Many bacteria that
cause intestinal disease adhere to the gut mucosa and the
adhesion of pathogenic E.coli is resistant to D-mannose.
The adhesive properties of the isolates from patients
with IBD were similar to those of pathogenic intestinal
E.coli and there was a similar proportion of adhesive
isolates in patients with infective diarrhoea due to
other bacteria. This suggested that these adhesive E.coli
may be of primary importance rather than arising
secondarily. Reports of clinical improvements of acute UC
patients when treated with tobramycin which is active
against this adhesive strain of E.coli increased interest
in this organism as a potential trigger of IBD.
Vancomycin and metronidazole which have different spectra
of activity proved as ineffective as placebo
(Burke et al., 1990).
Barnes et al. . (1990) reported that Crohn's disease
patients had higher than control levels of antibodies to
Saccharamvces cerevisiae (Baker's yeast) which correspond
with disease activity . These workers suggested that this
Baker's yeast may be important in the aetiology or
exacerbation of Crohn's disease.
Carrageenan, a product of red seaweed used as an
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emulsifier in food products such as chocolate, milk and
toothpaste, has been found to cause ulcerative colitis
like lesions in the guinea pig when given orally. This
experimental ulcerative colitis only occurs in the
presence of endogenous flora especially Bacteroides
vulgatus (Onderdonk, Bronson and Cisneros, 1987). This
may be a species-specific phenomenon as the combination
of these two factors has not been reported to cause
ulcerative colitis in man. Such reports suggest however
that a different combination of substances and bacteria
may apply in the case of the human disease.
Crohn's disease patients have a higher anaerobic bacteria
load including Bacteriodes species (especially
B.vulgatus), Eubacterium and peptostreptococci than
healthy controls. It is also noteworthy that recurrences
of active Crohn's disease occur consistently proximal
to the ileocolic anastomosis post resection. This is
invariably the area with higher microflora counts.
Pouchitis occurring after total colectomy in patients
with UC appears to be related to overgrowth of anaerobic
bacteria as metronidazole is frequently effective. In
contrast pouchitis is virtually non-existent after total




Direct injury to the gut could result from toxic cell
wall polymers produced by certain species of Eubacteria
(Wensick et al. . 1983). Both commensal and pathogenic
bacteria produce potent inflammatory molecules such as
lipopolysaccharide (LPS), peptidoglycan-polysaccharide
(PG-PS) and N-met-peptides including formly-methy1-
leucyl-peptides (Chadwick et al., 1988).
Lipopolysaccharide and PG-PS are among the most active
inducers of IL-1, TNF and other cyokines. These bacterial
products work synergistically, LPS primes macrophages and
polymorphonucleuocytes for triggering by f-met peptides
and LPS, while heterologous PG-PS or LPS reactivates PG-
PS induced inflammation (reviewed by Sartor, 1989) .
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IMMUNOPATHOGENESIS
Once immune activation has taken place established
effector immune mechanisms of tissue injury may come into
play. These are discussed below.
MECHANISMS OF TISSUE INJURY
ANTIBODY MEDIATED ENTEROPATHY
There is no evidence that IgE antibodies are important in
IBD immunopathology. Circulating IgE levels in IBD are no
different from healthy controls ( Kruis et al., 1981).
Immune mediated cytotoxicity may be involved either
directly or indirectly in IBD tissue injury.
The immune system may directly recognise and aim any of
its several effector mechanisms against a particular
antigen on the gut epithelium. This would apply to
the Mr 40,000 protein component of human intestinal
epithelium described by Takahishi and Das (1985) as
discussed above. The antibody to Mr 40,000 can be
adsorbed with ulcerative colitis mucosa and could
therefore be involved in cytotoxicity against colonic
epithelial cells. This is supported by some experiments
which show that antibody dependent cell cytotoxicity may
be directed against epithelial antigen (Shorter, McGill
and Barn, 1984). However, this cytotoxic reaction occurs
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only with colonic and not small bowel epithelial cells
even in patients with Crohn's disease limited to the
small intestine. Furthermore these results should be
interpreted with caution as freshly isolated epithelial
cells are labile and are unreliable as targets. The role
of this mechanism of tissue injury remains unresolved.
The immune system may cause tissue injury indirectly.
Cyotoxicity may occur when the mucosal tissue, while
not being the target of the immune response itself, is
damaged by an expanded inflammatory response that results
from the specific antibody-antigen reaction in the lumen.
IMMUNE COMPLEXES
Immune complexes have also been implicated in the
immunopathogenesis of IBD. Elevated levels of
antigen-antibody complexes are found in the blood of
patients with IBD (Doe et al.. 1973; Richens et al..
1982). Immune complexes can activate complement and there
is evidence of increased levels of activation products
(Teisberg & Gjone, 1975) and increased catabolic rates of
C3 and Clq in IBD (Potter et al., 1979) both indicating
complement activation.
Local deposition of terminal complement complexes
on intestinal epithelium has been reported in IBD
(Halstensen et al.. 1989).
Elmsgreen et al. (1985) studied in vitro the chemotactic
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activity of peripheral blood from CD patients and their
clinically unaffected first degree relatives.
They observed that in a subset of the affected, 38% of
patients and 18% of their relatives showed abnormal
generation of chemotactic activity and decreased
utilization of C3 by the alternative complement pathway.
The proposal by Wakefield and colleagues (1989) that
multifocal gastrointestinal infarctions mediate Crohn's
disease is consistent with complement-mediated disease.
Contrary to the above findings, Danis et al. (1984)
suggested that the levels of circulating immune complexes
in IBD are comparable to those observed in control
patients with other gastrointestinal conditions such as
peptic ulcers, implying that immune complexes and
complement may represent a common effector mechanism
rather than a primary defect.
CELL MEDIATED IMMUNITY
Cell, tissue, and cytokine studies have indicated an
important role for T cells in the pathogenesis of IBD. T
cell activation with anti-CD3 in organ culture of human
fetal jejunum led to villous atrophy and crypt cell
hyperplasia (MacDonald and Spencer, 1988), features which
have been demonstrated in the mucosa adjacent to aphthous
ulcers in Crohn's disease (Entrican, Busuttil and
Ferguson, 1987).
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The role of cellular immunity and the actions of various
cytokines are discussed in chapter 4.
SUMMARY
In summary, a picture begins to emerge of IBD being
dependent on the interactions between host responses, the
nature and quality of antigens, the site of challenge,
immunologic and genetic influences.
The probable course of events then would be as follows.
Firstly that the gut mucosa is exposed to yet unknown
antigen(s) (which may be microbial or dietary) and
probably early in life. Due to this antigen exposure
of the 'immature' immune system, or as a result of the
genetic status of the individual, an enhanced immune
reaction directed against the antigen is mounted. If this
antigen is expressed on the host tissue or shares epitopes
with the host tissue then the host tissue becomes a
target of the effector mechanisms (Alun Jones et al. ,
1985; Takahashi and Das, 1985). On the other hand the
host tissue may receive 'bystander damage' as a result of
the upregulated immune response and inflammation against
an unrelated antigen without itself being a direct target
(Broberger and Perlmann, 1959). Failure to clear the
stimulating antigen results in a persistent state of
upregulation. Under this scheme differences in
manifestation either as CD and UC would then depend on
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the site, nature and distribution of antigen(s).
The state of upregulated immune responsiveness could then
act as an adjuvant for any subsequent antigens to which
the host is exposed be they dietary, microbial or viral.
Hence the numerous reports of higher levels of antibodies
to various antigens found in IBD sera (Taylor and
Truelove, (1961); Barnes et al.. 1990; Koninckx et al..
1984 and Chapter 9).
The primary trigger of the intestinal immune
response could be a pathogen like the recently discovered
bacterium legionella or maybe IBD is a series of
diseases with some subsets induced and maintained by
infection and others of different aetiologies (Mayer,
1990). The absence of specific criteria for diagnosis,
which compounds the research obstacles, may be due to
the possibility that in reality IBD is a spectrum of
syndromes with considerable overlap in clinical symptoms,
signs, endoscopic appearance and histology.
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SECTION IB;
FOOD ANTIGENS AND THE GUT
INTRODUCTION
The gastrointestinal mucosa is under constant exposure to
various resident and 'traveller' antigens such as foods,
bacteria, parasites and viruses. Normal mucosa absorbs
food in forms and quantities able to induce an immune
response (Husby et al.. 1986), and perhaps higher amounts
cross inflamed mucosa (Jackson et al., 1986). This immune
response can take the form of a local production
of secretory IgA, a systemic immune response or
immunological tolerance.
ANTIGEN UPTAKE AND PRESENTATION.
In the small intestine the preferential sites for antigen
uptake are the Peyer's patches. Peyer's patches have a
specialised epithelium containing M (membranous) cells
that transport soluble or particulate antigens intact
across the epithelium to the lymphoreticular cells of the
dome region of the patch. Antigen can also cross the
mucosal barrier by entering lamina propria between
epithelial cells (persorption), by villous uptake or
active uptake via endocytosis or receptor mediated
mechanisms (Nicklin, 1987).
Epithelia of Peyer's patches, like small bowel epithelia,
express MHC class II molecules on the basolateral surface
(Mayer et al., 1991). These class II molecules may be
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involved in antigen presentation.
MUCOSAL EPITHELIAL SURFACE ANTIGENS
The demonstration of MHC class II antigens on the
basolateral membranes of human and rodent intestinal
enterocytes (Wiman et al.. 1978; Scott et al.. 1980)
raises the possibility that these cells may play a part
in antigen presentation. The expression of HLA class II
molecules is increased in IBD (Smolen et al.. 1982; Mayer
et al.. 1991). It is possible that this may lead to
enhanced presentation of 'self' or foreign antigen.
During inflammation colonic T cells release gamma
interferon (IFN-r) which induces class II MHC expression
on colonic epithelial cells. This increased class II MHC
expression leads to increased presentation of antigen to
the local T helper cells.
Other candidate antigen presenting cells in the gut
include dendritic cells, macrophages and B lymphocytes.
Activated but not resting B cells can take up and present
antigen in conjunction with class II MHC molecules, an
ability which is also heavily dependent on the LFA-1
molecule for cell to cell adhesion (Metlay et al. . 1989).
As only activated B cells can sensitise T cells their
role as antigen presenters is confined to the secondary
responses. Dendritic cells express high levels of MHC
class II products and may be involved in the primary
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response.
In healthy intestinal mucosa the overall result of
contact between gut mucosa and antigen leads to immune
exclusion, tolerance or a limited immune reaction. On the
other hand, aberrant expression of MHC class II products
on epithelial cells may trigger a persistent upregulated
immune inflammatory response as seen in IBD. Once T cells
have been sensitised and have become memory cells,
presentation of the antigen-MHC complex is enough to
trigger an immune response unlike resting cells that
require a second signal.
INTERACTIONS BETWEEN SYSTEMIC AND MUCOSAL IMMUNITY
Food antigens once in systemic circulation and peripheral
lymph nodes are processed in the normal way and can lead
to an immune response.
There is also an interaction between mucosal and systemic
immune responses. T lymphocytes and B lymphocytes primed
in the gut associated lymphoid tissue circulate through
the systemic circulation as they disseminate to other
mucosal sites. During this dissemination activated cells
produce antibody as well as cytokines. Mucosal derived
lymphocytes tend to home back into mucosal tissue.
One factor associated with this homing property of
lymphocytes is their possession of homing receptors for
endothelial determinants ('vascular addresins') that are
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tissue specific (Jalkanien et al., 1986).
HUMORAL IMMUNITY IN IBP
The hypothesis that there is an aberrant immune response
in IBD patients is supported by the finding of higher
in vitro secretion of IgG and IgM immunoglobulins by
intestinal mononuclear cells of IBD patients compared to
healthy controls (Macdermott et al. , 1981). Baklein and
Brandtzaeg (1975) reported that compared with control
specimens IBD mucosa has 30 times greater numbers of
IgG-containing cells and 5 times greater IgM-containing
cells. In ulcerative colitis these are mainly in the
IgG1 and IgG3 subclasses and in Crohn's disease the rise
in the number of cells involves all subclasses with
a predominant rise in IgG2» Whether these changes are
primary or secondary remains to be resolved. Both IgM and
IgG can activate complement and this can have deleterious
effects on the gut lumen. There have been a few reports
of food antibodies in IBD and these are discussed below.
FOOD ANTIGENS AND ANTIBODIES IN IBD
The evidence for the involvement of diet in
inflammatory bowel disease is patchy and circumstantial.
Yet as early as 1771 Sir George Baker addressing the
Royal College of Physicians in London gave a case report
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of a patient, Thomas Wood 'A miller of Billericay' whose
abdominal symptoms improved by a diet of 'sea biscuits
and salt water' (Drummond and Wilbraham, 1959). Early
this century the possibility that an aberrant immune
response to dietary antigens caused ulcerative colitis
was being seriously considered (Allchin, 1909).
Andresen (1925,1953) was among the first to mention an
improvement in ulcerative colitis patients when they
avoided a specific food - cow's milk. Taylor and Truelove
(1961) went on to show that this was different from
lactase deficiency and reported that these patients had
higher serum antibody titres to milk antigens compared to
normal controls. There have been many confirmatory
reports of raised serum antibody titres to cow's milk
proteins in UC since (Barnes et al.. 1990; Lerner et al..
1989; Knoflach et al.. 1987). Some workers have not found
the antibody levels to food antigens to be raised (Jewell
and Truelove, 1972). My work has shown that patients with
Crohn's disease and not ulcerative colitis have higher
antibody titres in intestinal secretions to ovalbulmin
and gliadin compared to controls but there were no
differences in serum antibody levels (see Chapter 9).
Ginsberg and Albert (1989) reported a case of a patient
with steroid dependent Crohn's disease who responded to
a milk exclusion diet with improvement in the appearance
of the small intestines on X-ray. Whereas he did not
react to a conventional lactose challenge, a challenge
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with whole milk produced severe cramping and diarrhoea
typical of his Crohn's disease. Apart from another case
report by Rowe et al. (1953), in whom avoidance of milk
led to marked improvement, cases linked with specific
single antigens in Crohn's disease are very rare.
Reports that patients with Crohn's disease consumed more
cornflakes than controls (James, 1977) have not been
confirmed by other workers (Archer, 1977; Mayberry,
Rhodes and Newcombe, 1978; Rawcliffe and Truelove, 1978).
It has also been reported that Crohn's disease
patients consume more refined sugars than healthy
controls (Thornton et al. . 1979) and that they also have
a lower intake of fibre, fresh fruit and vegetables.
These differences could be a result other than a cause of
Crohn's disease. Crohn's disease patients with narrowed
lumen, for example, may find refined foods which are rich
in sugar and poor in fibre content less likely to cause
abdominal symptoms.
Workman et al. (1984) reported that exclusion diets used
in irritable bowel syndrome can be effective in Crohn's
disease. The same group (Alun-Jones et a 1 . . 19 8 5 )
published a list of foods that most commonly aggravate
inflammatory bowel disease in which wheat and dairy
products, both common western foods, were top of the
list. They reported improvement in patients when these
foods were excluded. The improvement in the patients
reported by this group have not been reproduced in other
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centres. In support of a role for wheat probably is the
reported finding of significantly raised antigliadin
antibodies in the sera of Crohn's disease patients
compared to ulcerative colitis or controls
(Koninckx et al.. 1984).
Further evidence for the possible involvement of food
antigens in inflammatory bowel disease is the association
between early weaning and an increased incidence of UC
and CD (Whorwell et al.. 1979; Bergstrand & Hellers,
1983) .
The proven efficacy of elemental diets in acute IBD and
the prolongation of remission on exclusion diets (Jones,
1987) also adds further support to a dietary association.
This is reviewed in Chapter 5.
The exact trigger and the mechanism leading to the
initial immunological reactions in IBD remains unknown
and the amount of absorbed antigen is not of prime
importance to the magnitude of the immune response (Bruce
& Ferguson, 1986). What is surprising is the paucity of
any adverse effects seen that result from this constant
sensitisation in the normal population. The patients with
IBD may have had a breakdown in oral tolerance (reviewed
in Mowat, 1987) .
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ORAL TOLERANCE
Oral tolerance is the state of specific immunological
unresponsiveness induced by prior oral administration of
antigen. Oral tolerance is easily induced with soluble
antigens. Particulate antigens usually lead to systemic
and local immunity other than tolerance probably as a
defence mechanism against microbes (Klein and Kagnoff,
1984) . As only T-dependent antigens can induce tolerance
of the antibody response (Cowdery and Johlin, 1984), the
characteristics of the T-cells involved are discussed
below.
T CELLS IN ORAL TOLERANCE
Lymphocytes in the intestinal villous epithelium are
mainly CD8+ T cells, whereas the lamina propria harbours
mainly CD4+ T cells and B cells. The CD8+ suppressor T
cells are involved in the induction of oral tolerance as,
in the murine model, oral tolerance can be prevented by
depleting suppressor T cells with cyclophosphamide or
2'-deoxyguanosine (Mowat et al. . 1982; Mowat, 1986).
Helper T cell anergy but not T cell clonal deletion may
also play a prominent role in B cell (humoral) tolerance
(Vives et al. , 1980) . Cell mediated and not humoral
immune responses are suppressed consistently by adoptive
transfer of suppressor T cells (Richman et al.. 1978). In
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addition suppressed DTH responses in mice fed OVA are
much more easily abrogated by cyclophosphamide, to which
suppressor T cells are highly susceptible, than are
suppressed humoral responses (Mowat et a1.. 1982).
Overall this can be interpreted as indicating that
systemic DTH tolerance after feeding is suppressor T cell
controlled while systemic antibody tolerance results from
helper T cell anergy.
SUMMARY
The raised antibody levels specific for food antigens
could be just one aspect of an upregulated immune
response as stated in chapter 1A. Virtually all the
previous work on food antibodies in IBD has been done
looking at serum antibody levels which may not reflect
mucosal changes (O'Mahony et al..1991a).
One way of looking at an aetiological association between
antigen and disease is antigen withdrawal during active
disease and monitoring the level of immune activation
markers with disease remission. This thesis addresses
this problem in a variety of ways.
One approach was to look at the secretion of antibodies
at the single cell level and since there is continuous
traffic of lymphocytes between mucosal tissues and
systemic circulation, antibody producing cells to food
antigens could be enumerated in the peripheral blood by
29
an enzyme liked immunospot technique (ELISPOT). This
method is described in chapter 6B. The other approach was
to look at the levels of food antibodies in the sera of
patients with IBD compared to controls and also to
monitor the changes in the serum levels of food
antibodies when patients were on an elemental diet.
Mucosal immunity was studied by similar assays in whole
gut lavage fluid (WGLF). This technique of studying
mucosal immunity is discussed in chapter 6A.
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CHAPTER TWO:
GASTROINTESTINAL IMMUNOGLOBULIN A ACTIVITY
SECTION 2A:
STRUCTURE. REGULATION AND FUNCTION OF IaA
INTRODUCTION; THE IMMUNOGLOBULIN A SYSTEM
Immunoglobulin A (IgA) is the most abundant
immunoglobulin in the normal gastrointestinal tract
(Tomasi et al., 1965). In the normal intestinal juice
95% of the IgA is secretory IgA (slgA) with only a small
amount of polymeric forms of IgA (Delacroix et al. ,
1982) .
THE STRUCTURE OF SECRETORY IGA
Mucosal plasma cells synthesize predominantly dimeric IgA
(Mestecky et al.. 1983) bound together by the 'J' chain
(Kutteh, Prince and Mestecky, 1982). The J chain, binds
the two IgA monomers together by disulphide bonds via the
Fc portion (Brandtzaeg, 1976 and 1983).
The secretory component (SC) is mainly produced by
columnar cells of the crypt of LiberkUhn in the
small intestine and decreases in concentration in the
epithelium covering the villi (Mostov and Blobel, 1982) .
Secretory component is covalently linked by disulphide
bonds to one of the monomers forming the dimeric IgA
(Underdown, De Rose and Plaut, 1977). There are two
types of IgA, IgAl and IgA2. There is a higher proportion
of IgA2-producing cells in secretory tissues than in
systemic lymphoid tissues (Kett et al.,1986).
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THE REGULATION OF IaA ISOTYPE SWITCHING
There are mainly two broad theories on the mechanism of
IgA isotype switching. One theory as suggested by Cebra
and colleagues is that IgA isotype switch was an antigen
driven process independent of other cells. This would
apply in the mouse where the genes of the IgA
are
constant domain^the most downstream.In this case repeated
antigenic stimulation would progressively lead to
selection of more downstream heavy chains culminating in
the IgA chain (Gearhart and Cebra, 1979; Gearhart,
Horwitz and Cebra, 1980).
The argument against this theory is that if the switching
was sequential then IgG expressing B cells would develop
into IgA expressing B cells. This is not the case, IgG
B cell development is independent of IgA B cell
development. Secondly whereas in mice there is only one
immunoglobulin A chain at the most distal end of the
immunoglobulin heavy chain gene sequence, humans have two
immunoglobulin A genes, one in the middle and one at the
end of the sequence (Flanagan and Rabbitts, 1982).
The other theory is that other cells (T cells or
dendritic cells) control B-cell isotype switching either
by direct contact or via the controlled secretion of
cytokines.
Kawanishi, Salzman and Strober, (1983) showed that clonal
cell populations derived from murine Peyer's
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patches induced LPS activated slgM-positive B cells to
differentiate into slgA-positive B cells. Cloned cells
derived from the spleen induced differentiation into
slgG-positive B cells. They suggested that T cells from
Peyer1s patches induced the direct switch to the IgA
isotype.
Spalding and Griffin (1986) showed that bone-marrow
derived pre-B cell lines cultured with IL-3 could
differentiate into IgA expressing B-cells when cultured
in the presence of T cell-dendritic cell clusters derived
from mucosal follicles, but not if cultured with similar
clusters derived from the spleen. Dendritic cells and
not T cells had to be of Peyer's patch origin for
differentiation of IgA expressing B-cells. More recent
work has suggests that cytokines and not cell types may
control isotype switching.
Cytokines in IoA-isotype switch.
There have been reports that when transforming growth
factor-B (TGF-B) is added to LPS-stimulated B cells
there is enhanced secretion of IgA and suppressed IgM and
IgG secretion (Coffman et al.. 1989; Kim and Kagnoff,
1990a,b). The secretion of IgA was enhanced if IL-2 or
IL-5 were present in the LPS stimulated B-cell culture
(Lebman, Lee and Coffman, 1990).
Arguments against this are that these effects of TGF-B
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have only been shown under LPS and not under antigenic
stimulation and only a small proportion of cells were
induced to IgA synthesis. There have been no in vivo
experiments in support of this finding and the levels
of TGF-6 in mucosal follicles is similar to that in
non-mucosal lymphoid tissue. The possible explanation
for the high IgA in the gut is that TGF-6 is secreted in
the inactive form that requires proteolytic cleavage to
be activated. This is achieved in the intestinal lumen by
the presence of large quantities of proteolytic enzymes
of bacterial origin. Another possibility could be the
requirement of intense antigenic activity such as
the presence of mitogenic substances like LPS which are
abundant in the gastrointestinal tract. There may be
other local factors involved as these theories do not
cover all other mucosal surfaces with high IgA. There is
now little doubt that cytokines are involved in IgA
isotype switch, although the actual mechanisms has not
been elucidated.
FUNCTIONS OF COMPONENTS OF SECRETORY IqA
The role of secretory component
The secretory component is found on the basolateral
surface of intestinal epithelium (Mostov and Blobel,
1982) and serves as a carrier molecule of dimeric IgA
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across the epithelium into the lumen (Brandtzaeg, 1981).
It also confers resistance to dimeric IgA against
proteolytic enzymatic degradation (Lindh, 1975). In
addition the higher proportion of IgA2 which is more
resistant to bacterial proteases (Plaut, 1983) in the
intestinal secretions, approximately 35% compared to 28%
in serum (Jonard et a 1 . . 1984) ensures increased
stability. Haneberg (1974) showed that there was still
slgA antibody activity after passage of the antibody
through the infant gut.
Immunomodulation
Besides this higher resistance to proteolysis there are
other features that make secretory IgA more suited to the
mucosal surface. It can bind antigen without activating
the classical complement cascade (Boackle, Pruitt and
Mestecky, 1974). Secretory IgA does not bind to or
stimulate mast cells, basophils or platelets as other
classes of immunoglobulins do, though it can bind via
specific receptors for the Fc-a to neutrophils, monocytes
and some subpopulations of T and B cells (Fanger et al. .
1980). In this way, by binding antigen in the gut lumen
it can exert immune exclusion without triggering any
adverse inflammatory response. Even in the presence
of other classes of antibodies IgA may dampen the
inflammatory response as was shown by Eddie, Schulkind
35
and Robbins (1971) . They reported that lysis of
Salmonella by serum IgM and IgG antibodies was inhibited
by the addition of intestinal slgA antibodies. They
postulated that this inhibition was a result of these
antibodies being replaced by slgA via direct competition.
Immune exclusion
There is experimental evidence in animal studies that
slgA inhibits absorption of antigen (Swarbrick, Stokes
and Soothill, 1979) but evidence in humans is lacking. It
can be inferred, however, from the higher incidence of
atopy in IgA deficient individuals (see below) that a
similar mechanism applies. This must be taken with
caution as loss of 'immune exclusion' capability even
without reduced absorption could account for increased
antigenic exposure which may be a major factor in atopic
conditions.
The 'protective' role that slgA plays is quite apparent
and it would be expected that any dysregulation of this
system could lead to gastrointestinal disease.
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IMMUNOGLOBULIN A AND INFLAMMATORY BOWEL DISEASE (IBP)
Immunoglobulin A activity in IBP
Reports on the levels of IgA in IBD have been
conflicting. Studies of immunoglobulin production and
secretion in vitro by mononuclear cells from involved
mucosa have been reported as showing diminished IgA
levels compared with normal controls (Bookman and Bull,
1979; MacDermott et a1.. 1981; Wu et al.. 1989). Marteau
et al. (1990) also reported decreased levels using an in
vivo method. The latter group collected jejunal fluid
samples from 9 Crohn's disease, 5 ulcerative colitis and
11 normal controls during segmental jejunal perfusion
under an occluding balloon and determined the in vivo
jejunal secretion of polymeric IgA. They found a 50%
reduction in the level of polymeric IgA secreted from
normal uninvolved jejunal mucosa of Crohn's disease
patients compared with normal controls or patients with
ulcerative colitis. In contrast, using the same system,
Jones et al. (1976) reported normal levels of secretory
IgA in patients with Crohn's disease, though the failure
to prevent contamination of jejunal fluid by saliva or
pancreatic secretions was an important flaw in the
design of their study.
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Mucosal IgA containing cells in IBP
Immunohistochemical studies have also yielded contrasting
results. Reports of high numbers of igA-containing cells
in lamina propria of the diseased mucosa have come from
several workers (Baklein and Brandtzaeg, 1975 and Scott
et al.. 1983). The proportion of cells producing the
less proteolysis resistant IgAl has been found to be
increased in the colonic mucosa of both ulcerative coli¬
tis and Crohn's disease (Kett and Brandtzaeg, 1987) as
has the in vitro secretion (MacDermott et al., 1986). In
IBD mucosa there is reduced expression of secretory
component (Rognum et al. , 1987), reduced production of J
chain as well as a decrease in the capacity of mucosal
IgA cells to bind cytoplasmic secretory component (Kett,
Brandtzaeg and Fousa, 1988; Brandtzaeg and Korsud, 1984).
COMMENT
The different results obtained could be due to any of the
following: differences between the methods employed in
the studies; differences in the segments of the bowel
tested, as immunoglobulin secretion rates and the numbers
of mucosal plasma cells differs between different sites
of the intestine (Brandtzaeg et a 1 . . 1987); or the
transient changes in the level of immunoglobulins with
time as reported for serum in children
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(Klemola et al., 1988). However in adult populations IgA
activity within individuals is more constant as shown in
this study (chapter 10, Figure 10:2C). Furthermore,
isolated lamina propria lymphocytes may not be
representative of the proportions in the tissue. The
process of cell isolation includes treatment of the
tissue with various enzymes (Bookman and Bull, 1979)
which might interfere with subsequent cell function. In
addition when experiments are done with diseased tissue
one cannot exclude the possibility that the changes
observed are secondary rather than primary.
CONCLUSION
The ability of secretory IgA to bind antigen and perform
many immunoglobulin functions, but not to activate
complement is a very advantageous adaptive mechanism for
the gut. It ensures beneficial immune activity without
deleterious local inflammation. The concentrations of
secretory IgA in healthy individuals and IBD patients may
be related to levels of cytokines involved in the IgA
synthesis. However the reports of the levels of cytokines
in IBD have also not been consistent. This is discussed
in chapter 4. This inconsistency could be because of the
heterogenecity of IBD in terms of regional distribution
of disease as well as disease activity. These factors are
taken into consideration in this thesis.
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In this thesis, chapter 8 examines the levels of
secretory IgA and total IgA in whole gut lavage fluid
(see chapter 6A, Materials and Methods) in controls and
patients with IBD as well as the association between
disease activity and these immunoglobulins.
40
SECTION 2B!
ELISPOT - A METHOD FOR SINGLE CELL
SECRETORY STUDIES!
INTRODUCTION
Measurement of titres of antibody in fluids such as serum
or whole gut lavage fluid does not necessarily reflect
immediate secretory activity but is a sum total of
accumulation of secreted and circulating antibody
activity. This level is therefore influenced by the half
life of the antibody, tissue deposition, inhibitors in
the assay as well as the effect of clearance mechanisms
such as the reticuloendothelial system. Therefore the
detection and enumeration of cells secreting antibodies
usually provides additional information.
HISTORY
Jerne and Nordin (1963) were the first to develop a
method for studying single cell antibody secretion, the
•haemolytic plaque' assay. A similar method was described
around the same time by Ingraham and Bussard (1964).
Jerne and Nordin incubated, in an agar layer, a mixture
of sheep red cells (SRBC) with lymphocytes from rabbits
immunised with SRBC. In the presence of guinea pig
complement distinct "plaques" - areas of SRBC haemolysis
appeared around lymphoid cells. They attributed this to a
haemolysin produced by the individual lymphoid cells.
This haemolysin, was antibody to SRBC which had fixed
complement and caused the haemolysis.
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The assay depended on complement for lysis therefore only
cells that produced complement fixing classes of
antibodies could be enumerated directly. The ELISPOT
assay described below does not have these problems.
THE ELISPOT OR THE ELISA PLAQUE ASSAY
This method was described by two groups working
independently (Czerkinsky et a 1 . . 1983 ; Sedgwick
and Holt, 1983). It can be applied for detecting and
enumerating single cells producing any macromolecules.
Both groups applied the method initially to study
antibody secreting cells.
THE PRINCIPLE
Immunoglobulin secreting cells are incubated over a plate
coated with the relevant antigen. Only the immunoglobu¬
lins that are antibodies to the coated antigens are
immobilised at the site of secretion. Thorough washing
clears off the unbound immunoglobulins and the remaining
antibodies are visualised as spots after the sequential
addition of anti-Ig-alkaline phosphatase conjugate and
substrate. Since the concentration of lymphocytes added
is known, the proportion as well as the total number of
cells secreting the particular antibody can be calculated
(Figures 6B:1, 6B:2 and 6B:3, p!21-122).
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In essence as long as there is a purified antibody to the
macromolecule in question and the cells producing the
macromolecule can be induced to secrete it, in vitro or
in vivo prior to plating, this technique can be applied.
ADVANTAGES AND SOME RECENT APPLICATIONS OF THE ELISPOT
ASSAY.
ELISPOT is a very sensitive assay. Its sensitivity
is much higher than the indirect methods of measuring
antibody in the supernatant (Jannemieke et al.. 1988;
Holt et al.. 1984). It is also more sensitive than the
haemolytic plaque assay where the latter is applicable
(Czerkinsky et al.. 1983; Sedgwick and Holt, 1986).
Added to this is the fact that the plates once developed
can be stored for months to years without fading as long
as they are blocked with 3M NaOH.
As a result of the easy application of ELISPOT, the assay
has been used to enumerate antibody-secreting cells
(Held et al.. 1989; Czerkinsiky et al.. 1984), lymphokine
secreting cells (Jannemieke and Versteegen, 1988),
endotoxin secreting bacteria (Czerkinsky and
Svennerholm, 1983), cells producing antibody to
viruses (Lee et al., 1989).
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SUMMARY
The ELISA-plaque assay or ELISPOT is a versatile tool for
detecting and enumerating macromolecule secreting cells.
As the molecules are captured at the site of secretion,
the assay is not subject to dilutional or inhibitory
effects. Therefore in studying the dynamics of food
antibody levels with dietary manipulation, ELISPOT would
be expected to detect changes earlier than ordinary ELISA
(see chapter 6C). Human peripheral blood mononuclear
cells have been successfully used to study intestinal
antibody activity (Kantele et al.. 1986; Forrest, 1988;
Lycke et al., 1989 and ). In this thesis ELISPOT assay
was applied to detect changes in food antibody activity
in relation to antigen withdrawal (chapter IOC).
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CHAPTER THREE:
ALPHA-1 ACID GLYCOPROTEIN IN IBP
INTRODUCTION
Alpha-1 acid glycoproteins, sometimes called mucoproteins
or seromucoids are carbohydrate-protein complexes.
Alpha-1 acid glycoprotein (a-lAP) is mainly derived from
the liver as part of acute phase response (Greenspan,
1955; Werner, 1949). It is therefore probable that it can
reach the gut via the bile duct.
INDUCTION OF a-1 ACID GLYCOPROTEIN
Synthesis and secretion of a-lAP is induced by the
sequential activities of IL-1, IL-6 and TNF-a
(Figure 3:1). Whereas many cell types can produce any one
of these cytokines, in combination they are secreted
mainly by activated macrophages (Emery and Salmon, 1991).
THE FUNCTION OF a-1 ACID-GLYCOPROTEIN
The exact function of a-lAP is unknown. It is an
acute phase protein and is reported to be one of the most
reliable indicators of acute inflammation (Peters, 1980).
a-1 acid glycoprotein is increased in chronic
inflammatory disease, infections and malignant conditions
(Schmid, 1975). Pregnancy and intake of contraceptives
decreases the levels in serum by up to 15%. Low levels
have also been recorded in hypoproteinaemic states such
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Figure 3:1
THE a-1 ACID GLYCOPROTEIN CHAIN










When T cells are activated they produce and secrete IL-2 and IFN-y
which activate macrophages. Activated macrophages produce and
secrete IL-1a and p, TNFa and IL-6, a combination which leads to
increased hepatic synthesis and secretion of a-1 acid glycoprotein.
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as malnutrition, nephrotic syndrome and cachexia (Peters,
1980) . In addition, serum levels of a-lAP vary from day
to day in an individual (Statland et al.. 1976). It is
not surprising therefore that there has been some debate
as to what the normal values are (de la Hueuerga et al.,
1956; Lockey et al.. 1956; Schulze and Heremans, 1966).
ALPHA-1 ACID GLYCOPROTEIN AND INFLAMMATORY BOWEL DISEASE
There have been a few published reports suggesting that
a-lAP is raised in inflammatory bowel disease (Cooke et
al. . 1958; Lubega et al. . 1990). Cooke and colleagues
(1958) studied 50 patients with Crohn's disease and 25
patients with ulcerative colitis. They reported that in
Crohn's disease the level of a-lAP correlated with
disease activity and was more predictive of active
disease than the erythrocyte sedimentation rate. Similar
observations were made for patients with ulcerative
colitis. Whereas in both groups the serum level of a-lAP
was higher than in normal controls or inactive disease
groups only the Crohn's disease results showed a negative
correlation with plasma albumin. In patients responding
to treatment there was a steady fall of the level of
a-lAP to normal.
Park et al. (1988) reported that as a measure of disease
activity in inflammatory bowel disease, a-lAP was not
impaired by the presence of malnutrition. This makes it
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a particularly useful marker of disease activity in
inflammatory bowel disease as it is not uncommon for
these patients to be nutritionally impaired.
As a predictor of acute relapse of Crohn's disease
a-1 acid orosomucoid, which comprises mainly a-lAP, was
one of the two markers found to increase two to three
months before an acute episode (Wright et al.. 1987).
As macrophage activity is increased in IBD
(Mahida et a1.. 1988) increased synthesis and
release of IL-1, IL-6 and TNF-a may be monitored via the
levels of a-lAP.
Work described in chapter 11 involved measuring the
levels of a-lAP in the sera and gut secretions of
patients with inflammatory bowel disease, and monitored
the changes in the level in sera and intestinal





THE INTERLEUKIN-2 SYSTEM AND IBP
General introduction
Cytokines are soluble factors which can modify the
behaviour and/or growth pattern of other cells (Dexter
and Moore, 1986). They are released and act typically
at a purely microenvironment level. Although various
cytokines are structurally very different they can have
similar and overlapping effects. There is an interaction
of these effects ranging from inhibition to synergism.
It is now clear that cytokines are involved in the
modulation of immune responses in inflammatory bowel
disease. This chapter is divided into three sections. The
first two sections of this chapter review the properties
of interleukin-2 and tumour necrosis factor, as these
cytokines broadly cover T cell and macrophage activity.
In section C cytokines are discussed with respect to the
gastrointestinal tract and IBD in particular.
Introduction: The IL-2 system
In the 1960's it was thought that the immune response is
controlled solely by the continued presence of antigen.
This would mean that the size of the clone responding as
well as the duration of the response would be governed by
the magnitude and duration of antigenic stimuli. In 1965
two simultaneous reports appeared which described the
first soluble mitogenic factors derived from allogeneic
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mixed leukocyte culture conditioned medium (Kasakura and
Lowenstein, 1965; Maclean and Gordon, 1965).
In 1970 Bach et al. reported that adherent non lymphoid
accessory cells released substances that were mitogenic
in culture medium. To distinguish these from lymphocyte
products, Gerry and Walksman (1972) proposed the term
lymphocyte activating factors (LAF) for lymphocyte
products and macrophage activating factors (MAF) for
products of macrophages. This section is a brief review
of the lymphocye activating factor and its receptors.
Interleukin-2: Brief History
Non-antigen driven long term culture of T cells was
achieved by Morgan, Roscetti and Gallo (1976) when they
showed that normal human T cells could be cultured for
extended periods in media that had been 'conditioned' by
growth of mitogen-stimulated human peripheral mononuclear
cells. After these reports a number of other groups
achieved prolonged in vitro culture for cytolytic T cells
to specific murine tumour antigens (Gillis and Smith,
1977a,b) and for cytolytic cells to specific human
antigens (Gillis et al.. 1978).
Baker et al. (1979) established that other T cells were
the source of this powerful mitogenic factor and termed
it T cell growth factor (TCGF). It was subsequently
renamed interleukin-2 (IL-2) at the second international
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lymphokine workshop (Arden et al. . 1979).
The structure of IL-2
Biochemical analysis revealed that all the T cell growth
promoting activity could be ascribed to a single molecule
of about 15.5 kDa (Robb and Smith, 1981). With the
subsequent isolation of its cDNA clone (Taniguchi et al.,
1983) the molecule was fully characterized as a mature
protein of 15.42 kDa encoded by four exons and separated
by one short and two long introns on chromosome 4 (Fujita
et al.. 1983; Holbrook et al.. 1984) in mice.
IL-2 can promote T cell growth only in the complete
form (Ju et al.. 1987) and its tertiary structure is
obligatory (Yamada et al., 1987) for this action.
Interleukin-2 receptors
The structure of IL-2 receptor
High affinity IL-2 receptors (IL-2R) consist of two
distinct polypeptide chains, each of which contains an
IL-2 binding site (Tsudo et al. . 1986; Teshigawara et
al.. 1987). Each molecule consists of a smaller 55kDa
chain (Robb and Warner, 1983) and a larger 75kDa chain
(Tsudo et al., 1987a). Teshigawara et al♦ (1987) called
the bigger 75kDa polypeptide IL-2a and the smaller 55kDa
polypeptide chain IL-26 to conform with the convention
followed in naming receptor systems. The problem,
however, was that Sharon et al. (1986) had named these
receptors differently calling the 55kDa, a and the 75kDa,
6. In this thesis 6-chain will refer to the 75kDa
polypeptide and a-chain to the 55kDa receptor. The 55kDa
chain is also called the tac antigen (Robb, Green and
Rusk, 1984).
The p75 (intermediate-affinity) receptor
Tsudo et al. 1986 reported the existence of a protein
that interacted with IL-2 but did not precipitate with
anti-tac. This was the 75kDa (6) chain. The 6 chain
transmits the signal for T cell proliferation without a
requirement for any input from the 55kDa (a) chain, and
some supporting evidence for this will be reviewed.
Fujii et al. (1986) added radiolabelled IL-2 in an in
vitro culture of human T cells and reported that whereas
high affinity receptors (aS) were internalised after
contact with IL-2, p55 chains were not internalised to
any measurable extent.
Wang and Smith (1987) reported that IL-2 promoted human T
cell growth and proliferation in vitro in the presence of
antibody to the a-chain and at concentrations explicable
only by its interaction with the S-chain. Natural killer
cells with only 75kDa chains on their surface also
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respond fully to IL-2 (Tsudo et al. , 1987b; Siegel
et al., 1987).
The physico-chemical characteristics of IL-2 receptors
The two polypeptide chains are not connected via a
covalent disulphide bond but interact via non-covalent
forces to form a heterodimeric high affinity IL-2
receptor. The association is dynamic and subject to the
law of mass action and dissociation. For example
when anti-tac binds to the a-chain, it disrupts the a-B
heterodimer and completely prevents binding of IL-2 to
both the high affinity receptor (a-B) or the p55 chain
but it has no effect on the 75kDa chain.
IL-2 binds and dissociates from the 75kDa chain slowly
but it has a very rapid interaction both in terms of
binding and dissociation with the 55kDa chains (Wang
and Smith, 1987; Lowenthal and Green, 1987). The high
affinity receptor (a-B) derives its fast association rate
from the a-chain and its slow dissociation rate from the
B-chain giving it a thousand fold increase in binding
affinity compared to the individual affinities of the
chains.
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IL-2 and IL-2 surface receptor density
After contact with IL-2, high affinity IL-2R expression
decreases. This is because the receptor-interleukin
complex is endocytosed into the cell where it undergoes
degradation (Fujii et al. . 1986). The reduction in the
surface receptor acts as a down-regulatory mechanism of
the immune response. Thus unless there is continued
antigen-stimulated replenishment of the receptor the
immune reaction will tend to diminish secondary to the
reduced high affinity IL-2R levels. This down-regulation
of receptor levels is one of the mechanisms for
transferring control of the immune system from external
factors (foreign antigen) alone to endogenous factors
such as other cytokines which depend on and reflect the
state of the internal millieu. Other endogenous factors
include TNF-a (Beutler and Cerami, 1988), IFN-r (Heberman
et al. . 1979), IL-4 and IL-5 (Loughnan and Nossal, 1989)
and IL-2 itself, all of which affect expression of IL-2R.
IL-2R synthesis
During an immune response activated T cells have
increased DNA transcription and mRNA translation for the
synthesis of the 55kDa chain and IL-2. The genes
for these molecules have different promoter/enhancer
mechanisms which means that they have to be activated
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separately. It is likely that they respond to a common
signal generated by the T cell receptor that subsequently
bifurcates into two separate pathways promoting the IL-2
gene separately from the 55kDa chain gene (Fujita et al. .
1986). There is only a modest upregulation of the 75kDa
chain synthesis at the mRNA level following activation
(Hatakeyama et al., 1989).
Activated B cells also express IL-2 receptors. However
there are about ten times fewer IL-2 receptors as
expressed by activated murine (Nakanishi et al.. 1984) or
human B cells than are expressed by activated T cells
of the same species (Muraguchi et al., 1985), whether
quantified by radiolabelled IL-2 or monoclonal antibodies
to the 55kDa chain.
The T cell immune response and interleukin-2
Resting T cells neither produce IL-2 nor respond to
exogenously added IL-2 (Smith et al. . 1979). Antigen is
required for the initial induction of T cell response
moving the cell from the GQ to the G-^ stage of the cycle
(Meuer et al. . 1984). Once the cell has gone into the G-j^
phase, expression of functional IL-2 receptors is the
only other variable that ultimately determines whether
the process proceeds to synthesis and cell division
and how long the clonal expansion occurs after antigen
stimulation (Herzberg and Smith 1987). Further
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cell progression is dependent on three factors; the
concentration of IL-2, the density of IL-2 receptors and
the duration of contact between IL-2 and IL-2 receptors
(Cantrell and Smith, 1983 and 1984). IL-2 promotes a
gradual and sustained increase in cell size, the
lymphocyte blastic transformation, and prepares the cell
for DNA replication (Nowell, 1960) . During this process
the density of 55kDa may increase to 5-20 fold that of
high affinity receptors (Smith and Cantrell, 1985).
Some of the p55 is shed into the surrounding fluid and
this has been termed cell free or soluble interleukin-2
receptor.
Cell free or soluble IL-2R
This receptor is a very weak binder of IL-2 and
its function remains unknown. Some of the postulated
functions of soluble IL-2 receptor (sIL-2R) are reviewed
below.
One school of thought suggests that sIL-2R acts as part
of a feedback loop. In this model, sIL-2R is thought to
bind IL-2 before IL-2 reaches its target cells thereby
blocking its physical association. The more IL-2
activated cells there are, the higher the level of
SIL-2R, the higher the block (Rubin et al., 1986).
Smith and Cantrell (1985) proposed that sIL-2R down
regulates the immune response by covering the high
56
affinity receptor sites on the cell surface, as despite
an increase in the density of SIL-2R during an
immune response, sIL-2R does not itself facilitate
internalisation.
Others have suggested that sIL-2R facilitates the
upregulation the immune response. When sIL-2 binds IL-2,
the combined molecule may be stabler than IL-2 alone
thereby enabling the IL-2 to be transported over a longer
distance and along the cell membrane. This would increase
the chance of IL-2 associating with the complete high
affinity receptor (Saito et al. . 1988) or 75kDa chain.
Contact between this loose complex and the high-affinity
cell surface receptor leads to the transfer of IL-2 to
the higher affinity cell surface receptor and thereby
releasing the sIL-2R to capture some more IL-2. This has
been called the ' Schlepper1 effect. In this way IL-2 is
directed and concentrated onto the relevant receptor
sites.
The interleukin-2 system and inflammatory bowel disease
There have been conflicting reports regarding IL-2
production by IBD mucosa. Fiocchi et al. (1984) reported
decreased serum levels of IL-2 while Brynskov and Tvede
(1990) have reported that the levels are increased in
patients with IBD compared to healthy controls. These
differences could be a result of different methodology
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as the earlier work of Fiocchi et al. (1984) used a
bioassay which may be subject to many other influences
such as the presence of antibodies or/and natural
inhibitors and antagonistic cytokines in the culture
media. Evidence so far supports an upregulation of the
IL-2 system in IBD as other reports cited below indicate.
Mahida et al. (1990) reported that there was increased
sIL-2R in the serum from peripheral and mesenteric
vessels of patients with IBD than controls. This is
supported by studies in vitro which showed that there is
increased release of sIL-2R by colonic lamina propria
mononuclear cells of IBD patients (Schreiber et al..
1991). Mahida et al. (1990) also observed that mesenteric
SIL-2R levels were higher than levels in peripheral blood
suggesting that a considerable amount of this sIL-2R was
of intestinal origin. In addition operative specimens
showed higher intestinal tissue IL-2R in the IBD
specimens compared to controls.
Mullin et al. (1991) reported that the levels of IL-2
mRNA were increased in active Crohn's disease but not
in active or inactive ulcerative colitis tissue compared
to tissues from healthy controls.
Choy et a1. (1990) examined intestinal tissue from
children with inflammatory bowel disease and healthy
controls by staining for CD4, CD8, CD3, HLA-DR and CD25.
The CD25 antigen is the 55kDa surface antigen (Tac
antigen) which functions as a receptor of IL-2 on
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activated cells. They reported that most of the CD25+
cells in the lamina propria of active Crohn's disease
were CD3+, CD4+ but CD8- (T cells) whereas the cells in
the colonic mucosa of ulcerative colitis were CD3-, CD4+
and HLA-DR+ suggesting that they were not T cells but
macrophages. Colonic Crohn's tissue stained for cells in
the same distribution as small bowel Crohn's but
the percentage of CD25+ T cells was close to that of
ulcerative colitis. These findings if confirmed would
go some way in aiding the distinction between Crohn's
disease and ulcerative colitis in the 20% of cases
where colonic Crohn's is difficult to distinguish from
ulcerative colitis.
Therapeutic implications of IL-2 system
A number of commonly used immunosuppresive or
immunomodulatory drugs act via the IL-2 system. For
example glucocorticoids suppress the immune system
through a selective inhibition of IL-2 production with
reportedly very little effect on IL-2R expression (Gillis
et al.. 1979). In acute IBD cyclosporine has been found
to act by downregulating the interleukin-2 receptor
(Brynskov and Tvede, 1990).
It is therefore conceivable that the therapeutic effect
of elemental diet in IBD is via the downregulation of the
immune response; a down regulation in the IL-2 system may
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be one of the underlying mechanisms. This may be
detectable as a fall in T cell activation markers such
sIL-2R. This question was addressed in this thesis




TUMOUR NECROSIS FACTOR AND IBP
Introduction
The name tumour necrosis factor (TNF-a or TNF) originates
from the old observation that intercurrent bacterial
infections caused necrosis of malignant tumours (Old,
1985). Late last century, the American surgeon Coley
attempted to induce tumour necrosis by treating cancer
patients with broth from the culture of Streptococcus and
Serratia organisms. This met with limited success partly
due to sepsis (Old, 1985). The factor responsible for
causing tumour necrosis was later isolated (Aggarwal et
al. , 1985) and purified (Beutler et al., 1985a and 1985b)
and termed tumour necrosis factor (TNF).
In the mid 1970's other observations were made that
rabbits infected with T. brucei, despite anorexia and
a profound wasting diathesis, showed a marked
hypertriglyceridaemia. This was a result of lipoprotein
lipase deficiency. The factor responsible for this
hypertriglyceridaemia and cachexia was called cachectin
(Rouzer and Cerami, 1980). Cachectin was subsequently
shown to be identical to TNF-a by serological and cloning
studies and by direct comparison of biological activities
(Caput et al.. 1986 and Beutler and Cerami, 1986).
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Secretion of TNF-a
TNF-a is mainly derived from macrophages. A variety of
other cells can synthesise TNF such as natural killer
cells, astrocytes, Kupffer cells , lymphocytes (Sherry
and Cerami, 1988) and paneth cells (Kesha et al. .
1990) . The human TNF gene is located on the short arm of
chromosome 6. Production and secretion of TNF can be
triggered by heterogenous stimuli such as viral, fungal
or parasitic antigens, toxins and cytokines such as IL-1
and IL-6 (reviewed in Beutler and Cerami, 1988) .
Tumour necrosis factor and receptors
There are two forms of mature TNF; one is a cell-free
variety consisting of 157 amino acids (mol. wt. 17kDa),
and the other is a 26kDa transmembrane form that remains
cell-associated acting at the local tissue level (Sherry
and Cerami, 1988) .
There are two independent cell surface receptors for
TNF-a (Durum et al. , 1991) with molecular weights of
55kDa and 75kDa. Both can be shed and occur in the
soluble form being present in the serum of healthy
individuals at surprisingly high levels (l-4ng/ml). The
soluble receptor can serve firstly as a means to absorb
and inactivate TNF spreading outwith the local area of
inflammation, secondly as an important slow release
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reservoir to maintain some background of biologically
available TNF (Fomsgaard, Svenson and Bendtzen, 1989).
These receptors may act as an immediate feedback
mechanism to mitigate the potentially harmful effects of
a sudden surge of TNF. The latter function is supported
by the fact that there is rapid shedding of TNF receptors
when TNF is released (Bendtzen et al.. 1988).
All somatic tissue except erythrocytes possess receptors
for TNF. Probably internalisation of the receptor-TNF
complex is required for cell killing but not all cells
with receptors are killed (reviewed by Beutler and
Cerami, 1988).
Physiological and cvtopathic effects of TNF in vivo
The effect of TNF on target cells include fragmentation
of DNA, generation of free radicals and activation of
target cell lysosomal enzymes (reviewed in Beutler and
Cerami, 1988).
Tumour necrosis factor has widespread effects in vivo. It
mediates endotoxic shock by promoting production of
triglycerides. The hypertryglyceridaemia resulting from
the inhibition of lipoprotein lipase may act as a
substrate for the provision of additional energy for the
upregulated immune response (Porat, 1989). Tumour necro¬
sis results probably mainly from the effect of TNF on the
vascular supply to the tumour (Carswell et al. . 1975)
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through its toxicity to the endothelial cells (Nawroth
and Stern, 1986).
Many features that occur in IBD may also be a result of
the action of TNF. Tumour necrosis factor can cause fever
(Dinarello et al., 1986), the induction of acute phase
proteins (Sipe et al. , 1987) as well as neutrophilia
(Djeu et al. , 1986) features quite in keeping with acute
IBD.
Growth failure and cachexia are features of IBD. Many
workers have suggested that these features may also be
mediated by TNF. Some of the work addressing this link is
reviewed below.
Hyams et al. (1991) have reported that the level of serum
TNF was not elevated in children with inflammatory bowel
disease. Therefore, they suggested, it could not account
for much of the growth failure in these children.
Alstead et al. (1991) found that the levels of TNF in
serum was higher in inflammatory bowel disease patients
with extraintestinal manifestations such as joint
disease. They suggested that it may then be implicated in
the pathogenesis of extragastrointestinal manifestations
of inflammatory bowel disease.
Murch et a 1. (1991) also looked at the possible
contribution of TNF to suppression of lineal growth which
affects up to 30% of patients with childhood
chronic inflammatory bowel disease. These workers found
significantly higher serum TNF levels in children with
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relapsed colonic inflammatory bowel disease than in those
with small bowel Crohn's disease. This applied despite
the similarities in the severity of relapse by disease
indices. The colonic inflammatory bowel disease group
showed a lower current growth velocity. Even within
Crohn's disease the current growth velocity was
significantly greater in the group with relapsed small
bowel disease compared to those with relapse of Crohn's
colitis. These authors while acknowledging that chronic
undernutrition is the major cause of growth failure in
children , stated that these marked differences in serum
TNF levels between the groups also played a part in the
reducing growth in the colonic group. In addition TNF
per se can cause profound anorexia (Michie et al.. 1989).
At the cellular level TNF causes metabolic changes such
as increased catabolism (Torti et al. , 1985) that lead to
wasting despite unlimited food intake (Oliff et al.,
1987) .
Source of the TNF in gastrointestinal tract
Murch et al. (1991) commented further that serum TNF in
IBD may be just an overspill from local mucosa and
therefore may represent only a fraction of the mucosal
production. Paneth cells interspersed between epithelial
cells contain TNF mRNA and they could be an important
source of mucosal TNF (Kesha et al. , 1990) . Another
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source of TNF may be activated mucosal macrophages and T
cells both of which are abundant in active inflammatory
bowel disease (Mahida et a 1 . . 1988 ). MacDonald
et al. (1990) demonstrated by an ELISPOT technique that
there were higher numbers of cells secreting TNF-a in the
gut mucosa of IBD patients compared to healthy controls.
Neguchi et al. (1991) found that the release of TNF from
active colonic IBD mucosa into the medium in an in-vitro
culture was significantly higher compared to that of
control. Results presented in chapter 13 of this thesis
show that TNF levels in whole gut lavage fluid were
highest in the group with colonic inflammatory bowel
disease.
The association between TNF and IBD pathology
Organ culture studies have shown that the presence of
activated T cells can lead to local tissue damage of
human fetal jejunum (MacDonald and Spencer, 1988) and
nearly all this cytopathic effect was due to the presence
of TNF (Deem, Shanahan and Targan, 1991). Tumour necrosis
factor has been shown in animals to induce a cytopathic
effect on bowel mucosa (Tracey et al..1988).
The granuloma formation in Crohn's disease is probably
also cytokine mediated. IL-1 (Kobavashi et al., 1985),
IL-2, TNF and IFN-r (Murray et al.. 1987) have all been
found in granulomas. This compares with infection with
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Schistosoma mansoni where there is evidence that IL-1 is
important in the initiation of granulomas in vivo while
TNF is important for the maintenance of the granuloma
(Chensue et al., 1989).
Kindler et al. (1989) for example have shown that the
bacille Calmette-Guerin granuloma is related to the local
accumulation of TNF mRNA in the granuloma. Injection of
anti-TNF antibodies suppressed this granuloma formation.
Both the cytopathic effects and granuloma formation
suggest a role for TNF in the immunopathogenesis of both
ulcerative colitis and Crohn's disease.
On the other hand care must be taken as persistently
raised TNF activity might be the mechanism by which the
gut reduces the pathogenic effects of a condition it is
incapable of clearing as discussed below (Section C).
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SECTION 4C:
CYTOKINE INTERACTIONS IN INTESTINAL
DISEASES
Introduction
A knowledge of what cytokines are involved in IBD may
be of diagnostic and therapeutic benefit. It may aid
distinction between less distinct cases of ulcerative
colitis and Crohn's colitis (see Chapters 12 and 13).
Secondly whereas other molecular mediators, such as
prostaglandins, leukotrienes, platelet activating factors
and oxygen free radicles may be of pathogenic importance,
they mainly act at the effector end of the spectrum of
inflammation. Cytokines on the other hand are involved
throughout the immune response. This section reviews the
literature on cytokines and the gastrointestinal tract
with particular reference to inflammatory bowel disease.
Mucosal T cell function and cytokines
Intraepithelial lymphocytes proliferate poorly when
stimulated with mitogen but they produce cytokines and
their production of IL-2 and IFN-t is similar to that of
mitogen activated peripheral blood mononuclear cells
(Ebert et al. , 1990) . Studies from normal non-human
primates have shown that intestinal lymphocytes have
increased expression of 55kDa chain (Zeitz et al.. 1988).
Zeitz et al. (1988) also showed that when these lamina
propria T cells are cultured with recombinant IL-2R
(rIL-2) their proliferative response was higher than that
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of T cells from peripheral blood or mesenteric lymph
nodes. The steady state level of cytokines also differs
between lamina propria T lymphocytes and systemic T
lymphocytes. In experiments done in vitro using
activation by ionophore and phorbol myristate acetate,
both mesenteric lymph node and lamina propria T cells
expressed high levels of mRNA for IL-4 and IL-5 in
comparison to cells from peripheral blood, spleen or
peripheral lymph nodes (James, Kwan and Sneller, 1990).
In addition lamina propria lymphocytes had the highest
levels of IL-2 mRNA, whereas mesenteric lymph nodes had
lower IL-2 mRNA. IFN-r was also low in mesenteric lymph
nodes compared to all other sites.
Fais et al. (1991) reported that Crohn's disease lamina
propria in an in vitro culture spontaneously released
more IFN-t than lamina propria from healthy controls.
IFN-t increases expression of MHC class II antigens on
these cells, an effect augmented as well by TNF (Adams
and Hamilton, 1987). This leads to enhanced antigen
presentation. IFN-t also leads to a decrease in the
number of suppressor T cells as well as the enhancement
of the defective natural killing ability found in
patients with IBD (Strickland et al.. 1980). Both IL-2
and IFN-t activate cytotoxic T cells and arm NK cells to
become lymphokine activated killer cells leading to their
effector functions (reviewed by Balkwill and Burke,
1989). High levels of these cytokines therefore may lead
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to enhanced immune response and subsequent cytopathic
effects.
Mucosal B cell function and cytokines
In in vitro experiments both rIL-2 and recombinant
(rIFN-r) increased immunoglobulin synthesis of pokeweed
mitogen stimulated human lymphocyte in a dose dependent
fashion. IL-2 enhanced the helper activity of mucosal
T cells (James and Graeff, 1987).
The high levels of IL-2 and IFN-r reported in IBD lead to
increased expression of both surface IL-2R and MHC class
II molecules on B lymphocytes. Both these effects are
augmented by TNF. Furthermore the lamina propria has
high numbers IL-5 producing cells as reported the in
murine model (Taguchi et al. . 1990). Interleukin-5
increases the expression of the 55kDa chain of the
IL-2R (Loughnan et al.. 1987). The overall effect is to
upregulate the ability of B cells to present antigen and
produce antibody in inflammatory bowel disease.
Cytokines and mucosal mast cells
Mast cells are a prominent feature of inflamed mucosa.
There is mast cell hyperplasia in both forms of IBD. In
vitro these mast cells displayed chemotaxis
towards laminin, a major component of basement membranes
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(Thompson et al.. 1989). The chemotaxis increased when
mast cells were stimulated with antigen. Intestinal
epithelial antigens stimulated histamine secretion from
intestinal mast cells in IBD but not in intestinal mast
cells from non-IBD patients (Fox et al.. 1987). TNF has
recently been identified as a product of mast cells and
basophils (Steffen et al., 1989).
The effect of cytokines on intestinal mucosa
Human IFN-t and IL-4 enhance the expression of
secretory component in HT 29 epithelial cell lines
(Phillips et al. . 1990). Campbell et al. (1988) reported
that individually or in combination TNF or IFN-t were
capable of destroying isolated murine B-islet cells in
vitro.
The role played by IL-1 in the gastrointestinal tract is
yet to be fully elucidated. IL-1 directly inhibited
rabbit ileal mucosa ion transport in vitro by inhibiting
sodium and chloride absorption (Chinosone, Simon
and Smith, 1990). This feature and its proinflammatory
effects suggests that high levels of IL-1 in vivo would
lead to mucosal inflammation and diarrhoea. Indeed the
serum level of IL-1 was raised in IBD patients compared
to healthy controls (Ligumsky et al. , 1990). However,
whereas IL-1 was significantly raised in the early stages
of experimental immune complex colitis induced in
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rabbits, IL-1 itself inhibited both the acute
inflammatory infiltrate and the subsequent necrosis
(Cominelli et al., 1990). Furthermore in mice IL-1
was also found to be protective in radiation induced
intestinal mucosal injury (Wu and Miyamoto, 1990). The
effect of the increased levels of IL-1 found in
inflammatory bowel disease could be to limit or repair
the ongoing damage. In IBD, the beneficial effects of
IL-1 may be limited by the presence of high levels of
IL-1 antagonists such as IFN-r (Donnelly et al., 1990),
or IL-1 natural inhibitor. The co-factor for the
production of the latter is granulocyte-monocyte colony
stimulating factor which is also raised in IBD (Mazzei
et al., 1990).
Tumour necrosis factor may also play a protective role as
shown in leishmaniasis. Tumour necrosis factor promotes
the generation of nitric oxide which is one of the
effector mechanisms for intracellular killing (Liew, Li
and Millot, 1990) .
Conclusion
The initial role of these cytokines in experimental
immune complex colitis is protective. There is however
little doubt that some of these cytokine such as TNF do
cause tissue injury as discussed in chapter 4B. Perhaps
there is an optimum TNF response level for normal
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function, so that very high or very low levels are
deleterious.If infection is the trigger for IBD then IBD
may be the result of a defect in downregulation of the
immune response after an appropriate effective immune
reaction. Persistence of the antigen may also provoke
continued cytokine production. In either case the
blocking of the inappropriately high cytokine activity
would be beneficial to the host.
As this chapter shows cytokines play a prominent role in
gastrointestinal immunology. All the work cited above has
either been done in vitro, with animal models, or in
sera. Any or all of these may not reflect accurately in
vivo intestinal immune activity. In this thesis a novel
approach was used to study mucosal T cell activity by
measuring cytokine levels in whole gut lavage fluid. The
levels of sIL-2R in the serum and whole gut lavage fluid
of controls and IBD patients are discussed in chapter 12
and chapter 13 is a study of TNF levels in WGLF
of controls and IBD patients. These factors were also
studied in patients who were prescribed elemental diet.
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CHAPTER FIVE;
ELEMENTAL DIET; HISTORY AND POSTULATED
MECHANISMS OF ACTION IN IBP
Introduction
Elemental diets (ED) are chemically defined diets
composed of glucose polymers and sucrose as a source of
carbohydrates, essential and non-essential amino acids,
minerals, lipids and trace elements (see Table 5:1 at the
end of this chapter, p88). They are also sometimes
referred to as defined formula diets, but this term
includes diets containing polymeric peptides as a source
of protein. Elemental diets provide complete nutritional
support. There is no fibre or lactose in elemental diets.
The chemical compositions of the three types of defined
formula diets are shown in TABLE 5:2.
TABLE 5:2 Compositions of three types of defined formula
diets.
Elemental 10% amino acids
85% carbohydrate
5% fat
Polymeric 15% polymeric peptides
50% carbohydrates
35% fat





The general uses of elemental diets
An elemental diet was developed for potential use in
space travel as it has a low residue. In 1965 Winitz et
a 1. tested the diet on volunteer prison inmates. As
expected elemental diet provided complete nutrition
without any adverse effects with the added advantage of a
very low residue.
The first documented use of elemental diet in disease was
by Stephen and Randall (1969). They used elemental diet
in disease because they thought it was hypoallergenic,
easily absorbed and would provide full nutrition. Stephen
and Randall treated patients with a number of high
catabolic states arising from different conditions. These
included patients with short bowel syndrome,
pancreatitis, biliary fistula, ulcerative colitis,
duodenal Crohn's disease and oesophagea1-trachea1-
pleural-cutaneous fistula. They all benefited. The use of
elemental diets in inflammatory bowel disease is
discussed below.
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Elemental diet in inflammatory bovel disease
History
Stephen and Randall (1969) used elemental diet (ED) in
patients with inflammatory bowel disease (IBD) on the
grounds that since this diet did not have any
polypeptides or other antigens, it would be
hypoallergenic to the patients. In addition it would
provide nutrition which is readily absorbed without
leaving any residue. The diet was found to be of benefit
in both ulcerative colitis and Crohn's disease improving
nutrition and decreasing disease activity.
Voitk et al. (1973) treated 13 patients for an average
of 22 days with elemental diet. All but one showed weight
gain. Occasionally indications for surgery resolved
during elemental diet nutrition. They wondered whether
this was the natural course of disease or a primary
therapeutic effect of the diet. There was also a
reduction in steroid-associated nitrogen losses in
patients on ED and a positive nitrogen balance could be
induced even in the presence of toxic reactions, without
aggravating the colonic disease process.
Axelsson and Jarnum (1977) treated 34 patients (23UC,
11CD) with elemental diet. Thirty-one of these had had
high dose prednisolone therapy 1 to 4 weeks prior to the
diet with no or insufficient response. Fifteen of the 34
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(44%) went into remission on a regime of elemental diet
alone. A further 6 (18%) showed disease remission when
steroids were added.
O'Morain, Segal and Levi (1980) studied 32 patients with
acute Crohn's who were prescribed elemental diet alone
for four weeks. Twenty-nine went into remission and they
suggested that this remission was due to the fact that
the diet did not include any antigenic molecules. They
also suggested that the diet may act by altering bowel
flora. This could be important as many workers have
shown evidence for differences in intestinal bacterial
flora between patients with IBD and healthy controls.
Matthews et al. (1980) found that the sera from Crohn's
disease had higher numbers positive agglutination results
with Eubacterium and Peptostreptococcus than sera from
healthy controls. They also reported that a complement
fixation test against Chlamydia gave more positive
reactions with sera from IBD patients than healthy
controls. Various bacteria have been implicated
as discussed in chapter 1A. It is therefore probable that
a change in this bacterial balance may lead to beneficial
effects for IBD patient.
Le Quintrec et al. (1987) showed that these diets not
only induced clinical remission but in some cases allowed
steroid withdrawal in patients with corticosteroid
resistant and corticosteroid-dependent forms of Crohn's
disease. The patients on the diets showed an increase in
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haemoglobin and serum albumin.
Controlled trials of elemental diet
Comparison with standard steroid therapy
O'Morain, Segal and Levi (1984) conducted the first
controlled randomised trial of the efficacy of elemental
diets compared to standard steroid therapy. They
randomised 21 acutely ill patients with exacerbations of
Crohn's disease into two groups. Ten received 0.75mg/kg
prednisolone and 11 received elemental diet for 28 days.
The patients were assessed at 4 and 12 weeks. In both
groups 80% went into remission by the fourth week.
Clinical improvement started six to seven days before
positive nitrogen balance was attained.
Saverymuttu, Hodgson and Chadwick (1985a) also compared
prednisolone with a combination of elemental diet and
non absorbable antibiotics in active Crohn's disease.
Both the two types of treatment led to an improvement in
Crohn's disease activity index, erythrocyte sedimentation
rate, and reduction in their excretion of radioactive
Indium labelled autologous leukocytes in the faeces.
Recently O'Keefe et al. (1989) randomised 6 patients with
acute ileal Crohn's disease to either steroid therapy or
an elemental diet. There was clinical improvement in all
six patients with reductions in ESR, platelets, and an
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increase in albumin. Both groups showed an increase
in whole body protein turnover and the rates of
incorporation of amino acids into albumin. The increase
in the rate of protein metabolism induced by steroids was
at the expense of body protein stores resulting in a net
loss of 58g in 7 days. Both groups of patients showed
reduced numbers of lymphocytes subsets, complement and
circulating immune complexes. The steroids also
suppressed in vivo IgG synthesis.
Okada et al. (1990) compared an exclusive elemental diet
with prednisolone in the treatment of active Crohn's
disease. After six weeks they found that the simple
activity index, body weight, ESR, CRP and alpha-2
globulin and radiographic findings improved significantly
in the patients on elemental diet. Even those patients
who did not initially respond to steroids improved both
in terms of their bowel lesions and clinically after
being switched to elemental diet.
The multicentre European Co-operative Crohn's Disease
Study III (Malchow et al., 1990) involving 95 patients
arrived at different results. In this trial the efficacy
of treatment of active Crohn's disease by means of a
liquid defined diet was compared with treatment with a
combination of 6-methyl-prednisolone and sulfasalazine.
By the end of six weeks the drug treatment group showed a
significant improvement of the Crohn's Disease Activity
Index (p<0.05). Further analysis of the patients who
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finished the study showed no difference between the two
groups. Their final conclusion was that drug therapy was
superior to liquid defined formula diet in Crohn's
disease. It is important to emphasise here that this
study used a protein hydrolysate-containing defined diet
and not an elemental diet in the proper sense. They chose
this form of diet because of its proven better absorption
(Smith, Arteaga, and Heymsfield, 1982) and utilisation
(Silk et al., 1980).
Elemental diet versus polymeric diets in IBP
The results of these trials comparing elemental
and polymeric diets continue to be contradictory and
therefore inconclusive.
Cosnes (1988) compared the nutritional efficacy of
elemental and polymeric nutritive mixtures in Crohn's
disease. After 28 days there was no significant
differences in weight and anthropometric measurements
between patients on exclusive enteral diet, polymeric or
elemental. Transferrin and albumin, however improved much
faster in the exclusive elemental group. This certainly
implies some additional effect on inflammation.
Giaffer, North and Holdsworth (1990) conducted a
controlled randomised trial comparing an elemental diet
(16 patients) and a protein hydrolysate containing liquid
preparation (14 patients) in patients with active Crohn's
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disease. Twelve patients (75%) receiving elemental diet
achieved clinical remission compared to only five (36%)
remission among those receiving the hydrolysed diet
(p<0.03). The fall in the CDAI in the group treated with
elemental diet was statistically significant (p<0.01).
Laboratory findings, haemoglobin, ESR, platelet
count, plasma albumin and alpha-1 acid glycoprotein and
anthropometric measurements, arm and skin fold thickness,
showed no change in either group.
Two recent trials have shown different results.
Park et al. (1991) randomised seven patients to either
the polymeric or elemental diet for 28 days. They found
no difference in the disease remission rate or indices of
disease activity between the two groups.
Raouf et al. (1991) also reported that there was no
difference between the two diets and they suggested that
the therapeutic effect could be a result of nutritional
improvement other than a specific anti-inflammatory
effect.
There are a few postulates as to the mechanism of action
of elemental diets in IBD and these are discussed below.
81
Mechanisms of action of elemental diet
Non-immunoloqical mechanisms
Bovel rest
Some practitioners believe that elemental diet works by
giving adequate nutrition to the body without taxing its
digestive and absorptive systems of inflamed gut.
Experimental evidence, however, does not support this
theory. Greenberg et al. (1988) randomised 51 patients
with acute IBD to complete parenteral nutrition (17),
partial parenteral nutrition (15) and 19 to enteral
nutrition. They reported that total parenteral nutrition
was no better than partial parenteral nutrition or
defined formula diets in inducing disease remission.
Bowel rest therefore was not a factor in inducing
remission in IBD. They also suggested that parenteral
nutrition may be disadvantageous in that it denies the
epithelial tissue enteral glutamine which might be
important for its metabolism, differentiation as well
as for tissue repair.
Non-specific nutritional effect
The suggestion that improvement in disease activity when
on elemental diets is a result of generalised improved
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nutrition (Raouf et al. . 1991; Park et al. . 1991) is not
wholly supported by experimental evidence. In the first
place polymeric diets which are better absorbed (Horibe,
1987; Smith et al.. 1982) than elemental diet are not
more effective than elemental diets at inducing disease
remission (Giaffer et al. . 1990; Cosnes et al.. 1988). In
addition whenever elemental diets are effective, the
benefit becomes apparent within 4-7 days before there
are any nutritional changes in the recipients (Teahon et
al.. 1991; O'Morain et al.. 1980; 1984; Giaffer, North
and Holdsworth, 1990). These observations make a simple
nutritional effect unlikely as a primary mechanism.
Other workers have proposed that elemental diets act by
decreasing gut permeability (Teahon et al. , 1991) and
therefore intestinal protein losses (Logan et al.. 1981).
That gut permeability decreases with elemental diet
nutrition is supported by the study by
Sanderson et al. (1987) of fourteen children with Crohn's
disease. All the children had abnormally raised
lactulose/rhamnose permeability ratios which fell
significantly after six weeks of elemental diet. This
change coincided with marked clinical improvement as
assessed by CDAI. However the change in permeability
could be the result rather than the cause of improvement.
This has been discussed in chapter 1 under permeability
factors.
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Effect of elemental diet on gut flora
The effect of elemental diets on gut flora has been
studied with varied and inconclusive results.
Menge et al. (1985) found no differences in the small
intestinal flora in rats between the group fed elemental
diet for 60 days compared to a matched control group. In
both groups there were similar numbers of aerobic and
anaerobic colony forming bacteria per ml of jejunal
juice.
Two studies, one involving human volunteers (Crowthen et
a 1. . 1973) and one an animal study (Kehoe, Harvey and
Daly, 1986) found some difference.
Crowthen et a 1 . ( 1973 ) showed that consumption of
elemental diet altered both faecal flora and faecal
steroid levels in three normal volunteers. Enterobacteria
increased while enterococci and other lactic acid
bacteria decreased in number. Numbers of Streptococci
viridans were reduced in two of the three subjects.
However the total number of organisms per gram of faeces
remained at the control value of 1010-1011.
Kehoe, Harvey and Daly (1986) reported that when
rats were given elemental diet in combination with
methotrexate small bowel luminal cultures showed an
increase in the numbers of E. coli and Pseudomonas
species. Histology showed severe small bowel mucosal
enteritis in comparison with rats on a regular diet. In
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the absence of cytotoxic drugs there was a predominance
of coliform bacteria and enterococci (Stanford et al.,
1979) .
No firm conclusions can be made from these studies
regarding the effect of elemental diet on intestinal
flora. A controlled study of a large number of human
volunteers may resolve this question.
Immunological mechanisms
Inflammatory processes may be involved in the primary
pathogenesis of IBD and there is evidence of immune
upregulation in the established disease as discussed in
chapters 1,2 and 4. The potential antigenic substances
include resident and traveller bacterial flora and their
constituents (chapter 1) as well as food antigens
(chapter 2). The changes in antibody activity, in the
complement system and cytokines (chapter 4) also adds
further support to involvement of the immune system in
IBD. Chapter 9 of this thesis addresses the question of
food antibodies levels in IBD patients compared to
healthy controls.One of the long standing theories is
that since elemental diets do not contain any potentially
antigenic material, they act as hypoallergenic sources of
nutrition. Chapter 10 describes changes in antibody
levels observed in patients on elemental diet.
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The acute lesion in IBP
There is a large infiltration of the mucosa and submucosa
with neutrophils in the acute lesion of Crohn's disease
(Saverymuttu et al.. 1985b) and ulcerative colitis
(Saverymuttu et al.. 1985c). This infiltration may be due
to the presence of chemotactic factors such as the
cytokines in the intestinal lumen (as discussed in
chapter 4). There is need for a study of cytokine activity
in IBD with respect to elemental diet therapy so as to
delineate the role of the T cell arm of the immune system
in disease response. The IL-2 system which is pivotal to
all T cell immune activity and TNF which mainly secreted
by activated macrophages can be studied as a measure of T
cell and macrophage activity respectively. The changes in
T cell and macrophage activity are part of the subject of
this thesis and are discussed in chapters 12 and 13.
Summary and conclusion
Elemental diets can induce clinical remission in IBD,
although it is not proven an immunological mechanism
probably predominates. The determination of the mode
of action of elemental diets in IBD is not without
obstacles. In the first instance there is the difficulty
of determining disease activity in IBD. Among the many
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indices the most widely used has been CDAI for Crohn's
disease. The problem with this is that the most
subjective variables such as the severity of abdominal
pain and general well being account for close to 39% of
the index and the haematocrit is the only laboratory
parameter (reviewed by Bartholomew and Shearman, 1989). A
more reliable and simple way of measuring disease
activity is the measurement of IgG levels in whole gut
lavage fluid. The development of this method of measuring
disease activity is described in chapter 7.
Whole gut lavage fluid was also used to study the
changes in secretory immunity that occur when IBD pa¬
tients are put on elemental diet. Serum provided material
for the study of systemic immunity.
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The patients studied were those under routine
medical care of the Physicians and Surgeons in the
Gastroenterology Unit of the Western General Hospital.
The diagnosis of ulcerative colitis and Crohn's disease
was based on clinical findings, radiology, endoscopy as
well as histopathology.
Controls comprised of individuals who were referred to
any of our consultants for further investigation of
symptoms and in whom no abnormality was detected and
healthy volunteers.
INFORMATION MANAGEMENT
Patient details were obtained by personal interview
as well as by reviewing patient hospital records. The
„ information was stored in data base files using a dbase
III plus programme on an IBM compatible computer. The
files contained fields such as name, date of birth,
date of lavage, drugs, smoking habit and the results of
clinical and experimental investigations.
STATISTICS
Minitab 7.2 programme was used for the statistical
analysis. Most of the work involved correlations between
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various measured parameters and ascertaining the
magnitude and significance of differences in antibody
levels or cytokine levels. The data was non-parametric
and it is presented as medians and ranges. Spearman's
correlation coefficient was used for correlations
between any two variables and regression analysis
performed to determine the significance of the
correlations. The Mann-Whitney U test was done for
comparisons between groups and Wilcoxon rank sum test
for paired data. In all the tests p < 0.05 was accepted
as significant and p < 0.01 as highly significant.
ASSESSMENT OF DISEASE ACTIVITY AND DISTRIBUTION
Disease activity was based on a number of criteria which
included clinical assessment, Crohn's disease activity
index, Powell-Tuck index for ulcerative colitis and total
IgG concentration in whole gut lavage fluid. Disease
distribution was based on radiological and endoscopic
appearances and confirmed by histology.
COLLECTION OF SPECIMENS
COLLECTION OF SERUM
Venous blood was collected from the ante-cubital veins of
the forearm using 21mm sterile disposable needles and
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disposable syringes of varying capacity (20-60ml)
(Becton-Dickinson, Dublin). Blood was drawn from all the
patients and controls into plain tubes, stored at room
temperature till clotted and then centrifuged at 1500g.
The serum was aspirated and stored at -70°C till assay
for food antibodies. Blood samples for total plasma
immunoglobulins were collected in lithium heparin treated
containers and delivered to the Western general hospital
clinical chemistry laboratories for assay.
COLLECTION OF SALIVA
Parotid salivary flow was stimulated with four 0.5 ml
aliquots of 5% citric acid sublingually over
five minutes, and saliva was collected via a
Carlsson-Crittenden cup placed over the parotid duct using
gentle aspiration to maintain both position and suction.
Only stimulated saliva was collected.
COLLECTION OF WHOLE GUT LAVAGE FLUID
After an overnight fast the patients or control subjects
were encouraged to drink 200ml of a polyethylene glycol
(PEG) based electrolyte lavage solution, Golytely
(see appendix of this section) every 10 minutes till the
material passed from the rectum became liquid, clear and
free of faecal mater. Clear liquid material was usually
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obtained within 4 hours after about 2-2.5 litres of
golytely had been ingested.
Approximately 100ml of this clear fluid was collected,
filtered twice and treated with protease inhibitors (see
appendix for details). The specimens were stored at -70°C
till assay.
COLLECTION AND ISOLATION OF HUMAN LYMPHOCYTES FROM
PERIPHERAL VENOUS BLOOD
Ten ml of blood was collected by venepuncture into a
heparinised bottle. The blood was mixed with an equal
volume of RPMI 1640 in a Universal container. The mixture
(7.5ml) was gently layered on top of 2.5 ml ficcoll-pague
in a conical centrifuge tube. The tubes were spun at 400g
for 30 minutes in an MSE bench centrifuge. The white
cells formed a layer at the interface between the
ficoll-paque below and plasma above. The white cell
layer was then aspirated into a sterilin tube and an
equal volume of RPMI 1640 with 5% feotal calf serum
added. After mixing well the cells were washed twice by
centrifuging at a high speed close to 3000rpm for 2 to 3
minutes. The cells were finally resuspended in the
medium at concentrations compatible with the planned
experiment. The yield was between 1-1.7 million cells per
millilitre of blood processed with a viability of 93-98%
by trypan blue exclusion.
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MEASUREMENT OF TOTAL IMMUNOGLOBULINS
TOTAL IMMUNOGLOBULINS IN SERUM
Total immunoglobulins of the IgG, IgA, and IgM class in
sera were assayed by the Western General Hospital
clinical chemistry department by an immunoturbidimetric
method as part of a routine hospital service. Total
immunoglobulins were reported in IU/ml. A concentration
of lOOIU/ml is equal to 1.69g per litre for IgA, 8.7g per
litre for IgG and 0.87g per litre for IgM. Plasma total
protein and albumin assays were also performed as part of
a routine hospital service.
ELISA METHOD FOR THE MEASUREMENT OF TOTAL IMMUNOGLOBULINS
IN SALIVA AND WHOLE GUT LAVAGE FLUID
Reagents
Human colostral IgA (Sigma, UK)
Goat anti-human IgA, IgG, IgM (NorthEast Biomedicals, UK)
Alkaline phosphatase conjugated Goat anti-human
IgA,IgG,IgM (NorthEast Biomedicals, UK)
Human serum standard (SPS-01) (Sheffield Protein
Reference Unit)




Test samples from patients and controls were compared to
a standard curve constructed by serial two-fold dilutions
of the human serum standard. For example for IgG and IgM
assays doubling dilutions were made ranging from
1000 - 15.625ng/ml of a human serum standard. Serial
dilutions of test samples starting with different
concentrations depending on the test material were done
(see below). A standard curve was then constructed by
plotting the log of the concentration of the standards
against the corresponding optical density (Graph 6A:1 in
appendix of this section). Only when the optical density
readings of at least two of the test sample dilutions
fell within the range of the standard was the assay
considered successful. The optical density of these two
dilutions was then used to extrapolate the immunoglobulin
concentration. The immunoglobulin concentration was taken
as the mean of these dilutions. Human colostral IgA was
used as the standard for IgA assays.
Procedure
Assays were performed in 96 well micro-titre plates
(M129A, Dynatech). All reactants were added in volumes of
0.125ml per well and all washes were done three times
using saline with 0.05% Tween-20. The details of the
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composition of the solutions used are in the appendix of
this chapter. The wells were coated with 1/5000
dilution of the goat anti-human class specific antibody
in bicarbonate coating buffer (pH 9.6) incubated
overnight and washed. ELISA diluent was then added and
left for 30 min so as to block any remaining binding
sites. After decanting, serial twofold dilutions of
standard and samples (initial dilution 1/100 for IgA and
1/25 for IgG and IgM) were added to the coated wells.
Plates were incubated overnight at 4°C and washed. Goat
class specific anti-human Ig alkaline phosphatase
conjugate diluted 1/5000 in ELISA diluent was added and
the plates were incubated for three hours at 22°C. After
washing, lmg/ml PNPP in diethanolamine (DEA) buffer, pH
9.8, was added. Plates were read at optical density of
405nm with a 630nm reference filter in an MR5000
microELISA reader (Dynatech, UK). The immunoglobulin
concentration of any given sample was determined as
described above with adjustments for the dilution.
MEASUREMENT OF SECRETORY IMMUNOGLOBULIN A IN WHOLE GUT
LAVAGE FLUID
Reagents and procedures were the same as for total
immunoglobulins except for the coating antibody which was
a mouse monoclonal anti-human secretory component (Sigma)
diluted 1/2000. The assay was done in parallel with total
IgA assays on the same plates.
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ELISA METHOD FOR THE MEASUREMENT OF IqG. IqM. AND IqA
ANTIBODIES TO OVALBOMIN. GLIADIN AND BETA-LACTOGLOBPLIN
IN SALIVA. SERA AND WHOLE GUT LAVAGE FLUID
Antigens
Gliadin (GLI; gift from Dr H. Weiser, DFA fiir
Lebensmittelchemie, Garching, Germany).
Ovalbumin, five times crystallized (OVA; Sigma, UK)
Beta-lactoglobulin (Sigma, UK)
Standard
Serum from a patient with untreated coeliac disease who
had high titres of antibody against most antigens
was used as reference standard. The standard and test
specimens were studied at suitable dilutions varying for
the different assays (see below). The plates were read
when the optical density of the standard reached 1.0 and
the results expressed as percentage of the standard.
These results therefore are non-parametric and are not




Immulon 2 plates (M129B, Dynatech) were found superior to
M129A plates used for total antibody assays as they bound
antigen more avidly.
Wells were coated with antigen (GLI, BLG or OVA) at a
concentration of 5ug/ml in bicarbonate coating buffer.
The sample dilutions were as follows; for serum IgA and
IgM antibody 1/100 and for serum IgG antibody 1/200; and
1/2 for all saliva and WGLF antibody assays. Reference
standards and samples were added to the coated wells in
duplicate. The dilutions for the reference standard were
the same as for serum except for IgM antibodies where the
standard was used at 1/10. Adsorption assays confirmed
the specificity of these antibodies and the within plate
coefficient of variation was 7.3% and the between plate
optical density variation was 11.1%.
Interpretation of results of food antibody assay
Food antibodies were measured against a serum sample
with known high antibody titres to most food antigens.
In serum, values above 10 were taken as being positive
and values for IgA above 20, IgG above 40 and IgM above
60 were taken as showing high levels.
In whole gut lavage fluid (WGLF) and saliva any value
above 10 was considered as high.
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MEASUREMENT OF ALPHA-1 ACID GLYCOPROTEIN
Principle
When human a-1 acid glycoprotein (a-lAP) reacts with
specific antibody in the presence of polyethylene glycol
(PEG), precipitating immune complexes form. If the
antibody is present in large excess, these precipitates
produce a turbidity which is related to the concentration
of a-1 acid glycoprotein in the sample. The turbidity is
photometrically measured at the wavelength of 340nm.
Absorbance readings obtained by assaying calibration
standards are used to generate a standard curve, from
which the concentration of a-1 acid glycoprotein in the
sample is derived (Lubega and Jeffrey-Davies, 1990).
Reagents
All reagents are stored at 4°C.
PEG Reagent: 40g/litre polyethylene glycol 6000
(BDH-biochemical grade) in tris buffer (0.05M, pH 7.0)
containing 2ml/litre Tween 20 and lg/litre sodium azide.
Antibody Reagent: Goat anti-human a-1 acid glycoprotein
(PRU - Sheffield UK) diluted 1/50 with the PEG reagent on
the day of assay.
Diluent: A litre of diluent comprises 9g sodium chloride,
5g gelatin, and lg sodium azide.
98
Calibration Standards: The following dilutions of the
human calibration serum SPS-01 (PRU - Sheffield) were
used for producing the standard curve: 0.18ug/ml,
0.36ug/ml, 0.73ug/ml, 1.46ug/ml, 3.65ug/ml and 7.3ug/ml.
Procedure
All standards and samples were tested in duplicate. The
antibody reagent (950ul) was added to 50ul of one of the
paired samples in 3 millilitres polystyrene tubes. To the
other sample of the pair 950ul of PEG reagent without
the antibody was added so that each sample had its own
individual blank control. The blanks and tests were read
after 15-20 minutes at 340nm using the spectrophotometer.
A standard curve was constructed (see Graph 6A:2 in the
appendix to this section) and the test sample and blank
results extrapolated from this curve. The blank value is
subtracted from the test sample reading and this is taken
as the O.D. of the sample. Only the linear part of the
curve was used. Samples that were above this level were
further diluted and reassayed.
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ELISA METHOD FOR THE MEASUREMENT OF INTERLEPKIN-2
RECEPTOR IN SERUM AND WHOLE GUT LAVAGE FLUID
Principle
The polystyrene microtitre wells are precoated with
murine anti IL-2R monoclonal antibody. Standards or
samples are introduced to the wells followed immediately
by the addition of an enzyme conjugated anti-IL-2R
monoclonal antibody. The two monoclonal antibodies
specific for different epitopes on the released p55
component of IL-2R.
The soluble IL-2R present in the standards or samples
binds to the coating antibody while the conjugated
antibody binds to a second distinct epitope completing
the sandwich. Unreacted components are removed by
washing. A chromogen is then added to the wells forming a
coloured end product that is proportional to the amount
of soluble IL-2R in the sample. A stop solution (see
below) is added to stop the reaction and absorbance read
at 490nm. The concentration of the samples are determined
from the standard curve constructed using the standards
(see Graph 6A:3 in appendix).
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Reagents
Ninety-six well microtitre plate coated with an murine
anti- human IL-2R antibody.
Horseradish peroxide (HRP) conjugated murine monoclonal
antibody to human IL-2R (T-Cell Science, Cambridge USA).
Specimen Diluent: Made up of Normal saline and 10% equine
serum proteins and 0.01% thimerosal.
IL-2R standards: These are recombinant human IL-2R in a
buffered solution with bovine serum albumin in doubling
dilutions from 3200U/ml to 50ul/ml and OU/ml.
Two control specimens: One for the low concentration and
one for the high concentration.
6. O-Phenylenediamine Chromogen tablets (Sigma. UK.).
7. Substrate Diluent: A buffered solution containing
5.3mM/L urea peroxide and thimerosal.
8. Phosphate buffered saline (PBS pH = 7.2)
9. Stop solution: 2N H2S04
Procedure
The blank wells were left empty and 50ul of standard,
high and low controls and samples were pipetted into the
antibody coated wells. HRP conjugated anti-IL-2R antibody
(lOOul) was added to all the wells except the blanks. All
assays were done in duplicate. The plates were gently
agitated by tapping, covered and incubated at room
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temperature (24 ± 2°C) for three hours on a rotator set
at 150 (± 10) rpm.
After incubation the plates were uncovered and the
solution aspirated from all the wells. The wells were
then washed 3 times and O-Phenylenediamine in substrate
diluent was added. This was allowed to incubate for 30
minutes at room temperature before the addition of stop
solution into all the wells.
Absorbance of wells was read at 490nm and if there were
any values above the range at this wave length, the
absorbance was read again at 450nm.
A standard curve was constructed using the means of
each pair of standards (see Graph 6A:3 in appendix). The
concentrations of IL-2R in the samples were extrapolated
from the standard curves. In the pilot studies a few
spiking experiments were performed, it is a costly assay.
These showed that the results were reproducible though
there was a loss of some soluble IL-2R of less than 10%
(see Table 6A:3 in appendix).
ELISA METHOD FOR THE MEASUREMENT OF TPHOPR NECROSIS
FACTOR ALPHA IN WHOLE GUT LAVAGE FLUID
The assay used for this was an enzyme amplified
sensitivity immunoassay. It is based on the oligoclonal
system in which several monoclonal antibodies (Mabs)
directed against distinct epitopes of TNF-a are used. The
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use of several distinct Mabs avoids hyperspecificity and
allows high sensitive assays with wider range and short
incubation time.
Reagents
The reagents were obtained from Medgenix (Milton Keynes,
UK.) and comprised of the following.
Ninety-six well anti-TNF coated microtitre plates.
The following concentrations were used for constructing
the standard curve 1500 pg/ml, 500pg/ml, I50pg/ml,
50pg/ml, 15pg/ml and Opg/ml in human serum and
merthiolate.
Incubation buffer: Tris-maleate buffer with 10% Bovine
serum albumin




HjOj in acetate/citrate buffer (substrate buffer).
1.8N H2S04 stopping reagent.
Washing solution 0.05% Tween 20 in distilled water.
Standards and controls were reconstituted in distilled
water. Substrate solution was made by pipetting 0.2ml of
the chromogen TMB into 21ml of the substrate buffer. A 1%
conjugate buffer was made by dissolving the conjugate
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solution (Anti-TNF-a-HRP) in the conjugate buffer (TMB
buffer).
Procedure
Standards, controls or samples (200ul) were dispensed
into the wells of a microtitre plate followed by 50ul of
the incubation buffer. The plates were incubated at room
temperature on a horizontal shaker set at 700 (± 100) RPM
for two hours.
The wells were then washed three times with 400ul of
washing solution. Incubation buffer (lOOul) was dispensed
into all the wells followed by 50ul of anti-TNF-a-HRP
conjugate. The plates were incubated again at room
temperature on a horizontal shaker as above.
After a further three washes 200ul of the freshly
prepared substrate chromogen solution was dispensed into
each well. The plates were incubated for 30 minutes in a
dark room with continuous shaking. The reaction was then
stopped with the addition of 50ul of the 1.8N H2S04.
The absorbance was read within the hour and the
standard curve plotted (see Graph 6A:4 in appendix). The
concentrations of TNF-a in the samples are extrapolated
from the curve. Spiking experiments showed that most of
the TNF could be accurately measured in whole gut lavage
fluid (see Table 6A:4 in appendix).
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APPENDIX FOR CHAPTER 6A
APPENDIX FOR CHAPTER 6A
GUT LAVAGE PROCESSING
REAGENTS
O.lg of soya bean trypsin inhibitor (SBTI; Sigma. UK)in
100ml PBS (pH 7.2)
llg 0.3M EDTA (pH 8.0) in 100ml of distilled water.
0.1M Phenylmethylsulphonylfluoride (PMSF) 1.74g PMSF in
100ml of 95% alcohol.
2% sodium azide in distilled water.
New born calf serum (NBCS)
Procedure
Collect 40ml of clear gut lavage fluid in two Universal
Containers.
Filter 15-20 ml of lavage into a test tube.
Transfer 10 ml into a Universal container.
Add the following, mixing after each addition:
1 ml SBTI; 0.56 ml of 0.3M NaEDTA; 0.24 ml PMSF; 0.12 ml
sodium azide.
Leave for two minutes
Add 0.6 ml NBCS and Mix
Dispense into 6 x 1.5ml aliquots into freezer tubes.
Store tubes at -70°C.
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SOLUTIONS
WHOLE GUT LAVAGE FLUID fWGLF)
Polyethylene glycol (GoLYTELY) (Seward Medical Ltd.
London U.K)
236g polyethlene glycol 4000 BP
22.74g sodium sulphate BP
6.74g sodium bicarbonate BP
5.86g sodium chloride BP
2.97g potassium chloride BP
This mixture is reconstituted with water to a volume of 4
litres. The final solution contains;
125mmol/L sodium, lOmmol/L potassium, 40mmol/L sulphate,
20 mmol/L bicarbonate, 35mmol/L chloride, and 17.6 mmol/L
polyethylene glycol 4000.
ELISA DILUENT
Physiological saline with 10% bovine serum albumin (BSA;
SAPU, UK) and 0.05% Tween-20 (Sigma, UK)
ELISA WASH FLUID




lOOmls Diethanolamine (DEA; BDH Ltd, UK) this is solid at
room temperature, 800mls distilled water, 0.1015g
MgCl2.H2o (BDH Ltd, UK),0.2g Sodium azide (BDH Ltd, UK).
Used at pH 8.6.
COATING BUFFER
Reconstituted by adding 900ml of distilled water to a
100ml Sodium carbonate/ bicarbonate coating buffer
concentrate at PH=9.6 (NorthEast Biomedicals, UK).
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Graph 6A:1
STANDARD CURVE FOR THE ASSAY OF TOTAL







0 1 1 ' 1 1—
Log,0 value 1.79 2.09 2.39 2.69 3
IgA ng/ml 62.5 125 250 500 1000
Graph 6A:2
STANDARD CURVE FOR THE ASSAY cc-1 ACID
GLYCOPROTEIN
Standard curve used for extrapolation of total immunoglobulins and








STANDARD CURVE FOR THE ASSAY OF TNF IN WGLF
Tumour necrosis factor alpha (pg/ml)
Standard curve used for extrapolation of soluble IL-2R levels (top)
and TNF-a levels (bottom). A standard curve is constructed wih every
assay.
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TABLE 6A83 WGLF SIL-2R SPIKING EXPERIMENTS.The table
shows mean values of the levels of SIL-2R in WGLF before
(BEFORE) addition of recombinant sIL-2R, the expected
values after addition (EXP), actual values obtained
(ACTUAL) and percentage difference from the expected
value (%Dif).
SIL-2R LEVELS WGLF(U/ml)
NAME BEFORE EXP ACTUAL %DIF
SJ 34 354 360 1.8%
RC 10 330 320 3 . 0%
SB 0.00 320 310 3.1%
All the specimens were assayed on the same plate and in
duplicate.
EXP = The expected sIL-2R level in U/ml when lOul of a
1600U/ml standard has been added (spiking) to 40ul of the
lavage fluid
BEFORE = The SIL-2R levels in the plain lavage specimens
ACTUAL = The actual levels obtained in the specimen after
spiking.
%DIF = The difference from the expected level divided
by the expected value and multiplied by 100.
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TABLE 6A; 4 WGLF TNF SPIKING EXPERIMENTS. The table shows
mean values of the levels of TNF in WGLF before (BEFORE)
addition of recombinant TNF, the expected values after
addition (EXP), actual values obtained (ACTUAL) and
percentage difference from the expected value (%Dif).
TNF LEVELS WGLF(PCT/ml)
NAME BEFORE EXP ACTUAL %Dif
RC 0.00 100 89.5 10%
CC 1.9 102 97 5%
MA 30 130 125 4%
All the specimens were assayed on the same plate and in
duplicate.
EXP = The expected TNF level in pg/ml when 50ul of a
500pg/ml standard has been added (spiking) to 200ul of
the lavage fluid
BEFORE = The TNF levels in the plain lavage specimens
ACTUAL = The actual levels obtained in the specimen after
spiking.
%DIF = The difference from the expected level divided





STANDARDISATION OF THE ENZYME LINKED IMMUNOSPOT (ELISPOT)
ASSAY
A series of experiments was set up to standardise the
ELISPOT assay (see chapter 2C) using mouse splenocytes
prior to using it to study antibody producing cells
in human peripheral blood against three common dietary
antigens; 6-lactoglobulin (BLG), ovalbumin (OVA) and
gliadin (GLI). The first experiments were done with
murine splenocytes to determine the following criteria.
1. The optimum coating surface.
2. Optimum coating antigen concentration
3. The optimum concentrations of coating antibody and
coating antigen.
4. The optimum concentration of conjugate.
5. Whether modifications to the substrate would improve
the results.
6. The best time to read the plates.
IMMUNISATION TECHNIQUE
Mice (BDF-^) (obtained from the animal unit, Western
General Hospital) were immunised intraperitoneally (i.p.)
with lOOug of one of the three dietary antigens suspended
in 50ul complete Freund's adjuvant (CFA) (H37 Ra, Difco,
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UK) . The animals also received a booster injection of
lOOug of antigen in incomplete Freund1s adjuvant seven
days after primary immunisation.
PREPARATION OF SPLENOCYTES
Immediately after sacrifice of mice by cervical
dislocation the spleens were removed and dissected free
from surrounding tissue. The spleens were then placed on
a petri dish containing ice cold RPMI 1640 medium (Flow
Labs, Irvine, UK) with 10% feotal calf serum (FCS; Gibco,
UK)
The spleens were cut into smaller pieces and the segments
passed through a wide pore sterilised gauze to remove
cell clumps and connective tissue. Clumps were allowed
to settle for 10 minutes on ice and the supernatant
suspension was transferred to clean tubes. After
centrifugation for 10 minutes at 400g, the pelleted cells
were gently resuspended and exposed for 10 seconds to
4.5ml of distilled water to cause red blood lysis and
quickly rescued with 0.5ml of iox PBS. The ensuing cell
suspensions were then washed three times in RPMI with 10%
FCS at 400g in an MSE bench centrifuge.
The cells were resuspended in 5ml of RPMI with 10% FCS.
Finally they were counted in an improved Neubauer
haemocytometer using white cell diluting fluid.
The ability to exclude trypan blue was used to determine
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cell viability. The viability was generally between 90-
95%. The cells were finally resuspended in complete
medium (see solutions) to cell concentrations found
appropriate for the individual assays.
Procedure (illustrated schematically in Figure 6B:1)
Antigen or antibody in coating buffer (pH 9.6) was added
to the wells and incubated overnight at 4°C in a 'moist
chamber'. The plates were then washed three times with
normal saline (without tween). The final cell suspensions
are made up in complete medium (see appendix) and added
to the wells in appropriate cell densities. The plates
were then incubated at 37°C in 5-10% C02 humidified
chamber for 4hrs. They were then washed with ELISA wash
(0.05% tween 20 in normal saline) and the appropriate
conjugate added followed by incubation at room
temperature for 3hrs. Unreacted conjugate was washed
three times with ELISA wash and a chromogen (5-bromo-
chloro-indolyl-phosphate) added. After about 10-20
minutes blue spots became visible and these were counted
either directly or under a low power dissecting
microscope (see Figure 6B:2 and Figure 6B:3).
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Results
Initially twenty-five well tissue culture grade plates
(Repli-dishes; Sterilin, UK) were used as the coating
surface but later 96-well microtitre plates were found to
do as well. The M129B yielded more spots than the M129A
under the same conditions (Table 6B:1 in appendix)
Experiments with different concentrations showed that the
best concentration was lmg/ml for all the three antigens
as it gave the most spots with the least number of false
positives (see Table 6B:2 in appendix).
Checkerboard experiments for immunoglobulin secreting
splenocytes were performed. The wells were coated with
varying concentrations of antibody along the rows in
triplicate. After cell incubation conjugate, was added in
varying concentration along the columns and the counts
plotted. The best results were obtained with a conjugate
dilution of 1:1000 for IgA (Graph 6B:1) and IgM (Graph
6B:2) while for IgG the best results were obtained with
1:2500 (Graph 6B:3).
The murine splenocytes were incubated at 37°C for 3hours
in 90-100% humid chamber with 5% carbon dioxide. Human
peripheral blood antibody secreting cells requires 5
hours or overnight incubation for the best results.
The substrate 5-bromo-4-chloro-3-indolyl phosphate (see
solutions) was initially mixed with agar gel to give a
0.6% solution which provided a solid base for the spots.
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The use of gel matrix for the substrate gave a few
problems. It gave artifacts which had to be distinguished
from the true spots usually by the use of a low power
magnifying microscope. The number of spots also tended to
vary with time as illustrated in the appendix (Graph 6B:4
and Graph 6B:5). The possible reasons for this include
the following; the bigger spots tend to become more
diffuse as they spread in the gel this makes them less
distinct, the smaller spots grow with time till they
become visible and therefore countable. Persistently
adherent B cell membranes may sometimes be detected by
the developing agent. The latter artifacts take more
time to develop than secreted antibody
(Hutchings et al. , 1989). Washing and using EDTA in the
wash after cell incubation can reduce the last
phenomenon. Therefore at a given time it will be the sum
total of these effects that determined the count.
Omission of agar in the substrate solution gave better
results in that they were more consistent and had
minimal numbers of artifacts (Plate B in the above Graphs
6B:4 and 6B:5).
Section 6C is an animal experiment comparing the
sensitivity of ELISPOT and ordinary ELISA.
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APPENDIX FOR SECTION 6B
APPENDIX FOR SECTION 6B
COMPLETE RPMI 1640 MEDIUM
RPMI 1640 (Flow Labs, Irvine, UK) 445 ml




This makes up a solution of 10% FCS, 0.1% glutamine, 1%
Hepes and 0.01% Gentamycin in 500ml of the complete
medium.
BCIP STOCK SOLUTION
2-Amino-2-methyl-l-propranol solution (Sigma, UK)
Triton X-405 (Sigma, UK)
5-Bromo-4-chloro-3-indolyl phosphate (5-BCIP; Sigma, UK)
To prepare one litre of stock 2-amino-2-methyl-l-
propranol buffer,
Warm neat 2-amino-2-methyl-l-propranol solution to
25-30°C. It is solid at room temperature.
Dissolve the following in 500ml distilled water:
150mg MgCl2.6H20; (BDH Ltd, UK)
lOOul Triton X-405 and 1.0 g sodium azide. (BDH Ltd,
U.K.)
To this solution, add 95.8ml (1.0M) amino-methy1-
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propranol solution with stirring and leave for about lhr.
(amino-methyl-propranol is slow to dissolve). Solution may
still be cloudy after this time.
Add distilled water to approximately 900ml and adjust pH
to 10.25 with concentrated HCl (BDH Ltd, UK).
Leave overnight at 20°C, re-adjust pH to 10.25 with HCl,
and add water to 1 litre. Filter and store.
Stock buffer will store at 4°C for at least 3-4 months
but may require refiltering with age.
The 5-BCIP substrate solution is prepared fresh at a
final concentration of l.Omg/ml.
Take desired amount of 5-BCIP and dissolve in a
small volume of stock AMP buffer, then make up to correct
volume. Filter the solution through a 0.22 or 0.45um
filter. This step is to remove any insoluble material, as
particles in the substrate may give false spots. The
resulting solution is a clear, lightish brown liquid
(colour dependent on the purity of the 5-BCIP - the Sigma
product is almost colourless).
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TABLE 6B:1 A COMPARISON BETWEEN M129A AND M129B ELISA
PLATES FOR THE ELISPOT ASSAY FOR ANTIBODY-SECRETING
CELLS.The table shows the number of spot forming cells
secreting IgM or IgG antibody specific for each of the
three dietary antigens.
Spot Forming Cells/106 splenocvtes
Type of Plate
M129B M129A
IqG IqM IqG IqM
OVA 440 1100 200 30
BLG 830 95 400 10
GLI 100 75 70 36
M129B gave higher numbers than M129A plates for all
antigens tested. This could be because M129B plates bind
antigen more avidly than M129A (Czerkinsky et al.. 1983).
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TABLE 6B:2 EFFECT OF ANTIGEN CONCENTRATION
IqG spots/106 splenocvtes
Antigen fmq/ml) GLI OVA BLG
2 35 440 800
1 38 436 1164
0.5 28 396 858
0.25 20 180 52
Optimum results, both in terms of clarity and numbers




THE ADAPTATION OF THE ELISPOT ASSAY FOR
ANTIBODY SECRETING CELLS AGAINST ANY ANTIGEN
(ie GLIADIN)
1) Coat with antigen
Wash x 3 (No azide, no tween)
2) L i i i Block with culture medium containing 10%
FCS or NCS
A M G
3) | TfT TfT ITT Add the cells and incubate
Wash x 3 with PBS tween.
A M G








in j Wash and count spots.Count of spots=counts of anti-(Gli) IgM
producing cells
121
Figure 6B;2 Showing blue spots in one of the wells in a
twenty-five well tissue culture grade plate. The blue
cross was made outside the well as a marker for the well
*
I
4 f - * h
K « *
Figure 6B:3 showing blue spots in the wells of a 96-well
ordinary ELISA plate.
%*,■ I .M ' >
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Graph 6B:1
OPTIMUM COATING ANTIBODY AND CONJUGATE
CONCENTRATIONS FOR THE DETECTION AND




























The best results were obtained with coating concentrations of 1:1000
and conjugate concentration 1:1000
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Graph 6B:2
OPTIMUM COATING ANTIBODY AND CONJUGATE
CONCENTRATIONS FOR THE DETECTION AND



























The best results were obtained with a coating concentration of
1:1000 and conjugate concentration 1:1000.
SFC = spot forming cells (immunoglobulin secreting cells)
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Graph 6B:3
OPTIMUM COATING ANTIBODY AND CONJUGATE
CONCENTRATIONS FOR THE DETECTION AND


























1:500 1:1000 1:2,500 1:5000
Coating antibody concentration
The best results were obtained with a coating concentration of 1:500
and conjugate concentration 1:2,500
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Graph 6B:4
VARIATION OF THE NUMBER OF SPOTS COUNTED
WITH TIME AFTER ADDITION OF SUBSTRATE (IgG and













Plate A = Substrate in Agar gel
- - o— Plate B = Substrate without Agar gel




















IgG - Substrate in agar gel gave higher variation in the counts
(330±66) as compared to substrate without agar gel (334±17)
IgM - Substrate in agar gel gave higher variation in the counts (31 ±7)
as compared to substrate without^agar gel (27±2)
SECTION 6C:
ELISPOT AND ELISA IN THE STUDY OF MICE
REARED ON GLPTEN-FREE OR NORMAL DIET
SECTION 6C
ELISPOT AND ELISA IN THE STUDY OF MICE REARED ON
GLUTEN-FREE OR NORMAL DIET
INTRODUCTION
There has been published work suggesting that mice
exhibit oral tolerance to wheat gliadin, a normal dietary
constituent. When compared with mice from a colony
maintained on a gluten-free diet, animals taking a
conventional mouse diet (CRM(X), containing 2.8% gliadin)
had significantly suppressed serum IgG antibody levels
and delayed type hypersensitivity responses at three
weeks after parenteral immunisation with gliadin
(Troncone and Ferguson, 1988).
It is not established as to whether these differences
may manifest earlier depending on the sensitivity of
the test and how other immunoglobulin isotypes are
affected. This experiment was aimed at addressing the
following questions;
1. What is the isotype distribution of the serum antibody
and the changes of serum antibody levels in the early
phases of the immune response?
2. How early does the difference in the serum antibody
response begin to show and when does it become
significant?
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3. Can these differences be detected earlier by ELISPOT
than by ordinary ELISA? The hypothesis was that
differences would be manifest earlier b ELISPOT than
ordinary ELISA as the former is not subject to dilutional
effects.
EXPERIMENTAL PROTOCOL
After baseline studies in unimmunised mice age-matched
female BALB/c mice from the gluten free colony (GFD)
and normal diet mice of the same strain received i.p
immunisation with gliadin in CFA on day 1 (as described
previously). On day 7, 14, and 21 after immunisation
6 animals from each group were sacrificed (as described
previously). Blood for the ELISA studies was taken from
the subclavian arteries of sacrificed mice and
splenocytes isolated (as described previously) for
ELISPOT assay. A booster immunisation without CFA was
administered on day 21 and the final 6 animals from each
group sacrificed on the 28th day and studied as above.
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RESULTS
Antiqliadin antibodies in serum
There was no difference in the base line antibody levels.
During the course of the experiment mice reared on the
GFD had higher levels of antigliadin antibodies of all
classes compared with the normal diet reared mice. This
difference became significant by ELISA at two weeks
post-immunisation for antigliadin IgA antibodies (Graph
6C:3) and by the third week for the corresponding IgM
and IgG antibodies (Graphs 6C:l-2). The significant
difference was maintained for IgA and IgM antigliadin
antibodies even a week after the booster dose.
Antiqliadin spot forming cells
There was no difference in the baseline numbers of spot
forming splenocytes. During the course of the experiment
mice reared on the GFD had higher numbers of antigliadin
spot-forming cells than normal diet reared mice. This
difference became significant within the first 7 days
post-immunisation for IgM (Graph 6C:4) and 14 days
post-immunisation for IgG (Graph 6C:5). IgA antigliadin
antibody secreting splenocytes were not detected despite
earlier successful detection in single cell suspensions
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from intestinal mucosa (NOT SHOWN).
COMMENT
This work showed that mice raised on a normal,
gliadin-containing, mouse diet have specific suppression
of their responses to parenteral gliadin immunisation in
agreement with previous work (Troncone and Ferguson,
1988).
The earliest this tolerance can be demonstrated is by the
second week using ELISA (Graph 6C:3) and as early as 7
days using ELISPOT assay (Graph 6C:4). The ELISPOT assay
detects antibody at the point of secretion rather than
diluted in serum. This finding that the ELISPOT assay is
more sensitive than ordinary ELISA is in agreement with
other reports (Jannemieke et al.. 1988; Lee et al. .
1989) . This test therefore may be more useful in detect¬
ing early changes in antibody secretory activity of B
cells than ordinary ELISA. In this thesis the ELISPOT
assay was used to compare food antibody activity in
patients before and on elemental diet.
130
Graph 6C:1
THE KINETICS OF ANTIGLIADIN ANTIBODY TITRE
LEVELS IN 'NORMAL DIET and o GFD REARED
BALB/C MICE AFTER PARENTEREAL IMMUNISATION






































Both groups of BALB/C mice were immunised with an I.P injection of
Gliadin in CFA on day 0. Serial weekly ELISA for antigliadin
antibodies were performed.
+ p<0.05 ++ p<0.01 +++ p<0.001 ++++ p<0.0001
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Graph 6C:4
THE KINETICS OF ANTIGLIADIN ANTIBODY SECRETING
SPLENOCYTES IN • NORMAL DIET AND oGFD
























Both groups of BALB/C mice were immunised with an IP injection of
Gliadin in CFA on day 0. Serial weekly ELISPOT assays were
performed. + p<0.05 ++ p<0.01
132
CHAPTER SEVEN;
GPT LAVAGE FLUID PROTEINS
AND DISEASE ACTIVITY IN INFLAMMATORY BOWEL DISEASE
INTRODUCTION
The Crohn's Disease Activity Index (CDAI), developed in
the 1970s (Best et al. , 1976), has proved a reliable and
remarkably reproducible measure of health status in
patients with Crohn's disease (CD). In theory, the CDAI
is vulnerable to criticism because it is heavily weighted
by subjective factors of general well-being and
abdominal pain, and investigators have argued that the
CDAI is not so much a measure of disease activity as of
general disability (Bartholomeusz and Shearman, 1989).
Many factors apart from intestinal inflammation
will contribute to the index, including infection,
obstruction, malnutrition, psychological dysfunction and
the side effects of drugs. Nevertheless, the CDAI, and
similar indices for ulcerative colitis (UC) activity such
as the Powell-Tuck index (PTI) (Powell-Tuck, Bown
and Lennard-Jones 1978), provide standards for the
assessment of any new approach to the measurement of
disease activity in IBD.
Whole gut lavage is now widely used as a bowel
preparation for barium enema, endoscopy, or colorectal
surgery (DiPalma et al.. 1984). The clear fluid passed
after initial colonic cleansing is essentially a gut
perfusate.
Fluid obtained by whole gut lavage normally contains
traces of IgG, albumin and alpha-l-antitrypsin; higher
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concentrations are found in patients with IBD (Gaspari et
al. . 1988; Florent et al.. 1981; Boirivant et al. 1991).
In two separate studies of patients with active IBD
concentrations of IgG were significantly higher than those
of controls (Gaspari et al.. 1988; O'Mahony et al..
1990) . There was also high concentrations of WGLF
albumin, with a positive correlation between lavage IgG
and albumin content, suggesting that these tests are
measuring plasma leakage across inflamed mucosa
(O'Mahony et al.. 1991b).
RIM OF THIS STUDY
The aims of this study were to establish whether assay of
WGLF proteins could be used as a diagnostic test for IBD
and to assess to what extent concentrations of proteins
in WGLF parallel the global indices, CDAI and PTI? Do the
results of this make it possible to grade severity within
"active" disease, or to detect minimal abnormalities in
patients with CDAI at 150 or below, or PTI at 4 or below
(i.e. classified as inactive)? Does this approach offer
any advantage over conventional clinical tests (ESR,
C-reactive protein, platelet count), or a physician's
global assessment (for the purpose of this investigation,
recorded on a VAS - as described below) ?
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SUBJECTS AND PROTOCOL
A total of 46 patients with IBD were studied, 28 with CD
(11 male, 17 female), 18 with UC (8 male, 10 female).
The diagnosis and disease extent in all patients were
confirmed by histology, endoscopy and radiology. Full
details are given in Table 7.1 (in appendix to this
chapter). The patients were classified into various
sub-groups by the nature of previous resections and
current macroscopic disease. Five CD patients and one
UC patient were studied twice, and one man with UC was
studied three times.
Patients completed a diary card of symptoms for the week
preceding the lavage. Haematological and biochemical
indices included haemoglobin, platelet count, ESR,
C-reactive protein, total protein, albumin and serum
immunoglobulins. All patients were clinically assessed
by one physician, and the CDAI or PTI was calculated
in the standard fashion. In addition, the physician's
assessment of overall disease activity for the day
of lavage was recorded on a VAS, this being based on
symptoms, signs and results of the blood tests.
Whole gut lavage fluid (WGLF) was obtained from all the
subjects and processed as described in chapter 6A. ELISA
was performed for total IgG and total lavage albumin and
lavage A1AT assayed by an immunoturbimetric method as for
a-lAP (see Methods Chapter 6A).
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Correlation coefficients were calculated by using the
Spearman Rank Correlation test.
RESULTS
The patients studied were heterogeneous in disease
distribution, and in their previous and current
treatment. In CD, the CDAI range was from zero to 321;
24 lavages were in patients with CDAI of >150 (described
below as having active disease) and 9 in patients with a
CDAI < 150 (in remission) . In patients with UC, the PTI
ranged from zero to 13; 13 lavages were in patients with
active disease (PTI of >4) and 8 were in patients in
remission with a PTI of < 4.
WHOLE GUT LAVAGE FLUID PROTEIN CONCENTRATIONS
Reference ranges for WGLF IgG, albumin and A1AT
have previously been established by studies of 63
immunologically normal subjects: 20 men, age range 15-80
and 43 women, age range 24-88, all taking a normal diet,
none receiving immunosuppressive or anti-inflammatory
drugs (Brydon, Choudari and Ferguson submitted to gut) .
Normal values are for IgG < 10 ug/ml, for albumin < 26
ug/ml, and for A1AT < 19 ug/ml.
Values for WGLF protein concentrations in CD and UC
patients are shown in Figure 7.1, plotted against CDAI or
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PTI as appropriate.
DIAGNOSTIC POTENTIAL OF WHOLE GUT LAVAGE FLUID TESTS
If WGLF protein concentrations are always high when there
is overt intestinal mucosal inflammation (on radiological
or endoscopic visualisation), this would provide a means
of screening patients for the presence or absence of IBD.
This issue has been considered by analysis of the results
for WGLF IgG. High values for IgG concentration were
present in 24 of the 27 lavages performed in patients who
had unequivocal macroscopic small bowel or colonic CD,
and in 13 of the 15 lavages in patients with UC who had
positive X-ray or endoscopic findings. There was also
one patient with microscopic evidence of colonic CD, no
macroscopic disease but high WGLF IgG concentration.
WHOLE GUT LAVAGE FLUID PROTEINS AND DISEASE ACTIVITY
IaG. CROHN'S DISEASE
In 3 3 lavages from patients with CD, values for WGLF IgG
concentration were normal in 9. Seven of these were in
patients in remission and one in an 18-year old man with
a borderline CDAI of 168. He had ankylosing spondylitis,
and his anorexia and high ESR shortly after right
hemicolectomy for CD were thought to reflect activity of
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arthritis rather than of CD. There was one patient with
WGLF IgG concentration of 10 ug/ml and CDAI of 185.
Abnormally high concentrations of WGLF IgG were present
in 24 cases. Twenty-two had active disease; one was an
obese woman with oro-facial CD and a CDAI of zero, mainly
due to a high weight for height value; her WGLF IgG was
12ug/ml. A 13 year-old boy with perianal CD and
unexplained abdominal pain had a CDAI of 119 and WGLF IgG
was 20ug/ml. During the next six months his growth
stopped and pain became worse; both problems have
resolved with systemic steroid therapy.
IaG. ULCERATIVE COLITIS
In 21 lavages from patients with UC, values for WGLF IgG
concentration were normal in 8 cases (of whom 7 were in
remission) and high in 13 cases (12 with active disease).
Both discrepant cases were patients who had had
unequivocally active disease two weeks before and were
in the early stages of sulphasalaz ine or oral
corticosteroid treatment respectively.
ALBUMIN AND IBP
In 33 lavages from patients with CD, values for WGLF
albumin concentration were normal in 16 cases (of whom 9
were in remission, CDAI in the others ranging from
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168-283). Albumin concentrations were high in 17 cases,
all with active disease.
In 21 lavages from patients with UC, values for WGLF
albumin concentration were normal in 12 cases, (of whom 8
were in remission) ; and were abnormally high in 9 cases,
all with active disease.
ALPHA-1-ANTITRYPSIN AND IBP
In 33 lavages from patients with CD, values for WGLF
A1AT concentration were normal in 18 cases (of whom 8
were in remission), and were high in 15 cases (14 with
active disease).
In 21 lavages from patients with UC, values for WGLF A1AT
concentration were normal in 14 cases (of whom 7 were in
remission), and high in 7 cases, (6 with active disease).
COMMENT
These results show that these indices do not discriminate
between the presence and the absence of disease. Normal
values were found in patients with clinically inactive
disease but with definite radiological and macroscopic
evidence of IBD.
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CORRELATION OF LAVAGE PROTEINS CONCENTRATIONS WITH
ACTIVITY INDICES IN ACTIVE AND INACTIVE DISEASE
Correlation co-efficients for WGLF protein concentrations
against activity indices are detailed in Table 7.2 (in
appendix). For both CD and UC, and for all three
proteins studied, there was a highly significant positive
correlation between activity index and WGLF protein
concentration, with r values ranging from 0.439 to 0.714.
Since, as shown clearly in Figure 7.1, the relationship
between activity index and lavage protein concentration
is not linear but biphasic, correlations were separately
calculated for cases with active and inactive disease (as
defined by CDAI and PTI). Calculations were also
performed for the subsets of CD patients with active
colonic and active small bowel disease.
The results (Table 7.2 in appendix) show that only in
active disease are there significant correlations; that
the highest r values were found for IgG versus CDAI in
active CD (r=0.821), and particularly in the subset with
active small bowel CD (r=0.970); and that in active UC,
although there was good correlation between WGLF IgG
concentration and the PTI (r=0.740), the other two
proteins did not show significant correlation with the
PTI. In inactive CD and UC, WGLF protein concentrations
were independent of activity indices.
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CONVENTIONAL LABORATORY INDICES OF DISEASE ACTIVITY
For the purposes of this analysis, patients with CD who
had a CDAI of >150, and those with UC who had a PTI of
>4, have been designated as having active disease. The
numbers of cases with abnormal and normal values for ESR,
C-reactive protein and platelet count in the active and
remission groups are given in Table 7.3 (in appendix).
This table also includes, for comparison, numbers with
normal and abnormal WGLF IgG, albumin and A1AT values,
and the physician's overall assessment based on a VAS.
The three blood indices were normal in most patients with
inactive disease. However they were also normal in many
patients with unequivocally active disease, and this was
particularly so in the group of 13 assessments in active
UC - ESR was normal in 8 cases, C-reactive protein was
normal in 10 and platelet count was normal in 8.
GENERAL DISCUSSION
There have been many attempts to develop a single index
of illness in IBD (Best et al.. 1976; Powell-Tuck et al. .
1978; Truelove and Witts, 1955; Harvey and Bradshaw,
1980; Van Hees et al.. 1980; De Dombal et al.. 1974;
Myren et al. . 1984; Sandler et al. . 1988) by combining a
few clinical and/or laboratory criteria, and claims have
been made for the significance of single laboratory
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determinations in some situations (Sachar et al.f 1986;
Fegan et al.. 1982; Jansen et al ♦ . 1976; Meyers et al..
1985 and Harries et al. , 1983) . This was an alternative
approach, attempting to separate and independently
measure the various components of disability in IBD so
that those which are potentially treatable by medical,
anti-inflammatory regimes can be considered separately
from those which require other approaches.
Investigation of gut immunity requires direct study of
tissues and secretions, and thus presents major logistic
and ethical problems if serial in vivo studies are to be
undertaken. Exploitation of the relatively new method of
bowel cleansing by whole gut lavage has considerable
potential as a source of material for clinical
evaluation of intestinal immunity and inflammation
(Gaspari et al.. 1988).
There have been reports of high concentrations of IgA
but only trace amounts of IgG (<5ug/ml) in fluid from
control subjects, whereas there were significantly higher
IgG concentrations in WGLF from patients with active
Crohn's disease (Gaspari et al. . 1988). In another study
this was accompanied substantial amounts of IgG in WGLF
indicating that these tests may be detecting plasma
leakage into the gut (O'Mahony et al.. 1990). The assay
of A1AT, was included in the protocol in view of its
widespread acceptance as an index of GI protein loss
(Meyers et al., 1985).
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The aims of this study were to determine whether assay of
WGLF proteins can be used as a diagnostic test for IBD,
and whether this completely objective procedure can
substitute for, or complement, currently used clinical
tests and indices of disease activity. The best current¬
ly available index, the CDAI, was used as the reference
measure of disease activity in CD, and a similar index
for UC, the PTI.
This study shows that WGLF protein concentrations,
particularly IgG, discriminate well between active and
inactive IBD; and also, within the subsets of patients
with active disease, closely parallel disease activity
as defined by CDAI and PTI. Furthermore, these sensitive
tests were completely normal in most patients with CDAI
<150 and PTI <5, strongly supporting the present clinical
trials practice whereby such values are taken as
successful end-points, indicating that remission has been
achieved.
However WGLF protein assays cannot be used as screening
or diagnostic tests for IBD. Although high values are
found in many patients, the data in this paper clearly
show that values are normal in clinically inactive
disease, even when there are uneguivocal radiological or
endoscopic features of IBD such as cobblestone ulcers and
long, string-like strictures. Nevertheless WGLF IgG is a
valuable aid to diagnosis in some clinical situations
such as in patients with microscopic CD, when IBD
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co-exists with severe diverticular disease, and in
separating the effects of intestinal and joint disease in
IBD patients with ankylosing spondylitis.
As regards the source of WGLF total IgG a few factors
have to be considered. There is abundant evidence
to implicate IgG in the pathological lesions of IBD,
particularly CD - immunohistochemistry reveals an excess
of IgG-containing cells, deep in the mucosa (Baklien and
Brandtzaeg, 1976; see chapter 1); isolated intestinal
mononuclear cells from IBD patients spontaneously secrete
high amounts of IgG (MacDermott et al.. 1981; Verspaget
et al., 1988) ; and there are differences in intestinal
plasma cell IgG subclass distribution between controls,
UC and CD patients (Kett, Rognum and Brandtzaeg, 1987).
Thus, the possibility arose that IgG was probably largely
from the abundant IgG cells in diseased mucosa. However
the findings of high concentrations of two plasma
proteins, albumin and A1AT, in lavage fluid from patients
with active IBD suggests that at least some of the IgG
is plasma-derived. Furthermore, all three protein
concentrations were low in WGLF from some inactive CD
patients who have extensive chronic ulceration of the
intestine (diseased tissues known to be replete in IgG
cells).
It could be argued that these sensitive tests are merely
measuring plasma proteins entering the gut lumen as a
result of bleeding. However, in active IBD, when abundant
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amounts of the three proteins are present in WGLF, their
relative concentrations differ substantially from those
in plasma. The three proteins differ in molecular
weight, IgG 150,000 daltons, albumin 69,000 daltons, A1AT
45,000 daltons, and this suggests that there is a
selective increase in mucosa-to-lumen permeability in
active IBD, operating either at the level of the
capillary or the epithelial basal lamina.
Although fluids are processed within minutes of
collection, proteins leaking into the gut lumen
proximally will have been exposed to pancreatic and
bacterial proteases during the transit of fluid along the
gut (1-2 hours) . Ex vivo experiments show that at 37°C,
degradation of albumin by unprocessed WGLF is significant
(loss of 10-40% of measured albumin in one hour),
whereas IgG and A1AT are relatively resistant to such
proteolysis. This could explain the differences in
results for IgG and albumin in active disease, but not
the relative insensitivity of WGLF A1AT concentrations.
Various scientific approaches to the measurement of
disease activity have recently been reviewed (Singleton,
1987; Camilleri and Proano, 1989). Laboratory tests
such as ESR, platelet count, acute phase proteins,
are useful. However they may be normal in active IBD,
particularly in UC and in small bowel Crohn's disease
(see Table 7.3) and will be positive when there is active
inflammation or infection outwith the gut.
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Other techniques such as labelled leucocyte studies
(Saverymuttu et al.. 1986; Crama-Bohbouth et al.. 1988)
and measures of GI protein loss by A1AT clearance
(Florent et al.. 1981; Boirivant et al. 1991; Strygler
et al., 1990), have advantages and disadvantages which
have been fully discussed elsewhere (O'Mahony et
a_l., 1990; Singleton, 1987; Camilleri and Proano, 1989).
In general, they have been developed and applied without
being subjected to prospective evaluation against the
carefully developed standard activity indices such as
CDAI. Furthermore, labelled leucocyte studies are
expensive, involve exposure to radio-activity, depend on
complete faecal collection and usually require hospital
admission. The findings with these tests relate to
events in macroscopically affected gut and thus differ
with those obtained with the gut lavage technique which
appears to measure a more diffuse phenomenon.
There may be problems in interpretation of isotope-based
or A1AT clearance studies if the treatment used, such as
elemental diet therapy, changes intestinal transit rate
or otherwise influences defaecatory function; this
could either mask or mimic changes due to specific
anti-inflammatory effects of the test treatment. Since
the standard protocol for collection of whole gut
lavage fluid is not influenced by concurrent dietary or




Gut lavage is now widely used for bowel preparation prior
to endoscopy, radiology and surgery. The procedure is
well tolerated by patients and volunteers. Lavage fluid,
collected as described above, is aesthetically acceptable
to laboratory staff, resembling urine rather than faeces,
and specimens can be stored at -70°C for several months
without deterioration. Concentration of IgG in WGLF,
assayed by ELISA, discriminates very well between active
and inactive IBD, and accurately grades the degree
of activity. This new and direct approach to clinical
investigation of gut immunity was used in the analysis of
illness and of response to treatment in this thesis
and has considerable potential in clinical trials of
anti-inflammatory and immunomodulatory regimens.
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APPENDIX FOR CHAPTER 7
TABLE 7.1 CLINICAL DETAILS OF 46 PATIENTS WITH IBP.
UNDERGOING WHOLE GUT LAVAGE ON 54 OCCASSIONS
CROHN'S DISEASE

































































































































































































































































































































































































SECRETORY IMMUNOGLOBULIN A LEVELS IN IBP AND
CONTROLS
INTRODUCTION
There are reports that IBD patients have higher levels of
IgA in intestinal secretions than normal controls (see
chapter 2A). The importance of IgA to mucosal surfaces
both in terms of immune protection and down-regulating
inflammatory responses is well established (Tomasi et
al. . 1965; Eddie et al. . 1971), and was reviewed in
chapter 2A.
AIM OF THIS STUDY
The aims of the experiments described in this chapter
were as follows;
1. To establish the pattern of total IgA, non-secretory
IgA and secretory IgA immunoglobulins in WGLF of patients
with IBD and controls and to define similarities or
differences if any.
2. To find out whether there are any changes in the
levels of total IgA, non-secretory IgA and secretory IgA
corresponding with changes in disease activity.
SUBJECTS AND PROTOCOL
Details of the study population are listed in (Table 8:1
in the appendix to this chapter) . Whole gut lavage fluid
was collected from 60 patients (35 Crohn's disease and
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25 ulcerative colitis) and also from 16 controls. The
diagnosis and disease extent in all patients were
confirmed by histology, endoscopy and radiological
criteria. The median age of the patients with Crohn's
disease was 46 with a range of 14-83. The median age for
the ulcerative colitis patients was 47 with a range of
24-82.
Disease activity was based on clinical assessment and
WGLF total lavage IgG concentration (see chapter 7) .
At the time of lavage 20 of the Crohn's disease patients
had active disease, and 15 had inactive disease. The
macroscopic manifestations of the disease were as
follows: orofacial (1 patient), jejunal (5), terminal
ileum (3), ileocaecal (12), colonic (4), rectal (5),
perianal (4) . One patient had microscopic colitis.
Drug treatment in this group was as follows: twelve were
on oral steroid with a daily dose ranging between
lOmg and 40mg, 7 were on salazopyrine, 2 on 5 amino
salicylates and 14 on no drug treatment at all for their
Crohn's disease.
At time of lavage, 16 of the ulcerative colitis
patients had active disease and 9 had inactive disease.
The macroscopic involvement in patients with ulcerative
colitis was as follows: pancolitis (8), left-sided
colitis (5), proctitis (8) and pouchitis. One patient had
microscopic colitis. Eleven were on no drug treatment, 3
were on oral prednisolone and salazopyrine, 5 on
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salazopyrine only, 3 on an amino-salicylate type drug
plus rectal steroids, and one on a combination of
cyclosporin, oral steroids and colifoam enema.
The controls were healthy volunteers and subjects who
after investigation were found to have irritable bowel
syndrome or other non-inflammatory disease conditions. The
final diagnoses in the controls were as follows:
non-inflammatory polyps in the colon (2),irritable bowel
syndrome (7), and one each with colonic angiodysplasia,
duodenal ulcer, delusions, colonic cancer and abdominal
pain. There were two normal volunteers. The median age
was 47 years with a range of 21-79. All the subjects were
on a normal diet.
Whole gut lavage fluid (WGLF) was obtained from all the
subjects and processed as described in chapter 6. ELISA
for total IgA and secretory IgA (slgA) as described in
chapter 6 was performed simultaneously on the same plates
for each patient. Data were analysed to compare active
and inactive disease groups and controls in order to
ascertain firstly if there was any difference between
disease groups and controls and secondly whether the
differences were increased with higher disease activity.
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RESULTS
LEVELS OF SECRETORY ICTA AND THE PROPORTION OF SECRETORY
IoA TO THE TOTAL ICTA IN WGLF
There was no significant difference in the levels
secretory IgA between the groups (Table 8:2 in appendix).
Patients with active IBD had a higher median value than
controls or patients with inactive IBD, however this was
not statistically significant.
THE PROPORTION OF SECRETORY IGA
This was the expression of slgA as a percentage of the
total IgA in WGLF and was derived for each specimen as
follows;
WGLF slqA concentration X 100
WGLF IgA concentration
Differences in the proportions of slgA between controls
and disease groups would indicate alteration in the
assembly of slgA which involves •J* chains and the
secretory component in the disease groups or increased
leakage of serum derived IgA into intestinal secretions
in the disease groups. Distinction between these two
mechanisms would not be possible with this experiment but
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if the differences are well demarcated they could be used
as a marker of disease activity.
Control WGLF proportion of slgA gave a median of 100%
with a range of 7-117 (Table 8:2). All IBD patients as a
group gave a median of 69, range 4-107 significantly
lower than control values (p=0.003). When the IBD
patients were further divided into active and inactive
disease groups, the active IBD group gave a range of 4-97
with a median of 67, while the inactive IBD group had a
median of 72 with a range of 40-107. Both these results
were significantly lower than for the controls at
p=0.0028 for the active group and p=0.0244 for the
inactive group.
THE PROPORTION OF slaA IN CROHN'S DISEASE and ULCERATIVE
COLITIS SUBGROUPS
The proportions of slgA were significantly lower for both
Crohn's disease (p=0.0088) and ulcerative colitis
(p=0.0059) compared to controls (Table 8:3).
Among the Crohn's disease patients, the subgroup
with active disease had significantly (p=0.0130)
lower proportions of slgA than controls (Table 8:4). The
significance of the difference between controls and
inactive Crohn's disease (p=0.0459) was borderline.
The group of patients with active ulcerative colitis had
a significantly lower percentage of slgA compared to
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controls (p=0.0067); the proportions of slgA in the
patients with inactive ulcerative colitis did not differ
significantly from the control group (p=0.0842).
LEVELS OF NON-SECRETORY IctA IN WGLF
The concentration of non-secretory IgA was derived by
subtracting secretory IgA concentration from total IgA.
Controls had very low levels of non-secretory IgA in
WGLF, giving a median of 0 with a range of -35 to 860
(The minus value comes from a few results where secretory
IgA assay figures were higher than total IgA). The
difference in the levels of non-secretory IgA between the
controls and active IBD was significant (p= 0.0008) and
also inactive IBD had significantly higher (p=0.0169)
levels than controls (Table 8:5).
When Crohn's disease and ulcerative colitis groups
were compared to normal controls the differences were
significant for both Crohn's disease group (p=0.0041) and
ulcerative colitis group (p=0.0021). This difference held
for the active Crohn's disease group (p=0.0040) and
active ulcerative colitis group (p=0.0029) whereas for
both inactive Crohn's disease (p=0.0459) and inactive
ulcerative colitis (p=0.0445) the significance was
borderline (Table 8:6).
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THE PROPORTION OF NON-SECRETORY IaA IN WGLF OF IBP
PATIENTS
This was the expression of non-secretory IgA as a
percentage of the total IgA in WGLF and was derived for
each specimen as follows;
WGLF nsIqA Concentration x 100
WGLF IgA concentration
The proportion of secretory IgA was negligible in the
controls; a median of 0 with a range of -17 to 93. Both
active IBD (p=0.0031) and inactive IBD (p=0.0272) had
significantly higher proportions than controls (Table
8:7A). Further subdivisions into Crohn's disease and
ulcerative colitis similarly gave significantly higher
proportions than controls at p=0.0105 and p=0.0.0059
respectively. With respect to disease activity the
proportions of nsIgA were significantly higher for active
Crohn's (p=0.0149) and active ulcerative colitis
(p=0.0067). Both inactive ulcerative colitis (p=0.0842)
and inactive Crohn's disease (p=0.0528) gave proportions
of nsIgA not significantly higher than controls (Table
8:7B).
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COMPARISONS OF SECRETORY IOA LEVELS I slqA) . THE PROPOR¬
TION OF SECRETORY IaA <%SlaA). NON-SECRETORY IqA (nsIcrA)
AND THE PROPORTION OF NON-SECRETORY IqA (%ns!aA) BETWEEN
DISEASE GROUPS
Comparisons were made between disease groups for levels
of slgA, nsIgA and the proportions of slgA (%sIgA) and
nsIgA (%nsIgA). There was no difference between active
IBD and inactive IBD disease groups nor was there any
significant difference between Crohn's disease patients
and patients with ulcerative colitis. Even when the
disease groups were divided further into active and
inactive groups, there was no significant difference
between corresponding active CD and active UC or inactive
CD and inactive UC. Neither did all the parameters differ
significantly between active CD and inactive CD patients
or between active UC and inactive UC patients (Tables
8:8A and 8:8B).
RELATIONSHIP BETWEEN TOTAL IqA AND SECRETORY IqA
In IBD patients as a whole, total IgA correlated strongly
(r=0.806, p < 0.0001) with secretory IgA (Table 8:9A).
This was also the case among the various disease
subgroups, the correlation coefficient ranging from 0.690
for the active ulcerative colitis group to 0.945 for the
inactive Crohn's disease group (Tables 8:9B).
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The higher the total IgA the lower the proportion
of secretory IgA compared to the total (%sIgA); the
correlations between total IgA and proportion of
secretory IgA were all negative (r=-0.231 to -0.646),
except for the inactive UC group (r=0.226). These
correlations were significant for all IBD patients
(r=-0.388, p=0.01); and all UC patients (r=-0.231,
p=0.039) [Table 8:9A]. The negative correlation between
total IgA and the proportion of secretory IgA was
maintained even when the IBD patients were further
subdivided by diagnosis and disease activity. This
correlation was significant for active UC (r=-0.478,
p= 0.028) and inactive Crohn's (r=-0.646, p=0.006)
[Table 8:9B].
THE RELATIONSHIP BETWEEN DISEASE ACTIVITY AND SECRETORY
IqA
Disease activity was assessed by the total amount of IgG
in WGLF (chapter 6). Total IgG significantly correlated
with secretory IgA for all groups except the following;
controls, inactive IBD, inactive Crohn's disease, all
patients with ulcerative colitis (Table 8:10).
There was no significant correlation between the level of
IgG in WGLF and the percentage of secretory IgA except in
the controls (r=-0.225,p=0.001) where the higher the IgG
the lower the proportion of secretory IgA (Table 8:11).
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THE RELATIONSHIP BETWEEN NON-SECRETORY IcrA AND DISEASE
ACTIVITY
The level of non-secretory IgA in lavage correlated with
lavage IgG (r=0.241, p < 0.0001) for the IBD patients
taken as one group. Active IBD patients, Crohn's disease,
active Crohn's disease showed significant positive
correlations (Table 8:11). Taken separately all
ulcerative colitis groups, active or inactive did not
show any significant correlation between non-secretory
IgA and lavage IgG in WGLF.
The proportion of non secretory IgA in WGLF fluid was
correlated with disease activity as measured by total
lavage IgG for all the subject groups. There was no
significant correlation for all subject groups regardless
of disease activity. Potential sources of this non-
secretory IgA are discussed below.
COMMENT
The aims of these experiments were to establish the
pattern of IgA, slgA and non-secretory IgA in patients
with IBD compared to controls, and whether these changes
corresponded with disease activity.
My results show that IBD patients have higher levels of
total IgA in WGLF than controls, and that the levels of
secretory IgA were directly proportional to the levels
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of lavage IgA in WGLF for all the groups. Though the
absolute amounts of secretory IgA were higher in disease
groups than controls, the differences were not
significant. However secretory IgA as a proportion of
total IgA was much lower for the disease groups compared
to controls. The significant difference was confined to
both active Crohn's disease and ulcerative colitis groups
and not the inactive disease groups.
The finding of decreased proportion of secretory IgA as
part of the total IgA also agrees with previous reports.
Brandtzaeg and Korsud (1984) reported that there was a
decreased production of the 'J' chain by mucosal
lymphocytes as well as a reduced binding capacity for
secretory component by mucosal IgA in patients with IBD.
The decreased secretory IgA as a proportion of total IgA
could also be due to leakage of monomeric IgA from the
plasma into the intestinal secretions causing dilution
of the secretory IgA. The actual break in the mucosal
barrier in IBD may lead to increased plasma leakage into
the intestinal lumen (Saverymuttu et al.. 1985a and
1985b). Serum derived IgA would be mainly monomeric IgA
with a higher proportion of IgAl which has a low affinity
for the secretory component (Delacroix et al. . 1982;
Kett, Brandtzaeg and Fousa, 1988). These factors
therefore would lead to a decrease in the proportion of
secretory IgA to total IgA in IBD patients.
Both the absolute amount and the proportion of
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non-secretory IgA are significantly higher in active
disease than in controls. This is also the case
with WGLF IgG, where the increased leakage of WGLF IgG
corresponds with disease activity (see chapter 7). It
is therefore probable that the source of this increased
non-secretory IgA is the same as that of WGLF IgG,
namely serum. However non-secretory IgA was not found to
correlate consistently with disease activity. The lesser
discriminating ability of non-secretory IgA compared
to WGLF IgG could be because the concentration of
non-secretory IgA in intestinal secretions is subject to
the variable factors mentioned above (Brandtzaeg and
Korsud, 1984) apart from leakage from serum whereas WGLF
total IgG is mainly a leak from serum and not subject to
binding by secretory piece or 'J' chain. Therefore as a
marker of disease activity IgG would be a better index.
This work did not look at IgA subclasses even though
increased local production of IgAl has been reported in
IBD (Macdermott et al.. 1986; see chapter 2B).
These factors combined most probably account for the
significantly increased proportions of non-secretory IgA
in active IBD.
The strong correlation between secretory IgA and IgG in
WGLF, a measure of disease activity, suggests that
increased secretory IgA production and secretion is a
feature of disease activity in IBD.
There was no difference in the levels or the proportion
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of slgA or non-secretory IgA between disease groups
(Tables 8:8A and 8B), indicating that even in quiescent
disease IBD patients still have some immune dysregulation
which becomes prominent with increased disease activity.
SUMMARY
These results show increased levels of total IgA in
intestinal secretions of patients with IBD. Since IgA in
the intestinal lumen offers mucosal protection, high
levels could indicate an aberrant reaction to a normal
antigenic load, or persistence of ubiquitous antigen, or
an upregulation of the immune system intrinsic to IBD
patients.
The proportion of the protective secretory IgA is
significantly lower in patients with IBD as compared to
controls. However within the IBD group the levels are not
significantly different between disease groups regardless
of activity and therefore it is not a useful index of
disease activity.
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APPENDIX FOR CHAPTER 8












































16 active and 9 inactive
20 active and 15 inactive
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TABLE 8:2 LEVELS OF SECRETORY IgA AND THE PROPORTION OF
SECRETORY IctA TO THE TOTAL IqA IN WGLF OF IBP PATIENTS
AND CONTROLS
slgA (ug/ml) %slgA
GROUP N Median Median
(range) (range)
Control 16 151.5 100
(15-759) (7-117)
ALL IBD 60 148.5 69**
(30-1292) (4-107)
ACT IBD 36 178 67**
(30-1292) (4-97)
INAC IBD 24 134 72*
(39-924) (40-107)
%IgA slgA as a percentage of total IgA
*p < 0.05 levels of significance from controls
**p< 0.01 levels of significance from controls
ALL IBD = All patients with IBD
ACT IBD = Patients with active IBD
INACT IBD = Patients with inactive IBD
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TABLE 8:3 LEVELS OF TOTAL WGLF ICTA AND %SlqA IN








CONTROL 16 151.5 100
(15-759) (7-117)
UC 25 152 67**
(30-924) (4-103)
CD 35 147 71**
(30-1292) (12-107)
%sIgA = slgA as a percentage of total IgA
**p < 0.01 level of significance of difference from
controls.
UC = ulcerative colitis
CD = Crohn's disease
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TABLE 8;4 TOTAL WGLF IGA AND %SIGA IN ULCERATIVE COLITIS




































%sIgA = slgA as a percentage of total IgA
* p < 0.05 level of significance of difference from
healthy controls.
**p< 0.01 level of significance of difference from
healthy controls.
# p = 0.459 borderline significance
aUC = active ulcerative colitis
inaUC = inactive ulcerative colitis
aCD = active Crohn's disease
inaCD = inactive Crohn's disease.
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TABLE 815 LEVELS OF NON-SECRETORY IqA (nsIcrA) IN WGLF OF
CONTROLS AND PATIENTS WITH IBP.
nslgA (ug/ml)




ACT IBD 36 57 0.0008
(8-839)
INACT IBD 24 42 0.0169
(-9-651)
p = probability of the difference from controls being due
to chance.
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TABLE 8:6 LEVELS OF NON-SECRETORY IgA (nsIoA) in WGLF IN






































p = probability of the difference from controls being due
to chance.
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TABLE 8:7A THE PROPORTION OF NON-SECRETORY IqA (%ns!qA)
IN WGLF OF PATIENTS WITH IBP AND CONTROLS.
%ns!crA




ACT IBD 36 33 0.0031
(3-97)
INACT IBD 24 28 0.0272
(-8-60)
p = probability of the difference from controls being due
to chance.
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TABLE 8;7B THE PROPORTIONS OF NON-SECRETORY IqA %ns!qA IN





































p = probability of the difference from controls being due
to chance.
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TABLE 8:8A COMPARISONS OF SECRETORY IqA LEVELS (slqA) AND
THE PROPORTION OF SECRETORY iqA (%s!qA) BETWEEN DISEASE
GROUPS. Statistical comparisons by Mann-Whitney




















p = probability of the difference being due to chance.
TABLE 8;8B COMPARISONS OF NON-SECRETORY IqA (nsIqA) AND
THE PROPORTION OF NON-SECRETORY IqA (%ns!qA) BETWEEN
DISEASE GROUPS.Statistical comparisons by Mann-Whitney
p Values




















p = probability of the difference being due to chance.
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CORRELATIONS
TABLE 8:9A RELATIONSHIP BETWEEN TOTAL IcA. SECRETORY
IaA AND %SECRETORY ICTA IN CONTROLS AND PATIENTS WITH
IBP.
Total IgA vs slgA Total IgA vs %sIgA
GROUP N r D r D
CONTROL 16 0.708 0.0001 -0.284 0. 084
IBD 60 0.806 0.0001 -0.388 0.012
UC 25 0.731 0.0001 -0.231 0.039
CD 35 0.861 0.0001 -0.445 0.161
CONTROL = Controls as defined in text
IBD = all patients with inflammatory bowel disease
UC = ulcerative colitis patients
CD = Crohn's disease patients
p = probability that the correlation (r) would be a
chance finding.
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TABLE 8:9B RELATIONSHIP BETWEEN TOTAL IdA. SECRETORY
I CIA AND %SECRETORY IqA IN PATIENTS WITH CROHN'S DISEASE
AND ULCERATIVE COLITIS BY DISEASE ACTIVITY.
Total IgA vs slgA Total IgA vs %slgA
GROUP N r E T E_
aUC 16 0.690 0.0001 -0.478 0.028
inaUC 9 0.750 0.0001 0.226 0.605
aCD 20 0.797 0.0001 -0.245 0.783
inaCD 15 0.945 0.0001 -0.646 0.006
aUC = active ulcerative colitis
inaUC = inactive ulcerative colitis
aCD = active Crohn's disease
inaCD = inactive Crohn's disease.
p = probability that the correlation (r) would be a
chance finding.
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TABLE 8:10 RELATIONSHIP BETWEEN WGLF IQG (DISEASE
ACTIVITY) AND SECRETORY IqA. %SECRETORY IctA.
Total IgG vs slgA Total IgG vs %sIgA
GROUP N r D r D
CONTROL 16 0.182 0.415 -0.225 0.001
IBD 60 0.213 0.0001+ -0.156 0. 073
ACT IBD 36 0. 548 0.001 -0.218 0.201
INAC IBD 24 0.215 0.314 -0.124 0.563
UC 25 0.345 0.102 -0.044 0. 666
aUC 16 0. 560 0.014+ 0.077 0.932
inaUC 9 0. 553 0.010+ 0.043 0.898
CD 35 0.143 0.001 -0.172 0.078
aCD 20 0.122 0.012 -0.251 0.185
inaCD 15 -0.060 0.446 0. 135 0.631
CONTROL == Controls as defined in text
IBD = all patients with inflammatory bowel disease
UC = ulcerative colitis patients
CD = Crohn's disease patients
aUC and inaUC = active and inactive ulcerative colitis
aCD and inaCD = active and inactive Crohn's disease
p = probability that the correlation (r) would be a
chance finding.
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TABLE 8?11 RELATIONSHIP BETWEEN WGLF IqG (DISEASE
ACTIVITY) AND NON-SECRETORY IaA. %NON-SECRETORY IuA.
TOTAL IgG vs nsIgA Total IgG vs %ns!gA
GROUP N r P r P
CONTROL 16 0.143 0.166 0.143 0.166
IBD 60 0.241 0.0001+ 0.154 0. 091
ACT IBD 36 0. 306 0. 002 0.132 0.231
INA IBD 24 -0.132 0.522 -0.117 0.558
CD 35 0.226 0.0001 0.285 0.097
aCD 20 0.436 0.0001 0.249 0.217
inaCD 15 -0.296 0.431 -0.142 0. 633
UC 25 0. 135 0.228 0. 038 0. 676
aUC 16 -0.010 0.414 -0.077 0.925
inaUC 9 0. 150 0. 059 0. 043 0.897
CONTROL = Controls as defined in text
IBD = all patients with inflammatory bowel disease
UC = ulcerative colitis patients
CD = Crohn's disease patients
aUC and inaUC = active and inactive ulcerative colitis
aCD and inaCD = active and inactive Crohn's disease








The hypothesis that there is an association between food
antigens and inflammatory bowel disease is longstanding
(see chapter 1). There have been anecdotal clinical
reports of improvement when IBD patients avoided
particular food antigens (Ginsberg and Albert, 1989)
and also reports of elevated levels of serum antibodies
to a number of food antigens (Koninckx et al. .1984 ;
Taylor and Truelove, 1961; Lerner et al..1989). The
conclusions as to the prevalence of food antibodies in
IBD have varied. Despite all this interest there is a
lack of studies on mucosal immunity to food antigens in
inflammatory bowel disease. Yet the main site of disease
•activity' in IBD is at the local mucosal level, quite
different from the systemic (sera) compartment which in
immunological respects does not mirror mucosal events.
THE AIM OF THIS STUDY
The objective of the experiments described in this
chapter was to investigate humoral mucosal and humoral
systemic immunity to food antigens in patients with
Crohn*s disease, ulcerative colitis and controls. My
hypothesis was that small bowel disease was likely to
show high levels of food antibodies such as occurs in
coeliac disease where there is diffuse jejunal disease.
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It seemed likely that antibodies to food antigens are
stimulated by exposure of the damaged upper small bowel
to the many antigens present in this part of the
intestines.
SUBJECTS AND PROTOCOL
A total of 57 patients (38 Crohn's disease and 19
Ulcerative colitis) and 23 controls were studied
(Table 9:1 in the appendix).
The macroscopic manifestations of patients at the time of
lavage were as follows: orofacial (1), jejunal (1),
terminal ileum (10), ileocaecal (4) , colonic (9) , rectal
(3), perianal (2) (one associated with sigmoid-ilial
fistula and the other associated with rectal
involvement), microscopic colitis (1), and seven with
no macroscopic disease (5 after resections). All the
patients were on normal diet. As regards drug treatment
7 patients were on steroids the dose ranging
between 10-40mg per day, 17 on sulphasalazine, 3 on
sulphasalazine and steroids and 11 on no drug therapy for
their Crohn's disease. The age range was 13-76 with a
median of 38. Twenty-one had active disease and in 17 the
disease was inactive as assessed clinically and also
based WGLF total IgG (see chapter 7).
In the ulcerative colitis group none had had any
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resections. The macroscopic distribution of the disease
at time of sampling was as follows: 8 pancolitis, 4
left-sided involvement and 7 proctitis. Four were on
no drug treatment, 5 were on oral prednisolone and an
amino-salicylate type (ASA) drug plus rectal steroids, 3
were on an ASA group drug plus rectal steroids, 1 was on
rectal steroids only, 3 on an oral ASA group only and 3
were taking oral prednisolone as well as ASA. The age
range for this group was 23-81 with a median of 37. Of
the 19, 12 had active disease at time of study.
Most of the controls had presented with symptoms
that required gastro-intestinal investigations but
whose diagnosis was non-inflammatory dysfunction. The
final diagnoses in the controls were as follows:
non-inflammatory polyps in the colon (5) , constipation
(7), diarrhoea with no abnormality detected (5), colonic
angiodysplasia (1) and one each with oesophagitis,
duodenal ulcer, unexplained abdominal pain and 2 healthy
volunteers. The age range was 14-88 with a median of 53.
All the subjects were on normal diet
Total immunoglobulins of the IgA, IgG and IgM classes
and corresponding food antibodies to gliadin (GLI),
6-lactoglobulin (BLG) and ovalbumin (OVA) were measured
in serum and WGLF as described in chapter 6.
The serum was drawn on the day of gut lavage collection
so that the two specimens reflected systemic and mucosal
immune activity at corresponding times.
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Comparisons in the levels of total immunoglobulins and
antibodies to the three antigens in serum and WGLF were
made between the three groups. Comparisons were also
made when the disease groups were further subdivided
according to whether they had active or inactive disease
and according to the regional distribution of disease.
Finally the correlations between total immunoglobulins
and food antibodies within and between sera and gut
lavage fluid were performed in order to define the
relationships between the two compartments if any.
SECTION 9A
TOTAL IMMUNOGLOBULINS IN INFLAMMATORY BOWEL DISEASE
PATIENTS AND CONTROLS
The most abundant immunoglobulin in serum was IgG. The
levels of IgG, IgA and IgM were compared between
disease groups and controls. There was no significant
difference between controls and the inflammatory bowel
disease patients (Table 9A:2 in the appendix). All tables
are in the appendix of the chapter.
SERUM ANTIBODIES TO GLIADIN. B-LACTOGLOBPLIN AND
OVALBUMIN
Serum antibodies to the three food antigens were
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expressed as a percentage of a standard known to have
high levels of these antibodies. The result was expressed
as the figure without the percent symbol. For example a
level of 10 would indicate 10% as compared to the
standard.
Serum antibody levels above 10 of the standard were
considered positive and the levels were considered highly
positive if the were above 20% for IgA, above 40% for IgG
and above 60% for IgM. Table 9A:3A shows the prevalence
of high positive antibodies in the disease groups and
controls. Taking antigliadin IgG, for example, 3 out of
the 19 UC patients gave high positive results, 4 out of
the 23 controls and 15 out of the 38 Crohn's disease
patients gave high positive results. Analysis by
Mann-Whitney shows that there were no significant
differences between levels in patients with Crohn's
disease and controls or between disease groups. This lack
of significant differences applied to all the groups and
antibodies (Table 9A:3B).
SERUM FOOD ANTIBODIES IN ACTIVE AND INACTIVE INFLAMMATORY
BOWEL DISEASE
The patients were further subgrouped according to disease
activity and the prevalence of high positive antibodies
in the individual group enumerated for active and
inactive UC (Table 9A:4A) and for active and inactive
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Crohn's disease (Table 9A:4B).
For example of 12 patients with active ulcerative colitis
(Table 9A:4A), 2 had high positive antibody levels to GLI,
3 to BLG and 2 to OVA in the IgG class. And for the 7
patients with inactive ulcerative colitis, 1 had high
antibodies to GLI, 4 to BLG and 2 to OVA. The same
applies to IgA and IgM class antibodies. The patients
were further subdivided into subgroups according to
whether they had a predominantly left sided disease
(LSIDED), proctitis (PR) or pancolitis (EXTENSIVE). These
were also subdivided into active and inactive disease
subgroups based an clinical assessment and total WGLF
IgG. The rest of Table 9A:4A is essentially the same. For
example there were 7 patients with proctitis, of these
two had high positive antibody levels to GLI, 4 to BLG
and 2 to OVA in the IgG class.
For patients with Crohn's disease the format is the same.
For example there were 24 patients with active Crohn's
disease, 8 had high positive antibody levels to GLI, 6 to
BLG and 8 to OVA (Table 9A:4B). The patients were further
subgrouped as described earlier and their frequency of
high levels of antibodies to food antigens enumerated
according to disease group.
The frequency of high positive antibodies to food
antigens for controls is included in both Tables 9:4A and
9:4B to allow easy comparison.
The levels of antibodies were compared between disease
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groups and controls for active (Table 9A:4C) and inactive
disease (9A:4D).
Statistical analysis by Mann-Whitney showed that there
was no significant difference (Table 9A:4C) and this
applied to all patients with active IBD and inactive IBD
(Table 9A:4D).
The levels of serum food antibodies in active UC did not
differ significantly from inactive UC and neither was
their a significant difference between active Crohn's
disease and inactive Crohn's disease (Table 9A:5).
185
SECTION 9B
WHOLE GUT LAVAGE FLUID STUDIES
TOTAL IGA.IGG and IGM IMMUNOGLOBULINS IN WGLF OF IBP
PATIENTS AND CONTROLS
The levels of total IgG, IgA and IgM were measured in
WGLF of patients with Crohn's disease and ulcerative
colitis (Table 9B:1).
Controls gave a range for IgG of l-9ug/ml with a median
of lug/ml, IgA range of 12-478 with a median of 143 and
IgM range 1-9 with a median of 3.
Crohn's disease patients had IgG range of l-393ug/ml with
a median of 21.5ug/ml, IgM range of l-102ug/ml with a
median of 9ug/ml and IgA range of l-1217ug/ml median
of 171ug/ml. The levels of IgG and IgM were highly
significantly elevated compared with levels in
controls (p = 0.00001), whereas the total IgA was not
significantly different from controls (Table 9B:1).
Patients with ulcerative colitis, had a range between of
total IgG of l-20ug/ml with a median of 19ug/ml, IgM
range of 2-22ug/ml with a median of 9ug/ml and IgA range
of 18-551ug/ml with a median of 170.5ug/ml. The levels of
total IgG and total IgM were significantly higher than
controls at p=0.00001 and p=0.0005 respectively whereas
the IgA was not significantly different from controls.
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TOTAL IMMUNOGLOBULINS IN WGLF OF PATIENTS WITH ACTIVE AND
INACTIVE INFLAMMATORY BOWEL DISEASE
Patients were subgrouped according to disease activity
based on clinical assessment and whole gut lavage total
IgG. All groups active and inactive Crohn's disease and
active and inactive ulcerative colitis had significantly
higher levels of IgM in WGLF compared with controls.
The statistical comparisons gave the following highly
significant results: active (p=0.00001) and inactive
(p=0.0037) Crohn's disease, active (p=0.0017) and
inactive ulcerative colitis (p=0.0273) [Table 9B:2A],
There was no significant difference in total IgA in WGLF
between controls and disease groups regardless of disease
activity (Table 9B:2B).
Disease activity was defined on the basis of total IgG
levels in WGLF thus it is not surprising that active
Crohn's (p=0.00001), and active UC (p=0.00001) groups had
significantly higher levels of total IgG than controls.
The patients with inactive Crohn's disease had total IgG
values in their WGLF which were in the upper limit
(l-10ug/ml) of the normal range but statistically
significantly higher than the levels in controls
(p=0.0044) while the inactive ulcerative colitis group
had values in the lower range close to the controls and
not significantly different from controls (p=0.1698).
However there was no significant difference in total IgM
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or total IgA between all Crohn's patients as compared
with levels in all UC patients. Even within disease
groups the immunoglobulin levels for patients with active
Crohn's patients' levels were not significantly different
from those for patients with inactive Crohn's disease,
the same applied to the patients with active and inactive
ulcerative colitis (Table 9B:3).
RELATIONSHIP BETWEEN TOTAL SERUM IMMUNOGLOBULINS AND
TOTAL WGLF IMMUNOGLOBULINS
The levels of total IgA, IgM and IgG in WGLF were
correlated with corresponding class of total levels of
immunoglobulins in serum for each disease group.
There was no strong correlation between total WGLF IgA,
IgM and IgG and total serum immunoglobulins in the same
classes for all the IBD patients and controls (Table
9B:4A). The IBD patients were further subgrouped into
active and inactive groups based on clinical assessment
and WGLF IgG and comparisons between serum and WGLF
immunoglobulin of the three classes made. There was no
strong correlation in these immunoglobulins between the
two compartments for active disease groups (Table 9B:4B)
and inactive disease groups (Table 9B:4C).
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ANTIBODIES TO GLIADIN. fl-LACTOGLOBULIN AND OVALBUMIN IN
WGLF OF PATIENTS WITH CROHN'S DISEASE. ULCERATIVE COLITIS
AND CONTROLS
WGLF ICTG ANTIBODIES
In WGLF levels of antibodies to food antigens above 10%
of the reference standard were considered positive and
high. The prevalence of anti-food antibodies above this
level (above 10% of standard see Chapter 6A) in Crohn's
disease, ulcerative colitis and normal controls is shown
in table 9B:5A. There were no positive IgG antibodies to
any of the three dietary antigens tested in the controls
and patients with ulcerative colitis. In the Crohn's
disease group of a total of 114 measurements only 4 were
positive for IgG antibodies to food antigens and since 3
of these had high levels of corresponding antibodies in
serum as well, this probably reflected leaked IgG from
serum. In all therefore, IgG anti-food antibodies were
very low or negative in WGLF in this study. IgG anti-food
antibodies were therefore not considered any further
(TABLE 9B:5A).
WGLF ICTM and IqA ANTIBODIES
Unlike IgG there were a few patients with positive
anti-food antibodies in the IgA and IgM classes.
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In patients with Crohn's disease 18 out of the 38
patients had positive antigliadin IgA antibodies as
compared to only 1 out 23 (Table 9B:5A) for the control
group, 15 out 38 positive IgM antigliadin compared to 1
out of 23 for the controls and there were also 15
positive IgM antiovalbumin out of 38 results in Crohn's
disease patients compared to 1 out of 23 for the controls
(Table 9B:5A). All these results were significantly
higher than controls at p=0.0051, p=0.0207 and p=0.0203
respectively (Table 9B:5B).
In patients with ulcerative colitis 4 out of 19 patients
had positive antigliadin IgA antibodies and 4 out of 19
had positive IgM antigliadin with only three out the 19
being positive for IgM antiovalbumin antibodies (Table
9B:5A). There was no statistical difference between
these and control levels (Table 9B:5B). This lack of
statistical difference from controls applied for all the
food antibodies in patients with ulcerative colitis.
There was no significant difference in the levels of
anti-food antibodies between ulcerative colitis and
Crohn's disease.
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GLIADIN. B-LACTOGLOBULIN AND OVALBUMIN ANTIBODIES IN WGLF
OF CONTROLS. ACTIVE AND INACTIVE INFLAMMATORY BOWEL
DISEASE
Patients were further subgrouped according to disease
activity as described above.
Out of the 24 active Crohn's disease patients, 12 had
positive antigliadin IgA antibodies as compared to 1 out
of 23 normal controls and there were 20 out of 24
positive results for IgA antiovalbumin as compared to 13
out 23 positive among controls (Table 9B:5C). These
antibody levels were significantly higher than controls
at p=0.0073 and p=0.0132 respectively (Table 9B:5D).
There were 11 of 24 active Crohn's disease patients who
had positive antibodies for IgM antigliadin as compared
to 1 out of 23 controls and IgM antibodies to ovalbumin
were positive in 10 out 24 active Crohn's disease
patients and only in 1 out of 23 controls (Table 9B:5C).
These antibodies were significantly higher than controls
at p = 0.014 0 and p= 0 . 0269 respectively. There was
no significant difference in the levels of antibodies
between inactive Crohn's and controls for antibodies to
any of the food antigens (Table 9B:5E).
The same analysis was made for patients with active and
inactive ulcerative colitis. There was no significant
difference in the levels of anti-food antibodies between
ulcerative colitis patients, active (Table 9B:5D) and
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inactive subgroups (Table 9B:5E), and controls.
COMPARISON OF FOOD ANTIBODY LEVELS BETWEEN DISEASE GROUPS
Antibody levels to food antigens were compared between
disease groups. There was no significant difference
between active ulcerative colitis and active Crohn's
disease for all the antibodies studied except IgA
antiovalbumin which showed a borderline significance
(p=0.0441) [Table 9B:5D]. Comparison of antibody levels
between patients with inactive Crohn's and inactive UC
for any of the food-antigens showed that there was no
significant difference . A comparison of food antibody
levels between active and inactive Crohn's disease and
active and inactive ulcerative colitis also showed no
significant differences (Table 9B:5E and 9B:5F).
COMMENT
Despite the lack of significant differences between
disease groups the antibody levels show a repeating
pattern. Active Crohn's disease patients have the highest
levels followed by patients with active ulcerative
colitis and the inactive Crohn's group are intermediate
between active ulcerative colitis and inactive ulcerative






RELATIONSHIP BETWEEN SERUM ANTIBODY LEVELS AND LAVAGE
ANTIBODY LEVELS IN CROHN'S DISEASE. ULCERATIVE COLITIS
AND CONTROLS
Levels of antibodies to food antigens in WGLF were
correlated with levels of corresponding antibodies in
serum for each group of patients.
The following results showed a significant correlation:
controls IgA antibodies to B-lactoglobulin (r=0.232
p=0.00001), Crohn's IgA antibodies to gliadin (r=0.297
p=0.016) and antibodies to B-lactoglobulin (r=0.166
p=0.001) and in ulcerative colitis patients a strong
correlation for IgM antibodies to ovalbumin (r=0.464
p=0.002) [Table 9C:1].
Further analysis of these results shows that for the
controls the 7 out of 23 subjects who had positive lavage
IgA antibodies to B-lactoglobulin only 1 was highly
positive for serum. And for the two who had high positive
IgA anti-BLG antibodies in serum only one had a positive
result in WGLF (Table 9C:1; Graph 9C:1A).
For Crohn's disease of the 4 patients who had high
positive IgA anti-BLG in serum 2 had positive levels in
WGLF or alternatively of the 15 patients who had positive
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IgA antibodies to BLG in WGLF only two were highly
positive in serum (Graph 9C:1B). As for IgA antibodies to
gliadin in Crohn's disease, of the 18 out of 38 patients
with positive antibodies in WGLF only three had
simultaneously high positive results in serum. However
three of the 4 who had high positive serum IgA anti-GLI
also had positive levels in WGLF (Graph 9C:1C).
For ulcerative colitis 5 patients out of 19 had high
positive IgM antibodies to ovalbumin in serum and of
these only 2 had positive levels in WGLF. Alternatively
two of the three who had positive WGLF IgM antibodies to
ovalbumin also had high positive levels in serum (Graph
9C:ID).
As the graphs 9C:1A-D show the positive correlations for
these groups were accounted for mainly by negative (low)
results and therefore in actual fact there is no strong
correlation between positive lavage antibodies and high
serum antibodies to food antigens for any of the groups.
The two compartments are independent of one another.
THE RELATIONSHIP BETWEEN SERUM AND WGLF ANTIBODY OF
PATIENTS WITH ACTIVE IBP
A correlation analysis between WGLF and serum antibodies
to food antigens in patients with active disease (Table
9C:2) and inactive disease (Table 9C:3).
There was a strong positive correlation between serum
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and lavage IgA antibodies in active Crohn's disease for
gliadin (r=0.389 p=0.025) and IgM antibodies to ovalbumin
in ulcerative colitis (r=0.699 p=0.0001) [Table 9C:2].
Further analysis shows that only 2 of the 12 patients out
of 24 active Crohn's patients who had positive
antigliadin antibodies in lavage also had high positive
results in serum but the two who had high positive
results in serum also had positive levels of antigliadin
antibodies in lavage (Graph 9C:2A).
For the 12 patients with active ulcerative colitis, of
the 3 who had high positive IgM antibodies to ovalbumin
in serum, 2 had positive levels in gut lavage or
alternatively of the three with positive lavage IgM
anti-ovalbumin, two had high positive results in serum
(Graph 9C:2B). As the graphs (9C:2A-B) show these strong
correlations were also accounted for mainly by the
negative results. Therefore like the other results there
is no strong correlation between positive levels of WGLF
and serum antibodies to food antigens for all the groups.
RELATIONSHIP BETWEEN ANTIBODIES AND TOTAL IMMUNOGLOBULINS
IN WGLF OF PATIENTS WITH CROHN'S. ULCERATIVE COLITIS AND
CONTROLS
Antibody levels in lavage were correlated against total
levels of immunoglobulins of the same class for each
group.
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Total lavage IgA correlated very strongly with lavage
IgA antibodies to BLG (r=0.685 p=0.0001) in patients with
Crohn's disease. There was no correlation between total
lavage IgA and IgA antibodies to food antigens for the
controls and patients with ulcerative colitis. Total
WGLF IgA in Crohn's disease patients did not correlate
strongly with the levels of IgA antibodies in WGLF to
gliadin and ovalbumin (Table 9C:3).
There was no strong correlation between lavage total IgM
and IgM antibodies to food antigens in both ulcerative
colitis and Crohn's disease (Table 9C:4). The control
subjects had extremely low levels of total IgM so were
not subjected to statistical analysis.
THE RELATIONSHIP BETWEEN IqA AND IqM AND ANTIBODIES IN
WGLF OF PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE
COLITIS
Correlation analyses were done between IgA and IgM
antibodies in WGLF within each group.
Only IgA and IgM lavage antibodies to ovalbumin
correlated strongly with each other for Crohn's disease
(r=0.430 p=0.017). However further analysis of this
showed that of the 10 Crohn's disease patients out of 38
who were negative for IgA antibodies to ovalbumin in
WGLF, 8 of them were also negative for lavage IgM
antibodies to ovalbumin. Alternatively 28 out of the 38
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Crohn's disease patients with positive lavage IgA
antibodies to ovalbumin 13 were negative for IgM
antiovalbumin antibodies in WGLF (Table 9C:5 and Graph




WGLF FOOD ANTIBODIES ACCORDING TO DISEASE ACTIVITY AND
DISEASE DISTRIBUTION IN PATIENTS WITH IBP
The patient groups were regrouped according to regional
involvement of disease and disease activity. The
distribution and the numbers in each group are shown
in table 9D:1A. My hypothesis was that patients with
proximal disease involving the small bowel would have
more positive results than patients with 'distal* or
colonic disease.
The prevalence of positive anti-food antibodies
(above 10) in disease involving different regions of
the gastrointestinal tract is shown in table 9D:1B. For
example there were 19 patients with UC of these 4
had positive GLI, 4 positive antibodies to BLG and 10
positive antibodies to OVA in the IgA class. Similarly
the frequency of positive anti-OVA antibody levels in the
IgM class was 4 for anti-GLI, 2 for anti-BLG and 3
for anti-OVA. The patients were further analysed into
regional disease involvement. There were seven patients
with proctitis, of these 3 had positive antibodies to
GLI, 1 had positive antibodies to BLG and 3 positive
antibodies to OVA in the IgA class. Similar analysis was
made for patients with Crohn's disease.
The patients were further subgrouped according to
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disease activity for Crohn's disease (Table 9D:1C) and
for ulcerative colitis (Table 9D:1D). For example in
table 9D:ID of the 7 patients who had proctitis 4 had
active disease and in 3 the disease was inactive. Out of
the 4 patients with active proctitis, 3 had positive
levels of anti-GLI, 1 positive anti-BLG and 1 positive
anti-OVA in the IgA class. For the three patients with
inactive proctitis none had positive antibody levels to
BLG and two had positive IgA antibodies to OVA and one
was positive for IgM antigliadin.
The numbers studied in each group according to regional
involvement and disease activity were too small for
strong statistical analysis (Table 9D:1C and Table
9D:ID).
To further analyse the Crohn's patients the regional
distribution of the disease was revised and subdivided
into two broad categories; proximal involvement
which including orofacial, small bowel and ileocaecal
involvement; and distal including the colon and proctitis
(the patient with microscopic type disease was excluded
from this analysis).
The prevalence of positive levels (above 10) of
anti-food antibodies in the proximal and distal groups is
shown in Table 9D:2A. Though there are relatively more
numbers of positive results among the proximal group, 10
positive out of 19 as compared to 7 out of 18 in the
distal group for IgA antigliadin, on statistical analysis
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there was no significant difference (Table 9D:2B). There
was no difference either when patients were analysed
according to disease activity (Table 9D:2C and Table
9D:2D).
Finally as regards total immunoglobulins in gut lavage
there was no statistical difference in the levels between
proximal and distal disease involvement even when pa¬
tients were subdivided and corresponding active and
inactive varieties were compared (Table 9D:3A, Table
9D:3B and Table 9D:3C).
GENERAL SUMMARY AND COMMENT
The measurement of total immunoglobulins by ELISA
(Chapter 6A) gave actual concentration in ug/ml.
Anti-food antibody levels here are expressed as a ratio
to a known high standard, not as actual concentration
of antibody being more related to the overall binding
capacity of these antibodies. Since the same standard is
used for all measurements they enable comparisons to be
made by using non-parametric statistics.
The results in this study show that there is no
difference in total immunoglobulins and antibodies (to
the three food antigens studied) in systemic circulation
between controls on one hand and Crohn's or ulcerative
colitis patients on the other. And this applies for both
active and inactive disease groups.
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Differences only appear in WGLF with total IgM and IgG
being significantly higher in the active disease groups
than in controls. The antibodies to ovalbumin and gliadin
are also significantly higher in active Crohn's disease
than controls.
Furthermore there was no significant correlation between
systemic and mucosal antibodies or immunoglobulins
indicating that mucosal immune activity as measured in
this study was independent of systemic immunity.
It follows therefore that if indeed there is immune
dysregulation in IBD then mucosal secretions like WGLF
are more likely to show the changes than serum.
Whereas WGLF IgG is mainly of systemic origin leaking
into mucosal lumen (chapter 7), most of the lavage IgM is
probably locally produced hence the presence of positive
IgM antibodies. The lack of differences between active
and inactive disease for total IgM and food antibodies
implies that even during inactive disease, the immune
dysregulation (upregulation) still continues, albeit at a
lower level than during active disease. This pattern of
raised IgM levels is found also in other immune related
diseases such as coeliac disease (O'Mahony et_al., 1991a)
and may reflect an upregulated and persistent early
immune response with dysregulation of the maturation
process for the production of other classes of
immunoglobulins.
The lack of correlation between the levels of total
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immunoglobulins in WGLF and their corresponding anti-food
antibodies may indicate that the raised antibody levels
are not a result of a mitogenic (polygenic) non-specific
stimulation but are instead due to specific reactions to
particular food antigens.
Though Crohn's disease patients had significantly raised
antibodies in WGLF compared to controls, these levels
were not significantly higher than those of ulcerative
colitis patients. This indicates that both in UC and
Crohn's disease there is upregulated mucosal
immune activity and the difference is in the degree of
upregulation.
There was also no significant difference between UC and
controls. This may indicate that patients with UC occupy
an intermediate level in this hierarchy of upregulation
between controls and Crohn's disease. Alternatively, as
there are no pathognomonic criteria for their distinction
(chapter 1) a few UC patients might actually be
misdiagnosed and later will turn out to have Crohn's
disease.
WGLF antibodies and immunoglobulins cannot be used to
distinguish between proximal and distal disease. As the
small bowel is the area of most intense immune activity,
most of the antibodies may be of small bowel origin.
However the inability in this study to show any
differences between proximal and distal disease may be
explained by the fact that the gut lavage technique
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samples the whole gut. Perhaps if selective segmental
sampling of mucosal secretions were done, differences
that have not been shown could become apparent.
Alternatively these result may suggest that patients with
large bowel Crohn's disease may still have small bowel
involvement which is not clinically apparent.
It is clear from this study that Crohn's disease patients
represent a hyperimmune group as compared to controls and
patients with ulcerative colitis.
If these antibodies to food antigens are involved in
disease pathogenesis then the effect of treatment on their
levels in lavage would be informative.
The next chapter examines the effect of the withdrawal of
these food antigens by use of elemental diet on the
levels of food antibodies to the three antigens and the
relationship of these levels to disease remission.
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APPENDIX FOR CHAPTER 9
TABLE 9;1 STUDY POPOLATION
CROHN•S ULCERATIVE CONTROLS
DISEASE COLITIS
NUMBERS 38 19 23
M: F 16:22 6:13 8:15
AGE
MEDIAN 38 37 53
RANGE 13-76 23-81 14-88
DISEASE DISTRIBUTION AT TIME OF LAVAGE
CROHN'S DISEASE ULCERATIVE COLITIS
Orofacial 1 Rectum only 7
Jejunal 1 Left sided 4
T/ileum 10 Pancolitis 8





No macroscopic dis 7
21 active and 17 inactive
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TABLE 9A;2 TOTAL SERUM IMMUNOGLOBULINS (ma/ml) IN PATIENTS
WITH CROHN'S DISEASE. ULCERATIVE COLITIS AND IN CONTROLS
CONTROL CD DC
median median median







2.4 0.9203 2.04 0.5923 0.5205
(0.5-6.8) (1.2-4.0)
10.9 0.3861 10.5 0.3289 0.8501
(4.6-20.4) (6.7-15.6)
1.12 0.5594 1.1 0.7290 0.4445
(0.3-2.63) (0.5-3.4)
PI = probability that the difference between Crohn's
disease and controls is due to chance.
P2 = probability that the difference between ulcerative
colitis and controls is due to chance.
PI = probability that the difference between Crohn's
disease and ulcerative colitis is due to chance.
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TABLE 9Ai3A THE FREQUENCY OF HIGH LEVELS OF ANTIBODIES
IN SERUM TO GLIADIN (GLI) . B-LACTOGLOBULIN (BLG) AND








CONTROL 23 4 10 5 2 2 13 5 0 4
CD 38 15 12 13 4 4 22 13 3 3
UC 19 3 7 4 0 1 9 7 1 5
N = number of subjects in the group
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TABLE 9A;3B SERUM IcrA. IcrG, IaM CLASS ANTIBODIES TO
GLIADIN (GLI). B-LACTOGLOBULIN (BLG) AND OVALBUMIN (OVA)
IN PATIENTS WITH CROHN'S DISEASE. ULCERATIVE COLITIS AND
CONTROLS EXPRESSED AS A PERCENTAGE OF A KNOWN STANDARD.
CONTROL CD UC
median median median
(Rancre) (Rancre) Pi (Ranae) P2 P3
aGLIA 10 10 0.2086 10 0.7140 0.0889
(10-35) (10-69) (10-14)
aGLIG 27 30 0.4890 19 0.1724 0.0602
(10-60) (10-86) (10-57)
aGLIM 37 46 0. 3260 52 0.6334 0.3833
(15-86) (10-215) (10-124)
aBLGA 10 10 0.8234 10 0.3121 0.3562
(10-37) (21-62) (10-31)
aBLGG 34 28 0.5418 23 0.1360 0.4983
(10-104) (10-160) (10-83)
aBLGM 23 17 0.4614 21 0.5442 0.8061
(10-49) (10-152) (10-40)
aOVAA 22 25.5 0.5921 18 0.8795 0.6600
(10-42) (10-143) (10-66)
aOVAG 15 23 0.2612 23 0.4637 0.6721
(10-75) (10-290) (10-83)
aOVAM 38 29 0.5686 34 1.0000 0.4516
(13-67) (10-141) (10-97)
PI,P2 and P3 = The probability that the difference
between CD, UC and controls or CD and UC respectively is
due to chance.
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TABLE 9A;4A THE FREQUENCY OF HIGH LEVELS OF ANTIBODIES
IN SERUM TO GLIADIN (GLI). B-LACTOGLOBULIN (BLG) AND
OVALBUMIN (OVA) IN ULCERATIVE COLITIS IN DIFFERENT
REGIONAL DISTRIBUTION (ever) AND DISEASE ACTIVITY.
IgG IgA IgM
N GLI BLG OVA GLI BLG OVA GLI BLG OVA
uc 19 3 7 4 0 1 9 7 1 5
aUC 12 2 3 2 0 0 6 6 1 3
inaUC 7 1 4 2 0 1 3 1 0 2
PROCTITIS 7 2 4 2 0 0 4 3 0 0
active 5 1 3 2 0 0 4 3 0 0
inactive 2 1 1 0 0 0 0 0 0 0
LSIDED 4 1 1 1 0 1 1 1 1 0
active 3 1 0 0 0 0 0 1 1 0
inactive 1 0 1 1 0 1 1 0 0 0
EXTENSIVE 8 0 2 1 0 0 4 3 0 5
active 4 0 0 0 0 0 2 2 0 3
inactive 4 0 2 1 0 0 2 1 0 2
CONTROL (23) 4 10 5 2 2 13 5 0 4
N = The number of all the patients studied with the
condition.
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TABLE 9A;4B THE FREQUENCY OF HIGH LEVELS OF ANTIBODIES IN
SERUM TO GLIADIN (GLI). fi-LACTOGLOBULIN (BLG) AND
OVALBUMIN (OVA) IN CROHN'S DISEASE IN DIFFERENT REGIONAL
DISTRIBUTION (ever) AND DISEASE ACTIVITY.
IgG IgA igM
N GLI BLG OVA GLI BLG OVA GLI BLG OVA
CD 38 15 12 13 4 4 22 13 3 3
aCD 24 8 6 8 2 1 13 7 3 3
inaCRO 14 7 6 5 2 3 9 6 0 3
SB 11 4 3 2 2 2 3 3 0 1
active 6 1 0 0 1 0 1 2 0 0
inactive 5 3 3 2 1 2 2 1 0 1
IC 7 4 3 3 1 1 6 3 1 1
active 4 1 1 1 0 0 3 1 1 0
inactive 3 3 2 2 1 1 3 2 0 1
CN 13 4 3 5 1 0 9 4 1 2
active 9 3 2 4 1 0 5 2 1 2
inactive 4 1 1 1 0 0 4 2 0 0
MISC 7 3 3 3 0 1 4 3 1 2
active 5 3 3 3 0 1 3 2 1 1
inactive 2 0 0 0 0 0 1 1 0 1
CONTROL (23) 4 10 5 2 2 13 5 0 4
N = The number of all the patients studied with the
condition.
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TABLE 9A:4C SERUM IaA. IaG. IqM CLASS ANTIBODIES TO
GLIADIN (GLI). B-LACTOGLOBULIN (BLG) AND OVALBUMIN (OVA)
IN PATIENTS WITH ACTIVE CROHN'S DISEASE. ACTIVE
ULCERATIVE COLITIS AND CONTROLS EXPRESSED AS A PERCENTAGE










aGLIA 10 10 0.3658 10 0.9861 0.3829
(10-35) (10-69) (10-14)
aGLIG 27 21 0.8149 10 0.4438 0.1227
(10-60) (10-86) (10-57)
aGLIM 37 46 0.4126 63 0.5516 0.0649
(15-86) (10-108) (36-124)
aBLGA 10 10 0.5800 10 0.1698 0.2829
(10-37) (10-27) (10-15)
aBLGG 34 18 0.1835 21 0.0499 0.3474
(10-104) (10-160) (10-56)
aBLGM 23 18 0.5301 25 0.6767 0.2539
(10-49) (10-152) (25-40)
aOVAA 22 20 0.8315 23 1.0000 0.8932
(10-42) (10-66) (10-57)
aOVAG 15 16 0.6704 22 0.7677 0.8273
(10-75) (10-204) (10-52)
aOVAM 38 29 0.4752 40 0.6894 0.2443
(13-67) (10-73) (10-97)
PI, P2 and P3 = The probability that the difference
between CD, UC and controls or CD and UC respectively is
due to chance.
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TABLE 9A:4D SERUM IqA. IgG. IaM CLASS ANTIBODIES TO
GLIADIN (GLI). ft-LACTOGLOBULIN (BLG) AND OVALBUMIN fOVA^
INPATIENTS WITH INACTIVE CROHN'S DISEASE. INACTIVE
ULCERATIVE COLITIS AND CONTROLS EXPRESSED AS A PERCENTAGE
OF A KNOWN STANDARD.
CONTROL CD DC
median median median














































NA = Not applicable
P1,P2 and P3 = As above
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TABLE 9A:5 COMPARISONS OF SERUM ANTIBODIES BETWEEN
OUIESCENT DISEASE AND ACTIVE DISEASE WITHIN DISEASE
GROUPS.
P P





aBLGG 0. 0528 0. 0546
aBLGM 1.0000 0.0584
aOVAA 0.2502 0.7998
aOVAG 0. 3968 0.3749
aOVAM 0.8510 0.4990
p = probability of the difference being due to chance.
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TABLE 9B;1 TOTAL WGLF IMMUNOGLOBULINS (ug/ml) IN PATIENTS
WITH CROHN'S DISEASE# ULCERATIVE COLITIS AND CONTROLS.
CONTROL(23) CD(38) UC(19)
median median median
(Range) (Range) Pi (Range) P2 P3
TIgA 143 171 0.9937 170.5 0.8029 0.9850
(12-478) (1.0-1217) (18-551)
TIgG 1 21.5 0.00001 19 0.00001 0.6908
(1-9) (1.0-393) (1-120)
TIgM 3 9 0.00001 9 0.0005 0.5170
(1-9) (1.0-102) (2-22)
PI = probability that the difference between Crohn's
disease and controls is due to chance.
P2 = probability that the difference between ulcerative
colitis and controls is due to chance.
PI = probability that the difference between Crohn's
disease and ulcerative colitis is due to chance.
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TABLE 9B:2A COMPARISONS OF WGLF TOTAL IcrM (uq/ml) BETWEEN
DISEASE GROUPS AND CONTROLS.
P
GROUP N MEDIAN RANGE vs CONTROL
CONTROL 23 3 1-9 NA
aCD 24 11 1-102 0.00001
inaCRO 14 7 1-39 0.0037
aUC 12 9 3-22 0.0017
inaUC 7 9 2-19 0.0273
p = probability of the difference between the group and
controls being due to chance.
TABLE 9B:2B COMPARISONS OF WGLF TOTAL IqA (uq/ml) BETWEEN
DISEASE GROUPS AND CONTROLS.
P
GROUP N MEDIAN RANGE VS CONTROL
CONTROL 23 143 12-478 NA
aCD 24 158 1-1217 0.7836
inaCRO 14 264 1-1109 0.6390
aUC 12 151.5 39-523 0.9584
inaUC 7 220.5 18-551 0.6864
NA = Not applicable
p = probability of the difference between the group and
controls being due to chance.
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TABLE 9B:2C COMPARISONS OF WGLF TOTAL IqG (uq/ml) BETWEEN
DISEASE GROUPS AND CONTROLS.
GROUP N MEDIAN RANGE vs CONTROL
CONTROL 23 1 H 1 NA
aCD 24 35 11-393 0.00001
inaCRO 14 4 1-10 0.0044
aUC 12 34 17-120 0.00001
inaUC 7 3 1-90 0.1698
p = probability of the difference between the group and
controls being due to chance.
TABLE 9B:3 COMPARISONS OF WGLF TOTAL IMMUNOGLOBULINS
(uq/ml) BETWEEN DISEASE GROUPS.
UC aCD(24) aCD aUC(12) inaUC
vs vs vs vs vs
CD inaCRO aUC inaUC inaCRO
LTIgA 0.9850 0.5431 0.9032 0.8883 0.7079
LTIgM 0.5170 0.2173 0.3755 0.8883 1.0000
LTIgG 0.6908 0.00001* 0.7755 0.0005* 0.2794
p = The probability that the difference would be a chance
finding.
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TABLE 9B:4A CORRELATIONS BETWEEN TOTAL SERUM AND LAVAGE
IMMUNOGLOBULIN LEVELS IN CROHN'S DISEASE AND ULCERATIVE
COLITIS.
CROHN'S DISEASE ULCERATIVE COLITIS
_E E £ £
IgA 0.358 0.242 0.229 0.977
IgG -0.077 0.624 -0.002 0.302
IgM 0.175 0.488 0.269 0.237
p = The probability that the correlation (r) would be a
chance finding.
TABLE 9B:4B CORRELATIONS BETWEEN TOTAL SERUM AND LAVAGE
IMMUNOGLOBULIN LEVELS IN ACTIVE CROHN'S DISEASE AND
ACTIVE ULCERATIVE COLITIS.
CROHN'S DISEASE ULCERATIVE COLITIS
_E E r E_
IgA 0.017 0.699 -0.297 0.568
IgG -0.238 0.390 0.103 0.345
IgM 0.092 0.711 0.197 0.823
p = The probability that the correlation (r) would be a
chance finding.
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TABLE 9B:4C CORRELATIONS BETWEEN TOTAL SERUM AND LAVAGE
IMMUNOGLOBULIN LEVELS IN INACTIVE CROHN'S DISEASE AND
ULCERATIVE COLITIS.
CROHN'S DISEASE ULCERATIVE COLITIS
r E £ e_
IgA 0.776 0.184 0.982 0.290
IgG -0.063 0.675 0.632 0.985
IgM 0.224 0.591 0.982 0.542
p = The probability that the correlation (r) would be a
chance finding.
TABLE 9 B:5A THE FREQUENCY OF DETECTABLE ANTIBODIES
IN WGLF TO GLIADIN (GLI). B-LACTOGLOBULIN (BLG) AND
OVALBUMIN (OVA) IN UC. CROHN'S AND CONTROLS.
IgG IgA IgM




23 0 0 0
38 2 0 2








TABLE 9B:5B WGLF IqA. IaM CLASS ANTIBODIES TO GLIADIN
jGLI) jl B-LACTOGLOBULIN (BLG) AND OVALBUMIN (OVA) IN
PATIENTS WITH CROHN'S DISEASE. ULCERATIVE COLITIS AND
CONTROLS EXPRESSED AS A PERCENTAGE OF A KNOWN STANDARD.
CONTROL CD DC
median median median











































PI = probability that the difference between Crohn's
disease and controls is a chance finding.
P2 = probability that the difference between ulcerative
colitis and controls is a chance finding.
PI = probability that the difference between Crohn's
disease and ulcerative colitis is a chance finding.
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TABLE 9 B:5 C THE FREQUENCY OF DETECTABLE ANTIBODIES
IN WGLF TO GLIADIN (GLI) . fi-LACTOGLOBPLIN (BLG) AND
OVALBUMIN (OVA) IN PATIENTS WITH PC. CROHN'S DISEASE WITH






CD (38) 18* 14 28 15* 5 15*
aCD (24) 12* 9 20* 11* 4 10*
inaCRO (14) 6 5 8 4 1 5
UC (19) 4 4 10 4 2 3
aUC (12) 3 3 4 2 2 3
inaUC (7) 1 1 6 2 0 0
CONTROL (23) 1 7 13 1 1 1
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TABLE 9B:5D WGLF IaA. IaM CLASS ANTIBODIES TO GLIADIN
(GLI) . B-LACTOGLOBULIN (BLG) AND OVALBUMIN (OVA) IN
PATIENTS WITH ACTIVE CROHN'S DISEASE (24). ACTIVE
ULCERATIVE COLITIS (12) AND CONTROLS (23) EXPRESSED AS A
PERCENTAGE OF A KNOWN STANDARD.
CONTROL(23) aCD(24) aUC(12)
median median median
(Ranae) (Ranae) PI (Ranae) P2 P3
aGLIA 10 10 0. 0073* 10 0. 3571 0.1109
(10-30) (10-43) (10-23)
aGLIM 10 10 0.0140* 10 0.5664 0.1354
(10-14) (10-85) (10-14)
aBLGA 10 10 0.5163 10 0.8621 0.5458
(10-22) (10-75) (10-33)
aBLGM 10 10 0.4500 10 0.5901 0.9065
(10-13) (10-26) (10-12)
aOVAA 11 20.5 0. 0132* 10 0.4980 0.0541
(10-88) (10-87) (10-89)
aOVAM 10 10 0.0269* 10 0.3270 0.4402
(10-15) (10-45) (10-67)
PI = probability that the difference between active
Crohn's disease and controls is a chance finding.
P2 = probability that the difference between active
ulcerative colitis and controls is a chance finding.
PI = probability that the difference between active
Crohn's disease and ulcerative colitis is a chance
finding.
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TABLE 9B:5E WGLF IaA. IaM CLASS ANTIBODIES TO GLIADIN
(GLI) . ft-LACTOGLOBULIN (BLG) AND OVALBUMIN (OVA) IN
PATIENTS WITH INACTIVE CROHN'S DISEASE finaCRO). INACTIVE
ULCERATIVE COLITIS (inaUC) AND CONTROLS EXPRESSED AS A










aGLIA 10 10 0.0541 10 0.7314 0.2794
(10-30) (10-82) (10-27)
aGLIM 10 10 0.2161 10 0.3774 0.8520
(10-14) (10-89) (10-11)
aBLGA 10 10 0.6611 10 0.5080 0.4118
(10-22) (10-121) (10-12)
aBLGM 10 10 0.8879 10 NA NA
(10-13) (10-15) (10-10)
aOVAA 11 11.5 0.6725 18 0.1938 0.5506
(10-88) (10-80) (10-31)
aOVAM 10 10 0.1068 10 NA NA
(10-15) (10-35) (10-10)
NA = Not applicable
PI = probability that the difference between active
Crohn's disease and controls is a chance finding.
P2 = probability that the difference between active
ulcerative colitis and controls is a chance finding.
PI = probability that the difference between active
Crohn's disease and ulcerative colitis is a chance
finding.
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TABLE 9B:6 COMPARISONS OF FOOD ANTIBODY LEVELS IN LAVAGE
IN PATIENTS WITH ACTIVE AND INACTIVE DISEASE.
P P







NA = Not applicable
p = The probability that the difference would be a chance
finding.
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TABLE 9 C: 1 CORRELATION BETWEEN SERUM AND LAVAGE
ANTIBODIES TO B-LACTOGLOBPLIN (BLG). GLIADIN (GLI) AND
OVALBUMIN (OVA) IN PATIENTS WITH CROHN'S DISEASE.
ULCERATIVE COLITIS AS COMPARED TO CONTROLS.
CONTROL(n=23) CD(n=38) UC(n=19)
_r E r E r e
aGLIA -0.066 0.826 0.297 0.016* NA NA
aGLIM -0.111 0.717 0.005 0.619 -0.417 0.323
aBLGA 0.232 0.0001* 0.166 0.001* 0.392 0.937
aBLGM NA NA -0.114 0.624 NA NA
aOVAA 0.338 0.669 0.216 0.179 -0.633 0.195
aOVAM -0.097 0.753 -0.023 0.999 0.464 0.002*
NA = Not applicable




SERUM IgA ANTIBODIES TO BLG PLOTTED AGAINST
CORRESPONDING ANTIBODIES IN WGLF OF
CONTROLS














SERUM IgA ANTIBODIES TO BLG PLOTTED AGAINST

































SERUM IgA ANTIBODIES TO GLI PLOTTED AGAINST
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SERUM IgM ANTIBODIES TO OVA PLOTTED AGAINST


















TABLE 9C:2 CORRELATIONS BETWEEN LAVAGE AND SERUM FOOD
ANTIBODIES IN PATIENTS WITH ACTIVE DISEASE.
CROHN1S(n=24) DC(n=12)
_r E r B
aGLIA 0.389 0.025* NA NA
aGLIM 0.064 0.529 -0.470 0.362
aBLGA 0.295 0.450 NA NA
aBLGM -0.168 0.566 NA NA
aOVAA 0.291 0.223 -0.641 0.337
aOVAM -0.236 0.438 0.699 0.0001*
NA = Not applicable
p = The probability that the correlation (r) would be a
chance finding.
The significant results were accounted for mainly by
negative results (see Graphs 9C:2A-B)
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Graph 9C:2A
SERUM IgA ANTIBODIES TO GLI PLOTTED AGAINST
CORRESPONDING ANTIBODIES IN WGLF OF PATIENTS























SERUM IgM ANTIBODIES TO OVA PLOTTED AGAINST
CORRESPONDING ANTIBODIES IN WGLF OF PATIENTS












TABLE 9C:3 CORRELATIONS BETWEEN LAVAGE IqA ANTIBODIES AND
LAVAGE TOTAL IqA IN CROHN'S DISEASE. ULCERATIVE COLITIS
AND CONTROLS
CD UC CONTROLS
r e E E £ P
BLG 0.685 0.0001* 0.416 0.088 0.167 0.456
GLI 0.376 0.057 0.207 0.410 0.402 0.065
OVA 0.333 0.472 0.012 0.264 0.169 0.452
p = The probability that the correlation (r) would be a
chance finding.
TABLE 9Ci4 CORRELATIONS BETWEEN LAVAGE IaM ANTIBODIES
AND LAVAGE TOTAL IaM IN CROHN'S DISEASE AND ULCERATIVE
COLITIS.
CROHN'S DISEASE ULCERATIVE COLITIS
r p r E_
BLG 0.285 0.187 0.243 0.633
GLI 0.239 0.662 0.110 0.484
OVA 0.351 0.147 0.126 0.633
p = The probability that the correlation (r) would be a
chance finding.
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TABLE 9C:5 CORRELATIONS BETWEEN LAVAGE IaA AND LAVAGE IctH
IMMUNOGLOBULINS AND ANTIBODIES IN CROHN'S DISEASE AND
ULCERATIVE COLITIS.
CROHN'S DISEASE ULCERATIVE COLITIS
r D r D
LTIgA VS LTIgM -0.170 0.679 -0.034 0.924
LGLIA vs LGLIM 0. 042 0.919 0. 061 0.942
LBLGA vs LBLGM 0. 004 0.742 0. 178 0.815
LOVAA vs LOVAM 0.430 0.017+ 0.201 0. 653
LTIgA = WGLF total IgA LTIgM = WGLF Total IgM
LGLIA = WGLF IgA antigliadin antibodies
LGLIM = WGLF IgM antigliadin antibodies
LBLGA = WGLF IgA antibodies to B-lactoglobulin
LBLGM = WGLF IgM antibodies to 6-lactoglobulin
LOVAA = WGLF IgA antiovalbumin antibodies
LOVAM = WGLF IgM antiovalbumin antibodies
No significant correlation between lavage IgA and lavage
IgM
+ accounted for mainly by negative values
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Graph 9C:5
WGLF IgA ANTIBODIES TO OVA PLOTTED AGAINST
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ACTIVE SMALL BOWEL (SB) 6
INACTIVE SMALL BOWEL (SB) 5
ACTIVE ILEOCAECAL (IC) 4
INACTIVE ILEOCAECAL (IC) 3
ACTIVE COLONIC (CN) 9
INACTIVE COLONIC (CN) 4
ACTIVE MISCELLANEOUS (MS) 5
INACTIVE MISCELLANEOUS (MS) 2
MS - Comprised of 4 patients with Crohn's proctitis, 1




ACTIVE PANCOLITIS (PAN) 4
INACTIVE PANCOLITIS (PAN) 4
ACTIVE LEFT SIDED (LS) 3
INACTIVE LEFT SIDED (LS) 1
ACTIVE PROCTITIS (PR) 5
INACTIVE PROCTITIS (PR) 2
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TABLE 9D:1B THE FREQUENCY OF DETECTABLE ANTIBODIES
IN WGLF TO GLIADIN (GLI). B-LACTOGLOBPLIN (BLG) AND
OVALBUMIN (OVA) IN ULCERATIVE COLITIS. CROHN'S DISEASE IN






UC (n=19) 4 4 10 4 2 3
PROCTITIS (7) 3 1 3 1 0 0
L. SIDED (4) 1 2 2 2 0 1
EXTENSIVE (8) 0 5 5 1 2 2
CD (n=38) 18 14 27 15 5 14
SB (11) 5 2 6 4 3 7
IC (7) 4 3 6 3 0 2
CN (13) 6 6 11 5 1 4
MISC (7) 3 3 4 3 1 1
CONTROL (^2 3) 1 7 13 1 1 1
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TABLE 9D t1C THE FREQUENCY OF DETECTABLE ANTIBODIES IN
WGLF TO GLIADIN (GLI) . B-LACTOGLOBULIN (BLG) AND
OVALBUMIN (OVA) IN CROHN'S DISEASE IN DIFFERENT REGIONAL






CD (38) 18 14 27 15 5 14
aCD (24) 12 9 19 11 4 10
inaCRO (14) 7 5 8 4 1 4
SB (11) 5 2 6 4 3 7
active (6) 3 1 4 3 2 5
inactive (5) 3 1 2 1 1 2
IC (7) 4 3 6 3 0 2
active (4) 2 1 4 1 0 1
inactive (3) 2 2 2 2 0 1
CN (13) 6 6 11 5 1 4
active (9) 4 5 8 5 1 3
inactive (4) 2 1 3 0 0 1
MISC (7) 3 3 4 3 1 1
active (5) 3 2 3 2 1 1
inactive (2) 0 1 1 1 0 0
CONTROL (23) 1 7 13 1 1 1
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TABLE 9D;1D THE FREQUENCY OF DETECTABLE ANTIBODIES IN
WGLF TO GLIADIN fGLI) . fi-LACTOGLOBULIN (BLG) AND OVALBU¬
MIN (OVA) IN ULCERATIVE COLITIS DISEASE IN DIFFERENT






uc (19) 4 4 10 4 2 3
aUC (12) 3 3 4 2 2 3
inaUC (7) 1 1 6 2 0 0
PROCTITIS (7) 3 1 3 1 0 0
active (4) 3 1 1 0 0 0
inactive (3) 0 0 2 1 0 0
LEFT SIDED (4) 1 2 2 2 0 1
active (3) 0 1 1 1 0 1
inactive (1) 1 1 1 1 0 0
PANCOLITIS (8) 0 1 5 1 2 2
active (4) 0 1 2 1 2 2
inactive (4) 0 0 3 0 0 0
CONTROL (23) 1 7 13 1 1 1
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TABLE 9 D;2 A THE PREVALENCE OF DETECTABLE ANTI-FOOD
ANTIBODIES IN PROXIMAL AND DISTAL CROHN'S DISEASE.
IgA IgM
GLI BLG OVA GLI BLG OVA
PROXIMAL (19) 10 6 13 7 3 9
DISTAL (18) 7 8 13 7 1 4
TABLE 9D;2B IaA and IaM ANTIBODIES IN WGLF TO GLIADIN
(GLI) . B-LACTOGLOBULIN (BLG) AND OVALBUMIN (OVA) IN
PATIENTS WITH PROXIMAL AND DISTAL CROHN'S DISEASE
EXPRESSED AS A PERCENTAGE OF A KNOWN STANDARD.
PROXIMAL DISTAL
MED RANGE N MED RANGE D
LGLIA (19) 12 10-82 18 10 10-43 0. 370
LGLIM (19) 10 10-85 18 10 10-89 0.9758
LBLGA (19) 10 10-121 18 10 10-75 0.5844
LBLGM (19) 10 10-26 18 10 10-21 0.6161
LOVAA (19) 19 10-60 18 18 10-87 0.7497
LOVAM (19) 10 10-44 18 10 10-45 0.2875
LGLIA and LGLIM = WGLF IgA and IgM antigliadin antibodies
respectively.
LBLGA and LBLGM = WGLF IgA and IgM antibodies to
B-lactoglobulin respectively.
LOVAA and LOVAM = WGLF IgA and IgM antiovalbumin
antibodies respectively.
p = probability of the difference between proximal and
distal levels being a chance finding for the particular
antibody.
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TABLE 9D12C IaA AND IaM CLASS ANTIBODIES TO GLIADIN
(GLI) . B-LACTOGLOBULIN (BLG ^ AND OVALBUMIN (OVA) IN
PATIENTS WITH PROXIMAL AND DISTAL ACTIVE CROHN'S DISEASE
EXPRESSED AS A PERCENTAGE OF A KNOWN STANDARD.
PROXIMAL DISTAL
MED RANGE N MED RANGE D
LGLIA (11) 20 10-43 12 10 10-43 0.5383
LGLIM (11) 10 10-85 12 10 10-51 0.9020
LBLGA (ID 10 10-44 12 10 10-75 0.4417
LBLGM (11) 10 10-26 12 10 10-21 0.7119
LOVAA (11) 19 10-60 12 23 . 5 10-87 0. 4060
LOVAM (11) 12 10-44 12 10 10-45 0. 3248
p = probability of the difference between proximal and
distal levels being a chance finding for the particular
antibody.
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TABLE 9D:2 D laA AND IaM CLASS ANTIBODIES TO GLIADIN
(GLI) . 6-LACTOGLOBULIN f BLG ^ AND OVALBUMIN (OVA^ IN
PATIENTS WITH PROXIMAL AND DISTAL INACTIVE CROHN'S
DISEASE EXPRESSED AS A PERCENTAGE OF A KNOWN STANDARD.
PROXIMAL DISTAL
N MED RANGE N MED RANGE D
LGLIA 8 11 10-82 6 10 10-42 0.5186
LGLIM 8 10 10-21 6 10 10-89 0.6985
LBLGA 8 10 10-121 6 10 10-64 0.9485
LBLGM 8 10 10-15 6 10 10-10 NA
LOVAA 8 19 10-58 6 11.5 10-80 1.0000
LOVAM 8 12 10-35 6 10 10-22 0.7469
LGLIA and LGLIM = WGLF IgA and IgM antigliadin an
respectively.
LBLGA and LBLGM = WGLF IgA and IgM antibodies to
B-lactoglobulin respectively.
LOVAA and LOVAM = WGLF IgA and IgM antiovalbumin
antibodies respectively.
p = probability of the difference between proximal and
distal levels being a chance finding for the particular
antibody.
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TABLE 9Di3A TOTAL IqA and IcrM IN WGLF OF PATIENTS WITH
PROXIMAL AND DISTAL CROHN'S DISEASE. Statistical
comparisons by Mann-Whitney.
PROXIMAL DISTAL
N MED RANGE N MED RANGE p
LTIgA 17 97 1-778 18 208 23-1217 0.2834
LTIgG 19 12 1-64 18 25.5 1-90 0.4384
LTIgM 17 8 1-102 18 11.5 4-59 0.3302
LTIgA = WGLF total IgA LTIgM = WGLF Total IgM
LTIgG = WGLF total IgG
p = probability of the difference between proximal and
distal levels being a chance finding for the particular
antibody.
TABLE 9 D: 3 B TOTAL IaA. IaM IN WGLF OF PATIENTS WITH
ACTIVE 'PROXIMAL1 AND ACTIVE 'DISTAL' CROHN'S DISEASE.
Statistical comparisons by Mann-Whitney.
PROXIMAL DISTAL
N MED RANGE N MED RANGE P
LTIgA 11 97 1-371 12 184 27-1217 0.4417
LTIgG 11 36 11-64 12 30.5 19-90 0.6225
LTIgM 11 8 1-102 12 12 . 5 4-59 0.2679
p = probability of the difference between proximal and
distal levels being a chance finding for the particular
antibody.
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TABLE 9D;3C TOTAL IaA AND IqM IN PATIENTS WITH INACTIVE
PROXIMAL AND INACTIVE DISTAL CROHN'S DISEASE. Statistical
comparisons by Mann-Whitney.
PROXIMAL DISTAL
N MED RANGE N MED RANGE P
LTIgA 6 167 1-778 6 394 23-1109 0.4712
LTIgG 8 4 1-10 6 5.0 1-9 0.7963
LTIgM 6 6.5 1-39 6 7.5 4-30 0.9362
LTIgA = WGLF total IgA LTIgM = WGLF Total IgM
LTIgG = WGLF total IgG
p = probability of the difference between proximal and




HUMORAL IMMUNITY AND ELEMENTAL DIET
INTRODUCTION
A number of workers have reported increased food
antibody levels in the serum of patients with
inflammatory bowel disease to specific antigens such as
cow's milk protein (Taylor and Truelove, 1961) and
gliadin (Koninckx et al. . 1984; see chapter 2B) . Crohn's
disease patients have higher food antibody levels in
their intestinal secretions than controls (see chapter
9).Exclusion diets have been used in inducing and
prolonging disease remission in inflammatory bowel
disease (see chapter 5). Elemental diets have also been
shown to induce remission in acute inflammatory bowel
disease (Okada et al..1990; O'Morain et al.. 1980;
Giaffer et al.. 1990; see chapter 5).
One postulated mechanism is that since elemental
diets are devoid of polypeptides they are not antigenic.
Therefore the provision of nutrition without the
injurious antigenic stimulation may account for their
efficacy (see chapter 5) . If indeed this is the way
elemental diets act then one would expect patients who
respond to have positive food antibodies or sensitive T
cells and a change in food antibody levels or T cell
activity when on elemental diet.
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AIM OF STUDY
The aim of this study was to find out whether elemental
diets led to a down-regulation of humoral immune activity
and whether this down regulation correlated with
disease response. After studying the steady state of
immunoglobulins in parotid saliva and serum the effects
of elemental diet on humoral immunity were studied
in four ways. The first part examined the changes in
parotid saliva immunoglobulin and food antibody levels
when patients are prescribed elemental diet, the second
part similarly examined changes in serum immunoglobulins
and food antibodies. The third part is a study of the
changes in the numbers of immunoglobulin and antibody
secreting cells in peripheral blood and finally changes
in the levels of immunoglobulins and antibodies in whole
gut lavage fluid (WGLF) were studied. The food antibodies
studied were antigliadin (GLI), anti-B-lactoglobulin
(BLG) and anti-ovalbulmin (OVA) [see chapter 5]. No work
so far has been done to look at the effect of elemental
diets on circulatory and mucosal total immunoglobulins
and antibodies to food antigens. This work aims at
contributing to fill this gap.
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SERUM AND SALIVA STUDY
SUBJECTS AND PROTOCOL
A total of 33 patients were studied and 31 of these had
elemental diet for at least 7 days, two had a polypeptide
based liquid diet, triosorbin. All the patients provided
serum during the study (Table 10:1A and Table 10:IB).
Corresponding saliva and serum samples were collected
from 19 patients, 13 Crohn's disease, 2 ulcerative
colitis and one each with short gut syndrome, villous
adenoma, carcinoma of the colon and coeliac disease. The
age range was 20-82. Six patients were on steroids. In
the corresponding saliva and serum study group 16
patients had elemental diet for at least 7 days.
The other 14 who provided serum specimens only comprised
of 12 Crohn's disease, one each with ulcerative colitis
and coeliac disease.
Saliva and serum specimens were collected before
commencement of diet, at least once a week during dietary
therapy and within 4-7 days after completion of the
dietary regime.
For the analysis of food antibodies, only patients with
highly positive initial food antibody levels as compared
to a known standard (see chapter 6) were considered. Any
value above 10 in parotid saliva was considered positive.
Serum IgA antibody values above 20, IgG above 40 and
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IgM above 60 were considered highly positive. All
inflammatory bowel disease patients had active disease on
global assessment when elemental diet was started.
SIMULTANEOUS SERUM AND PAROTID SALIVA STUDY
The first part of the study examines the pattern of
immunoglobulins (Ig) and antibodies in saliva and serum
of these patients before commencing on elemental diet.
Where more than one specimen had been measured a mean
value was taken.
SECTION 10A ~ PAROTID SALIVA STUDIES
TOTAL IMMUNOGLOBULINS IN SALIVA
IgA was the most abundant immunoglobulin in saliva, for
example pre-elemental diet the range was 15-205ug/ml with
a median of 90ug/ml. One patient (LD) was IgA deficient.
The amounts of IgG and IgM were negligible (Table 10A:2
in appendix to this chapter). All graphs and tables for
this chapter are in the appendix to this chapter.
THE RELATIONSHIP BETWEEN TOTAL SALIVA IgA AND SERUM IaA
A mean total parotid saliva IgA for each patient was
calculated from all total saliva results obtained from
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each patient before elemental diet. The means for serum
IgA were similarly obtained.
There was no significant correlation (r=0.527, p=0.057)
between mean total saliva IgA and mean total serum IgA
(Graph 10A:2A in appendix to this chapter).
PATTERNS OF SALIVA TOTAL IaA LEVELS IN INDIVIDUALS
Whereas total IgA saliva levels tend to vary from day to
day (Graph 10A:2B) for each individual the variation is
within a very narrow range which allows for major
changes which may result from dietary manipulation or
drug administration to be studied.
THE RELATIONSHIP BETWEEN SMOKING AND TOTAL SALIVARY IaA
None of the patients smoked more than 20 cigarettes a
day. They were grouped into three categories; group 1
smoked 0-5/day, group 2 smoked 6-10/day and group 3
11-20/day (Graph 10A:2C). There was no correlation
between smoking and total salivary IgA (r=0.023,
p=0.924).
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THE RELATIONSHIP BETWEEN SALIVA AND SERUM FOOD ANTIBODY
LEVELS
SALIVA IaG ANTIBODIES AND SERUM IaG ANTIBODIES
Eight patients had at least one positive value of IgG
anti-food antibodies in saliva. One value from each of
these eight patients was used to calculate correlation
coefficients between the levels of food antibodies in
saliva and serum.
In individuals with positive IgG anti-food antibody
levels in saliva, there was a strong correlation with
antibodies in serum (r=0.364, p=0.045 and Graph 10A:3A).
However when the correlations were done using positivity
in serum as the index there was no correlation between
serum and saliva antibody levels to corresponding
antigens (r=0.233, p=0.804).
There was no correlation between total serum IgG and
total saliva IgG (r=0.378, p=0.267 and Graph 10A:3B).
This most probably implies a leak of serum IgG antibody
into the few positive IgG saliva specimens that showed a
positive correlation.
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THE RELATIONSHIP BETWEEN SALIVA IaA ANTIBODIES AND SERUM
IqA ANTIBODIES
Saliva specimens positive for IgA food antibodies were
correlated against their corresponding levels in sera.
There was no significant correlation between serum IgA
and saliva IgA antibodies (r=0.307, p=0.146 and Graph
10A:3C) neither was there a significant correlation
between total serum IgA and total saliva IgA levels
(r=0.482, p=0.109 and Graph 10A:3D).
THE EFFECT OF ELEMENTAL DIET ON TOTAL IMMUNOGLOBULIN
CONCENTRATIONS IN SALIVA
Total Immunoglobulin levels in saliva were plotted for
each individual at three time points; before elemental
diet (Before ED), during elemental diet (During ED) and 4
or more days after elemental diet (After ED) for IgA
(Graphs 10A:4A). The same was done for IgG and IgM total
immunoglobulins (Graph 10A:4B).
There was no significant fall in the total salivary
immunoglobulins of all classes during or after elemental
diet. This applied even when patients were subdivided
into responders and non-responders (Table 10A:4A, 10A:4B,
10A:4C and 10A:4D-F).
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THE EFFECT OF ELEMENTAL DIET ON FOOD ANTIBODIES IN SALIVA
On global assessment 6 of the 16 patients who had parotid
saliva studies improved with elemental diet. Food
antibodies in the patients with initial positive levels
were plotted. In parotid saliva antibody levels above 10%
of the known high standard were considered positive (see
chapter 6A).
Five of the 6 who improved had positive food IgA
antibodies in saliva (except LM) a total of 10 positive
results. And 5 of the 10 patients who did not respond also
had positive food antibodies to one or more antigens a
total of 9 positive results. One in this latter group
(LD) was IgA deficient. Both the non IBD patients, IM
(coeliac) and MD (villous adenoma), had positive initial
IgA antibodies.
The positive initial food antibody levels were
exclusively in the IgA class except for two positive IgM
results from one patient (CC). These specimens had been
contaminated with blood due to vigorous suction in the
learning phase of the collection of saliva. There were no
initial positive IgG antibodies.
There was no significant difference in the IgA food
antibody levels before and during elemental diet. There
was a statistically significant fall in IgA antibody
levels after the re-introduction of a normal diet
(p=0.030). What was more unexpected was that this
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difference was accounted for mostly by those who did not
improve (p=0.030) and not those who improved (p=0.477).
The significance of this at 3% level is debatable in view
of the many comparisons being made (Table 10A:5A, Table
10A:5B and Graph 10A:5).
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SECTION 10B
SERUM TOTAL IMMUNOGLOBULINS AND ANTIBODIES IN PATIENTS ON
ELEMENTAL DIET
SUBJECTS AND PROTOCOL
Serum was collected from 31 patients (including the 16 in
the saliva-serum study) at commencement of elemental
diet, during and 4 to 7days after elemental diet.
On global assessment 10 improved (Table 10:1A and Table
10:IB previously shown).
THE EFFECT OF ELEMENTAL DIET ON TOTAL SERUM
IMMUNOGLOBULINS
There was no significant fall in all immunoglobulin
classes during elemental diet as compared to the values
before elemental diet. There was a significant fall
(p=0.024) in the total IgG after the diet as compared to
the levels during the diet (Table 10B:1A and Table
10B:IB). This significant difference held even when only
IBD patients were considered (p=0.042) [Table 10B:1C and
Table 10B:1D].
When the subjects were subdivided into those who
responded (Table 10B:1E and Table 10B:1F) and those who
did not respond (Tables 10B:1G and Table 10B:1H) there
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was no significant difference in all immunoglobulin levels
with diet.
There were only three non IBD patients and they did not
show any significant fall in immunoglobulins (Graph
10B:1J).
THE EFFECT OF ELEMENTAL DIET ON LEVELS OF ANTI-FOOD
ANTIBODIES IN SERUM
The effect of elemental diet on all patients with highly
positive serum antifood antibodies was studied. These
were patients with antibody levels for IgA > 20%, IgG >
4 0% and IgM > 60% as compared to the known high standard
(referred to as 'positive'). These results were plotted
for three time points; before elemental diet (Before ED),
during elemental diet (During ED) and 4 or more days
after elemental diet (After ED). Where there was more
than one highly positive result during a particular
dietary regime a mean was taken.
SERUM IaA ANTIBODIES AND ELEMENTAL DIET
Five of the 10 responders had positive antibodies to at
least one antigen (a total of 8 positive results), 9 of
the non-responders had positive antibodies as well (a
total of 12 results). Two non-IBD patients (IM and MC)
had high levels of antibodies to OVA and a high level to
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BLG in one (MC) and GLI in the other (IM) [Graphs 10B:2H
appendix p.293].
Considering all the subjects there was no significant
fall in serum levels of IgA antibodies to the three food
antigens GLI, BLG and OVA while on ED the fall appearing
only after patients had returned to normal diet. The
difference in the levels of anti-food antibody levels
between during elemental diet and after returning to
elemental diet was significant (p=0.010) [Tables 10B:2A
and 10B:2B].
Similarly, when only IBD patients were considered,
the only significant drop in the level of anti-food
antibodies was for IgA after the patients had returned to
a normal diet (p=0.016) [Tables 10B:2C and 10B:2D].
However when only subjects with IBD who improved were
considered there was no significant difference in
anti-food antibody levels between diets (Tables 10B:2E
and Table 10B:2F). Whereas those that did not improve
still showed a significant fall in anti-food antibodies
between during elemental diet and after returning to
normal diet (p=0.022) [Tables 10B:2G and Table 10B:2H],
There were no marked changes in the levels of food
antibodies in non-inflammatory bowel disease patients
during and after a period of elemental diet and neither
was there any change in their clinical state.
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SERUM IqM ANTIBODIES AND ELEMENTAL DIET
Positive IgM antibodies to at least one antigen were
found in 4 responders (a total of 5 positive results), 8
non-responders (a total of 10 results) and two non-IBD
patients (a total of 3 results). Three responders showed
a fall of IgM antibody levels when on elemental diet in
the other two there was a rise during this period. In two
of the three who showed a fall, the decline in food
antibody levels continued after the re-introduction of
normal diet. The specimen of serum taken after the re-
introduction of normal diet for one patient (DM) was not
available. The other two responders showed a rise on
introduction of elemental diet which fell in one (JD) and
rose further in one (PM) after the re-introduction of
normal diet. The two none IBD patients referred to in
the graphs as 'others' showed a downward trend but
the numbers of patients involved were not adequate for
statistical valuations. There was no significant fall in
any of these antibodies during or after elemental diet in
IBD patients (Tables 10B:2B-H and Graphs 10B:2F, p.291).
SERUM IaG ANTIBODIES AND ELEMENTAL DIET
Positive IgG antibodies to at least one food antigen were
found in five responders (a total of 6 results), 12 non
responders (a total of 18 results) and two non IBD
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patients (a total of 4 results). There was no significant
fall in the antibody levels during and after a period of
ED regardless of the clinical response of IBD patients
(Tables 10B:2B-H as above and Graphs 10B:2G, p.292)
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SECTION IOC
THE NUMBERS OF IMMUNOGLOBULIN AND ANTIBODY SECRETING B
CELLS IN PERIPHERAL BLOOD BEFORE AND DURING ELEMENTAL
DIET
The AIM of this phase of the study was to find out
whether there was a fall in antibody activity
attributable to treatment with ED which was not
detectable by the less sensitive ordinary ELISA but would
be detected by an ELISPOT assay (Described in chapter
6B) .
SUBJECTS AND PROTOCOL
A total of nine patients were studied (Table 10C:1A). All
the IBD patients had active disease on global assessment.
Eight had inflammatory bowel disease and one had coeliac
disease. The age range was 23-34. All the patients
consumed an elemental diet for at least 7 days, and the
clinical condition of three improved.
Venous blood was drawn before, and on the seventh
or later days of elemental diet. The lymphocytes were




TOTAL IMMUNOGLOBULIN SECRETING CELLS AND ELEMENTAL DIET
There were no significant changes in the numbers of
peripheral blood B cells secreting IgA, IgG and IgM
during the diet compared to initial numbers (Graph
IOC:1A; Tables IOC:IB and Table 10C:1C).
ANTI-FOOD ANTIBODY-SECRETING CELLS AND ELEMENTAL DIET
There were few class-specific antibody producing cells to
any of the three dietary antigens (OVA, BLG, GLI) [Graph
10C:2A]. For all patients there were more IgA antibody
secreting B-cells (range 5-180 per million lymphocytes),
few IgG and IgM antibody secreting cells (ranges 4-19 per
million and 3-10 per million, respectively) [Data not
shown].
There was no significant fall in the number of IgM, IgG
and IgA antibody secreting cells attributable to ED when
all the patients were considered. However when only
patients with IBD were considered there was a borderline
significant fall in the numbers of IgA antibody spots




These results show that the ELISPOT assay did not detect
any reduction in antibody or immunoglobulin secretory
activity due to ED. These results confirm those obtained
in chapter 10A and 10B with ordinary ELISA for saliva and
serum respectively. Even here the significant fall in IgA
secretory activity of 1:20 (p=0.043; Table 10C:2A) is




WHOLE GUT LAVAGE (WGLF) IMMUNOGLOBULIN AND FOOD
ANTIBODIES IN PATIENTS ON ELEMENTAL DIET
INTRODUCTION
Systemic immunity does not necessarily reflect mucosal
immunity, as changes at the mucosal level may not be
reflected in peripheral circulation (this has been
discussed in chapters 2 and 9) .
The aim of this phase of the study therefore was to find
out whether there was a fall in the levels of food
antibodies in gut lavage fluid when patients were on
elemental diet, as it was in this compartment that higher
levels of anti-food antibodies in IBD patients compared
to controls were found (see chapter 9) .
SUBJECTS AND PROTOCOL
Lavage specimens were collected prior to commencing and
after more than 7 days of dietary treatment from 12
patients with inflammatory bowel disease (Table 10D:1A).
Eleven patients had elemental 028, and one (FK) had a
polypeptide based diet (Triosorbin) . One of the elemental
diet patients had ulcerative colitis, the rest had
Crohn's disease. All IBD patients had active disease and
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9 of them met the lavage IgG criteria for active disease
(total lavage IgG >10) . Three of these patients showed
clinical improvement (DM, DB, BS). One non-IBD (Coeliac)
patient was also studied. One patient DM was IgA
deficient.
TOTAL WGLF IMMUNOGLOBULINS AND ELEMENTAL DIET
Seven of the patients showed a rise in total WGLF IgA
immunoglobulins during ED, three showed a fall and in one
was IgA deficient. Nine showed a fall in total WGLF
IgG, one showed a rise (SJ) and in two the levels
remained unchanged (MI,BS). Total WGLF IgM fell in five
patients when on elemental diet, rose in five patients
and in one (DS) they levels remained unchanged (Graph
10D-.1A) .
Analysis of these levels showed that was no significant
difference in the levels of IgA and IgM immunoglobulins
before ED and during ED. There was a fall in the levels
of IgG of borderline significance (p=0.044) [Table
10D:1C).
THE EFFECT OF ELEMENTAL DIET ON WGLF FOOD ANTIBODIES
Positive food antibodies were mainly in the IgA and IgM
class. Of the eleven IBD patients on elemental diet 6
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had positive IgA antibodies to one or more of the three
dietary antigens (a total of 15 results). There were four
positive IgG antibody results, 3 from one patient (CCamp)
and one from patient AM. The IgG was probably derived
from serum (see discussion of WGLF IgG and disease
activity in chapter 7). Seven of the eleven IBD patients
had positive IgM food antibodies to one or more antigens
(A total of 13 positive IgM antibody results).
There was no significant difference in the food antibody
levels for the IgA and IgM class between before and
during elemental diet. There was a fall in IgG antibodies
(p=0.001) but this was for the two patients with a total
of four positive results (Table 10D:2A and Table 10D:2B).
Both these patients did not improve after the diet. The
individual results are plotted in Graph 10D:2A.
The patient (FK) on the polypeptide diet had initial
positive IgM and IgA anti-ovalbumin. The IgA antibody
levels fell and the IgM antibody levels rose while on the
diet (Graph 10D:2A). The clinical condition of this
patient improved. The coeliac patient (ES) had positive
IgA and IgM antibodies to all three antigens before
beginning ED which fell when on elemental diet and her
condition did not change (Graph 10D:2B).
261
GENERAL COMMENTS
SALIVA and SERUM IMMUNOGLOBULINS AND FOOD ANTIBODIES
In saliva the most abundant immunoglobulin class is IgA
as would be expected, the levels of IgG and IgM are very
low and the saliva samples that had levels above lOug/ml
had probably been contaminated with blood.
There was no significant correlation between saliva and
blood total IgA. This confirms what is already known that
the two compartments are independent (O'Mahony et al..
1991a).
The lack of correlation between the levels of IgA
specific for dietary antigens in serum and saliva also
adds further evidence to the independence of the two
compartments as already reported (discussed in chapter 2B
and chapter 9). Whereas there are day to day fluctuations
in the levels of salivary IgA immunoglobulins, each
individual tends to have their levels within a narrow
range so that it is possible to study large fluctuations
caused by disease or treatment.
The absence of correlation between smoking and total
lavage IgA in saliva in this study may be due to the fact
that most of this patient group were non-smokers and of
those who smoked none smoked more than twenty a day.
Smoking would not influence the results in this case as
only those who smoked more than 20 per day had lower
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levels of total parotid saliva IgA (Barton et al ., 1990).
There were no significant falls in salivary and serum
immunoglobulins or antibodies during elemental diet
regardless of the patient group or the outcome. The
paradoxical significant falls in saliva IgA antibodies
occurred only after the re-introduction of normal diet as
compared to the levels during ED (p=0.031). When this is
further analysed the significant fall was seen only in
non-improvers (p=0.030) and not those who improved
(p=0.477) [Table 10A:5B]. Total serum IgG fell after the
re-introduction of normal diet (p=0.024; Table 10B:1B).
However when the patients were divided into responders
and non responders, there was no significant difference
(Table 10B:1F and 10B:1H). Serum IgA antibodies also fell
when patients were back on normal diet(p=0.016, Table
10B:2D), the fall being confined only to the non-
responders (p=0.022; Table 10B:2H) and not responders
(p=0.234; Table 10B:2F). This could be a delayed
detection of the effect of the diet but then one would
have expected the fall in antibodies to be confined to
the patients who improved. Furthermore the numbers of
antibody secreting cells as measured by ELISPOT, which
would show changes earlier (see chapter 6C) , do not
support a possible early difference that may have not
been detected by ordinary ELISA. I propose that this is a
chance finding.
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IMMUNOGLOBULIN AND ANTIBODY SECRETING CELLS IN THE
PERIPHERAL BLOOD OF PATIENTS ON ELEMENTAL DIET
There were more B cells secreting IgA than the other
two classes. This confirms similar findings using other
techniques (Kutteh et al., 1980).
There were no changes in the numbers of class-specific
immunoglobulin producing cells before as compared to the
numbers during ED. The significant fall in IgA anti-food
antibody secreting cells (p=0.043; Table 10C:2A) is
influenced unduly by one result (BS). Without this result
the changes in the number of IgA antibody secreting cells
due to ED become non significant (p=0.075).
WHOLE GUT LAVAGE IMMUNOGLOBULINS AND FOOD ANTIBODIES IN
PATIENTS ON ELEMENTAL DIET
There was no fall in total IgA or IgM when patients were
on elemental diet. The borderline significant fall
(p=0. 044, Table 10D:1C) in total WGLF IgG which is a
measure of disease activity in inflammatory bowel disease
(see chapter 5) would indicate reduced disease activity
in the group as a whole despite the individual
variations. As before this significance of 1:20 is
debatable in view of the many comparisons being made. The
IgG immunoglobulin is probably plasma derived, and the
fall in WGLF total IgG indicates reduced leakage from
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plasma. Similarly the significant fall in IgG antibodies
(p=0.001) involves only two patients and this class of
antibodies are most likely serum derived (see chapter 9),
this fall therefore does not reflect a specific effect of
the diet on mucosal immunity.
SUMMARY
The expected response rate to elemental diet in acute
inflammatory bowel disease is about 80%, equivalent to
the response to steroid therapy (O'Morain et al.. 1984;
Okada et al., 1990). The proportion of responders is much
lower in this study, about 30%. Invariably the patients
in this study were prescribed elemental diet only when
other treatments had failed to alleviate their clinical
disease. Elemental diet was by no means a first line
treatment nor was the study evaluating the efficacy of
elemental diet.
The consistent feature of this study was that there was
no fall in antibody levels in serum, saliva and whole
gut lavage fluid when patients were on an elemental diet
i.e a diet which is devoid of antigenic polypeptides.
There was no fall either in the number of antibody
secreting cells in peripheral blood reflecting that a
delayed detection in the serum could not account for the
lack of significant differences in serum ELISA results.
This work therefore suggests that down regulation of
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systemic and mucosal B cell antibody activity IS NOT the
mechanism of action of elemental diet.
Though only one coeliac patient had WGLF studies the
dramatic fall in the antibody levels for food antigens


















































































































































































































































































































































































































































































































































































































































































































































APPENDIX FOR CHAPTER 10
TABLE 10A;2 TOTAL SALIVA IMMUNOGLOBULINS (uq/ml) BEFORE
ELEMENTAL DIET.
N MED RANGE
IgA 15 90 15-205
IgG 16 1.5 1-19
IgM 16 1.5 1-8
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Graph 10A:2A
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Group 2 Group 3
(6-10 cigarettes/ (11-20 cigarettes/
day) day)
On the x axis patients were divided into three groups according to
numbers of cigarettes smoked per day. On the y axis are the
concentrations of IgA. There was no difference between groups.
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Graph 10A:3A
PAROTID SALIVA IgG ANTIBODIES PLOTTED AGAINST
CORRESPONDING ANTIBODIES IN SERUM OF
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TABLE 10A; 4A TOTAL SALIVA IMMUNOGLOBULINS (ucr/mli BEFORE.
DURING AND AFTER ELEMENTAL DIET.
BEFORE ON ED AFTER ED
N MED MED MED
(RANGE) (RANGE) (RANGE)
IgA 15 90 101 87
(15-205) (14-186) (12-240)
IgG 16 1.5 2 1.5
(1-19) (1-34) (1-49)
IgM 16 1.5 2 1.5
(1-8) (1-13) (1-7)
TABLE 10A;4B TOTAL SALIVA IMMUNOGLOBULINS (uq/ml) BEFORE.
DURING AND AFTER ELEMENTAL DIET IN RESPONDERS.
BEFORE ON ED AFTER ED
N MED MED MED
IgA 6 113 123 76
(57-182) (65-186) (45-165)
IgG 6 1.5 1 1.0
(1-6) (1-5) (1-2)
IgM 6 1.5 1.5 1.0
(1-8) (1-7) (1-7)
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TABLE 10A;4C TOTAL SALIVA IMMUNOGLOBULINS (uq/ml) BEFORE.
DURING AND AFTER ELEMENTAL DIET IN NON-RESPONDERS.
BEFORE ON ED AFTER ED























TABLE 10A:4D TOTAL SALIVA IMMUNOGLOBULINS BEFORE. DURING
AND AFTER ELEMENTAL DIET IN ALL IBP PATIENTS. Statistical
comparisons by Mann-Whitney (p values).
IgA IgG IgM
BEFORE VS ON ED 0.443 0.295 0.666
BEFORE VS AFTER ED 0.670 0.471 0.824
ON ED VS AFTER ED 1.00 0.610 0.374
p= Probability that the difference is a chance finding
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TABLE 10A:4E TOTAL SALIVA IMMUNOGLOBULINS BEFORE. DURING
AND AFTER ELEMENTAL DIET IN THE PATIENTS WHO
RESPONDED.Statistical comparisons by Mann-Whitney (p
values).
IaA IgG IaM
BEFORE VS ON ED 1.000 0.181 0.590
BEFORE VS AFTER ED 0.059 0.371 0.789
ON ED VS AFTER ED 0.059 0.593 0.855
p= Probability that the difference is a chance finding
TABLE 10A:4F TOTAL SALIVA IMMUNOGLOBULINS BEFORE. DURING
AND AFTER ELEMENTAL DIET IBP THE PATIENTS WHO DID NOT
RESPOND. Statistical comparisons by Mann-Whitney (p
values).
IgA IgG IaM
BEFORE VS ON ED 0.407 0.933 0.310
BEFORE VS AFTER ED 0.058 1.000 0.529
ON ED VS AFTER ED 0.236 0.310 0.355
p= Probability that the difference is a chance finding
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TABLE 1OAi5A SALIVA IqA FOOD ANTIBODY LEVELS BEFORE.
DURING AND AFTER ELEMENTAL DIET.
BEFORE ED ON ED AFTER ED
N MED MED MED
(RANGE) (RANGE) (RANGE)
ALL 19 36 30 20
(14-124) (9-150) (4-150)*
RES 10 55 29 25
(20-124) (9-150) (2-150)
NON RES 9 33 35 18
(14-79) (11-69) (11-60)*
RES - patients who improved clinically
NON-RES Patients who did not improve clinically
*Significantly lower than when on elemental diet
TABLE 10A:5B SALIVA IqA FOOD ANTIBODIES BEFORE. DURING
AND AFTER ELEMENTAL DIET. Statistical analysis by
Wilcoxon paired signed rank test (p values)
ALL RES NON-RES
BEFORE VS ON ED
BEFORE VS AFTER ED










p= Probability that the difference is a chance finding
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Graph10A:5
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TABLE 10B:1A TOTAL SERUM IMMUNOGLOBULINS (IP/ml) OF ALL
IgA IgG IgM
N MED MED MED
(RANGE) (RANGE) (RANGE)
BEFORE 23 132 116 130
(78-294) (55-259) (23-334)
ON ED 19 158 121 171
(16-333) (64-334) (31-373)
AFT ED 22 132 100 135
(64-272) (53-261) (31-361)
TABLE lOBtlB COMPARISONS OF TOTAL SERUM IMMUNOGLOBULINS
OF ALL PATIENTS BEFORE. DURING AND AFTER ELEMENTAL DIET
Statistical analysis by Wilcoxon paired signed rank test
(p values)
BEFvsED BEFvsAFT EDvsAFT
IgA 0.142 1.000 0.557
IgG 0.073 0.114 0.024*
IgM 0.147 0.426 0.218
p= Probability that the difference is a chance finding
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TABLE 10B;1C TOTAL SERUM IMMUNOGLOBULINS (IU/ml) BEFORE.
DURING AND AFTER ELEMENTAL DIET IN IBP PATIENTS
IgA IgG IgM
N MED MED MED
(RANGE) (RANGE) (RANGE)
BEFORE 20 133 112 155
(78-294) (55-251) (23-334)
ON ED 17 158 118 170
(16-333) (64-205) (31-373)
AFT ED 19 130 96 134
(64-272) (53-261) (31-361)
TABLE lOBilD COMPARISON OF TOTAL SERUM IMMUNOGLOBULINS
BEFORE. DURING AND AFTER ELEMENTAL DIET IN IBP PATIENTS
Statistical analysis by Wilcoxon paired signed rank test
(p values)
BEFvsED BEFvsAFT EDvsAFT
IgA 0.256 0.968 0.642
IgG 0.127 0.167 0.042*
IgM 0.124 0.277 0.349
p= Probability that the difference is a chance finding
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TABLE 10B:IE TOTAL SERUM IMMUNOGLOBULINS (IP/ml) BEFORE.
DURING AND AFTER ELEMENTAL DIET IN IBP PATIENTS WHO
RESPONDED
IgA IgG IgM
N MED MED MED
(RANGE) (RANGE) (RANGE)
BEFORE 8 118 123 191
(78-181) (55-160) (23-311)
ON ED 7 120 134 188
(16-212) (92-155) (31-308)
AFT ED 7 115 100 153
(64-161) (58-154) (31-131)
TABLE 10B:IF COMPARISONS OF TOTAL SERUM IMMUNOGLOBULINS
BEFORE. DURING AND AFTER ELEMENTAL DIET IN IBP PATIENTS
WHO RESPONDED Statistical analysis by Wilcoxon paired
signed rank test (p values)
BEFvsED BEFvsAFT EDvsAFT
IgA 0. 554 0.933 0.834
IgG 0. 310 0.447 0.295
IgM 0.353 0.800 0.418
p= Probability that the difference is a chance finding
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TABLE 10B:1G TOTAL SERUM IMMUNOGLOBULINS (IP/ml) BEFORE.
DURING AND AFTER ELEMENTAL DIET IN IBP PATIENTS WHO DID
NOT RESPOND
IgA IgG IgM
N MED MED MED
(RANGE) (RANGE) (RANGE)
BEFORE 12 159 184 167
(108-294) (101-333) (104-272)
ON ED 10 97 104 92
(55-251) (64-205) (53-261)
AFT ED 12 90 126 115
(32-334) (33-373) (33-361)
TABLE lOBilH COMPARISONS TOTAL SERUM IMMUNOGLOBULINS
BEFORE. DURING AND AFTER ELEMENTAL DIET IN IBP PATIENTS
WHO DID NOT RESPOND Statistical analysis by Wilcoxon
paired signed rank test (p values)
BEFvsED BEFvsAFT EDvsAFT
IgA 0.415 1.000 0.838
IgG 0.328 0.345 0.075
IgM 0.221 0.108 0.919
p= Probability that the difference is a chance finding
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TABLE 10B;2A SERUM FOOD ANTIBODY LEVELS OF ALL PATIENTS
BEFORE. DURING AND AFTER ELEMENTAL DIET.
IgA IgG IgM
N MED MED MED
(RANGE) (RANGE) (RANGE)
INIT 27 31 64 78
(21-93) (41-165) (45-142)
ON ED 20 38.5 62 79
(17-79) (26-107) (52-152)
AFT ED 27 31 64 66
(6-71) (29-127) (19-144)
TABLE 10B:2B COMPARISON OF SERUM FOOD ANTIBODY LEVELS OF
ALL PATIENTS BEFORE. DURING AND AFTER ELEMENTAL DIET.
Statistical analysis by Wilcoxon paired signed rank test
(p values)
BEFvsED INIvsAFT EDvsAFT
IgA 0.514 0.119 0.010*
IgG 0.339 0.197 0.408
IgM 0.314 0.184 0.756
p= Probability that the difference is a chance finding
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TABLE 10B:2C SERUM FOOD ANTIBODY LEVELS OF IBP PATIENTS
BEFORE. DURING AND AFTER ELEMENTAL DIET
IgA IgG IgM
N MED MED MED
(RANGE) (RANGE) (RANGE)
BEFORE 22 33.5 72 73
(21-93) (41-165) (45-142)
ON ED 15 43 64 70
(17-79) (26-107) (52-152)
AFT ED 22 34 64 66
(6-71) (29-127) (19-144)
TABLE 1OB!2 D COMPARISON OF SERUM FOOD ANTIBODY LEVELS
BEFORE. DURING AND AFTER ELEMENTAL DIET IN IBP PATIENTS
Statistical analysis by Wilcoxon paired signed rank test
(p values)
BEFvsED BEFvsAFT EDvsAFT
IgA 0.650 0.131 0.016*
IgG 0.311 0.082 0.142
IgM 0.800 0.589 0.554
p= Probability that the difference is a chance finding
288
TABLE 10B;2E SERUM FOOD ANTIBODY LEVELS BEFORE. DURING
AND AFTER ELEMENTAL DIET IN IBP PATIENTS WHO RESPONDED.
IgA IgG IgM
N MED MED MED
(RANGE) (RANGE) (RANGE)
BEFORE 10 34 72 88.5
(26-47) (49-80) (62-142)
ON ED 8 38.5 65 86.5
(17-56) (26-80) (52-152)
AFT ED 10 28 60 96
(6-61) (32-92) (51-144)
TABLE 10B:2F COMPARISON OF FOOD ANTIBODY LEVELS BEFORE.
DURING AND AFTER ELEMENTAL DIET IN IBP PATIENTS WHO
RESPONDED Statistical analysis by Wilcoxon paired signed
rank test (p values)
BEFvsED BEFvsAFT EDvsAFT
IgA 0.402 0.476 0.234
IgG 0.855 0.554 0.584
IgM 1.000 1.000 0.855
p= Probability that the difference is a chance finding
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TABLE 10B;2G SERUM FOOD ANTIBODY LEVELS BEFORE. DURING
AND AFTER ELEMENTAL DIET IN IBP PATIENTS WHO DID NOT
RESPOND.
IgA igG IgM
N MED MED MED
(RANGE) (RANGE) (RANGE)
BEFORE 12 34 70 73
(21-93) (41-165) (45-101)
ON ED 7 45 64 70
(23-79) (33-107) (57-93)
AFT ED 12 38 65.5 66
(21-71) (39-127) (19-94)
TABLE 1OB 12H COMPARISON OF SERUM FOOD ANTIBODY LEVELS
BEFORE. DURING AND AFTER ELEMENTAL DIET IN IBP PATIENTS
WHO DID NOT RESPOND. Statistical analysis by Wilcoxon
paired signed rank test (p values)
BEFVSED BEFVSAFT EDvsAFT
IgA 0.735 0.241 0.022*
IgG 0.236 0.125 0.193
IgM 1.000 0.689 0.148
p= Probability that the difference is a chance finding
* Significantly lower than during elemental diet
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TABLE IOC:IB THE NUMBERS OF IMMUNOGLOBULIN SECRETING
CELLS PER MILLION LYMPHOCYTES IN PERIPHERAL BLOOD
BEFORE AND DURING ELEMENTAL DIET.
IgA IgG IgM
N MED MED MED
(RANGE) (RANGE) (RANGE)
BEFORE ED 9 465 100 101
(440-890) (14-460) (10-733)
DURING ED 9 495 97 128
(98-800) (20-506) (30-740)
TABLE IOC;1C COMPARISON OF THE NUMBERS OF IMMUNOGLOBULIN
SECRETING CELLS IN PERIPHERAL BLOOD BEFORE AND DURING
ELEMENTAL DIET. Statistical analysis by Wilcoxon paired





p= Probability that the difference is a chance finding
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TABLE IOC:2A COMPARISON OF NUMBERS OF ANTIBODY SECRETING
CELLS DIET IN PERIPHERAL BLOOD OF IBP PATIENTS BEFORE AND
PORING ELEMENTAL DIET Statistical analysis by Wilcoxon
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TABLE 10D;1B WGLF TOTAL IMMUNOGLOBULINS (uq/ml) BEFORE
AND DURING ELEMENTAL DIET IN IBP PATIENTS ONLY
IgA IgG igM
N MED MED MED
(RANGE) (RANGE) (RANGE)
BEFORE 10 162 19 8
(3-988) (1-196) (2-39)
DURING 11 203 12 15
(3-990) (1-196) (5-30)
TABLE 10D:1C COMPARISON OF WGLF TOTAL IMMUNOGLOBULINS
BEFORE AND DURING ELEMENTAL DIET IN IBP PATIENTS ONLY






p= Probability that the difference is a chance finding
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TABLE 1OP Z 2A WGLF FOOD ANTIBODIES BEFORE AND DURING
ELEMENTAL DIET.
IgA igG igM
N MED MED MED
(RANGE) (RANGE) (RANGE)
BEFORE 16 31 36 21
(12-87) (31-42) (11-51)
DURING 15 36 3 17
(11-98) (2-22) (6-36)
TABLE 10D;2B COMPARISON OF WGLF FOOD ANTIBODIES BEFORE
AND DURING ELEMENTAL DIET. Statistical analysis by





p= Probability that the difference is a chance finding
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The level of alpha-1 acid glycoprotein (a-lAP) has been
used as an index of disease activity in patients with
inflammatory bowel disease (see chapter 3). It has
also been found to be a good predictor of relapse of
inflammatory bowel disease (Wright et al.. 1987).
A combination of IL-1, IL-6 and TNF acting sequentially
increase acid glycoprotein production though individually
each induces a different set of acute phase proteins
(Emery and Salmon, 1991). As these systemically acting
cytokines can be produced in combination and in abundance
by macrophages, macrophage cytokine activity may be
studied via alpha-1 acid glycoprotein.
THE AIM OF THIS STUDY
The aims of this study were firstly to establish the
pattern of a-1 acid glycoprotein in serum and whole
gut lavage fluid (WGLF) of controls and patients with
inflammatory bowel disease and secondly, to establish if
a-lAP levels were associated with response or lack of
response to elemental diet therapy.
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PATIENTS AND PROTOCOL
A total of 51 patients with inflammatory bowel disease
(28 Crohn's disease and 23 ulcerative colitis) and 21
controls were studied (Table 11:1A).
Of the 28 patients with Crohn's disease the macroscopic
disease in this group at the time of lavage was as
follows: small bowel (13) (4 jejunal and 9 terminal
ileum) ileocolonic (5), colonic (6), rectal (2) (one
associated with anal disease), perianal (1) and one with
anal disease. Five had undergone resections. All the
patients were on normal diet. As regards drug treatment 4
patients were on steroids the dose ranging between 5-4Omg
per day, 7 on sulphasalazine, 3 on sulphasalazine and
steroids, 1 on prednisolone and colifoam enemas, 2 on
5-amino salicylates only , 1 on prednisolone and colifoam
and 10 on no drug therapy for their Crohn's disease. The
age range was 13-82 with a median of 39. Eighteen
had active disease and in 10 the disease was inactive as
assessed clinically and also based on WGLF total IgG (see
chapter 7).
None of the 23 patients with ulcerative colitis had
had any resections. The macroscopic distribution of the
disease at time of sampling was as follows: 10
pancolitis, 4 left-sided involvement, 7 proctitis, 1 UC
pouchitis and 1 with microscopic ulcerative colitis.
Seven were on no drug treatment, 3 were on oral
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prednisolone and an amino-salicylate (ASA) type drug plus
rectal steroids, 2 were on an ASA group drug plus rectal
steroids, 1 was on rectal steroids, 4 on an oral ASA
group only, 2 were taking oral prednisolone as well as
ASA, 1 was on a combination of colifoam, azathioprine and
ASA, 2 on prednisolone only and 1 was on cyclosporin in
addition to oral steroids and ASA. The age range for this
group was 22-78 with a median of 37. Of the 23, 13 had
active disease at time of study.
The final diagnoses in the controls were as follows:
non-inflammatory polyps in the colon (5), constipation
(4), diarrhoea with no abnormality detected (1), duodenal
ulcer (1), unexplained abdominal pain (5), colonic
angiodysplasia (1), megacolon (1) and 3 healthy controls.
The age range was 20-79 with a median of 47. All controls
were on normal diet
Serum and WGLF a-1 acid glycoprotein were measured by
immunoturbidimetry (described in chapter 6A).
Whole gut lavage fluid was collected from all the
patients. Serum specimens were obtained from 16 controls,
21 of the 23 patients with ulcerative colitis, 26 of the
28 patients with Crohn's disease and the four gluten
enteropathy patients. The collections were done on the
same day so that the two specimens reflected systemic and
mucosal a-1 acid glycoprotein activity at corresponding
times.
Comparisons in the levels a-1 acid glycoprotein in serum
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(SGLY) and WGLF (LGLY) were made between controls and
the IBD patients. Comparisons were also made when the
disease groups were further subdivided according to
whether they had active or inactive disease and according
to the regional distribution of disease.
Correlations analyses between the levels of a-1 acid
glycoprotein in sera and gut lavage fluid were performed
to define their relationship if any.
Finally levels of serum and lavage a-1 acid glycoprotein
were measured in patients who were prescribed elemental
diet, before and after seven or more days on elemental
diet.
SECTION 11A
SERPM a-1 ACID GLYCOPROTEIN LEVELS IN CONTROLS AND
PATIENTS WITH IBD
A total of 16 sera from controls were assayed for a-lAP.
The controls gave a range of 0.19-0.73mg/ml with a median
of 0.40 (Table 11A:1B). A level of 0.69mg/ml was two
standard deviations above the median and considered high
for further analysis of high values within groups.
The sera from the 21 patients with ulcerative colitis
gave a range of 0.42-5.40mg/ml with a median of 1.60, and
this was significantly higher than the control levels (p
= 0.00001). The 26 serum specimens from Crohn's disease
patients gave a range of 0.05-7.5mg/ml with a median
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of 3.90mg/ml, and this was significantly higher than
controls (p=0.00001) [Table 11A:1B; Table 11A:1C and
Graph 11:1].
DISEASE ACTIVITY AND SERUM a-1 ACID GLYCOPROTEIN
Patients were subgrouped according to disease activity
based on clinical assessment and WGLF total IgG.
Patients with active ulcerative colitis gave a range of
0.42-5.40mg/ml with a median of 1.9mg/ml, which was
significantly higher than controls (p=0.004). Active
Crohn's patients gave a range of 0.05-7.50 with a median
of 5.25mg/ml, and this was significantly higher than
controls (p=0.00001) [Table 11A:1C; Table 11A:1D and
Graph 11:1].
The range for inactive ulcerative colitis was 0.80-
4.2mg/ml with a median of 1.32mg/ml, significant higher
than controls (p=0.029). Inactive Crohn's gave a range of
0. 85-7.3mg/ml with a median of 2.70mg/ml, significantly
higher than controls (p=0.0001) [Table 11A:1C and Table
11A:IE].
A COMPARISON OF SERUM a-1 ACID GLYCOPROTEIN BETWEEN
DISEASE GROUPS
There was no significant difference in serum a-lAP
between Crohn's disease and ulcerative colitis or between
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active and inactive Crohn's. There was no significant
difference either between active and inactive ulcerative
colitis or inactive ulcerative colitis and inactive
Crohn's disease. Serum a-1 acid glycoprotein was
significantly higher in active Crohn's disease than in
patients with active ulcerative colitis (p=0.0032; Table
11A:IF).
COMMENT
Serum levels of a-1 acid glycoprotein in the controls in
this study were low compared to other reports even
though there has been disagreement about the normal
levels with ranges between the lowest reported
0.45-1.7 Omg/ml (de la Heuerga et a 1 . . 1956) and
the highest 0.83-2.03 (Lockey et al.. 1956) and some
intermediate levels. Despite the lower levels in
the controls in this study the patients with IBD had
unequivocally high levels hence the significant
differences with all the disease groups.
Though the differences between active and inactive
disease groups did not reach statistical levels of
significance, the active disease groups (means, 4.58mg/ml
and 1.94mg/ml for active Crohn's disease and active
ulcerative colitis respectively; p=0.00001) had higher
means and levels of significance against controls
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compared to inactive disease groups (means, 3.22mg/ml and
1.86mg/ml for inactive Crohn's disease and inactive
ulcerative colitis respectively; p=0.0001). This though
suggesting that serum a-1 acid glycoprotein increases
with disease activity shows that it does not distinguish
clearly between active and inactive disease.
Comparisons between disease groups shows that active
Crohn's disease has higher levels than active ulcerative
colitis (p=0.0032), this could be because systemic
manifestations such as arthritis or uveitis are more
prevalent in patients with Crohn's disease.
/ / » '
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REGIONAL INVOLVEMENT OF DISEASE AND SERUM a-1 ACID
GLYCOPROTEIN
Patients with Crohn's disease were further subdivided
according to regional disease involvement into two
groups. Patients with disease confined to the small bowel
with no colonic involvement were grouped as small bowel
(SB) Crohn's disease. Patients with disease confined to
the colon and no small bowel involvement were grouped
as colonic (CN) Crohn's disease. This classification
excluded the five patients with ileocolonic involvement.
Comparisons of the serum levels of a-1 acid glycoprotein
were made between the ulcerative colitis group, colonic
Crohn's disease group and the small bowel Crohn's disease
group to ascertain whether raised a-lAP was a feature of
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small bowel or large bowel disease.
The small bowel Crohn's gave a range of 0.05-7.5mg/ml
with a median of 5.25mg/ml. Colonic Crohn's gave a
range of 1.28-7.40mg/ml with a median of 4.49mg/ml not
significantly different from small bowel Crohn's
p=l.0000. Patients with ulcerative colitis gave a range
of 0.42-5.40mg/ml with a median of 1.60mg/ml and this was
significantly lower than the levels for small bowel
Crohn's disease p=0.0079 (Table 11A:2A). The prevalence
of high levels of serum a-lAP was also analysed. As table
11:2B shows 10 out of 11 patients with small bowel
Crohn's had high levels compared to 10 out 10 patients
with colonic Crohn's disease. Though out of a total of 21
patients with ulcerative colitis 20 had high levels
(>0.69mg/ml) these were statistically lower than those of
patients with small bowel disease (Table 11A:2B).
REGIONAL INVOLVEMENT OF DISEASE AND SERUM a-1 ACID
GLYCOPROTEIN LEVELS ACCORDING TO DISEASE ACTIVITY.
Patients were further subgrouped according to disease
activity based on clinical assessment and WGLF total IgG.
Active small bowel disease gave a range of 0.05-7.50mg/ml
with a median of 5.25mg/ml. Active colonic Crohn's gave
a range 1.28-7.40mg/ml with a median of 5.14mg/ml, not
significantly different from active small bowel
involvement p=0.8170. Active ulcerative colitis gave a
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range of 0.42-5.40mg/ml with a median of 1.90mg/ml, and
this was significantly less than for small bowel Crohn's
disease p=0.0312 (Table 11A:2C).
There were only three patients with inactive small bowel
Crohn's disease and 2 with inactive colonic Crohn's
disease, numbers inadequate for firm statistical
evaluations. This is why the figures for the whole
subgroups are the same as for the patients with active
disease only.
A COMPARISON OF SERUM a-1 ACID GLYCOPROTEIN LEVELS
BETWEEN COLONIC CROHN'S DISEASE AND ULCERATIVE COLITIS
Patients with colonic Crohn's disease had significantly
higher levels of serum a-lAP than patients with
ulcerative colitis (p=0.0031), as had patients with
active colonic Crohn's disease compared to patients with
active ulcerative colitis (p=0.0038). There were only two
patients with inactive colonic Crohn's disease and these
were not analysed further (Table 11A:2D).
COMMENT
These results show that there is no difference in a-1
acid glycoprotein activity between small bowel and large
bowel Crohn's disease. This may be explained by the fact
that most of the serum a-1 acid glycoprotein is of
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hepatic origin as an acute phase reactant, so it is the
overall systemic effect via the liver other than local
regional variations that would influence the serum levels
(Emery and Salmon, 1991). Both small bowel Crohn's and
colonic Crohn's have significantly higher levels of a-lAP
in serum than ulcerative colitis (p=0.0079 and p=0.0031
respectively). Patients with active Crohn's disease also
showed higher levels of serum a-lAP than patients with
acute ulcerative colitis (p=0.0312 and p=0.0038). The
fact that even Crohn's colitis has higher levels of
serum a-lAP than ulcerative colitis suggests that these
differences are a disease phenomenon other than due to
the part of the bowel affected.
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SECTION 11B
WGLF a-1 ACID GLYCOPROTEIN LEVELS IN CONTROLS AND
PATIENTS WITH IBP
Whole gut lavage fluid was obtained from 21 controls, 28
Crohn's disease and 23 ulcerative colitis patients and
assayed for a-1 acid glycoprotein by immunoturbidimetry
(see chapter 6A).
Controls gave a range of 1.80-7.20ug/ml with a median of
3.20ug/ml.
Patients with Crohn's disease gave a range of 1.20-
72.80ug/ml with a median of 23.65ug/ml, significantly
higher than the value for the control group (p=0.00001).
Patients with ulcerative colitis gave a range of 4.0-
72.80ug/ml with a median of 23.20ug/ml, significantly
higher than for the control group (p=0.00001) [Table
11B:1A and Graph 11B:1],
A level of 6.3ug/ml was two standard deviations above the
median and considered high for further evaluations. The
frequency of high levels of WGLF a-1 acid glycoprotein
as determined by this value was analysed according to
disease group (Table 11B:1B). Out of 21 controls, 2 had
high levels of a-lAP in WGLF as compared to 24 out of 28
Crohn's disease patients or 16 out of 23 patients with
ulcerative colitis. As stated above both these groups
showed higher levels than those for controls.
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DISEASE ACTIVITY AND WGLF a-1 ACID GLYCOPROTEIN
The patients with IBD were further subdivided according
to disease activity based on clinical assessment and the
levels of total IgG.
Active Crohn's disease patients gave a range of 6.6-
72.80ug/ml with a median of 25.65ug/ml, significantly
higher than controls (p=0.00001). Patients with active
ulcerative colitis gave a range of 5.2-72.80ug/ml with a
median of 29.20ug/ml, significantly higher than controls
(p=0.00001) [Table 11B:1C, Graph 11B:1].
Inactive Crohn's disease gave a range of 1.2-72.8ug/ml
with a median of 14.65ug/ml, not significantly higher
than controls (p=0.0993). Inactive UC gave a range of
4.0-67.50ug/ml with a median of 30.86ug/ml, significantly
higher than controls (p=0.0005) [Table 11B:1D].
COMPARISON OF WGLF a-1 ACID GLYCOPROTEIN BETWEEN DISEASE
GROUPS
Levels of a-1 acid glycoprotein were compared between
disease groups.
There were no significant difference in the levels
of WGLF a-1 acid glycoprotein between disease groups
regardless of disease activity (Table 11B:1E).
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COMMENT
The source of a-1 acid glycoprotein in WGLF is probably
serum, due to a leak of serum protein into the intestinal
lumen. This leakage would be expected to be greater when
the mucosal barrier is damaged as in inflammatory bowel
disease. Another source of WGLF a-lAP could be from the
bile flowing from the liver directly into the intestinal
lumen. Whereas both inactive Crohn's disease and inactive
ulcerative colitis had significantly higher levels of
a-lAP than controls in serum only, inactive ulcerative
colitis had higher levels in WGLF. The possible
explanation for this is that where the differences are
small as between inactive disease groups and controls,
difference in levels will be detected more easily if
sampling occurs nearer the source of the factor being
measured before dilution and diffusion occurs. Sera,
which reflects directly the levels of a-1 acid
glycoprotein, will be more representative.
REGIONAL INVOLVEMENT AND WGLF a-1 ACID GLYCOPROTEIN
Patients were subgrouped into regional involvement as for
serum a-1 acid glycoprotein above. Patients with small
bowel Crohn's disease gave a range of 1.2-72.80ug/ml with
a median of 35.60ug/ml. Colonic Crohn's disease gave a
range of 2.8-72.80ug/ml with a median of I8.60ug/ml, not
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significantly lower than small bowel Crohn's disease
(p=0.4757). Patients with ulcerative colitis gave a range
of 4.0-72.40ug/ml with a median of 29.20ug/ml, again not
significantly lower than small bowel Crohn's disease
(p=0.6097) [Table 11B:2A]
The patients were further analysed according to the
prevalence of high levels of a-lAP as described above
(level above 6.3ug/ml). Eight of the 16 controls had high
levels compared to 11 of the 13 patients with small bowel
Crohn's disease, 8 of the 10 patients with colonic
Crohn's disease or 20 of the 21 patients with ulcerative
colitis (Table 11B:2B). The same analysis was done for
patients with active and inactive disease, the results of
the statistical analysis are described below .
Active small bowel Crohn's disease gave a range of 9.2-
67.20ug/ml with a median of 39.45ug/ml. Active colonic
Crohn's disease gave a range of 6.6-72.8Oug/ml with a
median of 29.65ug/ml, not significantly different from
active small bowel Crohn's disease (p=0.6365) [Table
11B:2C]. Patients with active ulcerative colitis gave a
range of 5.2-72.80ug/ml with a median of 29.20ug/ml not
significantly different from small bowel Crohn's disease
(p=0.5382). There was no significant difference either
between the inactive disease subgroups (Table 11B:2D) or




There were no differences in the levels of a-lAP in
WGLF between disease groups or regional involvement,
regardless of activity. I suggest that this because
only a small fraction of serum a-lAP diffuses into the
intestinal secretions and that the contribution via bile
is minimal.
CORRELATIONS
THE RELATIONSHIP BETWEEN SERUM AND WGLF Ot-1 ACID
GLYCOPROTEIN
Coefficients of correlation between levels of a-lAP in
sera and WGLF were calculated for each disease group and
subgroup. These are shown in table 11B:3A.
There was no strong correlation between serum and lavage
a-lAP in controls or patients with ulcerative colitis
even when the latter were subdivided into active and
inactive subgroups (Table 11B:3A).
Crohn's disease gave a strong correlation (r=0.730,
p=0.0001) as did patients with active Crohn's disease
(r=0.615 p=0.002). The patients with inactive Crohn's




These findings would suggest that there is more free
leakage of a-1 acid glycoprotein into the intestinal
lumen in Crohn's disease than in ulcerative colitis.
I suggest that this is because unlike the mucosally
confined ulcerative colitis, Crohn's disease is panmural
(see chapter 1A). In addition it may indicate that
systemic disease parallels mucosal disease in Crohn's
disease more than in ulcerative colitis so that the
increased leakage of proteins into the lumen, though
independent of the acute phase response, corresponds
to the increase in the hepatic production of a-1 acid
glycoprotein (see chapter 4) .
THE RELATIONSHIP BETWEEN SERUM AND WGLF a-1 ACID
GLYCOPROTEIN AND DISEASE ACTIVITY IN IBP
Coefficients of correlation between levels of a-lAP
and WGLF total IgG (a measure of disease activity) were
calculated for each disease group and subgroup. These are
shown in table 11B:3B.
There was no strong correlation between WGLF or
serum a-lAP and WGLF total IgG for all patients with
ulcerative colitis even when subgrouped according to
disease activity (Table llB:3B).The same applied to
patients with Crohn's disease (Table 11B:3C).
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COMMENT
The lack of a relationship between WGLF or serum a-lAP
and WGLF IgG could be because , the levels of the a-lAP,
as an acute phase protein, are affected by many other
conditions such as infections, malignancy or other
inflammatory conditions like rheumatoid arthritis (see
chapter 3).
THE RELATIONSHIP BETWEEN WGLF OR SERPM a-1 ACID
GLYCOPROTEIN AND WGLF TUMOUR NECROSIS FACTOR
Coefficients of correlation between levels of a-lAP and
WGLF tumour necrosis factor were calculated for each
disease group and subgroup. These are shown in tables
11B:4A-C.
There was no strong correlation between a-1 acid
glycoprotein levels either in serum or lavage and tumour
necrosis factor levels in the same patients for
controls as well as all patients with Crohn's disease or
ulcerative colitis (Table 11:4A) even when they were
further subgrouped into active disease groups (Table
11B:4B) or inactive disease groups (Table 11B:4C).
COMMENT
There was no correlation between the levels of a-lAP in
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serum or WGLF and the levels of tumour necrosis factor in
WGLF. This applied even when patients were subgrouped
according to disease activity. I suggest that though TNF
is one of the cytokines involved synergistically, with
IL-1 and IL-6, in inducing hepatic synthesis of a-lAP, as




ELEMENTAL DIET AND a-1 ACID GLYCOPROTEIN
STUDY POPULATION
Eleven IBD patients were involved in this study. Serum
and WGLF specimens were collected before and on day 7
after commencing elemental diet therapy. The same
specimens were analysed for TNF, as TNF plays a part in
the control of a-1 acid production. Table 11C is a
summary of the patient data and their a-lAP levels in
serum and WGLF.
RESULTS
On global clinical assessment 3 of the IBD patients
improved, 4 showed no change and four deteriorated. Their
results are plotted in Graph 11C.
The patient with coeliac disease had initially normal
levels of serum and WGLF a-lAP that remained normal
during the elemental diet.
SERUM a-1 ACID GLYCOPROTEIN AND ELEMENTAL DIET
Two of the responders (the patients who improved
clinically) started with high levels of serum a-lAP which
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increased despite the improvement in their clinical
condition. In third responder who had an initially 'low'
level of serum a-lAP, there was a slight fall during
elemental diet treatment.
Three of the patients who clinically showed no change in
their condition started with high serum levels of a-1
acid glycoprotein. In two of these the levels of a-lAP
rose while in the third patient the serum level of a-lAP
remained unchanged during elemental diet. The fourth
patient started with a normal concentration of a-1 acid
glycoprotein which rose while on elemental treatment.
All the four patients whose clinical condition
deteriorated started with high levels of serum a-lAP and
these increased during the course of treatment.
Therefore initial levels of serum a-1 acid glycoprotein
did not predict the outcome of treatment with elemental
diet.
WGLF a-1 ACID GLYCOPROTEIN AND ELEMENTAL DIET
Three patients improved clinically (responders). Two of
the patients who responded started with high levels of
lavage a-lAP and the levels fell subsequently while on
elemental diet (BS and DM). These are the same patients
who had high levels in serum which rose despite
improvement in their clinical condition. The level of
a-lAP in WGLF of the third patient who improved was
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initially low (DB) and it did not change during the course
of treatment.
The four patients whose clinical condition remained
unchanged started with levels of a-lAP in their WGLF
similar to that of responders. In two of them the levels
showed little change (DS, EM) one showed a slight rise
while in one there was a slight fall.
Three of the four patients who deteriorated began with a
high levels of a-1 acid glycoprotein. In two of these the
levels decreased and in one there was an increase. One
patient had a low initial level and this did not change
during the course of ED therapy.
The only uniform result is in patients whose clinical
condition remained unchanged: their levels of a-lAP also
did not change during the course of the treatment.
The patient with coeliac disease had already been on a
gluten free diet and her levels a-1 acid glycoprotein
were low and remained low during the whole study. She did
not show clinical improvement on this treatment.
COMMENT
These results show that there is no relationship between
a response or lack of response to elemental diet and
a-lAP levels whether in lavage or serum. The number of
patients on elemental diet is small (11). This is because
patients were prescribed elemental diet only when other
325
modalities of treatment had failed. Perhaps if more
numbers of a patients were studied their may be a
relationship. This is however more unlikely as a-lAP
being an acute phase protein is subject to many factors
such as infections and other connective tissue disease
(see chapter 4).
GENERAL COMMENT
The aim of these experiments was to establish the pattern
of a-1 acid glycoprotein levels in controls and IBD
patients. The levels in serum and WGLF were significantly
higher in patients than in controls for both active and
inactive IBD groups except for inactive Crohn's disease
WGLF a-1 acid glycoprotein. Further breakdown showed that
the level of significance compared to controls was higher
in patients with active disease. There was no difference
between active and inactive IBD probably reflecting the
insensitivity of this acute phase protein or suggesting
that there is usually underlying active disease in
patients who may be clinically classified as inactive.
The same applied to the levels in WGLF which largely
reflect leakage from serum (discussed above chapter 11B).
The contribution from the liver via the bile duct is
therefore minimal.
Comparisons between Crohn's disease patients with small
bowel and those with large bowel disease showed that the
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patients with Crohn's disease have higher serum levels of
a-1 acid glycoprotein than ulcerative colitis patients
regardless of the region involved.
There was no relationship between disease response to
elemental diet and a-1 acid glycoprotein levels both in
lavage and serum. This lack of relationship could be
probably because a-1 acid glycoprotein is a more general
index of disease activity rather than specific to
inflammatory bowel disease.
Despite the fact that a-1 acid glycoprotein was found to
be a predictor of relapse in IBD (Wright et al., 1987),
for the patients studied there was no relationship to
disease response with elemental diet therapy.
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APPENDIX FOR CHAPTER 11

















































Prednisolone only (Pred) 4
Sulphasalazine (SLZ) 7
5-Amino Salicylates only (ASA) 2
SLZ and Pred 3
Pred, ASA and Colifoam (cfm) 0
SLZ, Pred and CFM 0




Pred, ASA and CFM 3
ASA and CFM 2
ASA only 4
ASA and PRED 2
ASA,CFM and Azath 1




TABLE 11A: IB SERUM a-1 ACID GLYCOPROTEIN Imct/ml) IN
CONTROLS AND PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE
COLITIS.
GROUP N MEAN MEDIAN p
(RANGE)
CONTROL 16 0.43 0.40
(0.19-0.73)
CRO 26 4.11 3.90 0.00001
(0.05-7.50)
UC 21 1.90 1.60 0.004
(0.42-5.40)
p = Probability that the difference is a chance finding
TABLE llAi 1C THE PREVALENCE OF HIGH LEVELS OF SERUM
g-1 ACID GLYCOPROTEIN IN CONTROLS. CROHN'S DISEASE AND
ULCERATIVE COLITIS. Levels above 0.69mg/ml.
ALL ACTIVE INACTIVE
N >0.69 N >0.69 N >0.69
CONTROL (16) 1 NA NA
CD (26) 25*** (17) 16*** (9) 9
UC (21) 20*** (12) 11* (9) 9
NA = Not applicable
* p < 0.05 ** p < 0.01 *** p < 0.005
N = Number of subjects in the group
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Graph 11A:1
SERUM a-1 ACID GLYCOPROTEIN IN CONTROLS,




























On the x axis are the subject groups plotted against their levels of
serum a-1 acid glycoprotein on the y axis. All subgroups, active and
inactive, had significantly higher levels than controls.
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TABLE 11A:ID SERUM a-1 ACID GLYCOPROTEIN fma/ml) IN
CONTROLS AND PATIENTS WITH ACTIVE CROHN'S DISEASE AND
ACTIVE ULCERATIVE COLITIS.


















TABLE HAilE SERUM a-1 ACID GLYCOPROTEIN (ma/ml) IN
CONTROLS AND PATIENTS WITH INACTIVE CROHN'S DISEASE AND
INACTIVE ULCERATIVE COLITIS.
GROUP N MEAN MEDIAN p
(RANGE)
CONTROL 16 0.43 0.40
(0.19-0.73)
inaCRO 9 3.22 2.70 0.0001
(0.85-7.30)
inaUC 9 1.86 1.32 0.029
(0.80-4.20)
p = Probability that the difference is a chance finding
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TABLE HAilF COMPARISON OF SERUM Ct-1 ACID GLYCOPROTEIN
LEVEL8 BETWEEN CROHN'S DISEASE AND ULCERATIVE COLITIS
PATIENTS.
DISEASE GROUPS P Value
CRO VS UC 0.3751
aCRO vs inaCRO 0.2053
inaCRO vs inaUC 0.1333
aCRO vs aUC 0.0032
inaUC vs AUC 0.8870
p = Probability that the difference is a chance finding
TABLE llAi2A A COMPARISON OF SERUM a-1 ACID GLYCOPROTEIN
(mq/ml) LEVELS BETWEEN SMALL BOWEL (SB) CROHN'S DISEASE
AND COLONIC (CN) CROHN'S DISEASE OR ULCERATIVE COLITIS
(PC) .
GROUP N MEAN MEDIAN p
(RANGE)
CRO (SB) 11 4.58 5.25
(0.05-7.50)
CRO (CN) 10 4.49 5.10 1.0000
(1.28-7.40)
uc 21 1.90 1.60 0.0079
(0.42-5.40)
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TABLE 11A:2B THE PREVALENCE OF HIGH LEVELS OF SERUM
g-1 ACID GLYCOPROTEIN IN SMALL BOWEL (SB) CROHN'S
DISEASE. COLONIC (CN) CROHN'S DISEASE AND ULCERATIVE
COLITIS (UC). Levels above 0.69mg/ml.
ALL ACTIVE INACTIVE
N >0. 69 N >0.69 N >0.69
CONTROL (16) 1 NA NA
SB (ID 10 (6) 6 (5) 4
CN (10) 10 (8) 8 (2) 2
UC (21) 20** (12) 11* (9) 9
* p < 0. 05 ** p < 0.01 * * * p < 0.005
NA = Not applicable
TABLE 11A;2C A COMPARISON OF SERUM a-1 ACID GLYCOPROTEIN
LEVELS (ma/ml) BETWEEN ACTIVE SMALL BOWEL CROHN'S
DISEASE. ACTIVE COLONIC CROHN'S AND ACTIVE ULCERATIVE
COLITIS.
GROUP N MEAN MEDIAN p
(RANGE)
CRO (SB) 7 4.66 5.25
(0.05-7.50
CRO (COL) 8 5.14 6.05 0.8170
(1.28-7.40
UC 12 1.94 1.90 0.0312
(0.42-5.40)
p = Probability that the difference is a chance finding
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TABLE 11A;2D A COMPARISON OF SERUM a-1 ACID GLYCOPROTEIN
LEVELS BETWEEN COLONIC CROHN'S DISEASE AND OLCERATIVE
COLITIS. Statistical comparisons by Mann-Whitney (p
values)
E
CRO(COL) vs UC 0.0031*
aCRO(COL) vs aUC 0.0038*
inaCRO(COL) vs inaUC 0.2861
p = Probability that the difference is a chance finding
* = significant difference at 5% level
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TABLE 11B:1A THE LEVELS OF Q-l ACID GLYCOPROTEIN (ua/ml)
IN WGLF OF CONTROLS AND PATIENTS WITH CROHN'S DISEASE AND
ULCERATIVE COLITIS.















TABLE 11B:IB THE PREVALENCE OF HIGH LEVELS OF WGLF
tt-1 ACID GLYCOPROTEIN IN CONTROLS. CROHN'S DISEASE AND
ULCERATIVE COLITIS. Levels above 6.3ug/ml.
ALL ACTIVE INACTIVE










NA = Not applicable
* p < 0.05 ** p < 0.01 *** p < 0.005
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Graph 11B:1
WGLF oc-1 ACID GLYCOPROTEIN IN CONTROLS,






























On the x axis are the subject groups plotted against their levels of
WGLF a-1 acid glycoprotein on the y axis.
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TABLE UBilC THE LEVELS OF a-1 ACID GLYCOPROTEIN fug/ml)
IN WGLF OF CONTROLS AND PATIENTS WITH ACTIVE CROHN'S

















TABLE 11B;ID THE LEVELS OF a-1 ACID GLYCOPROTEIN fug/ml)
IN WGLF OF CONTROLS AND PATIENTS WITH INACTIVE CROHN'S















p = Probability that the difference is a chance finding
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TABLE 11B!IE COMPARISON OF WGLF a-1 ACID GLYCOPROTEIN
LEVELS BETWEEN CROHN'S DISEASE AND ULCERATIVE COLITIS.
Statistical comparisons by Mann-Whitney (p values)
DISEASE GROUPS P Value
CRO VS UC 0.9773
aCRO vs inaCRO 0.1436
inaCRO vs inaUC 0.3075
aCRO vs aUC 0.5482
inaUC vs aUC 0.6642
p = Probability that the difference is a chance finding
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TABLE 1IB:2A A COMPARISON OF WGLF a-1 ACID GLYCOPROTEIN
LEVELS (ua/ml) BETWEEN SMALL BOWEL (SB) CROHN'S DISEASE.
COLONIC (CN) CROHN'S DISEASE AND ULCERATIVE COLITIS (UC)
GROUP N MEAN MEDIAN p
(RANGE)
CRO (SB) 13 36.74 35.60
(1.20-72.80)
CRO (CN) 10 28.41 18.60 0.4757
(2.80-72.80)
UC 23 31.31 29.20 0.6097
(4.00-72.80)
TABLE 11B:2B THE PREVALENCE OF HIGH LEVELS OF WGLF
a-1 ACID GLYCOPROTEIN IN SMALL BOWEL (SB) CROHN'S
DISEASE. COLONIC (CN) CROHN'S DISEASE AND ULCERATIVE
COLITIS (UC) . Levels above 6.3ug/xnl.
ALL ACTIVE INACTIVE
N >6.3 N >6.3 N >6.3
CONTROL (16) 8 NA NA
SB (13) 11 (8) 8 (5) 3
CN (10) 8 (8) 8 (2) 0
UC (21) 20 (12) 11 (9) 9
NA = Not applicable
* p < 0.05 ** p < 0.01 *** p < 0.005
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TABLE 11B;2C A COMPARISON OF WGLF a-1 ACID GLYCOPROTEIN
LEVELS (ua/ml) BETWEEN ACTIVE SMALL BOWEL (SB) CROHN'S
DISEASE. ACTIVE COLONIC (CN) CROHN'S AND ACTIVE















TABLE 11B:2D A COMPARISON OF WGLF a-1 ACID GLYCOPROTEIN
LEVELS fug/ml) BETWEEN INACTIVE SMALL BOWEL (SB) CROHN'S










p = Probability that the difference is a chance finding
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TABLE 11B;2E A COMPARISON OF WGLF a-1 ACID GLYCOPROTEIN
LEVELS BETWEEN COLONIC CROHN'S DISEASE AND ULCERATIVE
COLITIS. Statistical comparisons by Mann-Whitney (p
values)
DISEASE GROUPS p values
CRO(CN) vs UC 0.7540
aCRO(CN) vs aUC 0.6122
p = Probability that the difference is a chance finding
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CORRELATIONS
TABLE 11B5 3A CORRELATION BETWEEN SERUM AND WGLF a-1 ACID
GLYCOPROTEIN LEVELS.
GROUP N r P
CONTROL 16 -0.186 0.323
UC 21 -0.039 0. 608
aUC 12 0.409 0. 157
inaUC 9 -0.482 0. 364
CRO 26 0.730 0.0001
aCRO 17 0. 615 0. 002
inaCRO 9 0.917 0.0001
p = Probability that the correlation (r) is due to chance
TABLE 11B:3B CORRELATIONS BETWEEN WGLF (LGLY) OR SERUM
(SGLY) g-1 ACID GLYCOPROTEIN AND WGLF TOTAL IGG (LIGG) IN
CONTROLS AND PATIENTS WITH PLCERATIVE COLITIS.
N LGLY VS LIGG N SGLY VS LIGG
r P r P
CONTROL 21 -0.107 0.776 16 0. 301 0.514
UC 23 -0.027 0.467 21 -0.144 0.551
aUC 13 -0.337 0.315 12 -0.186 0.434
inaUC 10 0.298 0.363 9 -0.543 0.244
p = Probability that the correlation (r) is due to chance
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TABLE 11B:3C CORRELATIONS BETWEEN WGLF (LGLY) OR SERUM
(SGLY) g-1 ACID GLYCOPROTEIN AND WGLF TOTAL IGG (LIGG) IN
CONTROLS AND PATIENTS WITH CROHN'S DISEASE.
N LGLY vs LIGG N SGLY VS LIGG
r e r e
CRO 28 0.204 0.752 26 0.067 0.513
aCRO 18 -0.270 0.684 17 -0.348 0.121
inaCRO 10 0.488 0.666 9 0.275 0.768
p = Probability that the correlation (r) is due to chance
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TABLE 11B: 4 A CORRELATIONS BETWEEN WGLF Ct-1 ACID
GLYCOPROTEIN (LGLY) OR SERUM a-1 ACID GLYCOPROTEIN (SGLY)
AND WGLF TUMOUR NECROSIS FACTOR.
GROUP LGLY SGLY
N r e N r e
CONTROL 15 0.125 0.586 15 -0.033 0.743
CRO 26 -0.048 0.480 23 -0.018 0.143
UC 21 0.178 0.816 23 -0.158 0.127
TABLE 11B:4B CORRELATIONS BETWEEN WGLF a-1 ACID
GLYCOPROTEIN (LGLY) OR SERUM a-1 ACID GLYCOPROTEIN (SGLY)
AND WGLF TUMOUR NECROSIS FACTOR IN ACTIVE IBP.
GROUP LGLY SGLY
N r e N r e
aCRO 17 0.041 0.337 17 0.045 0.559
aUC 12 0.279 0.725 12 -0.511 0.087
TABLE 11B:4C CORRELATIONS BETWEEN WGLF a-1 ACID
GLYCOPROTEIN (LGLY) OR SERUM a-1 ACID GLYCOPROTEIN (SGLY)
AND WGLF TUMOUR NECROSIS FACTOR IN INACTIVE IBP.
GROUP LGLY SGLY
N r e N r e
inaCRO 9 -0.259 0.407 10 -0.044 0.310
inauc 9 -0.031 0.338 10 -0.303 0.964




























































































































































































































































































































ABBREVIATIONS 1=ILEALCROHN'SDISEASE 2=ULCERATIVECOLI IS 3=CCELIACDISEASE COL=colonicr h 'sdisease ILC=ileocolonicCroh 'sdisease
CLINICALOUTCOME(C )
*=IMPROVED D=DETERIORATED N=OCHANGE
LGLY=WGLFALPHA-1ACIDG YCOPROTEIN SGLV-ERUMALPHA-1CIDGLY OPROTEIN DOD=AYSONIET
Graph 11C
SERUM cc-1 ACID GLYCPROTEIN AND WGLF


























































Levels of a-1 acid glycoprotein in serum (top) and WGLF (bottom)
before and during elemental diet. Initial levels of a-1 acid





There is growing evidence that T cell function is of
primary importance in the immunopathogenesis of IBD (Choy
et al. . 1990; Mueller et al.. 1990). Interleukin-2 and
its receptors are pivotal in the immune function of T
cells (Smith and Cantrell, 1985). The density of the
inducible IL-2 receptor on the cell membranes determines
whether the immune response progresses or not (Wang and
Smith, 1987; chapter 4A). Soluble interleukin 2 receptor
(sIL-2R), a shed variety of the p55 molecule has been
found to be increased in the serum of patients with
active IBD patients. There is little literature
describing intestinal T cell activity in IBD in vivo
despite the acknowledged fact that the intestinal mucosa
is an area of intense immune activity (reviewed in
chapter 1) .
THE AIM OF THIS STUDY
The primary aim of this study was to evaluate
systemic (serum) and intestinal (WGLF) T cell activity
by measuring levels of sIL-2R in controls and disease
groups. Secondly, having established the pattern to
study T cell activity in patients who had been prescribed
elemental diet for clinical reasons. My hypothesis was
that elemental diet works by influencing the immune
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system. Results presented in chapter 10 in this thesis
showed that improvement with elemental diet was not via
the humoral arm of the immune response. If, indeed immune
modulation is the mechanism by which elemental diets act,
then it would be expected that patients who responded to
elemental diet would show a down-regulation of their T
cell activity.
SUBJECTS AND PROTOCOL
A total of 69 IBD patients (45 Crohn's disease and 24
ulcerative colitis), 8 gluten enteropathy patients and
20 controls were studied (Table 12:1).
Of the 45 patients with Crohn's disease the macroscopic
disease at the time of lavage was as follows: small bowel
(15) (4 jejunal and 11 terminal ileum), ileocolonic (13) ,
colonic (10), rectal (5) (one associated with anal
disease), perianal (1) and one with microscopic disease.
Ten had undergone resections. All the patients were on
normal diet. As regards drug treatment 10 patients were
on steroids the dose ranging between 5-40mg per day, 13
on sulphasalazine, 7 on sulphasalazine and steroids, 1
on prednisolone, mesalazine and azathioprine, 1 on
sulphasalazine, prednisolone and colifoam enemas, 1 on
prednisolone and colifoam enemas and 12 on no drug
therapy for their Crohn's disease. The age range was 14-
83 with a median of 44. Twenty-eight had active disease
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and in 17 the disease was inactive as assessed clinically
and also based on WGLF total IgG (see chapter 7).
None of 24 patients with ulcerative colitis had had any
resections. The macroscopic distribution of the disease
at time of sampling was as follows: 11 pancolitis, 3
left-sided involvement, 8 proctitis, 1 UC pouchitis and 1
with microscopic ulcerative colitis. Seven were on no
drug treatment, 3 were on oral prednisolone and an amino¬
salicylate (ASA) type drug plus rectal steroids, 2 were
on an ASA group drug plus rectal steroids, 1 was on
rectal steroids, 6 on an oral ASA group only, 3 were
taking oral prednisolone as well as ASA, 1 was on a
combination of colifoam enemas, azathioprine and ASA and
1 was on cyclosporin in addition to oral steroids and
ASA. The age range for this group was 22-79 with a median
of 38. Of the 24, 14 had active disease at time of study.
The age range for the 8 patients with gluten related
enteropathy was 19-68 with a median of 41. Seven had
coeliac disease and these were all on a gluten-free diet.
One had dermatitis herpetiformis and was on a normal
diet.
Most of the controls had presented with symptoms that
required gastro-intestinal investigations but on final
clinical assessment the diagnosis was non-inflammatory
bowel conditions. The final diagnoses in the controls
were as follows: non-inflammatory polyps in the colon
(2), constipation (5), diarrhoea with no abnormality
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detected (1), duodenal ulcer (1), unexplained abdominal
pain (8) and 3 controls. The age range was 21-85 with a
median of 46.
All controls were on normal diet.
Serum and WGLF sIL-2R was measured by ELISA as described
in chapter 6.
The serum was drawn on the day of gut lavage collection
so that the two specimens reflected systemic and mucosal
immune activity at corresponding times.
Comparisons in the levels SIL-2R in serum (BIL2R) and
WGLF (LIL2R) were made between controls and the IBD
patients. Comparisons were also made when the patients
with IBD were further subgrouped according to whether
they had active or inactive disease and according to the
regional distribution of disease.
Correlations analyses between the levels of sIL-2R in
sera and gut lavage fluid were performed to define their
relationship if any.
Finally levels of BIL2R and LIL2R were measured in
patients who were prescribed elemental diet before and
after a period of elemental diet.
SECTION 12A
SERUM SIL-2R (BIL2R) LEVELS IN CONTROLS AND IBD PATIENTS
A total of 11 specimens of serum were collected from
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controls, 20 from patients with ulcerative colitis and 38
from patients with Crohn's disease and assayed for
SIL-2R.
The controls gave a range of 171-544U/ml with a median
of 235U/ml.
The range for patients with ulcerative colitis (UC)
was 50-1986U/ml with a median of 461U/ml, this was
significantly higher than the levels for the controls
(p=0.039) . Crohn's disease (CD) patients gave a range of
10-2844U/ml with a median of 610U/ml, again this was
significantly higher than controls (p=0.0045) (Table
12A:IB and Graph 12A:1).
On further analysis of levels in controls, values of more
than 510U/ml were 2 standard deviations above the mean,
and were classified as high when studying the freguency
of high levels in disease groups. Only one of the 11
controls had high levels of serum SIL-2R compared to 9
out of 20 patients with ulcerative colitis or 25 out of
38 patients with Crohn's disease (Table 12A:1C). These
results were significantly higher than the levels for the
controls as shown above (Table 12A:1B). Similarly the
prevalence of high levels of serum sIL-2R in patients
with active and inactive diseases was analysed as shown
in table 12:1C; the results of the statistical analysis
are shown and discussed below.
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DISEASE ACTIVITY AND SERUM SIL-2R
Patients were further subdivided according to whether
they had active disease or inactive disease based on
clinical assessment and WGLF total IgG (chapter 7) . Both
patients with active Crohn's disease (p=0.0016) and
those with active ulcerative colitis (p=0.0151), had
significantly higher levels of sIL-2R in the serum than
controls (Table 12A:1C, Table 12A:1D and Graph 12A:1).
Conversely, both inactive CD (p=0.1320) and inactive UC
(p=0.4090) did not have significantly higher levels than
controls (Table 12A:1C, Table 12A:1E and Graph 12A:1).
A COMPARISON OF SERUM SIL-2R BETWEEN DISEASE GROUPS
There was no significant difference in the serum sIL-2R
concentrations between UC and CD (p=0.3904), active CD
and inactive CD (p=0.0526), or between active UC and
inactive UC (p=0.1535). There was no significant
difference between active CD and active UC (p=0.5702) nor




These results show that serum sIL-2R is raised in
patients with active IBD. This is in agreement with other
reports (Brynskov and Tvede, 1990; Mahida et al. . 1990).
There was no significant difference in serum SIL-2R
levels between patients with ulcerative colitis and those
with Crohn's disease. There was no significant difference
between the serum levels of SIL-2R of patients with
active IBD compared to the with inactive IBD. Though the
levels of statistical significance were not reached
(perhaps with more numbers these would be reached) the
trend for serum levels of sIL-2R as shown by the means,
median and difference from controls (Tables 12A:1D and
12A:1E) is that the levels were higher in patients with
active IBD than the levels for patients with inactive
IBD. Similarly the mean and median for the levels of
serum sIL-2R were higher in patients with inactive IBD
than in controls (Table 12A:1E).
The patients with inactive IBD therefore had intermediate
values between active disease and controls. This suggests
that patients who are clinically classified as having
inactive disease still have some underlying disease
activity for which we do not have clinical means
sensitive enough to monitor.
Thus there is always a background of upregulated immune
activity, as measured by serum sIL-2R levels, despite the
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lack of overt clinical manifestations. On the otherhand
the lack of significant differences in the levels of
serum SIL-2R between controls and inactive disease groups
means that, with disease remission, there is down-
regulation of immune activity towards normal in the
inactive groups.
REGIONAL INVOLVEMENT AND SERUM SIL-2R IN CROHN'S DISEASE
Crohn's disease patients were further subdivided
according to the distribution of disease into four
groups; small bowel (mouth to ileum with no colonic
involvement), ileocolonic, colonic (no small bowel
involvement) and Crohn's proctitis.
Patients with small bowel (SB) Crohn's disease had
significantly higher levels of serum SIL-2R than controls
range 63-1484U/ml with a median of 664U/ml (p=0.015). The
patients with colonic (CN) Crohn's disease gave a range
of 304-2845U/ml with a median of 1077U/ml, again this was
significantly higher than for controls (p=0.0014). There
was no significant difference between either ileocolonic
(ILC) Crohn's disease (p=0.1106) or Crohn's proctitis
(PR) (p=0.0.0786) and controls (Table 12A:2A and Graph
12A:2).
The prevalence of high levels of sIL-2R in serum
(>510U/ml) were analysed according to regional
involvement of Crohn's disease. As table 12A:2B shows
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only 1 out 11 controls had high levels of serum SIL-2R
compared to 9 out of 13 patients with small bowel Crohn's
disease and 7 out of 9 patients with colonic Crohn's
disease. The same was applied for patients with active
and inactive disease. The results of the statistical
evaluations are discussed below.
LEVELS OF SERUM SIL-2R IN SERUM OF PATENTS WITH CROHN'S
DISEASE ACCORDING TO DISEASE ACTIVITY AND REGIONAL
INVOLVEMENT
Patients with Crohn's disease were further subgrouped
according to regional involvement of disease and disease
activity based on clinical assessment and WGLF total IgG.
Their sera were assayed for sIL-2R and the results
compared with those of controls (Table 12A:2C).
Patients with active small bowel disease had
significantly higher levels than controls with a range
of 63-1484U/ml and a median of 638U/ml (p=0.0186), as did
the patients with active colonic Crohn's disease
(p=0.0021) and active Crohn's proctitis (p=0.0223). The
seven patients with active ileocolonic disease patients
gave high levels median 609U/ml and range of 80-1181U/ml
but not significantly different from controls (Table
12A:2C).
There was no significant difference between controls and




These results show that the levels of serum sIL-2R were
significantly higher than controls in all active disease
subgroups except for the patients with ileocolonic
Crohn's disease. This is partly explained by the fact
that 7 out of these 9 ileocolonic patients had had
resections so that their area of disease activity would
be less than with an intact gastro-intestinal tract.
Since serum sIL-2R may be derived predominantly from the
gastro-intestinal tract, as discussed in chapter 4A, it
would reflect only a fraction of the true levels in the
intestines and the difference from controls would not be
apparent. However as WGLF SIL-2R reflects local activity
and is of local origin it would be more likely to show
true similarities or differences for intestinal
diseases. A similar analysis was done for levels of sIL-
2R in WGLF of these groups (see below).
LEVELS OF SERUM SIL-2R IN ULCERATIVE COLITIS ACCORDING TO
REGIONAL INVOLVEMENT
Ulcerative colitis patients were further subdivided
according to the distribution of disease into three
groups; pancolitis (involving the whole colon), left
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sided (LS) and ulcerative proctitis (PR) .
Patients with pancolitis had significantly higher levels
of serum sIL-2R levels than controls range 209-1800U/ml
with a median of 544U/ml (p=0.0265). The patients with
ulcerative proctitis gave a range of 236-1986U/ml with a
median of 493U/ml again this was significantly higher
than the levels for the controls (p=0.0444) [Table 12A:3A
and Graph 12A:3).
Table 12A:3B shows the prevalence of high levels of serum
sIL-2R in ulcerative colitis patients according to
regional involvement of disease. Out of 10 patients with
pancolitis, 5 had high levels and out of 6 patients with
ulcerative colitis 3 had high levels these differences
were significant compared to controls who had only 1 high
levels out of 11 (Table 12A:3A). The analysis was also
done for patient with active and inactive ulcerative
colitis in the subgroups. The statistical evaluations of
these are discussed below.
There were only 3 patients with left sided disease from
whom two results were obtained no statistical analyses
were carried out. This group therefore is not considered
any further.
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REGIONAL INVOLVEMENT. DISEASE ACTIVITY AND SERUM SIL-2R
IN ULCERATIVE COLITIS
Patients with active pancolitis had significantly higher
levels of serum sIL-2R than controls with a range of
249-1800U/ml and a median of 669U/ml (p=0.005), but not
the three patients with active proctitis (p=0.0617)
though all had high values (367, 583, and 1986U/ml). The
lack of significant difference from controls for the
ulcerative proctitis group could be due to the small
numbers studied (Table 12A:3B and Table 12A:3C).
The numbers of patients with inactive ulcerative colitis
were small; 3 with inactive pancolitis and 3 with
inactive ulcerative proctitis. Statistical analysis were
not performed for these groups.
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SECTION 12B
THE LEVELS OF WGLF SIL-2R IN CONTROLS AND IBP
Whole gut lavage fluid specimens were collected from 20
controls, 24 patients with ulcerative colitis and 45 with
Crohn's disease.
In whole gut lavage fluid from controls sIL-2R was
largely undetectable (<10U/ml) with a range of <10-97U/ml
and a median of <10U/ml. Patients with ulcerative colitis
gave a range of <10-149U/ml with a median of 39U/ml and
this was not significantly higher than controls
(p=0.0533). Patients with Crohn's disease gave a range of
10-350U/ml with a median of 56U/ml and this was
significantly higher than the levels for controls
(p=0.0003). The values of the ulcerative colitis group
were midway between controls and Crohn's disease patients
(Table 12B:1A and Graph 12B:1).
Analysis of the sIL-2R in WGLF of controls showed that 70
was 2 standard deviations above the median and this was
used to denote high values for further analysis (Table
12B:1B). This showed that out of 20 controls ,2 had high
levels of SIL-2R in their WGLF compared to 8 out of 24
patients with ulcerative colitis or 17 out of 45 patients
with Crohn's disease. These were significantly higher
than the levels for controls as discussed above. Further
analysis of the frequency of high levels in active and
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inactive disease were made (Table 12B:1B). The statistical
results of the active and inactive subgroups are
discussed below.
DISEASE ACTIVITY AND WGLF SIL-2R
Patients were further subgrouped according to disease
activity and their levels of sIL-2R in WGLF compared with
controls.
Both active Crohn's disease (p=0.0005) and active ulcera¬
tive colitis (p=0.0136) had significantly higher levels
of SIL-2R in WGLF than controls (Table 12B:1B and Table
12B:1C and Graph 12B:1).
There was no significant difference between inactive UC
and controls (p=0.6284). The inactive CD group gave a
range of <10-350U/ml with a median of 45U/ml and this was
significantly higher than controls (p=0.0064) [Table
12B:1D; Table 12B:1B and Graph 12B:1].
There was no significant difference in the levels of
SIL-2R in WGLF between ulcerative colitis patients and
Crohn's disease (p=0.0659), active CD and inactive CD
(p=0.4329), active UC and inactive UC (p=0.0895) or
between active CD and active UC (p=0.7387). Patients with
inactive CD had higher values median 45U/ml range 10-
350U/ml than inactive UC median 24U/ml range 10-73U/ml
and the difference was of borderline significance
(p=0.042) [see Table 12B:1E].
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COMMENT
There were a few controls who had detectable levels (10
out of 20 with only 2 above 70) in their WGLF. This is
probably due to the fact that most of the controls were
hospital referrals with some abdominal symptoms. Levels
of SIL-2R are raised with increased immune activity (see
chapter 2A), though this is not specific to IBD, the fact
than IBD patients had higher levels than controls who
also had abdominal symptoms suggests that there is an
upregulation of the immune response in IBD which is
significantly higher in active disease. However as levels
of sIL-2R are also raised in some controls, sIL-2R levels
can not be used for diagnosing IBD.
These results though similar to those in blood, show some
differences. Whereas serum sIL-2R in UC was significantly
raised compared to controls (p = 0. 039) in WGLF the
difference was not significant (p=0.0533). However both
WGLF and serum SIL-2R were significantly higher in CD
than controls and the differences were more pronounced in
lavage (p=0.0003) as compared to serum (p=0.0016). This
is in keeping with the report by Mullin et al. (1991), of
increased IL-2mRNA in intestinal mucosa of Crohn's
disease but not in ulcerative colitis patients compared
to controls. The levels of SIL-2R in WGLF of patients
with inactive disease were largely not significantly
different from controls except for the inactive Crohn's
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disease group (p=0.0064). This group gave even borderline
significantly higher levels of sIL-2R in WGLF than
patients with inactive UC (Table 12B:1E, p=0.042). This
is explained by the fact that this inactive CD group had
a preponderance of patients who were in the higher range
of normal with regard to disease activity, and their WGLF
total IgG was significantly higher than for inactive UC
(p=0.0420) [see Table 12B:4C].
LEVELS OF SIL — 2 R IN WGLF ACCORDING TO REGIONAL
INVOLVEMENT OF CROHN'S DISEASE
Patients were subdivided into subgroups as for serum
SIL-2R. Patients with small bowel Crohn's disease had a
range <10-350U/ml with a median of 68U/ml. The
ileocolonic Crohn's disease group gave a range of <10-
234U/ml with a median of 49U/ml. Patients with colonic
Crohn's disease gave a range of <10-347U/ml with a
median of 45U/ml, and the patients with Crohn's proctitis
gave a range of 18-249U/ml with a median of 69U/ml. All
these values were significantly higher than controls
(p=0.0020, 0.0116, 0.0263 and 0.0288 respectively) [Table
12B:2A and Graph 12B:2].
The patients were further analysed according to the
prevalence of high levels of SIL-2R in WGLF (>70U/ml).
Out of 20 controls, 2 had high levels compared to 6 out
of 15 patients with small bowel Crohn's disease, 5 out of
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13 patients with ileocolonic Crohn's disease, 2 out of 10
patients with colonic Crohn's disease and 3 out of 6
patients with Crohn's proctitis (Table 12B:2B). The
patients were further subgrouped into active and inactive
disease groups, and similarly analysed. The statistical
analyses are discussed below.
REGIONAL INVOLVEMENT. DISEASE ACTIVITY AND WGLF SIL-2R
LEVELS IN CROHN'S DISEASE
All Crohn's disease subgroups with active disease had
significantly higher levels of WGLF sIL-2R than controls.
Patients with active small bowel Crohn's disease gave a
range of 10-181U/ml with a median of 66U/ml (p=0.0089),
active ileocolonic Crohn's disease gave a range of 10-
167U/ml with a median of 87U/ml (p=0.0358), active
colonic Crohn's disease gave a range of 10-347U/ml with a
median of 48U/ml (p=0.0348) and active Crohn's proctitis
gave a range of 46-249U/ml with a median of 79U/ml
(p=0.0223) [Table 12B:2B and Table 12B:2C].
Only two inactive groups, inactive small bowel Crohn's
disease and inactive ileocolonic Crohn's disease gave
enough numbers for statistical evaluation. Patients with
inactive small bowel Crohn's disease had significantly
higher levels of sIL-2R in their WGLF than controls,
with a range of 10-350U/ml and a median of 73U/ml
(p=0.0263). The inactive ileocolonic Crohn's disease
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group whose range was 10-234U/ml with a median of 46U/ml,
did not differ significantly from controls (p=0.0638)
[Table 12B:2B and Table 12B:2D).
LEVELS OF SIL-2R IN WGLF OF PATIENTS WITH ULCERATIVE
COLITIS ACCORDING TO REGIONAL INVOLVEMENT
Ulcerative colitis patients were further subdivided
according to the distribution of disease as for serum
SIL-2R above.
Only the active UC proctitis group gave significantly
higher values than controls with a range of 44-149U/ml
with a median of 107U/ml (p=0.0095). There was no
significant difference between the other subgroups and
controls (Tables 12B:3A-D and Graph 12B:3). The
prevalence of high levels of SIL-2R in WGLF was analysed
according to disease distribution of ulcerative colitis
(Table 12B:3B). Out of 20 controls, 2 had high levels
compared to 3 out 11 patients with pancolitis, 1 out of
three with left sided ulcerative colitis and 3 out of 8
with ulcerative proctitis. The same analysis was done for
patients grouped according to disease activity.
COMMENT
All regional subgroups in CD gave significantly higher
levels than controls except for the inactive groups.
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When ulcerative patients were subgrouped according to
regional involvement only, the active proctitis group
gave significantly higher levels of sIL-2R in WGLF than
controls (Table 12B:3C). The inclusion of 4 of these
patients as ulcerative proctitis is not fully conclusive
and they are being followed up as they may turn up to
have Crohn's disease or indeed high levels of SIL-2R in
patients with ulcerative colitis could be a feature of
ulcerative proctitis.
COMPARISON OF DISEASE ACTIVITY BETWEEN DISEASE GROUPS
The difference between the two disease groups with
respect to controls, could be due to one group having
patients with more active disease. As disease activity
was based on WGLF IgG, comparisons of the levels of gut
lavage IgG were made between the two groups. The IgG
level in patients with ulcerative colitis was between 1-
120ug/ml with a median of 27ug/ml, and the range for*the
Crohn's disease was between l-150ug/ml. These levels were
not statistically different (p=0.7480). However active UC
patients median 53ug/ml and a range of 19-120ug/ml had
significantly higher WGLF IgG than active Crohn's disease
(median 26ug/ml with a range of ll-150ug/ml; p=0.0196).
Inactive Crohn's disease gave a median of 5ug/ml with a
range of l-10ug/ml which was significantly higher than
the IgG values for inactive ulcerative colitis (median of
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2.5ug/ml with a range of l-8ug/ml; (p=0.0420) [Tables
12B:4A-C).
COMMENT
The patients with ulcerative colitis were well matched
with the patients with Crohn's disease as regards disease
activity as there was no significant differences in their
IgG levels. Patients with active UC had significantly
higher levels of total IgG in their WGLF than patients
active Crohn's disease. This is interesting in view of
the fact that active Crohn's disease patients gave higher
levels of statistical significance compared to controls
than did patients with active ulcerative colitis compared
with controls (Table 12B:1C; p=0.0005 and p=0.0136
respectively). It indicates that SIL-2R measurement looks
at a different aspect of disease activity from WGLF total




THE RELATIONSHIP BETWEEN DISEASE ACTIVITY AND LEVELS OF
SIL-2R IN SERPH AND WGLF
Levels of sIL-2R in WGLF were correlated with the levels
of WGLF total IgG (a measure of disease activity) for
each disease subgroup.
There was no significant correlation between disease
activity, as measured by WGLF IgG, and WGLF SIL-2R for
the controls as well as the disease groups (Table 12C:1).
The result for patients with ulcerative colitis (r=0.486
and p=0.016) is accounted for mainly by negative values.
Levels of SIL-2R in serum were correlated with the levels
of WGLF total IgG (a measure of disease activity) for
each disease subgroup.
There was a strong correlation between disease activity
and serum SIL-2R for all the patients with Crohn's
disease (r=0.540, p=0.0001), also for patients with
active Crohn's disease (r=0.474, p=0.017) [Table 12C:1].
Other subgroups showed no significant correlation
between serum SIL-2R and WGLF total IgG.
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THE RELATIONSHIP BETWEEN SIL-2R LEVELS IN WGLF. SERUM
AND DISEASE ACTIVITY IN REGIONAL INVOLVEMENT OF DISEASE
Crohn's disease and ulcerative colitis patients were
subgrouped according to regional involvement as outlined
above (disease distribution for serum sIL-2R).
Correlation coefficients were done between their levels
of SIL-2R in WGLF and total WGLF IgG. There was no
significant correlation between these measurements for
any of the groups (Tables 12C:2A-C).
Correlation coefficients were also performed between
SIL-2R levels in serum and WGLF total IgG. Serum sIL-2R
correlated with lavage IgG for colonic Crohn's disease
(r=0.757/ p=0.018) and Crohn's proctitis (r=0.852,
p=0.031) [Table 12C:2A].
None of the subgroups with UC showed any strong
correlation between WGLF IgG and sIL-2R (RESULTS NOT
SHOWN) .
When the groups were divided further into active and
inactive subgroups there was no significant correlation
between WGLF IgG and SIL-2R in WGLF or serum (Table
12C:2B and Table 12C:2C). The lack of significant
correlation for serum SIL-2R in active colonic and
Crohn's proctitis groups could be because fewer numbers
were studied. The lack of correlation between WGLF total
IgG and WGLF sIL-2R in the active and inactive proctitis
subgroups is in keeping with the findings in the general
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Crohn's and ulcerative colitis study group were no
significant correlation was found (Table 12C:1).
Furthermore the level of significant correlation for the
whole 6 Crohn's proctitis group is borderline at p=0.031.
THE RELATIONSHIP BETWEEN WGLF SIL-2R AND SERUM SIL-2R
Serum levels of SIL-2R and WGLF levels of SIL-2R were
correlated for the individual groups.
There was no strong correlation between serum sIL-2R and
WGLF SIL-2R for all the groups (Table 12C:3A).
COMMENT
There was a strong correlation between disease activity
as measured by lavage IgG and serum sIL-2R for the whole
Crohn's disease group, active Crohn's disease, colonic
and Crohn's proctitis (Table 12C:1 and 2A). This probably
reflects the fact that Crohn's disease patients tend to
have more complications such as fistula formation,
intestinal obstruction and intestinal perforations,
concomitant with panmural bowel disease. The panmural
involvement may increase the leakage of sIL-2R from the
bowel lumen into systemic circulation. A combination of
these complications and the panmural character of the
disease involvement in patients with IBD, may lead to the
corresponding increase in serum sIL-2R.
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The lack of correlation between disease activity and WGLF
sIL-2R for any of the disease groups may reflect the fact
that the latter is a measure of a different phenomenon,
such as its involvement in the upregulation of the immune
response as discussed in chapter 4A (the Schlepper
effect) unlike WGLF total IgG which is a result of
leakage from plasma and not directly involved with immune
activity. The upregulation of the immune response may be
involved in the immunopathogenesis of IBD.
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SECTION 12D
COMPARISONS OF LEVELS OF SIL-2R BETWEEN UPPER AND LOWER
GASTRO-INTESTINAL INVOLVEMENT WITH IBP
To determine whether the levels of SIL-2R were related
to upper or lower gastrointestinal bowel involvement,
analysis of sIL-2R levels were done with patients divided
into two groups, small bowel and large bowel involvement
regardless of diagnosis. Small bowel involvement patients
were invariably patients with Crohn's disease. The
patients with ileocolonic disease were excluded.
COMPARISON OF LEVELS OF SIL-2R IN SERUM OF PATIENTS WITH
SMALL BOWEL AND LARGE BOWEL IBP
Controls gave a range of 171-544U/ml with a median of
235U/ml. Patients with small bowel disease Crohn's
disease gave a range of 63-1484U/ml with a median of
664U/ml, which was significantly higher than the levels
for the controls (p = 0.0150). Patients with large bowel
Crohn's disease gave a range of 50-2845U/ml with a median
of 804U/ml, which was significantly higher than for the
controls (p=0.0051) [Table 12D:1A].
The prevalence of high levels within disease groups is
shown in table 12D:1B. Out of 11 controls, only one had
high levels of sIL-2R in serum, compared to 9 out of 13
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patients with small bowel disease or 16 out of 29 patients
with large bowel disease. The large bowel disease group
included patients with Crohn's colitis and ulcerative
colitis. The statistical analyses of these are given
above. These patient groups, small bowel and large bowel
involvement, were further subgrouped according to disease
activity and the prevalence of high levels determined
(Table 12D:1B). The results of the statistical evaluation
of these are discussed below.
SERUM SIL-2R LEVELS IN SMALL BOWEL AND LARGE BOWEL IBP
ACCORDING TO DISEASE ACTIVITY
Patients with active small bowel disease gave a range
of 63-1484U/ml with a median of 638U/ml, which was
significantly higher than the levels for the controls
(p=0.0186). The patients with large bowel disease gave a
range of 50-2845U/ml with a median of 831U/ml, which was
significantly higher than for the controls (p=0.0014)
[Table 12D:1C]. There was no significant difference
between the inactive disease groups and controls (Table
12D:1B and Table 12D:1D).
Comparisons in the levels of serum SIL-2R were made
between large bowel and small bowel involvement. There
was no significant difference in the serum levels of
SIL-2R between the disease groups regardless of disease
activity (Table 12D:1E).
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LEVELS OF SIL-2R IN WGLF OF PATIENTS WITH SMALL BOWEL AND
LARGE BOWEL DISEASE
The level of SIL-2R in the WGLF of patients with small
bowel disease or large bowel disease were compared with
levels in controls.
As before patients with small bowel disease gave a
range of <10-350U/ml with a median of 68U/ml, which was
significantly higher than the levels in controls
(p=0. 0020). Patients with large bowel disease gave a
range of <10-347U/ml and a median of 42U/ml, which was
significantly higher than for controls (p=0.0172) [Table
12D:2A].
The prevalence of high levels of sIL-2R in WGLF in small
bowel disease and large bowel disease was evaluated. Out
of 20 controls, 2 had high levels of sIL-2R in their WGLF
compared to 6 out of 15 with small bowel disease or 10
out of 34 with large bowel disease (Table 12D:2B).
Patients with large bowel disease included Crohn's
colitis and ulcerative colitis. These patients were
further subgrouped into active and inactive disease and
their prevalence of high levels of SIL-2R in WGLF fluid
analysed (Table 12D:1B). For example in patients with
active disease 3 out 9 patients with small bowel
involvement had high levels of SIL-2R in WGLF, as did 9
out of 22 patients with large bowel disease. The
statistical evaluations of these patient groups compared
374
to controls are described below.
LEVELS OF SIL-2R IN WGLF OF IBP PATIENTS WITH SMALL BOWEL
AND LARGE BOWEL IBP ACCORDING TO DISEASE ACTIVITY
Active disease groups had significantly higher levels
of sIL-2R in their WGLF than controls. For small bowel
disease the range was <10-181U/ml with a median of
66U/ml, and for large bowel the range was <10-347U/ml
with a median of 55U/ml, both significantly higher than
for controls (p=0.0089 and p = 0.0046, respectively)
[Table 12D:2B and Table 12D:2C]. There were only 9
patients with small bowel disease involvement as compared
to 22 patients with large bowel disease involvement;
hence the greater significance with the large bowel group
as compared to the small bowel group. However the medians
and means were higher for the small bowel group (Table
12D:2C).
Patients with inactive small bowel disease gave a
range of <10-350U/ml with a median of 73U/ml, which was
significantly higher than the levels for controls
(p=0.0263) while levels of SIL-2R in WGLF of patients
with inactive large bowel disease gave a range of <10-
73U/ml with a median of 34U/ml, which was not
significantly higher than the levels for controls
(p=0.4363) [Table 12D:2B and Table 12D:2Dj.
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COMPARISON OF SIL-2R LEVELS IN WGLF BETWEEN SMALL BOWEL
AND LARGE BOWEL INVOLVEMENT OF IBP
Comparisons in the levels of sIL-2R in WGLF were made
between small bowel disease involvement and large
bowel disease involvement (Table 12D:2E). There was no
significant difference between the large bowel disease
group taken as a whole compared to the levels in all the
patients with small bowel disease involvement (p=0.0701).
The levels in patients with active small bowel disease
did not differ significantly from those with large bowel
disease (p=0.5423). Patients with inactive small bowel
disease gave a range of <10-350U/ml with a median of
73U/ml and the patients with inactive large bowel disease
gave a range of <10-73U/ml with a median of 34U/ml. The
levels in the small bowel group were higher than for the
large bowel group with a borderline significance
(p=0.0492) [Table 12D:2E].
COMMENT
These results show that sIL-2R levels were higher in the
SB group on average than the large bowel group and the
difference became significant when inactive small bowel
patients are compared with inactive large bowel IBD
patients (p = 0.0492) [Table 12D:2A-D]. The higher levels
of sIL-2R in upper gastrointestinal involvement could be
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because there is more lymphoid tissue in this region
especially the ileum. Secondly as this is the area most
exposed to exogenous antigens, immune activity would be
expected to be higher in this region. In addition to
this, by the time antigen such as polypeptides have
reached the distal part of the intestines, a larger
proportion of it will have been processed into less
antigenic forms such as amino acids, as compared to the
higher exposure to polypeptides in the upper gastro¬
intestinal tract. Increased immune activity would be
reflected by an increase in the levels of sIL-2R, a
receptor whose concentration increases when there is an
immune response (see chapter 2A).
Further examination of the levels of SIL-2R in WGLF of
patients with active and inactive small bowel disease
yields some interesting paradox. Active small bowel
disease gave a range of <10-181U/ml with a mean and
median of 74U/ml and 66U/ml respectively (Table 12D:2C).
The patients with inactive small bowel disease gave a
range of <10-3 50U/ml with both the mean and median being
73U/ml (Table 12D:2D). This is interesting as it may
suggest that high levels of sIL-2R are facilitatory in
disease remission. If this were the case it would tend to
render support to the suggestion by Smith and Cantrell
(1985) and Rubin et al.(1986) that SIL-2R serves to down
regulate the immune response. However it could equally
suggest that the high levels are in keeping with the
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result of an appropriately effective upregulated immune
response which leads to the elimination of the offending
antigen.
Levels of SIL-2R in patients with active large bowel
disease gave a range of <10-347U/ml, a mean of 71U/ml
with a median of 55U/ml (Table 12D:2C) which were higher
than the inactive large bowel disease ( range <10-73U/ml,
mean 27U/ml with a median of 34) [Table 12D:2D]. This
could indicate that high levels of SIL-2R are a feature
of active disease. The lower levels in active small bowel
disease than in inactive small bowel disease could be a
result of increased degradation of sIL-2R in active small
bowel disease compared to inactive small bowel disease.
The source of these proteolytic enzymes apart from the
lumen itself, which applies for both active and inactive
small bowel disease, could be from the increased leakage
of serum from systemic circulation (see chapter 7), and
also the enzymes released from polymorphonuclear cells
that leak into the bowel lumen in active disease
(Saverymuttu et al.. 1985b and 1985c). The effect of
these enzymes would be greater for small bowel disease
compared to large bowel disease due to the increased
transit time for WGLF from the small bowel as compared
from the large bowel. This question could be resolved by
segmental sampling of the upper intestine perhaps as
performed by Marteau et al. 1990, and comparing the
levels of sIL-2R between active and inactive small bowel
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disease groups. It is probable that patients with active
disease would have higher levels of SIL-2R in their
intestinal secretions than those with inactive disease.
As discussed above a number of suggestions have been made
regarding the role of sIL-2R in the immune response and
none has been proven. In view of this the results of
treatment with elemental diet with respect to levels of
sIL-2R may be quite informative. This point is discussed




LEVELS OF SIL-2R in WGLF AND SERUM OF PATIENTS WITH
GLUTEN RELATED ENTEROPATHY (GRE)
Patients with coeliac disease or dermatitis
herpetiformis were grouped together as a gluten-related
enteropathy group because both these groups do show
enteral hypersensitivity to gluten.
Levels of SIL-2R were studied in the serum and WGLF of
eight patients with gluten-related enteropathy. Seven of
these patients had coeliac disease and were on a gluten
free diet. The eighth patient had dermatitis
herpetiformis and he was on a gluten free diet as well.
All the patients in the gluten-related group (GRE) were
in disease remission.
SERUM LEVELS OF SIL-2R IN GRE PATIENTS COMPARED TO IBP
PATIENTS AND CONTROLS
There were four serum specimens studied from this group.
The range was 172-1396U/ml with a median of 289U/ml. This
was not significantly different from either controls
(p=0.7441) or patients with ulcerative colitis (p=0.3350)
or Crohn's disease (p=0.4160). The median and range for
the patients with gluten-related enteropathy (289U/ml and
172-1396U/ml respectively) were lower than that of
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patients with ulcerative colitis (461U/ml and 60-1986U/ml
respectively) or for Crohn's disease (611U/ml and
10-2844U/ml respectively). The median and range for the
GRE group however were higher than for the controls
whose median and range were 235U/ml and 171-544U/ml
respectively (Table 12E:1A).
Comparisons in the serum levels of SIL-2R between the GRE
group and patients with active ulcerative colitis or
active Crohn's disease were made. These showed that there
was no significant difference between the gluten-related
enteropathy group and active ulcerative colitis or active
Crohn's disease (p=0.2175 and p=0.249 respectively; Table
12E:1B).
WHOLE GUT LAVAGE FLUID SIL-2R IN GRE COMPARED TO CONTROLS
AND IBP GROUPS
Whole gut lavage was obtained from all the eight GRE
patients and assayed for sIL-2R as described in chapter
6A. The levels of SIL-2R in WGLF of the GRE group were
compared with those of controls and IBD patients (Table
12E:2A).
The range of the levels of sIL-2R in WGLF of GRE patients
was <10-169U/ml with a median of 59U/ml. Patients with
ulcerative colitis gave a range of <10-149U/ml with a
median of 38U/ml, this was not significantly different
from the GRE group (p = 0.5734). The patients with
381
Crohn's disease gave a range of <10-350U/ml with a median
of 56U/ml, this was not significantly different from the
GRE group (p = 0.7950). Even the SIL-2R levels in WGLF of
controls with a range of <10-97U/ml and a median of
lOU/ml, were not significantly lower than for the GRE
group (p= 0.1281) [Table 12E:2A].
Comparisons in the levels of sIL-2R in WGLF were made
between the GRE group and patients with active ulcerative
colitis or Crohn's disease. Patients with active
ulcerative colitis gave a range of <10-149U/ml with a
median of 66U/ml, and patients with active Crohn's
disease gave a range of <10-347U/ml with a median of
59U/ml both these levels were not significantly different
from the GRE group (p=0.1429 and p=0.7371 respectively)
[Table 12E:2B] .
COMMENT
These results do not reflect findings in acute untreated
(active) gluten enteropathy. The levels of sIL-2R in WGLF
and serum were intermediate between the levels in
patients with active Crohn's disease or active ulcerative
colitis and controls. The levels of sIL-2R did not differ
significantly from either active ulcerative colitis,
active Crohn's disease or controls, an intermediate
position as observed before for patients with inactive
Crohn's disease or inactive ulcerative colitis. As stated
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above, all these GRE patients were in remission so these
findings may not apply to the patients with untreated
active gluten-related enteropathy. Furthermore no strong
statistical conclusions could be made for the serum
results of the GRE group as only 4 sera were assayed for
SIL-2R.
SECTION 12F
COMPARISON OF LEVELS OF SIL-2R IN IBP PATIENTS
CLASSIFIED AS SMALL BOWEL. COLONIC CROHN'S DISEASE AND
ULCERATIVE COLITIS WITH CONTROLS
The groups of patients analysed above as large bowel
disease included both Crohn's colitis and patients with
ulcerative colitis. Therefore the findings with respect
to the large bowel could not be attributed either to
large bowel Crohn's disease or ulcerative colitis. In
order to resolve this question the large bowel group was
further subdivided according to whether they had Crohn's
colitis or ulcerative colitis. The comparison in the
levels of sIL-2R with small bowel Crohn's disease and
controls was again performed.
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COMPARISON OF LEVELS OF SEROM SIL-2R IN IBP PATIENTS
CLASSIFIED AS SMALL BOWEL. COLONIC CROHN'S DISEASE AND
ULCERATIVE COLITIS WITH CONTROLS
The serum levels of sIL-2R in controls gave a range of
171-544U/ml with a median of 235U/ml. Patients with small
bowel disease gave a range of 63-1484U/ml with a median
of 664U/ml. Crohn's colitis patients gave a range of 304-
2845U/ml with a median of 1077U/ml, and patients with
ulcerative colitis gave a range of 60-1986U/ml with a
median of 461U/ml. All these values were significantly
higher than for controls (p=0.0150; 0.0014 and 0.039
respectively) [Table 12F:1A]
The prevalence of high level of SIL-2R in serum was
further analysed in these groups. Levels of serum SIL-2R
above 510U/ml were considered high (see above). Out of 11
controls, 1 had high levels compared to 9 out of 13
patients with small bowel Crohn's disease, 7 out of 9
patients with colonic Crohn's disease and 9 out of 20
patients with ulcerative colitis. The same analysis was
done for patients with active disease. Out of 8 patients
with active small bowel disease, 6 had high levels of
serum sIL-2R, out of 7 patients with active colonic
Crohn's disease, 6 had high levels just as 7 out 12
patients with active ulcerative colitis. Statistical
evaluation (see below) showed that all these values were
significantly higher than for controls. Three out of five
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patients with inactive small bowel disease had high
values, one of the two with inactive colonic Crohn's
disease had a high value, as had 2 of the 8 with inactive
ulcerative colitis. Statistical evaluation of the levels
in these inactive group compared to controls, where
applicable, showed no significant difference (see below).
COMPARISON OF LEVELS OF SIL-2R IN ACTIVE IBP PATIENTS
CLASSIFIED AS ACTIVE SMALL BOWEL. ACTIVE COLONIC CROHN'S
DISEASE AND ACTIVE ULCERATIVE COLITIS WITH CONTROLS
Patients were further subdivided according to whether
they had active disease or inactive disease on global
clinical assessment and total lavage IgG levels (see
chapter 7).
Patients with active small bowel Crohn's disease gave a
range of 63-1484U/ml with a median of 638U/ml, active
colonic Crohn's disease patients gave a range of 304-
2845U/ml with a median of 1084U/ml, and active ulcerative
colitis patients gave a range of 50-1986U/ml with a
median of 591U/ml. All these values were significantly
higher than for controls (p=0.0186, 0.0021, and 0.0151,
respectively) [Table 12F:1C],
Patients with inactive small bowel Crohn's disease gave a
range of 162-847U/ml with a median of 680U/ml and
inactive ulcerative colitis gave a range of 209-1195U/ml
with a median of 359U/ml. Both these values were not
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significantly different from controls (p=0.1408 and
0.4090, respectively) [Table 12F:1D]. There were only two
patients with inactive colonic Crohn's disease and the
statistical analysis for these were not done.
COMPARISON OF SERUM LEVELS OF SIL-2R BETWEEN
ULCERATIVE COLITIS. SMALL BOWEL CROHN'S DISEASE AND
COLONIC CROHN'S DISEASE
The levels of serum SIL-2R were compared between patients
with small bowel Crohn's disease, colonic Crohn's disease
and ulcerative colitis. Even when these groups were
subdivided according to disease activity there was no
significant difference (Table 12F:1E).
COMMENT
Though there was no significant difference between small
bowel Crohn's disease, colonic Crohn's disease and
ulcerative colitis regardless of disease activity a
pattern emerges. Patients with Crohn's disease have
higher medians and mean levels of serum SIL-2R than
ulcerative colitis. For small bowel Crohn's disease, the
mean and median serum SIL-2R were 649U/ml and 664U/ml
respectively and for colonic Crohn's disease the mean and
median were 1150U/ml and 1077U/ml respectively (Table
12F:1A). Ulcerative colitis gave a mean of 648U/ml with a
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median of 461U/ml lower than the two Crohn's disease
groups. This suggests that raised sIL-2R are a feature of
Crohn's disease as a whole compared to ulcerative
colitis. I suggest that with more numbers levels of
statistical significance could be reached. However serum
SIL-2R may reflect only part of sIL-2R (see chapter 2A) .
This is discussed further after the next section.
COMPARISON OF LEVELS OF WGLF SIL-2R IN IBP PATIENTS
CLASSIFIED AS SMALL BOWEL. COLONIC CROHN'S DISEASE AND
ULCERATIVE COLITIS WITH CONTROLS
Whole gut lavage fluid from 20 controls, 15 patients with
small bowel Crohn's disease, 10 patients with colonic
Crohn's disease and 24 patients with ulcerative colitis
was assayed for sIL-2R by ELISA (see chapter 6A).
The level of SIL-2R in the WGLF fluid of controls gave a
range of <10-97U/ml with a median of lOU/ml. The patients
with small bowel disease gave a range of <10-350U/ml with
median of 68U/ml, significantly higher than controls
(p=0.0020) and the patients with colonic Crohn's disease
gave a range of <10-347U/ml with a median of 45U/ml,
significantly higher than controls (p=0.0263). Patients
with ulcerative colitis gave a range of <10-149U/ml with
a median of 39U/ml, and this was not significantly higher
than for controls (p=0.1124) [Table 12F:2A].
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The prevalence of high levels of SIL-2R in WGLF of the
groups studied were analysed. Levels of SIL-2R in WGLF
above 70U/ml were considered high (see above). Two out of
the 20 controls had high levels, 6 out of the 15 with
small bowel Crohn's disease, and 2 out the 10 patients
with colonic Crohn's disease (Table 12F:2B). The values
of these patients when analysed statistically were
significantly higher than for controls (see Table 12F:2A.
Eight out 24 ulcerative colitis patients had high
values but when analysed statistically these were not
significantly different from controls.
A similar analysis was done for patients with active
disease which showed that 3 out of 9 patients with active
small bowel Crohn's disease had high levels, 2 out of 8
patients with active colonic Crohn's disease and 7 out of
14 patients with active ulcerative colitis (Table
12F:2B). On statistical analysis (see below) these levels
of WGLF SIL-2R were significantly higher than for
controls. Of the inactive disease groups only the
inactive small bowel Crohn's disease group, with 3
patients with high levels out of 6 patients, showed
significant differences from controls. Of the 10 patients
with inactive ulcerative colitis only 1 had high levels
and this was not significant as shown below.
388
COMPARISON OF LEVELS OF WGLF SIL-2R IN ACTIVE IBP
PATIENTS CLASSIFIED AS ACTIVE SMALL BOWEL. ACTIVE COLONIC
CROHN'S DISEASE AND ACTIVE ULCERATIVE COLITIS WITH
CONTROLS
Patients were further subgrouped according to disease
activity based on global clinical assessment and WGLF
total IgG.
Patients with active small bowel disease gave a range of
<10-181U/ml with a median of 66U/ml, active colonic
Crohn's disease patients gave a range of <10-347U/ml with
a median of 48U/ml and patients with ulcerative colitis
gave a range of <10-149U/ml with a median of 68U/ml. All
these levels of sIL-2R in lavage were significantly
higher than for controls (p=0.0089, 0.0348 and 0.0136,
respectively) [Table 12F:2C]
Only patients with inactive small bowel Crohn's disease
with a range of <10-350U/ml and a median of 73U/ml gave
significantly higher levels than for controls (p=0.0263).
The patients with inactive ulcerative colitis gave a
range of <10-73U/ml with a median of 24U/ml and this was
not significantly different from controls (p=0.6284).
There were only two patients with inactive colonic
disease and these were not included in the calculations.
(Table 12F:2D).
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COMPARISON OF WGLF LEVELS OF SIL-2R BETWEEN ULCERATIVE
COLITIS SMALL BOWEL CROHN'S DISEASE AND COLONIC
CROHN'S DISEASE
The levels of sIL-2R in WGLF were compared between
disease groups. There were no significant differences in
the levels of sIL-2R in WGLF between small bowel Crohn's
disease, colonic Crohn's disease or ulcerative colitis
(Table 12F:2E).
COMMENT
Compared to the results in serum the results in WGLF,
which may reflect directly intestinal immune activity,
(see chapter 4A; Mahida et al.. 1990) show a more clear
cut pattern. There are significantly higher levels in
patients with Crohn's disease compared to controls
whether the disease involves the small bowel or colon.
The levels in WGLF of patients with ulcerative colitis
however are not significantly higher than for controls.
The mean and median levels are highest in patients with
small bowel Crohn's disease (87U/ml and 68U/ml
respectively), followed by those with colonic Crohn's
disease (72U/ml and 45U/ml respectively) and lastly for
the patients with ulcerative colitis with a mean of
49U/ml and a median of 39U/ml (Tables 12F:2A and 12F:2B).
The level of significance compared to controls is higher
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for small bowel Crohn's compared to controls (p=0.0020)
than for colonic Crohn's compared to controls (p=0263).
This suggests that high levels of sIL-2R are more a
feature of Crohn's disease than ulcerative colitis and
that even within Crohn's disease higher levels are
associated more with small bowel disease.
That Crohn's disease should show higher immune activity
than ulcerative colitis would be in keeping with the
postulates made by Lewkonia and McConnel (1976) that
patients with Crohn's disease may have inherited more of
the relevant genes than those with ulcerative
colitis.
This is in keeping with the results of chapter 9, which
showed that the Crohn's disease patients are the
•hyper-immune' group. The next section is a study of T
cell activity, as measured by levels of SIL-2R, in
relation to elemental diet.
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SECTION 12G
ELEMENTAL DIET AND SOLUBLE INTERLEPKIN-2 RECEPTOR IN WGLF
AND SERUM
STUDY POPULATION
Fourteen patients were prescribed elemental diet in the
clinical management of their gastrointestinal disease. Of
the fourteen patients, 12 had Crohn's disease, one
ulcerative pancolitis and one coeliac disease
(Table 12G).
The patients were prescribed an exclusive elemental diet
for at least 7 days. Serum and whole gut lavage fluid
were collected before the introduction of the diet and
after at least 7 days of exclusive elemental diet feeds.
The specimens were assayed for SIL-2R by ELISA as
described in chapter 6A. At the commencement of the diet
all the IBD patients had active disease on global
clinical assessment. The disease distribution in the
patients with Crohn's disease was as follows; ileal
disease (4), colitis (3), ileocolonic (3), perianal and
rectal (1) and one with microscopic Crohn's disease.
Drug treatment within three weeks of commencement of the
diet was as follows, no drug treatment at all (2),
5-amino salicylic acid only (5), prednisolone only (1),
5-amino salicylate and prednisone (3) and prednisolone
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and colifoam (1). The patient with ulcerative colitis
had been on a combination of 5-amino-salicylate, oral
prednisolone and prednisolone enema and the coeliac
disease patient had been on a gluten free diet and
no other medication.
All the nutritional requirements were provided for by
elemental diet supplying an average of 2000kcal per day.
No other food supplements were allowed.
RESULTS
The levels of SIL-2R in WGLF and serum for specimens taken
before and while on elemental diet are shown with patient
data (Table 12G). These are described below.
On global assessment, the clinical condition of 4 of the
IBD patients improved (responders), 5 showed no change
and four deteriorated. Their results are plotted in
graphs 12G:1 (serum levels) and 12G:II (WGLF levels). A
pattern, as described, below tends to form.
SERUM SIL-2R and ELEMENTAL DIET
The levels of SIL-2R in serum before the commencement of
the diet were highest in the patients who did not
respond to elemental diet. Though the initial levels of
SIL-2R in the sera of those who responded were higher
than for the controls studied (median 235, mean 314 see
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Table 12F:1D), the levels in these responders were much
lower than those of the group that deteriorated.
The concentration of sIL-2R in the sera of all the non
responders rose while the levels in responders were more
or less constant. In patients who showed no change,
initial SIL-2R levels in serum were in the same range as
for the responders except for one patient (DS) who had
lower levels. In two the levels of serum SIL-2R rose (MI)
and (DS). For the other two (AM) and (EM) the levels
remained unchanged (Graph 12G:I).
WHOLE GUT LAVAGE FLUID SIL-2R AND ELEMENTAL DIET
The results in this intestinal fluid were more striking.
All the four patients who responded to elemental diet
therapy started with very high levels of SIL-2R in WGLF
(above lOOU/ml, higher than the high levels described in
earlier sections of this chapter) and the levels were
lower in the second specimens taken after the patients
had been on an exclusive elemental diet for at least
seven days.
The non-responders and those whose clinical condition
remained static, had initial levels that were low
below 100 and these levels did not fall in the specimens
collected after at least seven days on an exclusive
elemental diet. The patient with coeliac disease had
already been on a gluten-free diet and her initial lavage
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SIL-2R level in WGLF was 49U/ml. The level of sIL-2R in
the second WGLF specimen after 28 days of elemental diet
was 42U/ml. Her clinical condition did not change. More
patients with more acute disease need to be studied. This
patient is not discussed any further.
COMMENT
The finding in the responders of low initial levels of
sIL-2R in serum and high initial levels in whole gut
lavage fluid could indicate that in these responders the
main site of disease was the gastrointestinal tract. The
high serum and low WGLF levels of SIL-2R in patients
whose clinical condition deteriorated could indicate that
the main site of disease activity may not be intestinal
or that their exacerbation is due to some phenomenon
other an inflammatory stimulus such as infection.
The corollary to this hypothesis, is that interleukin-2
receptor itself, during reduced antigenic stimuli, plays
a part in the efficacy of elemental diet by a negative
feedback leading to its own down regulation, a mechanism
of action not very dissimilar from that of cyclosporin
(Brynskov and Tvede, 1990).
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GENERAL COMMENT
The aim of these experiments was to study the pattern of
SIL-2R in WGLF and serum in IBD patients. The results
from the two fluids were different in some respects. For
example in serum, patients with ulcerative colitis or
Crohn's disease gave significantly higher levels of
sIL-2 R than for controls (p = 0 . 039 and 0 . 0045 ,
respectively) [Table 12A:1A]. The results of SIL-2R in
WGLF fluid are different, with Crohn's disease giving
highly significantly higher levels compared to controls
(p=0.0003) but not the patients with ulcerative colitis
(p=0.0533) [Table 12B:1A].
These differences between the trends shown by the WGLF
and serum sIL-2R results could reflect the different
sources of the sIL-2R in the two fluids. Serum SIL-2R may
be primarily of systemic origin (from the systemic
lymphoid system), the source of SIL-2R in lavage fluid is
not clear. Evidence from other workers (Mahida et al..
1990 and Choy et al. 1990) suggests that it is mainly of
local intestinal origin. There is an increased expression
of IL-2R by cells in the gastrointestinal tract of
patients with active IBD (Mahida et al.. 1988; Choy et
al.. 1990). When Mahida et al. (1990) measured the levels
of SIL-2R in the mesenteric vessels of IBD patients for
whom they had peripheral blood as well, they found that
the levels were higher in the mesenteric vessels. They
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proposed that there was a significant contribution by
intestinal mononuclear cells to the circulating sIL-2R
concentration.
In this study lavage IgG correlated with serum SIL-2R
for the Crohn's disease group but there was no strong
correlation between lavage IgG and lavage SIL-2R. Whole
gut lavage IgG is probably mainly from serum (Chapter
7) , but the source of lavage SIL-2R has not been
determined. It may be secreted by cells in the lamina
propria, mesenteric lymph nodes or it may be of systemic
origin. The lack of correlation with lavage IgG makes a
systemic origin less likely in addition to the evidence
from other workers sited above.
If then the sIL-2R in WGLF is of local origin, it would
be a more accurate mirror of local immune activity than
the levels of serum SIL-2R which are subject to other
systemic conditions such as infections and other
autoimmune diseases (Keicho et al.. 1990; Koukkou et al. .
1990 and WUthrich et al.. 1990). The lack of a clear
demarcation between active and inactive IBD in WGLF
levels could be attributed to the persistence of the
upregulated immune activity in the clinically quiescent
IBD. This is clinically important as it brings into
question the criteria for stopping active treatment in
patients who are in remission clinically.
There was no significant difference in the levels of
SIL-2R in WGLF between ulcerative colitis and controls
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(p=0.0533; Table 12B:1A) and even in blood the
differences were more significant with Crohn's disease
(p=0.0045) than for ulcerative colitis (p=0.039) [Table
12A:1B]. This pattern is as found in the experiments
performed to find the hyperimmune group, with higher
anti-food antibodies (see Chapter 9) suggesting that
patients with ulcerative colitis occupy a midway position
between controls and Crohn's disease in the degree of
immune upregulation.
Whether high levels of sIL-2R are a feature of large
bowel or small bowel disease is partly answered by the
comparisons in the levels of SIL-2R between large bowel
(Crohn's colitis and ulcerative colitis) involvement,
small bowel Crohn's disease and controls. In all these
comparisons, regardless of disease activity, the
magnitude of significant difference in sIL-2R in WGLF
between the two groups and controls is highest with the
small bowel group (Table 12F:1A-E and Table 12F:2A-E).
The results of SIL-2R levels before and after elemental
diet are interesting in view the reported type of
patients who respond to elemental diet (see Chapter 5)
and in view of the pattern of sIL-2R levels established
in these series of experiments.
In the first place only 4 patients out of the 13 IBD
patients responded which represents less than 33%
response rate, much lower than the 80-90% reported in
large trials (O'Morain et al.. 1984; Okada et al.. 1990
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and see chapter 5). However this is explained by the fact
that elemental diet in this study was being used for
clinical reasons only as a tertiary treatment, after
other treatment (steroids, aminosalicylates) had failed
to induce a remission. The study was not designed as a
trial of the efficacy of elemental diet in IBD which has
been proved by others workers (see chapter 5).
It must be emphasised that the levels of SIL-2R in serum
were also raised in the patients who responded, most
likely reflecting a gastro-intestinal contribution of
SIL-2R to the systemic circulation.
The interpretation of this very high initial levels of
SIL-2R in the lavage of responders could be that it is a
marker of immunological exacerbation of IBD which would
be amenable to immunological treatment such as antigen
withdrawal. Malchow et a 1 . ( 1990) in their study
comparing polymeric diets with standard steroid therapy
found that the steroids were initially superior. They
however observed that there was a cohort of patients that
tended to respond to diet which needed defining. If these
results are confirmed, with further studies these
patients with high lavage sIL-2R would represent one such
cohort.
It is also interesting to note that patients with Crohn's
disease had relatively higher levels of SIL-2R in WGLF
than patients with ulcerative colitis and even among
these the small bowel Crohn's disease patients had
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relatively higher levels than those with large bowel
Crohn's disease. This supports previous observations that
elemental diet was only effective in Crohn's disease and
that small bowel Crohn's disease was more responsive than
large bowel Crohn's disease. However the large lOyr
review by Teahon et al. (1991) showed that this was not
always the case, some patients with colonic Crohn's
disease also responded to elemental diet. If high levels
of SIL-2R in WGLF are associated with disease response as
shown in this study then my finding of high lavage sIL-2R
in some patients with ulcerative colitis as well as
Crohn's colitis probably explains these apparently
contradictory findings.
Once these findings of high lavage SIL-2R levels are
confirmed, investigations towards the basic mechanisms of
action of elemental diet would become feasible, thereby
rationalising further the management of IBD.
SUMMARY
There were increased levels of SIL-2R in the blood and
WGLF of patients with active IBD.
Whereas there was a strong correlation between disease
activity as measured by lavage IgG and serum SIL-2R in
Crohn's disease, there was no such correlation for WGLF
SIL-2R.
High levels of soluble IL-2R as measured in WGLF were
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associated mainly with upper gastrointestinal disease.
The patients with ulcerative proctitis who gave
significantly higher levels than controls form an
interesting group that is being monitored. These patients
may turn out to have Crohn's disease or as stated, high
WGLF SIL-2R in ulcerative proctitis may be a
distinguishing feature for this group.
Patients with high levels of soluble interleukin-2
receptor in WGLF responded to elemental diet. The
mechanism of action of elemental diet remains unknown as
does the immunopathogenesis of inflammatory bowel
disease. Elemental diets could act by antigen withdrawal
or antigen modification. The antigen could be dietary,
intestinal flora or their immunostimulatory products.
This preliminary work has characterised a cohort of
responders to elemental diet which would form a possible
base for further investigations.
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APPENDIX FOR CHAPTER 12





















































Prednisolone only (Pred) 10
Sulphasalazine (SLZ) 13
5-amino salicylates only (ASA) 0
SLZ and Pred 7
Pred, ASA and colifoam (CFM) 1
SLZ, PRED and CFM 1









PRED, ASA and CFM 3
ASA and CFM 2
ASA only 6







TABLE 12A;1B LEVELS OF SERUM IL2R (O/ml) IN PATIENTS
WITH CROHN'S DISEASE (CD), ULCERATIVE COLITIS (PC) AND
CONTROLS.
N RANGE MEAN MEDIAN P
CONTROL 11 171-544 314 235
UC 20 60-1986 648 461 0.039
CD 38 10-2844 611 611 0.0045
p = probability that the difference is a chance finding.
TABLE 12A:1C THE FREQUENCY OF HIGH LEVELS OF SIL-2R IN THE
SERA OF PATIENTS WITH ULCERATIVE COLITIS (UC). CROHN'S
DISEASE (CD) PATIENTS AND CONTROLS. SIL-2R levels above
510U/ml
ALL ACTIVE INACTIVE
N >510 N >510 N >510
CONTROL (11) 1 NA NA
UC (20) 9* (12) 7* (8) 2
CD (38) 25** (25) 19*** (13) 6
NA = Not applicable
* p < 0.05 ** p < 0.01 *** p < 0.005
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Graph 12A:1
SERUM SOLUBLE INTERLEUKIN-2 RECEPTOR IN


























On the x axis are disease groups according to diagnosis and disease
activity plotted against their levels of soluble interleukin-2 receptor in
their sera. Both ulcerative colitis and Crohn's disease had
significantly higher levels compared to controls and this was
accounted for mainly by patients with active disease.
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TABLE 12A:1D LEVELS OF SIL-2R fU/ml) IN SERUM OF PATIENTS
WITH ACTIVE CROHN'S DISEASE TCP). ACTIVE ULCERATIVE
COLITIS (UCn AND CONTROLS.
N RANGE MEAN MEDIAN £
CONTROL 11 171-544 314 235
UC 12 50-1986 775 591 0.0151
CD 25 10-2844 865 742 0.0016
p = probability that the difference is a chance finding.
TABLE 12A:IE LEVELS OF SIL-2R (U/ml) IN SERUM OF PATIENTS
WITH INACTIVE CROHN'S DISEASE (CD). INACTIVE ULCERATIVE
COLITIS (UC) AND CONTROLS.
N RANGE MEAN MEDIAN P
CONTROL 11 171-544 314 235
UC 8 209-1195 457 359 0.4090
CD 13 162-847 484 476 0.1320
p = probability that the difference is a chance finding.
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TABLE 12A:IF COMPARISON OF LEVELS OF SIL-2R (O/ml) IN
SERUM BETWEEN DISEASE GROUPS.
DISEASE GROUPS
UC VS CD 0.3904
aUC VS aCD 0.5702
inaUC vs inaCRO 0.6904
aUC vs inaUC 0.1535
aCD vs inaCRO 0.0526
p = probability that the difference is a chance finding.
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TABLE 12A;2A LEVELS OF SERUM SIL-2R (O/ml) IN PATIENTS







N RANGE MEAN MEDIAN
11 171-544 314 235
13 63-1484 649 664 0.0150
9 80-1181 545 580 0.1106
9 304-2845 1150 1077 0.0014
6 208-1597 704 516 0.0786
SB - Small bowel Crohn's disease CN - Colonic Crohn's
disease
ILC - Ileocolonic Crohn's disease PR - Crohn's Proctitis
TABLE 12A:2B THE FREQUENCY OF HIGH LEVELS OF SIL-2R IN THE
SERA OF CROHN'S DISEASE PATIENTS CLASSIFIED BY REGIONAL
INVOLVEMENT.
ALL ACTIVE INACTIVE
N >510 N >510 N >510
CONTROL (11) 1 NA NA
SB (13) 9* (8) 6* (5) 3
ILC (9) 6 (5) 4 (4) 2
CN (9) 7** (7) 6** (2) 1
PR (6) 3 (4) 3* (2) 0
* p < 0. 05 ** P < 0.01 *** p < 0. 005
N = Total numbers of patients studied in the group
p = probability that the difference is a chance finding.
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Graph 12A:2
SERUM SIL2R IN CONTROLS AND CROHN'S DISEASE





































Regional involvement of Crohn's disease (x axis) plotted against
serum slL-2R on the y axis, p values against controls.
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TABLE 12A:2C LEVELS OF SIL-2R fU/ml^ IN SERUM OF PATIENTS
WITH ACTIVE CROHN'S DISEASE CLASSIFIED BY REGIONAL
INVOLVEMENT.
N RANGE MEAN MEDIAN D
CONTROL 11 171-544 314 235
SB 8 63-1484 696 638 0.0186
ILC 5 80-1181 640 609 0.0699
CN 7 304-2845 1333 1084 0.0021
PR 4 337-1597 885 802 0.0223
p = probability that the difference is a chance finding.
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TABLE 12A:2D LEVELS OF SIL-2R fU/mH IN SERUM OF PATIENTS
WITH INACTIVE CROHN'S DISEASE CLASSIFIED BY REGIONAL
INVOLVEMENT.
N RANGE MEAN MEDIAN P
CONTROL 11 171-544 314 235
SB 5 162-847 575 680 0.1408
ILC 4 171-748 427 395 0.5569
CN 2 NA 512 NA NA
PR 2 NA 342 NA NA
NA = Not applicable
p = probability that the difference is a chance finding.
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TABLE 12A:3A LEVELS OF SIL-2R (U/ml) IN SERPH OF PATIENTS
WITH ULCERATIVE COLITIS CLASSIFIED BY REGIONAL
INVOLVEMENT.
N RANGE MEAN MEDIAN P
CONTROL 11 171-544 314 235
PAN 10 209-1800 691 544 0.0265
LS 2 212-365 289 NA NA
PR 6 236-1986 704 493 0.0444
PAN - Pancolitis LS - Left sided
PR - Proctitis
NA = Not applicable
p = probability that the difference is a chance finding.
TABLE 12A:3B THE FREQUENCY OF HIGH LEVELS OF SIL-2R IN
THE SERUM OF ULCERATIVE COLITIS PATIENTS CLASSIFIED BY
REGIONAL INVOLVEMENT. SIL-2R levels above 510U/ml.
ALL ACTIVE INACTIVE
N >510 N >510 N >510
CONTROL (ID 1 NA NA
PAN (10) 5* (7) 5** (3) 0
LS (2) 0 (1) 0 (1) 0
PR (6) 3* (3) 2 (3) 1
N = Total numbers of patients studied in the group
* p < 0.05 ** p < 0.01 *** p < 0.005
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Graph 12A:3
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Disease groups on the x axis according to regions affected by
ulcerative colitis plotted against their levels of slL-2R in serum on the
y axis. Patients with pancolitis and proctitis had significantly higher
levels than healthy controls. Patients with left sided disease were too
few for firm statistical analysis.
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TABLE 12A:3C LEVELS OF SIL-2R fU/ml) IN SERUM OF PATIENTS
WITH ACTIVE ULCERATIVE COLITIS CLASSIFIED BY REGIONAL
INVOLVEMENT.
N RANGE MEAN MEDIAN J)
CONTROLS 11 171-544 314 235
PAN 7 249-1800 850 669 0.0050
PR 3 367-1986 978 583 0.0617
p = probability that the difference is a chance finding.
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SECTION 12B
TABLE 12B:1A LEVELS OF SIL-2R (U/ml) IN WGLF OF PATIENTS
WITH CROHN'S DISEASE (CD). ULCERATIVE COLITIS (PC) AND
CONTROLS.
N RANGE MEAN MEDIAN P
CONTROL 20 <10-97 24 <10
UC 24 <10-149 49 38 0.0533
CD 45 <10-350 82 56 0.0003
p = probability that the difference is a chance finding.
TABLE 12B:IB THE FREQUENCY OF HIGH LEVELS OF SIL-2R IN
THE WGLF OF ULCERATIVE COLITIS (UC) PATIENTS. CROHN'S
DISEASE (CD) PATIENTS AND CONTROLS. SIL-2R levels above
70U/ml.
ALL ACTIVE INACTIVE
N >70 N >70 N >70
CONTROL (20) 2 NA NA
UC (24) 8 (14) 7* (10) 1
CD (45) 17*** (28) 10*** (17) 7**
* p < 0.05 ** p < 0.01 *** p < 0.005
NA = Not applicable
N = Total numbers of patients studied in the group
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Graph 12B:1
WHOLE GUT LAVAGE FLUID SOLUBLE INTERLEUKIN-2

























On the x axis are the subject groups plotted against their levels of
slL-2R in whole gut lavage fluid. All the patients with active disease
(UC, CD) had significantly higher levels than controls as did the
patients with inactive Crohn's disease.
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TABLE 12B:1C LEVELS OF SIL-2R fU/ml) IN WGLF OF PATIENTS
WITH ACTIVE CROHN'S DISEASE (CDK ACTIVE ULCERATIVE
COLITIS rUC) AND CONTROLS.
N RANGE MEAN MEDIAN P
CONTROL 20 <10-97 24 10
UC 14 <10-149 66 68 0.0136
CD 28 <10-347 83 58 0.0005
p = Probability that the difference is a chance finding.
TABLE 12B;1D LEVELS OF SIL-2R fU/ml) IN WGLF OF PATIENTS
WITH INACTIVE CROHN'S DISEASE (CD). INACTIVE ULCERATIVE
COLITIS (UC) AND CONTROLS.
N RANGE MEAN MEDIAN P
CONTROL 20 <10-97 24 10
UC 10 <10-73 25 24 0.6284
CD 17 <10-350 80 45 0.0064
p = probability that the difference is a chance finding.
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Graph 12B:2
WHOLE GUT LAVAGE FLUID SIL2R IN CONTROLS AND



































On the x axis are disease groups by regional involvement plotted
agains their WGLF soluble interleukin-2 receptor on the y axis,
p values against controls
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TABLE 12B:1E COMPARISON OF WGLF SIL-2R (P/ml) BETWEEN
DISEASE GROUPS.
DISEASE GROUPS p
UC VS CD 0.0659
aUC vs aCD 0.7387
InaUC vs inaCRO 0.0420*
aUC vs inaUC 0.0895
aCD vs inaCRO 0.4329
p = probability that the difference is a chance finding.
419
TABLE 12B:2A LEVELS OF SIL-2R (U/ml) IN WGLF OF PATIENTS
WITH CROHN'S DISEASE CLASSIFIED BY REGIONAL INVOLVEMENT.
N RANGE MEAN MEDIAN D
CONTROL 20 <10-97 24 10
SB 15 <10-350 87 68 0.0020
ILC 13 <10-234 82 49 0.0116
CN 10 <10-347 72 45 0.0263
PR 6 18-249 93 69 0.0288
SB Sma 11 bowe1 Crohn's disease PR -
Proctitis
ILC - Ileocolonic Crohn's disease CN - Colonic Crohn's
disease
TABLE 12B:2B THE FREQUENCY OF HIGH LEVELS OF SIL-2R IN
THE WGLF OF CROHN'S PATIENTS CLASSIFIED BY REGIONAL
INVOLVEMENT. SIL-2R levels above 70U/ml.
ALL ACTIVE INACTIVE
N >70 N >70 N >70
CONTROL (20) 2 NA NA
SB (15) 6*** (9) 3** (6) 3*
ILC (13) 5* (6) 3* (7) 2
CN (10) 2* (8) 2* (2) 0
PR (6) 3* (4) 2* (2) 1
NA = Not applicable
N = Total numbers of patients studied in the group
* p < 0.05 ** p < 0.01 *** p < 0.005
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TABLE 12Bi2C LEVELS OF SIL-2R fU/ml) IN WGLF OF PATIENTS
WITH ACTIVE CROHN'S DISEASE CLASSIFIED BY REGIONAL
INVOLVEMENT.
N RANGE MEAN MEDIAN D
CONTROL 20 <10-97 24 10
SB 9 <10-181 74 66 0.0089
ILC 6 <10-167 88 86 0.0358
CN 8 <10-347 81 48 0.0348
PR 4 46-249 113 79 0.0223
p = probability that the difference is a chance finding.
TABLE 12B:2D LEVELS OF SIL-2R fU/ml) IN WGLF OF PATIENTS
WITH INACTIVE CROHN'S DISEASE CLASSIFIED BY REGIONAL
INVOLVEMENT.
N RANGE MEAN MEDIAN P
CONTROL 20 <10-97 24 10
SB 6 <10-350 73 73 0.0263
ILC 7 <10-234 46 46 0.0638
CN 2 NA 38 NA NA
PR 2 NA 54 NA NA
NA = not applicable
p = Probability that the difference is a chance finding
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TABLE 12B: 3A LEVELS OF SIL-2R (\J/ml) IN WGLF OF PATIENTS
WITH ULCERATIVE COLITIS CLASSIFIED BY REGIONAL
INVOLVEMENT.
N RANGE MEAN MEDIAN P
CONTROL 20 <10-97 24 10
PAN 11 <10-144 39 18 0.2079
LS 3 <10-70 28 14 0.7150
PR 8 <10-149 62 45 0.0984
PAN - Pancolitis PR - Proctitis LS - Left sided
p = Probability that the difference is a chance finding
TABLE 12B:3B THE FREQUENCY OF HIGH LEVELS OF SIL-2R IN
THE WGLF OF ULCERATIVE COLITIS PATIENTS CLASSIFIED BY
REGIONAL INVOLVEMENT. SIL2R levels above 70U/ml.
ALL ACTIVE INACTIVE
N >70 N >70 N >70
CONTROL (20) 2 NA NA
PAN (ID 3 (7) 2 (4) 1
LS (3) 1 (2) 1 (1) 0
PR (8) 3 (4) 3** (4) 0
* p < 0. 05 ** P < 0.01 *** p < 0.005
NA = Not applicable
N = Total numbers of patients studied in the group
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TABLE 12B:3C LEVELS OF SIL-2R fU/ltm IN WGLF OF PATIENTS





















PAN - Pancolitis PR - Proctitis
p = Probability that the difference is a chance finding
TABLE 12Bi3D LEVELS OF SIL-2R (P/ml) IN WGLF OF PATIENTS
WITH INACTIVE ULCERATIVE COLITIS CLASSIFIED BY REGIONAL
INVOLVEMENT.
N RANGE MEAN MEDIAN D
CONTROL 20 <10-97 29 10
PAN 4 <10-73 21 22 0.5613
PR 4 <10-46 19 0.9691
PAN - Pancolitis PR - Proctitis
p = Probability that the difference is a chance finding
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Graph 12B:3
WHOLE GUT LAVAGE SOLUBLE INTERLEUKIN-2

























Disease groups on the x axis according to regions affected by
ulcerative colitis plotted against their levels of slL-2R in whole gut
lavage fluid on the y axis.
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TABLE 12BMA COMPARISON OF THE DISEASE ACTIVITY (WGLF
total IqG ug/ml) BETWEEN ULCERATIVE COLITIS (UC) AND
CROHN'S DISEASE (CD).
N RANGE MEAN MEDIAN D
UC 24 1-120 38 27
CD 45 1-150 27 15 0.7480
p = Probability that the difference is a chance finding
TABLE 12B;4B COMPARISON OF THE DISEASE ACTIVITY CWGLF
total IaG ua/ml) BETWEEN ACTIVE ULCERATIVE COLITIS (UC)
AND ACTIVE CROHN'S DISEASE (CD).
N RANGE MEAN MEDIAN £
UC 14 19-120 63 53
CD 28 11-150 40 26 0.0196
p = Probability that the difference is a chance finding
TABLE 12B:4C COMPARISON OF THE DISEASE ACTIVITY (WGLF
total IaG uq/ml) BETWEEN INACTIVE ULCERATIVE COLITIS
(UC) AND CROHN'S DISEASE (CD) .
N RANGE MEAN MEDIAN p
UC 10 1-8 3 2.5
CRO 17 1-10 5 5 0.0420
p = Probability that the difference is a chance finding
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CORRELATIONS
TABLE 12C;1 CORRELATIONS BETWEEN SIL-2R in WGLF . SIL-2R
IN SERUM AND DISEASE ACTIVITY (WGLF total IqG)
GROUP WGLF SIL-2R Serum SIL-2R
N r D N r D
CONTROL 20 -0.099 0.679 11 0.159 0. 642
CRO 45 -0.041 0.789 38 0.540 0.0001*
UC 24 0.486 0.016+ 20 0.104 0. 664
aCRO 28 -0.055 0.782 25 0.474 0.017*
aUC 10 -0.316 0.271 8 -0.178 0.579
inaCRO 17 -0.494 0.044 13 -0.067 0.829
inaUC 10 -0.318 0.371 8 -0.444 0.270
+ Accounted for mainly by low results (negative results)
p = Probability that the correlation is a chance finding
TABLE 12C12A CORRELATIONS BETWEEN WGLF SIL-2R. SERUM
SIL-2R AND DISEASE ACTIVITY (WGLF total IqG) IN REGIONAL
INVOLVEMENT OF CROHN'S DISEASE.
GROUP WGLF SIL-2R SERUM SIL-2R
N r e N r p
SB 15 0.059 0.834 13 -0.288 0.340
ILCOL 13 -0.117 0.702 9 -0.203 0.601
COL 10 -0.035 0.923 9 0.757 0.0018*
PROCT 6 -0.038 0.943 6 0.852 0.031*
* significant correlation p > 0.05
426
TABLE 12C:2B CORRELATIONS BETWEEN WGLF SIL-2R. SERUM
SIL-2R AND DISEASE ACTIVITY (WGLF total IqG) IN REGIONAL
INVOLVEMENT OF PATIENTS WITH ACTIVE CROHN'S DISEASE.
GROUP WGLF SIL-2R SERUM SIL-2R
N r e N r e
SB 9 0.620 0.075 8 -0.571 0.140
ILCOL 13 -0.254 0.627 9 -0.678 0.208
COL 6 -0.144 0.733 5 0.688 0.088
PR 4 -0.606 0.394 4 0.922 0.078
TABLE 12C;2C CORRELATIONS BETWEEN WGLF SIL-2R, SERUM AND
DISEASE ACTIVITY (WGLF total IqG) IN REGIONAL
INVOLVEMENT OF PATIENTS WITH INACTIVE CROHN'S DISEASE.
GROUP WGLF SIL-2R SERUM SIL-2R
N r E N r p
SB 6 -0.350 0.496 5 0.126 0.840
ILCOL 7 -0.841 0.018 4 -0.010 0.990
COL 2 NA NA 2 NA NA
PR 2 NA NA 2 NA NA
NA = Not applicable
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TABLE 12C13A CORRELATIONS BETWEEN SIL-2R IN WGLF AND
SIL-2R IN SERUM.
N r e
CONTROL 9 0.285 0.396
CRO 38 0.139 0.404
UC 20 -0.214 0.366
GRE 8 0.799 0.201
aCRO 25 0.094 0.653
aUC 12 -0.416 0.179
inaCRO 13 0.297 0.325
inaUC 8 0.225 0.592
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TABLE 12D:1A LEVELS OF SIL-2R (U/ml) IN SERUM OF
IBP PATIENTS CLASSIFIED AS SMALL BOWEL (SB) AND LARGE
BOWEL (LB) INVOLVEMENT.
N RANGE MEAN MEDIAN p
CONTROL 11 171-544 314 235
SB 13 63-1484 649 664 0.0150
LB 29 50-2845 804 598 0.0051
p = Probability that the difference is a chance finding
TABLE 12D:IB THE FREQUENCY OF HIGH LEVELS OF SIL-2R IN
THE SERA OF IBP PATIENTS CLASSIFIED AS SMALL BOWEL (SB)
AND LARGE BOWEL (LB) INVOLVEMENT. SIL-2R levels above
510U/ml.
ALL ACTIVE INACTIVE
N >510 N >510 N >510
CONTROL (11) 1 NA NA
SB (13) 9* (8) 6* (5) 3
LB (29) 16** 19) 13*** (10) 3
* p < 0.05 ** p < 0.01 *** p < 0.005
SB - Small bowel Crohn's disease
LB - Large bowel involvement (ulcerative colitis and
Crohn's colitis)
NA = Not applicable
429
TABLE 12D:1C LEVELS OF SERUM SIL-2R fU/ml) IN THE SERA OF
ACTIVE IBP PATIENTS CLASSIFIED AS ACTIVE SMALL BOWEL I SB)
AND ACTIVE LARGE BOWEL (LB^ INVOLVEMENT.
N RANGE MEAN MEDIAN p
CONTROL 11 171-544 314 235
SB 8 63-1484 696 638 0.0186
LB 19 50-2845 981 831 0.0014
p = Probability that the difference is a chance finding
TABLE 12D;ID LEVELS OF SIL-2R fU/ml) IN THE SERA OF
INACTIVE IBP PATIENTS CLASSIFIED AS INACTIVE SMALL BOWEL
(SB) AND INACTIVE LARGE BOWEL (LB) INVOLVEMENT.
N RANGE MEAN MEDIAN P
CONTROL 11 171-544 314 235
SB 5 162-847 575 680 0.1408
LB 10 209-1195 468 413 0.2050
p = Probability that the difference is a chance finding
TABLE 12D;1E COMPARISON OF SERUM SIL-2R LEVELS BETWEEN
SMALL BOWEL (SB) DISEASE AND LARGE BOWEL INVOLVEMENT
(LB) .
ALL ACT INACT
SB vs LB 1.0000 0.8681 0.4260
P = Probability that the difference is a chance finding
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TABLE 12D: 2 A LEVELS OF SIL-2R (U/ml) IN WGLF OF IBP
PATIENTS CLASSIFIED AS SMALL BOWEL (SB). LARGE BOWEL (LB)
INVOLVEMENT AND CONTROLS.
N RANGE MEAN MEDIAN P
CONTROL 20 <10-97 24 10
SB 15 <10-350 87 68 0.0020
LB 34 <10-347 56 42 0.0172
SB - Small bowel Crohn's disease
LB - Large bowel involvement includes Crohn's colitis
and ulcerative colitis
P = Probability that the difference is not a chance
finding
TABLE 12D:2B THE FREQUENCY OF HIGH LEVELS OF SIL-2R IN
WGLF OF IBP PATIENTS CLASSIFIED AS SMALL BOWEL (SB) AND
LARGE BOWEL (LB) INVOLVEMENT. sIL-2R levels above 70U/ml.
ALL ACTIVE INACTIVE
N >70 N >70 N >70
CONTROL (20) 2 NA NA
SB (15) 6*** (9) 3* (6) 3
LB (34) 10* (22) 9** (12 1
* p < 0.05 ** p < 0.01 *** p < 0.005
NA = Not applicable
N = Total numbers of patients studied in the group
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TABLE 12D;2C LEVELS OF SIL-2R (U/ml) IN WGLF OF PATIENTS
WITH ACTIVE IBP CLASSIFIED AS ACTIVE SMALL BOWEL (SB).
ACTIVE LARGE BOWEL fLB) INVOLVEMENT AND CONTROLS.
N RANGE MEAN MEDIAN P
CONTROL 20 <10-97 24 10
SB 9 <10-181 74 66 0.0089
LB 22 <10-347 71 55 0.0046
p = Probability of the difference being a chance finding.
TABLE 12D:2D LEVELS OF SIL-2R fU/mH IN WGLF OF PATIENTS
WITH INACTIVE IBP CLASSIFIED AS INACTIVE SMALL BOWEL
(SB). INACTIVE LARGE BOWEL TLB) INVOLVEMENT AND CONTROLS.
N RANGE MEAN MEDIAN P
CONTROL 20 <10-97 24 10
SB 6 <10-350 73 73 0.0263
LB 12 <10-73 27 34 0.4363
p = Probability of the difference being a chance finding.
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TABLE 12D:2 E COMPARISON OF WGLF SIL-2R LEVELS BETWEEN
INACTIVE SMALL BOWEL (SB) AND INACTIVE LARGE BOWEL (LB1
INVOLVEMENT.
ALL ACT INACT
SB VS LB 0.0701 0.5423 0.0492
p = Probability of the difference being a chance finding.
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TABLE 12E;1A SERUM LEVELS OF SIL-2R (U/ml) IN GRE RELATED
GROUP COMPARED WITH IBP AND CONTROLS.
N RANGE MEAN MEDIAN P
CONTROL 11 171-544 314 235 0.7441
UC 20 60-1986 648 461 0.3350
CD 38 10-2844 611 611 0.4160
GRE 4 172-1396 536 289
p = Probability of the difference being a chance finding.
TABLE 12 E:IB SERUM LEVELS OF SIL-2R (U/irm IN GRE
RELATED GROUP COMPARED WITH ACTIVE IBP PATIENTS.
N RANGE MEAN MEDIAN P
aUC 12 50-1986 775 591 0.2175
aCRO 25 10-2844 865 742 0.2493
GRE 4 172-1396 536 289
TABLE 12E!2A LEVELS OF SIL-2R (P/ml) IN WGLF OF PATIENTS
WITH GLPTENRELATED ENTEROPATHY COMPARED WITH IBP AND
CONTROLS.
N RANGE MEAN MEDIAN P
CONTROL 20 <10-97 24 10 0.1281
UC 24 <10-149 49 38 0.5734
CD 45 <10-350 82 56 0.7950
GRE 8 <10-169 60 59
p = Probability of the difference being a chance finding.
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TABLE 12Ei 2B LEVELS OF SIL-2R (U/mll IN WGLF OF PATIENTS
WITH GLUTEN-RELATED ENTEROPATHY COMPARED WITH PATIENTS
WITH ACTIVE IBP.
N RANGE MEAN MEDIAN P
aUC 14 <10-149 66 68 0.1429
aCRO 28 <10-347 83 58 0.7371
GRE 8 <10-169 60 59
p = Probability of the difference being a chance finding.
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COMPARISONS BETWEEN UPPER AND LOWER GASTROINTESTINAL
INVOLVEMENT OF IBP.
TABLE 12F i 1A LEVELS OF SIL-2R (U/ml) IN THE SERA OF
PATIENTS WITH IBP PATIENTS CLASSIFIED AS SMALL BOWEL (SB)
CROHN'S DISEASE, COLONIC (CN) CROHN'S DISEASE AND
ULCERATIVE COLITIS (PC).
N RANGE MEAN MEDIAN P
CONTROL 11 171-544 314 235
SB 13 63-1484 649 664 0.0150
CN 9 304-2845 1150 1077 0.0014
UC 20 60-1986 648 461 0. 039
p = Probability of the difference being a chance finding.
TABLE 12F;1B THE FREQUENCY OF HIGH LEVELS OF SIL-2R IN
THE SERA OF IBP PATIENTS CLASSIFIED AS SMALL BOWEL
(SB) CROHN'S DISEASE. COLONIC (CN) CROHN'S DISEASE AND
ULCERATIVE COLITIS (PC). SIL-2R levels above 510U/ml.
ALL ACTIVE INACTIVE
N >510 N >510 N >510
CONTROL (ID 1 NA NA
SB (13) 9* (8) 6* (5) 3
CN (9) 7** (7) 6** (2) 1
UC (20) 9* (12) 7* (8) 2
* p < 0. 05 ** P < 0.01 *** •oVa 005
N = Total numbers of patients studied in the group
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TABLE 12F:1C LEVELS OF SIL-2R fU/ml) IN THE SERA OF
PATIENTS WITH ACTIVE IBP CLASSIFIED AS SMALL BOWEL
(SB) CROHN'S DISEASE. COLONIC fCN) CROHN'S DISEASE AND
ULCERATIVE COLITIS (UC).
N RANGE MEAN MEDIAN P
CONTROL 11 171-544 314 235
SB 8 63-1484 696 638 0.0186
CN 7 304-2845 1333 1084 0.0021
UC 12 50-1986 775 591 0.0151
p = Probability of the difference being a chance finding.
TABLE 12F:1D LEVELS OF SIL-2R (U/ml) IN THE SERA OF
PATIENTS WITH INACTIVE IBP CLASSIFIED AS INACTIVE SMALL
BOWEL (SB) CROHN'S. COLONIC (CN) CROHN'S DISEASE AND
ULCERATIVE COLITIS (UC) .
N RANGE MEAN MEDIAN P
CONTROL 11 171-544 314 235
SB 5 162-847 575 680 0.1408
CN 2 NA 512 NA NA
UC 8 209-1195 457 359 0.4090
p = Probability of the difference being a chance finding.
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TABLE 12F:IE COMPARISON OF SIL-2R LEVELS SERUM BETWEEN
ULCERATIVE COLITIS (PC). SMALL BOWEL (SB) CROHN'S DISEASE





ALL 0.3866 0.1090 0.0562
ACT 0.8471 0.0562 0.1179
INACT 0.4208 NA NA
NA = Not applicable
p = Probability of the difference being a chance finding.
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TABLE 12F:2A COMPARISON OF LEVELS OF SIL-2R (U/ml) IN
WGLF OF PATIENTS WITH IBP CLASSIFIED AS SMALL BOWEL
(SB) CROHN'S DISEASE. COLONIC (CN) CROHN'S DISEASE AND
ULCERATIVE COLITIS (PC) .
N RANGE MEAN MEDIAN P
CONTROL 20 <10-97 24 10
SB 15 <10-350 87 68 0.0020
CN 10 <10-347 72 45 0.0263
UC 24 <10-149 49 39 0.1124
p = Probability of the difference being a chance finding.
TABLE 12F:2B THE FREQUENCY OF HIGH LEVELS OF SIL-2R
IN WGLF OF IBP PATIENTS CLASSIFIED AS SMALL BOWEL
(SB) CROHN'S DISEASE. COLONIC (CN) CROHN'S DISEASE AND
ULCERATIVE COLITIS (UC). sIL-2R levels above 70U/ml.
ALL ACTIVE INACTIVE
N >70 N >70 N >70
CONTROL (20) 2 NA NA
SB (15) 6*** (9) 3** (6) 3*
CN (10) 2* (8) 2* (2) 0
UC (24) 8 (14) 7* (10) 1
* p < 0. 05 ** p < 0. 01 *** p < 0.005
NA = Not applicable
N = Total numbers of patients studied in the group
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TABLE 12F:2C LEVELS OF SIL-2R fU/ml) IN WGLF OF PATIENTS
WITH ACTIVE IBP PATIENTS CLASSIFIED AS ACTIVE SMALL BOWEL
rSB^ DISEASE. ACTIVE COLONIC fCN) CROHN'S DISEASE AND
ULCERATIVE COLITIS fUC).
N RANGE MEAN MEDIAN P
CONTROL 20 <10-97 24 10
SB 9 <10-181 74 66 0.0089
CN 8 <10-347 81 48 0.0348
UC 14 <10-149 66 68 0.0136
p = Probability of the difference being a chance finding.
TABLE 12Fi2D LEVELS OF SIL-2R fU/ntl) IN WGLF OF PATIENTS
WITH INACTIVE IBP PATIENTS CLASSIFIED AS INACTIVE SMALL
BOWEL rSB) CROHN'S DISEASE. COLONIC fCN) CROHN'S DISEASE
AND ULCERATIVE COLITIS rUCl .
N RANGE MEAN MEDIAN P
CONTROL 20 <10-97 24 10
SB 6 <10-350 73 73 0.0263
CN 2 NA 38 NA NA
UC 10 <10-73 25 24 0.6284
NA = Not applicable
p = Probability of the difference being a chance finding.
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TABLE 12 F:2 E COMPARISON OF LEVELS OF SIL-2R IN WGLF
BETWEEN ULCERATIVE COLITIS (DC). SMALL BOWEL (SB) CROHN'S





ALL 0.1124 0.1204 0.4844
ACT 0.9247 0.2482 0.8645
INACT 0.0509 NA NA
NA = Not applicable
p = Probability of the difference being a chance finding.
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Levels of soluble interleukin-2 receptor in serum (Top I) and whole
gut lavage fluid (Bottom II) before and after at least seven days on
elemental diet. On the y axes are the levels of IL-2R and on the x
axes the time span. Patients are grouped according to global clinical
response as improved, no change or deteriorated. *
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CHAPTER THIRTEEN:
TUMOUR NECROSIS FACTOR IN WHOLE GUT
LAVAGE FLUID
INTRODUCTION
Tumour necrosis factor (TNF) is produced and secreted
mainly by macrophages. These cells are abundant in
intestinal mucosa. In IBD mucosa there are increased
numbers of activated macrophages (Mahida et al.. 1988)
and activated T cells (Choy et al.. 1990, see chapter
4B). The numbers of TNF secreting cells have been
reported to be increased in the intestinal mucosa of IBD
patients compared to controls (Macdonald et al., 1990).
It is therefore not surprising that this cachexia causing
substance (Tracey et al.. 1988) has been implicated in
the pathogenesis and complications of IBD (see chapter
4C). Tumour necrosis factor plays an important role in
granuloma formation (Kindler et al., 1989), a feature of
Crohn's disease. Attempts to study TNF activity in
intestinal mucosa have been made difficult by the labile
nature of TNF and the technical complexity of obtaining
and preventing proteolysis in intestinal specimens. The
little amount of work that has been done on TNF activity
in patients with intestinal disease has relied on blood
specimens which may not reflect intestinal mucosa TNF
activity.
THE AIM OF THIS STUDY
The aims of this study were to investigate intestinal TNF
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activity of individuals with healthy mucosa and diseased
mucosa by measuring the levels of TNF in WGLF. This was
performed in the following ways. The first part defined
the pattern of TNF activity in relation to disease
activity and regional distribution of disease in
patients with IBD as compared to controls. The second
part was a study of the relationship between the levels
of whole gut lavage fluid TNF and other polypeptides
assayed in the same lavage specimens such as sIL-2R and
total IgG. Thirdly the relationship between intestinal
TNF activity and response to elemental diet was studied
by measuring the levels of TNF in WGLF of patients who
had been prescribed elemental diet (as described below
section).
SUBJECTS AND PROTOCOL.
The details of the subjects studied are shown in table
13:1A. The experiments were performed simultaneously with
those for soluble interleukin-2 receptor in whole gut
lavage fluid (WGLF) and serum, these results were
reported in chapter 12.
Tumour necrosis factor in whole gut lavage fluid was
assayed by ELISA as described in chapter 6A.
Comparisons of the levels of TNF were made between
controls and IBD patients. Comparisons were also made
after subdivision of groups according to disease activity
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and regional distribution of the disease.
Correlation analyses were performed between WGLF IgG (a
measure of disease activity), serum sIL-2R, WGLF SIL-2R
and WGLF TNF to ascertain the relationship if any.
LEVELS OF TNT IN WGLF OF CONTROLS AND PATIENTS WITH IBP
Controls gave a range of <l-20pg/ml with a median of
less than lpg/ml (undetectable) . Patients with ulcerative
colitis gave a range of <l-184pg/ml with a median of 1,
this was significantly higher than controls (p=0.0420).
Similarly patients with Crohn's disease had a range of 1-
217pg/ml with a median of 2pg/ml . This was significantly
higher than for controls (p=0.0064) [Table 13A:1B and
Graph 13:1 in the appendix to this chapter].
Analysis of the control results showed the value 10 was
two standard deviations above the median and patients
with values above 10 were considered to have high levels
(Table 13A:1C). Out of 20 controls, 1 had high levels of
TNF in their WGLF as compared to 8 out of 23 patients
with ulcerative colitis and 16 out of 45 patients with
Crohn's disease. Statistical analyses of their values
showed that these were significantly higher than for
controls (as above Table 13A:1B). For patients with
active disease, 7 out of 13 patients with active
ulcerative colitis had high values, and 9 out of 28
patients with Crohn's disease had high values, both these
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results were significantly higher than for controls as
shown below. Of the patients with inactive disease, 1 out
of 10 patients with inactive ulcerative colitis had a
high value and 7 out of 17 with inactive Crohn's disease
had high values. Both these results when statistically
analysed were not significantly different from controls.
LEVELS OF TNF IN WGLF OF PATIENTS WITH ACTIVE AND
INACTIVE IBP
Disease activity was based on clinical assessment as well
as WGLF total IgG (see chapter 7). Both active CD with a
range of l-184pg/ml and a median of 3pg/ml and active
ulcerative colitis with a range of l-217pg/ml and a
median of 36pg/ml had significantly higher TNF levels
than controls (p=0.0072 and p=0.0034 respectively) [Table
13A:1C and Table 13A:1D]. There was no significant
difference between normal controls and inactive Crohn's
disease (p=0.0549) or inactive ulcerative colitis
(p=0.1524) [Table 13A:1C an Table 13A:1E].
Comparisons between disease groups showed that patients
with active UC had higher levels than patients with
inactive UC (p=0.02). There was no significant difference
between UC and CD (p=0.8458), active UC and active CD
(p=0.2125), inactive UC and inactive CD (p=0.1524) or




Both patients with ulcerative colitis and Crohn's disease
gave higher levels of TNF in WGLF than controls. This is
in keeping with the work of Macdonald et al. (1990) who
showed by ELISPOT assay that there were higher number of
TNF secreting cells in IBD mucosa than controls.
Alstead et al. (1991) reported similar findings although
they assayed for TNF in serum.
In this work patients were subgrouped into active and
inactive disease groups. This showed that the significant
differences for the whole groups (UC or CD) were
accounted for by the higher values of the patients with
active disease (active ulcerative colitis and active
Crohn's disease). There was no significant difference
between inactive disease groups and controls. This shows
that the levels of TNF are higher with active disease.
LEVELS OF TNF IN WGLF BY REGIONAL INVOLVEMENT OF CROHN'S
DISEASE
Crohn's disease patients were further subdivided
according to the distribution of disease into four
groups; small bowel (mouth to ileum with no colonic
involvement), ileocolonic, colonic (no small bowel
involvement) and Crohn's proctitis (PR).
Small bowel (SB) Crohn's disease had significantly higher
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TNF levels than controls, range l-63pg/ml with a median
of lpg/ml (p=0.0196). The colonic disease (CN) group gave
a range of l-217pg/ml with a median of 14pg/ml,
significantly higher than for controls (p=0.0073).
Patients with Crohn's proctitis gave a range of
l-217pg/ml with a median of 26pg/ml significantly higher
than controls (p=0.0263). Patients with ileocolonic
disease gave a range of l-104pg/ml and a median of lpg/ml
(p=0.2240) and this was not significantly higher than
controls (Table 13A:2A).
As for the analysis of disease groups above, the
prevalence of high levels of TNF (above 10) was analysed
in these regional subgroups of Crohn's disease. Of the 15
patients with small bowel Crohn's disease, 4 had high
levels and of the 10 with colonic Crohn's disease, 5 had
high levels. Four of the 6 with Crohn's proctitis had
high levels, and 3 of the 13 with ileocolonic Crohn's
disease had high levels. The values of TNF in these
patients when compared to controls of whom 1 out the 20
had a high level, were significantly higher except for
the subgroup with ileocolonic Crohn's disease as shown
above. Analysis of the prevalence of high levels
according to disease activity showed that, 1 out 9
patients with active small bowel Crohn's disease had high
levels, 3 out of 8 patients with active colonic Crohn's
disease had high levels and 1 out of the 6 patients with
active ileocolonic Crohn's disease had a high level. On
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statistical analysis (see below) all these values were
significantly higher than controls except for the
patients with ileocolonic disease. This is because the
active ileocolonic had on average lower values than the
active small bowel group, even though 1 out 6 of their
group had a high value compared to 1 out 9 of the
patients with active small bowel disease (see below). The
prevalence of high levels in patients with inactive
disease showed that 3 out of 6 patients with inactive
small bowel disease had high levels and 2 out of 7
patients with inactive ileocolonic Crohn's disease had
high levels. On statistical analysis these results were
not significantly higher than the levels for control.
This appears contradictory in view of the higher
proportion of high positive compared to patients with
active disease with the same disease distribution.
However an examination of the figures shows that the
median for both inactive small bowel and ileocolonic were
very low. Both the two patients with inactive colonic
disease had high levels of TNF in WGLF and none of two
with inactive Crohn's proctitis had high levels
(Table 13A:2B)
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LEVELS OF TNF IN WGLF BY REGIONAL INVOLVEMENT OF CROHN'S
DISEASE AND DISEASE ACTIVITY.
Patients with Crohn's disease were further subdivided
according to regional involvement and disease activity.
Active small bowel disease gave a range of l-41pg/ml
with a median of lpg/ml significantly higher than
controls (p=0.0359). Active colonic gave a range of 1-
118pg/ml with a median of 5pg/ml significantly higher
than controls (p=0.0371). Active proctitis gave a range
of 20-217pg/ml with a median of 32pg/ml significantly
higher than controls (p=0.0022). The active ileocolonic
group gave a range of l-51pg/ml with a median of
1.5pg/ml not significantly different from controls
(p=0.4652).
There were only two patients with inactive colonic
Crohn's disease and two with inactive proctitis, so these
were not evaluated further. Patients with inactive small
bowel Crohn's disease gave a range of l-63pg/ml with a
median of <lpg/ml, this was not significantly different
from controls (p=0.1281). Patients with inactive
ileocolonic Crohn's disease gave a range of 1-104 with a
median of <1 and this was not significantly different
from controls (p=0.2567) [Table 13A:2D].
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COMMENT
All subgroups of Crohn's disease had significantly higher
levels of TNF in WGLF than controls except for the
ileocolonic group. In this group, as pointed out in
chapter 12, seven of the patients had had resections and
probably the actual area of inflammation was not as
widespread as the term ileocolonic implies.
Again raised TNF was a feature of active disease as the
inactive groups, where numbers allowed for comparison,
had levels not significantly different from controls.
Though there were only 4 patients with active proctitis,
they had the highest levels a mean of 76 and a median of
32 (p=0.0022). This could be a specific feature of
Crohn's proctitis or it could be due to the reduced
transit time which gives less time for proteolytic
degradation. This point is discussed further with respect
to ulcerative proctitis below.
LEVELS OF TNF IN WGLF BY REGIONAL INVOLVEMENT OF
ULCERATIVE COLITIS.
Ulcerative colitis patients were further subdivided
according to the distribution of disease into three
groups; pancolitis (involving the whole colon), left
sided (LS) and ulcerative proctitis (PR).
Patients with pancolitis had significantly higher levels
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of TNF in WGLF than controls, range of l-184pg/ml with a
median of 4pg/ml (p=0.0235). There were only three
patients with inactive left-sided disease and their WGLF
TNf levels were lpg/ml, 3pg/ml and 73pg/ml. The patients
with proctitis gave a range of l-100pg/ml with a median
of lpg/ml not significantly different from controls
(p=0.4924) [Table 13A:3A].
The patients with ulcerative colitis were further
analysed for the prevalence of high levels of TNF (above
lOpg/ml) in WGLF according to regional involvement of
disease and disease activity. Four out of the 9 patients
with ulcerative pancolitis had high levels of TNF in
WGLF, and on statistical analysis of their levels they
were significantly higher than for controls as above.
Three of the 6 patients with active ulcerative pancolitis
had high levels and analysis of their results showed that
these were significantly higher than for controls (see
below). One out of the three patients with pancolitis had
a high level and this was one of the 2 patients with
active left sided ulcerative colitis. Two of the 8
patients with ulcerative proctitis had high levels of TNF
in their WGLF and these were the 2 of the four with
active disease. Statistical analyses of these were
applicable are discussed below.
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LEVELS OF TNF IN WGLF OF ULCERATIVE COLITIS PATIENTS BY
REGIONAL INVOLVEMENT AND DISEASE ACTIVITY.
Ulcerative colitis patients were further subgrouped
according to disease activity based on global assessment
and WGLF total IgG.
Active pancolitis patients had significantly higher TNF
than controls, range l-183pg/ml with a median of 46pg/ml
(p=0.0056). There were only 2 patients with active left
sided ulcerative colitis, this number was too small for
statistical evaluation and they are not considered any
further. The four active ulcerative proctitis patients
gave a range of l-100pg/ml, with a median of 21pg/ml.
This was not significantly different from controls
(p=0.1752).
Inactive pancolitis gave a range of l-14pg/ml with a
median of <lpg/ml, not significantly different from con¬
trols (p=0.6701). Patients with inactive ulcerative
proctitis had barely detectable TNF level of lpg/ml, not
significantly different from control. There was only
one patient with inactive left sided disease with a TNF
level of 3pg/ml (Table 13A:3C and Table 13A:3D).
COMMENTS
The nine patients with pancolitis had significantly
higher (p=0.0235; Table 13A:3A) levels of TNF than
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controls and the level of significance increased despite
the smaller numbers (6) with active pancolitis
(p= 0.0056). The numbers in ulcerative colitis regional
involvement subgroups were too small for statistical
evaluations, the median levels of their TNF in WGLF was
<1, barely detectable.
Of note here, is the result from the 4 patients with
active ulcerative proctitis. Unlike the patients with
active Crohn's proctitis, the levels of TNF in the WGLF
of patients with active ulcerative colitis were not
significantly higher than controls. Therefore the highly
significant levels with Crohn's proctitis may not be
explained on the basis of reduced transit time, thus
giving shorter period for proteolytic degradation.
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SECTION 13B
LEVELS OF TNF IN WGLF OF CONTROLS» SMALL BOWEL (SB) AND
LARGE BOWEL (LB) IBP
Patients with inflammatory bowel disease were divided
according to whether they had small bowel or large bowel
disease. The small bowel disease group were invariably
Crohn's disease patients and Crohn's colitis and
ulcerative colitis comprised the large bowel group. The
patients with ileocolonic Crohn's disease were not
included.
Patients with small bowel IBD gave a range of <l-63pg/ml
with a median of lpg/ml. This was significantly higher
than controls (p=0.0196). Patients with large bowel IBD
gave a range of <l-217pg/ml with a median of 2pg/ml and
this was significantly higher than controls (p=0.0078)
(Table 13B:1A)
The prevalence of high levels of TNF in WGLF (above 10)
was analysed as before. Four of the patients 15 with
small bowel disease had high levels, and 13 of the pa¬
tients with large bowel IBD had high levels. Both groups
were significantly higher than controls as shown above. A
similar analysis was done with patients further
subgrouped according to whether they had active or
inactive disease. One out of the 9 patients with active
small bowel disease had a high level, and 10 the 21
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patients with large bowel disease had high levels. Both
these results were significantly higher than for controls
(see below). Although only one of the 9 with active small
bowel disease had a high level of TNF in WGLF, the other
8 levels of TNF close to 10, hence the significant
difference from controls (Table 13B:1B and Table 13B:1C).
LEVELS OF TNF IN WGLF OF CONTROLS. SMALL BOWEL (SB) AND
LARGE BOWEL (LB) IBP ACCORDING TO DISEASE ACTIVITY
Patients were further subgrouped according to disease
activity based on global clinical assessment and WGLF
total IgG.
Patients with active small bowel IBD gave a range of
<l-41pg/ml with a median of lpg/ml, significantly higher
than controls (p=0.0359). The mean of this active small
bowel IBD group of 7pg/ml, was less than the mean
(14pg/ml) level for the small bowel IBD group as a whole.
Patients with active large bowel disease gave a range of
l-184pg/ml and a median of 41pg/ml which was
significantly higher than controls p=0.0016 (Table
13B:1C).
There was no significant difference in the TNF levels
between controls and the inactive disease groups (Table
13B:1D). There was no significant difference either
between disease groups (Table 13B:1E).
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COMMENT
Both small bowel and large bowel IBD groups had higher
TNF levels than controls showing, as before, that high
lavage TNF is a feature of inflammatory bowel disease.
And the lack of significant difference between the
inactive group and controls indicates that high levels of
TNF are associated with active disease.
However closer analysis of the results shows some
interesting phenomenon. Whereas the mean, median as well
as levels of significance in patients with large bowel
disease are highest with the active disease followed by
the levels for the whole group with the exclusively
inactive being the lowest, the order for the small bowel
group is the reverse. This could be a result of
increased transit time allowing for the higher levels of
proteolytic enzymes in the lavage of active disease
patients to have an effect on the levels as discussed
with in chapter 12. It is possible, however, that high
levels of TNF may not be a feature of active small bowel
Crohn's disease. Murch et a1. (1991) also reported
significantly higher levels in the serum of patients with
colonic disease than in those with small bowel disease
despite similarities in disease activity. The children
with colonic Crohn's disease also showed a lower current
growth rate than those with small bowel disease, in
keeping with the possible role of TNF in causing cachexia
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(Tracey et al.. 1988). Braegger et al. (1992) have also
reported low levels of TNF in the stool of patients with
active disease confined to the small bowel. The lower
values for the patients with active small bowel disease
therefore are probably a feature of active small bowel
disease and not a result of increased proteolytic
degradation. This, as stated in chapter 12 may be
resolved by collecting intestinal fluids directly from
different segments of the bowel, a technically demanding
exercise. The reports by Murch et al. (1991) refers to
serum levels, and serum TNF would not be influenced by
transit time. Even though the low levels reported in this
study are in agreement with the reports of Murch et al.
(1991), it would still be better to confirm these results
with direct sampling of intestinal secretions as systemic
immunity does not always mirror intestinal immune
activity (O'Mahony et al.. 1991a and see chapter 9).
SECTION 13C
LEVELS OF TNF IN WGLF OF PATIENTS WITH IBP CLASSIFIED AS
SMALL BOWEL (SB) CROHN'S . CROHN'S COLITIS (CN) AND
ULCERATIVE COLITIS (PC)
The large bowel disease group (colonic Crohn's and
ulcerative colitis) were further subdivided into
ulcerative colitis and colonic Crohn's subgroups and
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compared with controls. These are repetitions of results
shown earlier; they have been put together only to
facilitate comparison in Tables 13C:1A-1E.
The TNF levels in the patients with colonic Crohn's
ranged between <l-217pg/ml with a median of I4pg/ml, this
was significantly higher than controls (p=0.0073). The
patients with UC had a range of <l-184pg/ml with a median
of <lpg/ml significant p=0.042 (Table 13C:1A)
The prevalence of high levels (>10pg/ml) of TNF was
analysed in these groups. As stated before, out of 15 of
the patients with small bowel Crohn's disease 4 had high
levels, out of 10 patients with colonic Crohn's disease 5
had high values, and out 23 patients with ulcerative
colitis 8 had high values. All the values for the three
groups were significantly higher than for controls as
shown above. Closer examination of the figures, however,
shows that, with a mean of 47 and a median of 14 (Table
13C:1A), Crohn's colitis patients had the highest levels
of the three groups. When the prevalence was further
analysed according to disease activity, 1 out 9 patients
with active small bowel disease had a high value, 3 of
the 8 with active Crohn's colitis had high values and 7
of the 13 with active ulcerative colitis had high
values. The statistical evaluations of the levels on the
three active disease subgroups showed that they were all
significantly higher than controls (see below) . Three of
the 6 patients with inactive small bowel disease had
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high levels, both the patients with inactive colonic
Crohn's had high levels, and 1 out of the 10 with
inactive ulcerative colitis had a high level. There was
no significant different in the levels of TNF between
these inactive subgroups and controls (see below)
[Table 13C:IB].
LEVELS OF TNF IN WGLF OF PATIENTS WITH IBP CLASSIFIED AS
SMALL BOWEL(SB) CROHN'S. CROHN'S COLITIS (CN) AND
ULCERATIVE COLITIS (PC) ACCORDING TO DISEASE ACTIVITY.
The range for active colonic Crohn's was l-118pg/ml with
a median of 5, significantly higher than controls
(p=0.0371) [Table 13C:1B and Table 13C:1C]. There were
only two patients with inactive colonic colitis and
their levels were 20pg/ml and 217pg/ml.
The active UC group gave a range of <l-184pg/ml with a
median of 36pg/ml, and this was significant (p=0.0034)
compared to controls, the level of significance, as
expected, was higher in the active group than for the
group as a whole (Table 13C:1C).
There was no significant difference between the TNF
levels in WGLF of controls compared to inactive small
bowel Crohn's disease group or inactive ulcerative
colitis (Table 13C:1D). There was no significant
difference between disease groups either (Table 13C:1E)
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COMMENT
When the patients were subgrouped into the three
categories, small bowel, colonic and ulcerative colitis,
the levels of TNF in WGLF were higher for all groups
compared to controls. Further analysis showed that the
means and median of patients with colonic Crohn's disease
or ulcerative colitis were higher than those for small
bowel Crohn's. This agrees with other reports (Murch et
al.. 1991 and Braegger et al.. 1992) and may indicate
that high TNF levels are a feature of large bowel Crohn's
disease. High levels of TNF in lavage were also found in
patients with active ulcerative colitis in this study
(Table 13C:1B and Table 13C:1C); this probably suggests
that high levels of TNF are a feature of large bowel
disease whether Crohn's disease or ulcerative colitis.
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SECTION 13D
LEVELS OF TNF IN WGLF OF PATIENTS WITH GLUTEN RELATED
ENTEROPATHY GROUP
Whole gut lavage fluid was collected from eight patients
with gluten-related enteropathy (7 with coeliac disease
and one with dermatitis herpetiformis) , and assayed for
TNF by ELISA (see chapter 6A) . The levels of TNF in this
group were compared with those of controls and patients
with IBD.
The gluten related group gave WGLF levels of TNF with a
range of <1-44, and a median of <1. These levels were not
significantly different from either the IBD patients
(UC and CD) or controls (Table 13D:1A). There was no
significant difference either when their levels of TNF in
WGLF were compared with the levels in patients with
active ulcerative colitis or Crohn's disease (Table
13D:1A) .
It must be restated that these were patients in
remission, on long term gluten free diet and therefore
may not represent the true picture with active disease.
Whereas their mean level of TNF in WGLF (6pg/ml) were
higher than controls (<lpg/ml) they were much lower than
the mean levels for ulcerative colitis (28pg/ml) or
Crohn's disease (26pg/ml) [Table 13D:1A]. A study of
active gluten-related enteropathy is needed to ascertain
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THE RELATIONSHIP BETWEEN DISEASE ACTIVITY (WGLF total
IqG) AND GUT LAVAGE TNF
Levels of TNF in WGLF were correlated with levels total
IgG in WGLF (see chapter 7) to ascertain whether TNF
levels correlated with disease activity.
There was no strong correlation between WGLF IgG for all
the groups, controls, ulcerative colitis and Crohn's
disease regardless of disease activity (Table 13E:1).
However when Crohn's disease patients were divided into
regional involvement, the Crohn's proctitis group showed
a borderline significant positive correlation between
WGLF IgG and TNF (r=0.815, p=0.048)[Table 13E:2A]. In the
other subgroups active and inactive small bowel,
ileocolonic and colonic TNF did not have any strong
correlation with gut lavage IgG [Tables 13E:2B-C).
There was no strong correlation between TNF and WGLF IgG
for any of the ulcerative colitis groups regardless of
the disease activity or distribution (Tables 13E:2A-C).
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THE RELATIONSHIP BETWEEN WGLF SIL-2R. SERUM SIL-2R AND
WGLF TNF
Levels of TNF in WGLF were correlated with levels of
SIL-2R in WGLF and in serum in controls and all the IBD
patient subgroups.
There was no strong correlation between serum SIL-2R,
whole gut lavage SIL-2R and gut lavage TNF for all
Crohn's disease patients and ulcerative colitis
regardless of disease activity (Table 13E:3A-C). There
was no correlation either when Crohn's disease patients
were further subdivided according to regional involvement
and disease activity (Table 13E:4A-C).
A similar analysis of patients with ulcerative colitis
clearly showed that there was no relationship between the
levels of TNF in WGLF and SIL-2R in WGLF or serum (Table
13E:5A-C). This probably suggests that these three
measurements mirror different aspects of immune activity.
These aspects are discussed later as part of the general
comment of this chapter and in chapter 14, as part of the
general discussion.
COMMENT
These results show that there is no strong correlation
between disease activity as measured by WGLF total IgG
and lavage TNF levels. The strong correlation between
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disease activity (WGLF total IgG) and TNF levels in WGLF
for the patients with Crohn's proctitis is of borderline
significance. This level of significance at 1:20 could be
expected in view of the many statistical evaluations
made. On the otherhand this group showed higher levels of
TNF in WGLF (Table 13A:2A) which were much higher than
controls especially in the patients with active disease
(p=0.0022) [Table 13A:2C]. In addition only the patients
with active Crohn's proctitis had high levels on
evaluation of the prevalence and not the 2 of the six
with inactive disease (Table 13A:2B). Therefore though
not many patients with Crohn's proctitis were studied
(6), and the level of significance with regard to
correlation with disease activity is borderline, it is
possible that TNF plays a more prominent role in Crohn's
proctitis, than in other disease distributions. A high
TNF in a patient with proctitis may be a feature of
Crohn's proctitis as the levels of TNF in WGLF of
patients with ulcerative proctitis were not higher than
the levels for controls (Table 13A:3A). The relationship
between disease activity and levels of TNF in WGLF of
Crohn's proctitis and the possibility that TNF in lavage
may aid distinction between Crohn's proctitis and
ulcerative proctitis could be resolved with more numbers
studied.
The lack of correlation between sIL-2R in WGLF and lavage
TNF despite the fact that they are both raised in Crohn's
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disease may be a result of the differences in the
predominant sources of these factors. TNF is mainly of
macrophage origin while sIL-2R is mainly a product of T
cells. Whereas the latter is involved mainly in the early
inductive phase (Smith et a 1 . . 1979) of the immune
response the former is largely involved in effector




ELEMENTAL DIET AND WHOLE GUT LAVAGE TNF
STUDY POPULATION
Eleven patients were prescribed elemental diet in the
management of their inflammatory bowel disease for purely
clinical reasons. Of the eleven patients, 10 had Crohn's
disease, one had ulcerative pancolitis. One patient with
coeliac disease was also studied. Whole gut lavage fluid
and serum were collected before and after 7 or more days
on an exclusive elemental diet and assayed for levels of
TNF. At the commencement of the diet all the IBD patients
had active disease on global clinical assessment and 9
also by their lavage total IgG (Table 13E).
The disease distribution in the patients with Crohn's
disease was as follows; ileal disease (4), colitis (3),
ileocolonic (2), and one with both perianal and rectal
involvement. The patient with ulcerative colitis had
pancolitis.
Drug treatment within three weeks of commencement of
the diet was as follows; no drug treatment at all (1) ,
5-amino salicylic acid only (5), prednisolone only (1),
5-amino salicylate and prednisone (2) and prednisolone
and colifoam (1). The patient with ulcerative colitis
had been on a combination of 5-amino-salicylate, oral
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prednisolone and prednisolone enema and the coeliac
disease patient had been on a gluten free diet and
no other medication.
All the nutritional requirements were provided for by
elemental diet supplying an average of 2000kcal per day.
No other food supplements were allowed.
RESULTS
The levels of TNF in WGLF for specimens taken before and
while on elemental diet are shown with patient data
(Table 13F) .
On global assessment 3 of the IBD patients improved, 4
showed no change and four deteriorated.
Their results are plotted graph 13F. This shows that the
three patients who responded to elemental diet therapy
all started with low levels of TNF in their WGLF (<1
undetectable) while the patients whose clinical condition
deteriorated had high levels initially (above 10, as
described in earlier sections of this chapter). The
levels of TNF in WGLF of the responders remained
undetectable in the subsequent specimens. In two of the
patients whose clinical condition deteriorated, the TNF
level fell to undetectable levels, but one of the group
showed a rise in TNF level and in the fourth member of
the group (SJ), there was a minimal fall with the levels
remaining still high (SJ). Three of this group underwent
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laparatcmy leading to resections of part of their
intestines as they did not respond to medical treatment.
The group of 4 whose condition remained static began with
TNF levels higher than the responders but less than the
group that deteriorated except in one (EM) where the
level was <lpg/ml.
COMMENT
Though the numbers are small and the response rate is not
as high as reported in literature for reasons given in
chapter 12, a pattern again emerges. Invariably all the
three responders had undetectable levels of TNF in WGLF.
The patients with the highest levels of TNF in WGLF
did the worst. This is discussed further in the final
discussion (chapter 14).
COELIAC DISEASE AND ELEMENTAL DIET
The patient with coeliac disease had already been on a
gluten free diet and her initial lavage TNF was <lpg/ml
and rose to 44pg/ml while on elemental diet. There was
little change in her clinical condition and not much can
be inferred from this single case. This patient is not
discussed any further. As for the study of sIL-2R more




A few observations can be made from the study of TNF in
WGLF. The pattern of levels of TNF in disease and
controls has been elucidated. The results show that
patients with IBD have higher levels of TNF in their WGLF
than controls. This is in agreement with the few studies
that have looked at TNF levels in serum (see chapter 4B)
and the one study that involved measuring TNF levels in
stool (Braegger et al.. 1992).
Further subdivisions of the disease groups has shown that
high levels of TNF in WGLF were accounted for mainly by
the patients with active disease (Table 13A:1D).
The median and means were higher for colonic Crohn's
disease than for patients with small bowel Crohn's
disease as were the levels of significance compared to
controls (Table 13A:2A). This is in agreement with the
reports of Braegger et al. (1992) who observed that in
children with Crohn's disease, which usually involves the
colon in this age group, the lowest levels of faecal TNF
were recorded in the patient with exclusive ileal
disease. Similar observations had been made by
Murch et al. (1991) in serum studies.
Patients with ulcerative colitis had significantly higher
levels of TNF in their WGLF than controls (p=0.042; Table
13A:IB) and the level of significance compared to
controls was higher for patients with active ulcerative
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colitis (p=0.0034; Table 13A:1D). These observation
suggest that high levels of TNF are associated with
colonic disease and whether ulcerative colitis or
Crohn's colitis. High levels of TNF in ulcerative colitis
are probably largely from macrophages in keeping with
the finding by Choy et al. (1991) who reported that
activated CD25+ cells in UC were of the macrophage
dendritic type while in Crohn's colitis this marker
(CD25+) of activity was associated with T cells.
Macrophages are the main producers of TNF.
The levels of TNF did not correspond with disease
activity as measured by whole gut lavage fluid (chapter
7). This is probably because the two substances, whole
gut lavage total IgG and TNF are involved in different
processes, though they are both raised in active disease.
Tumour necrosis factor is involved in the effector and
inductive mechanism of the inflammatory response and
while lavage total IgG is predominantly a leak from serum
(see chapter 7).
The source of the TNF found in whole gut lavage fluid is
yet to be fully determined. It could be secreted by
macrophages and neutrophils that have leaked from
systemic circulation into the bowel lumen in active
disease (Saverymuttu et al. . 1985b and 1985c) or it may
be predominantly of intestinal mucosa origin such as from
paneth cell (Kesha et a 1 . . 1990) mast cells
(Steffen et al.. 1989) and indeed T cells (Sherry and
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Cerami, 1988). This question is being addressed by other
workers in our team.
The group with CD proctitis appears to be different from
the patients with CD as a whole. These patients had high
individual levels of TNF in WGLF, and in those with
active disease the levels were higher. As this did not
apply to patients with UC proctitis it is worth following
up to see if it would be a distinguishing feature for
this group.
The findings in the elemental diet study though involving
only 11 patients, are in keeping with previous
observations as regards response to the diet. There have
been reports that elemental diets were not effective in
Crohn's colitis and ulcerative colitis, in this study
these two groups had higher levels of TNF compared to
controls than small bowel Crohn's. Three patients who
responded to elemental diet in this study, two had small
bowel disease and one had pancolitis, one of the common
denominators was that they all had very low
(undetectable) levels of TNF in their WGLF. Larger
reviews have shown that even patients with Crohn's
colitis do respond to elemental diet (Teahon et al.,
1991). These results therefore would tend to explain
these findings. In that in keeping with the experience
of Crohn's colitis and ulcerative colitis (Endo et al. .
1985) being less responsive, in some studies, to
elemental diet it is these groups that has high TNF
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levels. However as not all UC or Crohn's colitis patients
have high levels of TNF, there will be some that will
respond to elemental diet.
The physiological or pathological role of TNF in the IBD
gut is still an area of intense research. My hypothesis
with regard to elemental diet and TNF is that there is
always TNF in the intestine which saves a physiological
role in inflammatory activity (Bendtzen, 1988 and
Bendtzen et al.. 1989). This 'regular' TNF is kept under
control by homeostatic mechanisms such as the
negative feedback exerted by interleukin 4,
(Bello-Fernandes et al., 1991), natural antibodies and
inhibitors (Seckinger, Isaaz and Dayer, 1989). The
patients with the highest levels are the ones in whom
regulatory mechanisms have failed and the effector arm
(including TNF) continues to operate at higher level
without any link to its specific trigger. This non
specific inflammatory reaction would not respond to the
withdrawal of the triggering factors such as antigen.
SUMMARY
Tumour necrosis factor levels are higher in patients with
IBD compared to controls.
These studies suggest that TNF is more associated with
colonic disease than small bowel disease. Patients with
active UC have the highest levels even significantly
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higher than patients with inactive UC (Table 13A:1F).
Patients who responded to elemental diet had low
(undetectable) levels of TNF while those who deteriorated
had high levels. This, if confirmed, would be a useful
marker for patient management decisions in inflammatory
bowel disease.
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APPENDIX FOR CHAPTER 13
TABLE 13:1A STUDY POPULATION
CROHN•S ULCERATIVE CONTROLS
DISEASE COLITIS
NUMBERS 45 24 20
SEX M:F 24:21 10:14 7:13
AGE
MEDIAN 44 38 46
RANGE 14-83 22-79 21-85
DISEASE DISTRIBUTION
CROHN'S DISEASE ULCERATIVE COLITIS
Jejunal 4 Rectum only 8
Terminal ileum 11 Left sided 3
Ileo-colonic 13 Pancolitis 11
Colonic 10 Pouchitis 1
Rectal 5 Microscopic 1
Perianal 1 14 Active and 10 inactive
Microscopic 1














Prednisolone only (Pred) 10
Sulphasalazine (SLZ) 13
5-amino salicylates only (ASA) 0
SLZ and Pred 7
Pred, ASA and colifoam (CFM) 1
SLZ, PRED and CFM 1
Pred and CFM 1
ULCERATIVE COLITIS
No Drugs 7
PRED, ASA and CFM 3
ASA and CFM 2
ASA only 6







TABLE 13A:IB LEVELS OF TNF <pq/ml) IN WGLF OF PATIENTS
WITH CROHN'S DISEASE. ULCERATIVE COLITIS AND CONTROLS.
N RANGE MEAN MEDIAN P
CONTROL 20 <1-20 1 <1
UC 23 <1-184 28 1 0. 042
CD 45 <1-217 26 2 0.0064
p = Probability that the difference is a chance finding.
TABLE 13A:1C THE FREQUENCY OF HIGH LEVELS OF TNF IN THE
WGLF OF PATIENTS WITH ULCERATIVE COLITIS. CROHN'S DIS¬
EASE AND CONTROLS. TNF levels above lOpg/ml.
ALL ACTIVE INACTIVE
N >10 N >10 N >10
CONTROL (20) 1 NA NA
UC (23) 8* (13) 7*** (10) 1
CD (45) 16** (28) 9** (17) 7
* p < 0.05 ** p < 0.01 *** p < 0.005
NA = Not applicable
N = Total numbers studied in group
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Graph 13:1
WGLF TUMOUR NECROSIS FACTOR (p/ml) IN





















Disease groups on the x axis plotted against their levels of tumour
necrosis factor on the y axis. Both ulcerative colitis (p=0.042) and
Crohn's disease (p=0.0064) had significantly higher values than
controls.
479
TABLE 13A;ID LEVELS OF TNFfpq/ml) IN WGLF OF PATIENTS WITH
ACTIVE CROHN'S DISEASE. ACTIVE ULCERATIVE COLITIS AND
CONTROLS.
N RANGE MEAN MEDIAN D
CONTROL 20 <1-20 1 <1
aUC 13 <1-184 49 36 0.0034
aCD 28 <1-217 23 3 0.0072
p = Probability that the difference is a chance finding.
TABLE 13A:1E LEVELS OF TNF fpg/ml) IN WGLF OF PATIENTS
WITH INACTIVE CROHN'S DISEASE. INACTIVE ULCERATIVE
COLITIS AND CONTROLS.
N RANGE MEAN MEDIAN P
CONTROL 20 <1-20 1 <1
inaUC 10 <1-14 2 <1 0.8776
inaCRO 17 <1-217 30 <1 0.0549
p = Probability that the difference is a chance finding.
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TABLE 13AHF COMPARISON OF LEVELS OF TNF IN WGLF BETWEEN
DISEASE GROUPS.Statistical comparisons by Mann-Whitney
(p values).
DISEASE GROUPS
UC vs CD 0.8458
aUC vs aCD 0.2125
inaUC vs inaCRO 0.1524
aUC vs inaUC 0.0200
aCD vs inaCRO 0.8791
p = Probability that the difference is a chance finding.
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TABLE 13Ai2A LEVELS OF TNF (pq/ml) IN WGLF OF PATIENTS
WITH CROHN'S DISEASE CLASSIFIED BY REGIONAL INVOLVEMENT.
N RANGE MEAN MEDIAN P
CONTROL 20 <1-20 1 <1
SB 15 <1-63 14 1 0.0196
ILC 13 <1-104 14 <1 0.2240
CN 10 <1-217 47 14 0.0073
PR 6 <1-217 26 26 0.0288
SB - Small bowel Crohn's disease CN - Colonic Crohn's
disease
ILC - Ileocolonic Crohn's disease PR - Crohn's Proctitis
TABLE 13A;2B THE FREQUENCY OF HIGH LEVELS OF TNF IN THE
WGLF OF CROHN'S DISEASE PATIENTS CLASSIFIED BY REGIONAL
INVOLVEMENT. TNF levels above lOpg/ml.
ALL ACTIVE INACTIVE
N >10 N >10 N >10
CONTROL (20) 1 NA NA
SB (15) 4* (9) 1* (6) 3
ILC (13) 3 (6) 1 (7) 2
CN (10) 5** (8) 3* (2) 2
PR (6) 4* (4) 4** (2) 0
* p < 0. 05 ** p < 0. 01 *** p < 0.005
NA = Not applicable
N = Total numbers studied in group
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TABLE 13A:2C LEVELS OF TNF fog/ml) IN WGLF OF PATIENTS
WITH ACTIVE CROHN'S DISEASE CLASSIFIED BY REGIONAL
INVOLVEMENT.
N RANGE MEAN MEDIAN D
CONTROL 20 <1-20 1 <1
SB 9 <1-41 7 1 0.0359
ILC 6 <1-51 10 1.5 0.4652
CN 8 <1-118 28 5 0.0371
PR 4 20-217 76 32 0.0022
p = Probability that the difference is a chance finding.
TABLE 13Ai2D LEVELS OF TNF fpq/ml) IN WGLF OF PATIENTS
WITH INACTIVE CROHN'S DISEASE CLASSIFIED BY REGIONAL
INVOLVEMENT.
N RANGE MEAN MEDIAN p
CONTROL 20 <1-20 1 <1
SB 6 <1-63 19 1 0.1281
ILC 7 <1-104 14 <1 0.2567
CN 2 NA NA NA NA
PR 2 NA NA NA NA
NA = Not applicable
p = Probability that the difference is a chance finding.
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TABLE 13A:3A LEVELS OF TNF (pg/ml) IN WGLF OF PATIENTS
WITH ULCERATIVE COLITIS CLASSIFIED BY REGIONAL
INVOLVEMENT.
N RANGE MEAN MEDIAN J)
CONTROL 20 <1-19 1 <1
PAN 9 <1-183 40 4 0.0235
PR 8 <1-100 18 <1 0.4924
p = Probability that the difference is a chance finding.
TABLE 13Ai3B THE FREQUENCY OF HIGH LEVELS OF TNF IN THE
WGLF OF ULCERATIVE COLITIS PATIENTS CLASSIFIED BY
REGIONAL INVOLVEMENT. TNF levels above lOpg/ml.
ALL ACTIVE INACTIVE
N >10 N >10 N >10
CONTROL 20 1 NA NA
PAN 9 4* 6 3** 4 1
LS 3 1 2 1 1 0
PR 8 2 4 2 4 0
* •d A o • 05 ** p < 0.01 *** p < 0. 005
p = Probability that the difference is a chance finding.
484
TABLE 13A;3C LEVELS OF TNF fpq/ml) IN WGLF OF PATIENTS
WITH ACTIVE ULCERATIVE COLITIS CLASSIFIED BY REGIONAL
INVOLVEMENT.
N RANGE MEAN MEDIAN P
CONTROL 20 <1-19 1 <1
PAN 6 <1-183 65 46 0.0056
LS 2 NA NA NA NA
PR 4 <1-100 35 21 0.1752
NA = Not applicable
p = Probability that the difference is a chance finding.
TABLE 13A13D LEVELS OF TNF fpq/ml) IN WGLF OF PATIENTS
WITH INACTIVE ULCERATIVE COLITIS CLASSIFIED BY REGIONAL
INVOLVEMENT.
N RANGE MEAN MEDIAN P
CONTROL 20 <1-19 1 <1
PAN 4 <1-14 4 <1 0.6701
LS 1 NA NA NA NA
PR 4 HV1HV <1 <1 NA
NA = Not applicable
p = Probability that the difference is a chance finding.
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TABLE 13B:1A LEVELS OF TNF (pq/ml) IN WGLF OF IBP
PATIENTS CLASSIFIED AS SMALL BOWEL (SB) AND LARGE BOWEL
(LB) INVOLVEMENT.
N RANGE MEAN MEDIAN £>
CONTROL 20 <1-20 1 <1
SB 15 <1-63 14 1 0.0196
LB 33 <1-217 34 2 0.0078
p = Probability that the difference is a chance finding.
TABLE 13B:IB THE FREQUENCY OF HIGH LEVELS OF TNF IN THE
WGLF OF IBP PATIENTS CLASSIFIED AS SMALL BOWEL AND LARGE
BOWEL INVOLVEMENT. TNF levels above lOpg/ml.
ALL ACTIVE INACTIVE
N >10 N >10 N >10
CONTROL (20) 1 NA NA
SB (15) 4* (9) 1* (6) 3
LB (33) 13** (21) 10*** (12) 3
NA = Not applicable
* p < 0.05 ** p < 0.01 *** p < 0.005
p = Probability that the difference is a chance finding.
N = Total numbers in studied in the group
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TABLE 13B:1C LEVELS OF TNF fpg/ml) IN WGLF OF PATIENTS
WITH ACTIVE IBP CLASSIFIED AS SMALL BOWEL AND LARGE BOWEL
INVOLVEMENT.
N RANGE MEAN MEDIAN D
CONTROL 20 <1-20 1 <1
SB 9 <1-41 7 1 0.0359
LB 21 <1-184 41 8 0.0016
p = Probability that the difference is a chance finding.
TABLE 13B:ID LEVELS OF TNF (va/ml) IN WGLF OF PATIENTS
WITH INACTIVE IBP CLASSIFIED AS SMALL BOWEL AND LARGE
BOWEL INVOLVEMENT.
N RANGE MEAN MEDIAN P
CONTROL 20 <1-20 1 <1
SB 6 <1-63 25 1 0.1281
LB 12 <1-217 21 <1 0.3603
p = Probability that the difference is a chance finding.
TABLE 13B:1E COMPARISONS IN LEVELS OF TNF IN WGLF BETWEEN
SMALL BOWEL AND LARGE BOWEL INVOLVEMENT. Statistical
comparisons by Mann-Whitney (p values).
ALL ACT INACT
SB VS LB 0.6727 0.2133 0.4260
p = Probability that the difference is a chance finding.
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TABLE 13C;1A LEVELS OF TNF (pq/ml) IN WGLF OF PATIENTS
WITH IBP CLASSIFIED AS SMALL BOWEL (SB) CROHN'S DISEASE.
COLONIC (CN) CROHN'S DISEASE AND ULCERATIVE COLITIS (PC).
N RANGE MEAN MEDIAN D
CONTROL 20 <1-20 1 <1
SB 15 <1-63 14 1 0.0196
CN 10 <1-217 47 14 0.0073
UC 23 <1-184 28 <1 0.042
p = Probability that the difference is a chance finding.
TABLE 13CiIB THE FREQUENCY OF HIGH LEVELS OF TNF IN THE
WGLF OF IBP PATIENTS CLASSIFIED AS SMALL BOWEL (SB)
CROHN'S DISEASE. COLONIC (CN) CROHN'S DISEASE AND
ULCERATIVE COLITIS (UC). TNF levels above lOpg/ml.
ALL ACTIVE INACTIVE
N >10 N >10 N >10
CONTROL (20) 1 NA NA
SB (15) 4* (9) 1* (6) 3
CN (10) 5** (8) 3* (2) 2
UC (23) 8* (13) 7** (10) 1
NA = Not applicable
* p < 0.05 ** p < 0.01 *** p < 0.005
N = Total numbers in studied in the group
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TABLE 13C t 1C LEVELS OF TNF fpcr/ml) IN WGLF OF PATIENTS
WITH ACTIVE IBP CLASSIFIED AS ACTIVE SMALL BOWEL (SB>
CROHN'S DISEASE. COLONIC fcm CROHN'S DISEASE AND
ULCERATIVE COLITIS (UC) .
N RANGE MEAN MEDIAN D
CONTROL 20 <1-20 1 <1
SB 9 <1-41 7 1 0.0359
CN 8 <1-118 28 5 0.0371
UC 13 <1-184 49 36 0.0034
p = Probability that the difference is a chance finding.
TABLE 13C;ID LEVELS OF TNF (pa/ml) IN WGLF OF PATIENTS
WITH INACTIVE IBP CLASSIFIED AS INACTIVE SMALL BOWEL (SB)
CROHN'S DISEASE. INACTIVE COLONIC (CN) CROHN'S DISEASE
AND ULCERATIVE COLITIS (UC) .
N RANGE MEAN MEDIAN P
CONTROL 20 <1-20 1 <1
SB 6 <1-63 25 1 0.1281
CN 2 NA NA NA NA
UC 10 <1-14 2 <1 0.8776
NA = Not applicable
p = Probability that the difference is a chance finding.
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TABLE 13C:IE COMPARISONS OF LEVELS OF TNT IN WGLF BETWEEN
SMALL BOWEL (SB) CROHN'S DISEASE. COLONIC (CN) CROHN'S
DISEASE AND ULCERATIVE COLITIS (UC) . Statistical
comparisons by Mann-Whitney (p values).
SB VS PC SB vs CN PC VS CN
ALL 0.9524 0.2330 0.2814
ACT 0.2045 0.4414 0.6378
INACT 0.2123 NA NA
NA = not applicable
p = Probability that the difference is a chance finding.
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TABLE 13D;1A LEVELS OF TNF (PCT/ml) IN WGLF OF PATIENTS
WITH GLUTEN RELATED ENTEROPATHY COMPARED WITH IBP AND
CONTROLS.
N RANGE MEAN MEDIAN P
CONTROL 20 <1-20 1 <1 0.6841
UC 23 <1-184 28 <1 0.1604
CD 45 <1-217 26 2 0.2887
GRE 8 <1-44 6 <1
p = Probability that the difference is a chance finding.
GRE = Gluten related enteropathy
TABLE 13D;1B LEVELS OF TNF fpq/mll IN WGLF OF PATIENTS
WITH GLUTEN RELATED ENTEROPATHY COMPARED WITH ACTIVE IBP
PATIENTS.
N RANGE MEAN MEDIAN P
aUC 13 <1-184 49 36 0.1429
aCD 28 <1-217 23 3 0.0550
GRE 8 <1-44 6 <1
GRE = Gluten related enteropathy
p = Probability that the difference is a chance finding.
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CORRELATIONS
TABLE 13E:1 CORRELATIONS BETWEEN DISEASE ACTIVITY (WGLF
total IaG) AND TNT LEVELS IN WGLF
GROUP CROHN'S UC
N r E> N r p
ALL 45 0.060 0.694 23 0.493 0.067
ACT 28 0.163 0.406 13 0.225 0.459
INACT 17 -0.090 0.731 10 -0.242 0.501
P = the probability that the correlation is a chance
finding.
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TABLE 13E12A CORRELATIONS BETWEEN LEVELS OF TNF IN WGLF
AND DISEASE ACTIVITY (WGLF total IqG) BY REGIONAL
INVOLVEMENT OF IBP.
GROUP CROHN'S DISEASE GROUP ULCERATIVE COLITIS
_N r e N r e
SB 15 -0.059 0.834 PAN 10 0.525 0.120
ILC 13 -0.156 0.611 PRO 8 0.635 0.091
CN 10 -0.219 0.543
PR 6 0.815 0.048
TABLE 13E;2B CORRELATIONS BETWEEN LEVELS OF TNF IN WGLF
AND DISEASE ACTIVITY (WGLF total IaG) BY REGIONAL
INVOLVEMENT OF ACTIVE IBP.
GROUP CROHN'S DISEASE GROUP ULCERATIVE COLITIS
N r D N r D
SB 9 0.554 0.122 PAN 7 0. 307 0.554
ILC 6 -0.333 0. 519 PRO 4 0. 484 0.516
CN 8 0.130 0.759
PR 6 0.941 0. 059
P = the probability that the correlation is a chance
finding
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TABLE 13E;2C CORRELATIONS BETWEEN LEVELS OF TNF IN WGLF
AND DISEASE ACTIVITY fWGLF total IaG) BY REGIONAL
INVOLVEMENT OF INACTIVE IBP.
GROUP CROHN'S DISEASE GROUP ULCERATIVE COLITIS
N r P N r P
SB 6 0.001 0.998 PAN 4 -0.396 0. 604
IL 7 0. 615 0.141 PRO 4 NA NA
CN 2 NA NA
PR 2 NA NA
P = the probability that the correlation is a chance
finding
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TABLE 13E;3A CORRELATIONS BETWEEN SIL-2R in SERUM OR WGLF
AND LEVELS OF TNF IN WGLF OF PATIENTS WITH ULCERATIVE
COLITIS. CROHN'S DISEASE AND CONTROLS.
GROUP TNF vs LIL2R TNF VS BIL2R
N r g N r e
CONTROL 20 0.602 0.005 11 0.134 0.695
CRO 45 -0.183 0.230 38 0.223 0.178
UC 23 0.259 0.232 19 0.065 0.791
BIL2R = SIL-2R in serum
LIL2R = SIL-2R in WGLF
TABLE 13E:3B CORRELATIONS BETWEEN LEVELS OF SIL-2R IN
SERUM OR WGLF AND LEVELS OF TNF IN WGLF OF PATIENTS WITH
ACTIVE IBP.
GROUP TNF VS LIL2R TNF VS BIL2R
N r e N r e
CRO 28 -0.184 0.350 25 0.281 0.173
UC 13 0.077 0.802 11 -0.077 0.823
BIL2R = sIL-2R in serum
LIL2R = SIL-2R in WGLF
P = the probability that the correlation is a chance
finding
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TABLE 13E;3C CORRELATIONS BETWEEN SIL-2R IN WGLF OR SERUM
AND LEVELS OF TNF IN PATIENTS WITH INACTIVE IBP.
GROUP TNF VS LIL2R TNF VS BIL2R
N r E N r £
CRO 17 -0.179 0.491 13 -0.293 0.331
UC 10 0.095 0.794 8 -0.080 0.851
BIL2R = sIL-2R in serum
LIL2R = SIL-2R in WGLF
P = the probability that the correlation is a chance
finding
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TABLE 13E:4A CORRELATIONS BETWEEN SIL-2R IN WGLF OR SERUM
AND THE LEVELS OF TNF IN CROHN'S DISEASE CLASSIFIED BY
REGIONAL INVOLVEMENT.
GROUP TNF VS LIL2R TNF vs BIL2R
N r D N r D
SB 15 -0.054 0.848 13 -0.087 0.778
ILC 13 -0.225 0.461 9 0.524 0.147
CN 7 -0.308 0.386 4 -0.249 0.518
PR 6 -0.174 0.741 6 0.848 0.033
BIL2R = sIL-2R in serum
LIL2R = sIL-2R in WGLF
P = the probability that the correlation is a chance
finding
TABLE 13E:4B CORRELATIONS BETWEEN SIL-2R IN WGLF OR SERUM
AND LEVELS OF TNF IN WGLF OF PATIENTS WITH ACTIVE CROHN'S
DISEASE CLASSIFIED BY REGIONAL INVOLVEMENT.
GROUP TNF VS LIL2R TNF VS BIL2R
N r p. N r p
SB 9 -0.029 0.941 8 -0.509 0.198
ILC 6 -0.223 0.671 5 0.797 0.107
CN 8 -0.381 0.352 7 -0.097 0.835
PR 4 -0.446 0.554 4 0.814 0.186
BIL2R = SIL-2R in serum
LIL2R = SIL-2R in WGLF
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TABLE 13Ei4C CORRELATIONS BETWEEN SIL-2R IN WGLF OR SERUM
AND LEVELS OF TNF IN WGLF OF PATIENTS WITH INACTIVE
CROHN'S DISEASE CLASSIFIED BY REGIONAL INVOLVEMENT.
GROUP TNF VS LIL2R TNF VS BIL2R
N r D N r D
SB 6 -0.184 0.727 5 0. 628 0.256
ILC 7 -0.218 0.630 4 -0.664 0.336
CN 2 NA NA 2 NA NA
PR 2 NA NA 2 NA NA
NA = Not applicable
BIL2R = SIL-2R in serum
LIL2R = SIL-2R in WGLF
P = the probability that the correlation is a chance
finding
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TABLE 13Ei5A CORRELATIONS BETWEEN SIL-2R IN WGLF OR SERUM
AND THE LEVELS OF TNF IN ULCERATIVE COLITIS CLASSIFIED BY
REGIONAL INVOLVEMENT.
GROUP TNF VS LIL2R TNF vs BIL2R
N r e N r e
PAN 10 0.170 0.638 9 0.161 0.680
PRO 8 0.552 0.156 6 -0.256 0.624
BIL2R = SIL-2R in serum
LIL2R = SIL-2R in WGLF
TABLE 13E;5B CORRELATIONS BETWEEN SIL-2R IN WGLF OR SERUM
AND THE LEVELS OF TNF IN ACTIVE ULCERATIVE COLITIS
CLASSIFIED BY REGIONAL INVOLVEMENT.
GROUP TNF VS LIL2R TNF vs BIL2R
N r e N r e
PAN 6 0.133 0.801 6 -0.113 0.831
PR 4 0.305 0.695 3 -0.603 0.588
BIL2R = SIL-2R in serum
LIL2R = SIL-2R in WGLF
P = the probability that the correlation is a chance
finding
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TABLE 13E;5C CORRELATIONS BETWEEN SIL-2R IN WGLF OR SERUM
AND THE LEVELS OF TNF IN INACTIVE ULCERATIVE COLITIS
CLASSIFIED BY REGIONAL INVOLVEMENT.
GROUP TNF VS LIL2R TNF VS BIL2R
N r e N r e
PAN 4 0.097 0.903 4 0.881 0.314
PRO 4 NA NA 3 NA NA
NA = Not applicable
BIL2R = SIL-2R in serum
LIL2R = SIL-2R in WGLF
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Levels of tumour necrosis factor in WGLF before and after at least
seven days on elemental diet. On the y axis are the levels (p/ml) and
the x axis the time span. Patients were grouped according to global





The aim of this thesis was to study the biology of immune
responses to food antigens in inflammatory bowel disease
(IBD). There have been reports of raised serum levels of
antibodies to food antigens in patients with inflammatory
bowel disease (Taylor and Truelove, 1961; Koninckx
et al.. 1984), and these were discussed in Chapter 2B.
Whereas no single food antigen has been found to be
consistently associated with ulcerative colitis or
Crohn's disease, as for example is the case with coeliac
disease, the exclusion of polypeptides by the use of
elemental diets has been found to alleviate clinical
symptoms (O'Morain et al.. 1980; 1984; Giaffer et al..
1990) and this was discussed in chapter 5. Elemental
diets have been found to be beneficial in many other
conditions, such as pancreatitis, ischaemic colitis and
radiation enteropathy. The mechanisms by which they act
in these conditions probably vary. In IBD the mechanism
by which elemental diets act remains unknown, but in view
of the immunological disturbances that are part of IBD as
discussed in chapters 1,2A,4D and by other workers
(Broberger and Perlmann, 1962 ; Mahida et al. . 1990;
MacDermott and Stenson, 1988; ) and shown in this thesis
(chapters 7,10,12,13), the involvement of the immune
system in their action is probable.
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Assessment of disease activity by clinical symptoms
and signs can be subjective and makes scientific study
difficult. An objective and universal measurement of IBD
disease activity was developed as described in Chapter 7.
The concentration of IgG in whole gut lavage fluid (WGLF)
was found to correlate strongly with Crohn's disease
activity index (CDAI) for Crohn's disease and Powell-Tuck
index for ulcerative colitis. The IgG in the gut lavage
fluid is probably of serum origin.
Defining this marker of disease activity facilitated the
objective subgrouping of patients into active and
inactive groups. As the total IgG concentration in WGLF
correlated with disease activity, it was possible to
assess whether the degree of disease activity was linked
to cytokine (T cell) activity or the presence of
antibodies to food antigens. Further detailed study of
the patients was achieved by subdividing patients
according to the predominant regions of gut grossly
affected as determined by radiology, endoscopy and
histopathology.
Measurement of IgA levels in WGLF showed that the levels
were increased in patients with IBD. The proportion of
secretory IgA to total IgA was diminished in patients
with IBD compared to controls (Chapter 8). This could
indicate that the secretion of IgA outstrips the capacity
for binding cytoplasmic secretory component (Brandtzaeg
and Korsud, 1984). As the binding of secretory component
504
is required for the transport of IgA across the epithelium
into the lumen, reduced binding capacity of secretory
component is probably not the main factor for the
decreased proportions of secretory IgA in IBD patients
compared to controls. However the concentration of
non-secretory IgA in IBD patients increased with disease
activity and it correlated with whole gut lavage IgG
(r=0.241 p<0.0001) [Table 8:11]. Thus I suggest that much
of the non-secretory IgA in WGLF is serum derived the
same as for whole gut lavage IgG, reflecting a protein
losing enteropathy. Further studies of the subclasses of
IgA in WGLF of patients with active disease will confirm
the source of luminal IgA. An increased proportion of
IgAl in the WGLF of patients with active disease compared
to controls would support the possibility that serum as
the source of non-secretory IgA.
In chapter 9 total immunoglobulins and levels of
antibodies to three dietary antigens were measured in the
intestinal secretions (WGLF and parotid saliva) and sera
of IBD patients and controls. The three ubiquitous food
antigens studied were ovalbumin, B-lactoglobulin and
gliadin. The patients were studied according to their
disease activity (based on global clinical assessment and
the levels of IgG in WGLF) and the regional distribution
of their disease.
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The results were as follows.
No differences between disease groups and controls were
detected in serum. By definition patients with active
disease had higher levels of IgG in WGLF than controls or
patients with inactive disease. There were no significant
differences between disease groups and controls in WGLF
total IgA.
Total IgM in WGLF was higher for patients with active IBD
than controls. IgM is also raised in other immune based
diseases such as coeliac disease (O'Mahony et_al., 1991a) .
This raised IgM could be due to the fact that IgM, being
the immunoglobulin class of the primary immune response,
increases non-specifically whenever there is increased
drive to B cell activity; however it is likely that this
is coupled with an aberration in the maturation process.
It is therefore conceivable that the more active
disease would be associated with a higher degree of
immune aberration and therefore a higher concentration of
IgM as was seen in this study. The higher levels of IgM
in the whole gut lavage fluid of patients with active
inflammatory bowel disease would therefore reflect this
non-specific aberration in the maturation process.
A study of antibody levels to the three dietary antigens
gave significant differences between IBD patients and
controls in WGLF and not in serum. Patients with active
Crohn's disease had higher levels of food antibodies to
ovalbumin and gliadin in the IgA (p=0.0269 and p=0.0073)
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and IgM (p=0.0140 and p=0.0269) classes. There was no
difference in food antibody levels between patients with
ulcerative colitis and controls or Crohn's disease
patients. This puts the patients with ulcerative colitis
in an intermediate group, in terms of immune upregulation
to food antigens, between active Crohn's disease (greater
immune upregulation) and controls. Two possible
explanations for this are that contact between antigen
and immune cells in the lamina propria may be easier in
Crohn's disease patients due to the transmural nature
of their disease or that Crohn's disease patients have
intrinsically an upregulated underlying gut immune
activity.
Only WGLF and not serum showed significant differences
between controls and disease groups for total
immunoglobulins and food antibody levels. There was no
correlation between levels of antibodies in serum and
levels in WGLF. This is additional evidence that
systemic immunity and mucosal immunity are independent.
Having established that Crohn's disease patients were the
hyperimmune group, the experiments described in chapter
10 measured the effect of elemental diets on these
antibodies in serum and intestinal secretions (WGLF and
saliva).
Baseline studies showed that parotid saliva total
immunoglobulins were mainly in the IgA class. The levels
of total IgA in saliva in each subject varied from day to
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day within a narrow range for each subject (Graph 10:2B).
This meant that large changes in these levels resulting
from, for example, treatment with antigen withdrawal
could be studied. There was no correlation between total
serum IgA and saliva IgA. Smoking has been reported to
reduce saliva IgA (Barton et al. . 1990) but this
relationship was not confirmed in this study probably
because the patients smoked less than 20 cigarettes a day
and a few consumed alcohol as well which is known to
increase IgA levels.
The antibodies specific for the three antigens
(gliadin, B-lactoglobulin and ovalbumin) in saliva were
also predominantly in the IgA class, and their levels did
not correlate with the serum IgA antibody levels.
When patients were prescribed elemental diet, there was
no significant change in serum or saliva total
immunoglobulin levels regardless of the clinical outcome
(i.e. whether or not the diet altered the symptoms). The
same applied to the levels of antibodies to the three
food antigens, even when patients were divided into those
who responded to elemental diet and those who did not
respond.
Studies of WGLF immunoglobulins and food antibodies with
respect to elemental diet also showed that there were no
significant change in their levels that could be related
to disease response or lack of it. Total IgG in WGLF fell
(Table 10D:2 and Table 10D:2A) in keeping with the
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general improvement in the clinical condition of
patients, most probably as a result of reduced leakage of
serum IgG into the intestinal lumen. The more sensitive
ELISPOT assay which involved enumeration of cells
secreting particular antibodies in peripheral blood was
performed to see if there were changes that were too
early for detection by ordinary ELISA. There was no
significant change in the number of cells secreting
antibody to food antigens in patients taking elemental
diet regardless of the clinical outcome. This phase of
the work therefore showed that modulation of humoral
immunity was not a primary mechanism in the action of
elemental diets in IBD.
To test whether elemental diet modifies macrophage
activity two assays, one indirect and one direct were
used. The indirect method was by measuring a-lAP in serum
and WGLF. IL-1, IL-6 and TNF are produced in abundance
mainly by macrophages, and a-1 acid glycoprotein is
produced by the liver as a result of their actions. The
possible secretion of a-lAP from the liver via bile was
studied by using whole gut lavage fluid. The levels of a-
1 acid glycoprotein were higher in both active and
inactive disease groups compared to controls. The results
in WGLF followed the pattern in serum, this could be
because WGLF a-1 acid glycoprotein, despite the
contribution from bile was mainly leaking from serum.
When a-1 acid glycoprotein was studied with respect to
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acute changes as in the response to elemental diet, there
was no relationship between disease response and the
levels of a-1 acid glycoprotein in serum or WGLF.
Direct measurement of macrophage secretory activity via
tumour necrosis factor (TNF) levels in WGLF was more
informative. Patients with active Crohn's disease and
active ulcerative colitis had significantly higher
levels than controls. When patients were further studied
according to regional involvement of disease, the
patients with Crohn's colitis and ulcerative colitis had
relatively higher levels than patients with small bowel
involvement (Table 13C:1A-1E). When elemental diet was
prescribed, it was the patients with the low levels of
TNF who responded. The patients with high levels did not
respond to elemental diet. I suggest that high levels of
TNF indicate a later, more generalised upregulation of
the inflammatory activity not amenable to treatment by
specific antigen withdrawal. The finding of high levels
of TNF in Crohn's colitis and ulcerative colitis might
explain why some workers have found that these patients
(Endo et al.. 1985) are less responsive to elemental
diet.
Soluble interleukin-2 receptor (sIL-2R), the p55 chain
of the T-cell receptor, was used as a marker of T cell
activity and measured in WGLF and serum. In keeping with
previous reports (Mahida et al.. 1988; Brynskov and
Tvede, 1990) SIL-2R in serum was significantly higher in
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patients with active Crohn's disease and active
ulcerative colitis compared to controls (Table 12:1A).
There was no significant difference in serum SIL-2R
levels between inactive disease and controls (Table
12:ID). In whole gut lavage fluid SIL-2R was largely
undetectable in controls. There was no significant
difference in WGLF SIL-2R between patients with
ulcerative colitis and controls (p = 0.0533). Crohn's
disease patients had significantly higher levels than
controls (p = 0.003) [Table 12B:1A and Table 12B:1B].
However, both active disease groups (CD and UC) had
significantly higher levels than controls (Graph 12B:1).
Further subdivisions showed that the patients with small
bowel disease had relatively higher levels of sIL-2R than
patients with disease confined to the large bowel.
When patients were prescribed elemental diet, the
patients that improved had high initial levels of SIL-2R
in their lavage fluid which fell with disease
improvement. It was these same patients who had low
levels of TNF. The patients with low levels of SIL-2R in
lavage also had high levels of TNF. I suggest that high
sIL-2R in lavage serves not only as a marker of patients
with predominantly immune related bowel disease which may
be amenable to antigen withdrawal, but also may have been
facilitatory in the down regulation of the immune
response by elemental diets just as cyclosporin acts in
IBD (Brynskov and Tvede, 1990). The mode of action of
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cyclosporin involves the blocking of the induction of
mRNA for IL-2 in T cells (Granelli-Piperno, Inaba and
Steinman, 1984). I would suggest that in the absence of
stimulatory antigens SIL-2R may act as a negative
feedback, blocking the action of IL-2 by binding with it
before it reaches the target cells. Levels of IL-2 were
not measured in this study but these have been reported
to be increased in patients with active IBD compared to
controls (Brynskov and Tvede, 1990).
The primary antigen(s) in inducing or exacerbating IBD is
(are) still unknown. However the immune response in IBD
is upregulated as shown in this thesis. The levels of
antibodies to food antigens were higher in IBD as were
the levels of tumour necrosis factor and sIL-2R. With
this background of an upregulated immune response it is
probable that the immune reaction to any antigens is not
finely controlled and directed (Poo, Conrad and Janeway,
1988) . This makes it difficult to identify the primary
antigen(s) in the immunopathogenesis, as the effector
mechanisms would be non-specifically upregulated against
a variety of antigens. I propose that food antigens being
one of the commonest antigens in the intestinal lumen are
non-specifica1ly involved in the exacerbation or
induction of the upregulated immune response. Their
withdrawal therefore leads to a diminished antigen load
and, in patients whose regulatory mechanisms are still
intact (such as those with raised SIL-2R) , there is
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concomitant down regulation of the immune response. In
the patients who have raised macrophage activity, the
effector mechanisms may have become too non-specific for
any specific withdrawal of antigens to be effective.
Food antigens may not be responsible directly for
exacerbating IBD but their effect on the gut microbial
flora may be the underlying mechanism. For example; in
the guinea pigs the presence of Bacteriodes vulgaris is
necessary for carrageenan to cause the ulcerative
colitis-like mucosal lesions (Onderdonk et_al. , 1987) . If
a similar mechanism is involved in human IBD, then a
change in the load or strains of the bacteria in the gut
may be the mechanism by which elemental diet leads to a
down regulation of the immune response. The reports on
the effect of elemental diet on bacterial flora are not
conclusive (Menge et al.. 1985; Crowthen et al.. 1976)
and discussed in Chapter 5. Menge et al. (1988) found no
difference while Crowthen et al. (1973) had reported an
increase in enterobacteria and a decrease in enterococci.
The effect of elemental diet on gut flora needs to
be resolved and work toward resolving this guestion is
needed.
The two markers that were associated with disease
response (TNF and SIL-2R) reflect both the regulator and
effector ends of the immune response. Tumour necrosis
factor is involved in the effector mechanisms while the
IL-2 system is mainly involved in the controlling stages
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of the immune response. As cytokines seldom act in
in order to get the full picture; for example, IL-4
which may be involved in down-regulating TNF
(Bello-Fernandez et al. . 1991). Deficiency of IL-4 in
patients with raised TNF might therefore result in the
failure of down regulation of immune responses
in the gut.
In summary this thesis was a study of immune responses to
food antigens in IBD. Levels of antibodies to the three
food antigens were raised in patients with Crohn's
disease compared to controls in whole gut lavage fluid,
but not in serum. Serum and WGLF sIL-2R levels were
raised in active IBD patients which indicated increased T
cell activity compared to controls. The patients who
responded to elemental diet had high initial levels of
SIL-2R in their WGLF. On the other hand, patients who
had raised levels of TNF, a marker of macrophage
activity, were not responsive to elemental diet. The
possible explanation for these findings have been
discussed. The source of the sIL-2R and TNF in WGLF of
IBD patients is not fully ascertained. They could both
originate from the systemic circulation and reach WGLF by
leakage through disease-damaged epithelium, but the lack
of correlation between levels of sIL-2R in WGLF and serum
suggested independent sources. There is now increasing
evidence that both SIL-2R (Mahida et al.. 19 8 8; Choy et
isolation more data on other cytokines
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al. . 1990) and TNF (MacDonald et_a_l. , 1990) are largely of
local mucosal origin. There may be other cytokines
involved. The combination of these cytokines may point
towards the type of T cell involved in the down-
regulation of IBD immune activity by elemental diet.
The patients defined by high levels of whole gut lavage
SIL-2R and low levels of TNF is a cohort that responds
to elemental diet. If confirmed, these criteria will
contribute towards making the clinical management of IBD
patients less empirical. There is also the need to
examine how these factors relate to cases which respond
to other types of treatment.
The limitation to using these criteria routinely is that
the two useful markers TNF and SIL-2R in WGLF are very
expensive to assay. However if the usefulness of these
assays is proved they may become less expensive or they
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